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Abstract 
 
In recent years, there has been a growing interest towards the use of transdermal drug 
delivery systems (TDDS). However, a great challenge in this arena is the formidable barrier 
posed by the skin that can limit permeation of therapeutic agents. Therefore, there is a need 
for novel strategies or enhancement techniques to deliver the drug across the skin. The use 
of hot melt extrusion technology (HME) to prepare these TDDS is also generating 
considerable interest in the pharmaceutical field. This work combines these interests through 
preparation of several hot melt extruded formulations screened for their potential for 
transdermal development. A substantial database has been generated on physicochemical 
characteristics of these formulations with a prime focus on their in vitro drug release and 
permeation properties.  
 
Processing parameters (temperature, heating duration and mixing speed) for preparing hot 
melt extruded compositions comprising ibuprofen (model drug) and various carrier 
excipients were established with minimal thermal degradation. Ibuprofen displayed a 
plasticizing effect enough to perform extrusion. HME processing facilitated the formation of 
solid solutions and dispersions. The feasibility of delivering ibuprofen from Eudragit RS 
PO-based extruded patches was investigated. The formation of solid solutions with high 
drug loading (35% w/w) was achieved in relatively stable extruded Eudragit RS PO matrices 
under dry conditions. However, these systems were associated with limited drug release. 
This has given the way to explore the effect of addition of release modifiers (sucrose, 
methylcellulose, Xantural®75, Pluronic® F127, Gelucire 44/14) and hydration influence. 
Gelucire 44/14 containing formulations emerged as the most satisfactory systems which 
improved in vitro drug permeation profiles significantly by means of hydration. Intriguing 
structural changes upon hydration are believed to facilitate drug release as observed from the 
medicated and non-medicated formulations. These include consistency changes, softening of 
the extruded films and surface imperfections. Similar changes were detected in vivo using 
non-medicated Eudragit RS PO/Gelucire 44/14 carrier extruded systems after human skin 
occlusion. This employed strategy holds the promise for potential of a novel transdermal 
drug delivery activated by hydration. 
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1.1 General introduction 
 
In pharmaceutical drug delivery research around 40% of drug delivery candidate products 
are under clinical evaluation for transdermal applications (Barry, 2001; Dhamecha et al., 
2009) with approximately 500 trials listed on ClincalTrials.gov in June 2012 (Watkinson, 
2013). This illustrates the strong trend towards the use of the skin as one of the main routes 
of administration for the next decade. Similarly, the growing interest in the use of hot melt 
extrusion (HME) technology presents a range of opportunities to design responsive drug 
delivery systems that can combine the benefits of transdermal delivery and HME processing 
technology. Therefore, the work in this thesis details the development of various hot melt 
extruded formulations in attempt to design simple matrix-type patches for transdermal drug 
delivery, evaluated on the basis of solid state characteristics, in vitro drug release and 
permeation performance. Before a more detailed introduction of the research objectives is 
given, a review of hot melt extrusion and transdermal drug delivery is provided. 
 
1.2 Hot melt extrusion (HME) for pharmaceutical systems 
 
Hot melt extrusion (HME) technology is emerging as one of the most widely used 
techniques for pharmaceutical applications. This technique was originally established in the 
plastic and food industry during the mid 1930s (Crowley et al., 2007). There is ample 
literature on the dosage forms and drug delivery systems prepared via melt extrusion such as 
granules (Gryczke et al., 2011), pellets (Young et al., 2003), tablets (Bruce et al., 2005), 
suppositories (Byrne and Aylott, 1981), implants (Gosau and Müller, 2010), stents (Healy 
and Dorfman, 1997), topical and transdermal systems (Aitken-Nichol et al., 1996; 
Breitenbach et al., 2009; Repka et al., 1999).  
 
Hot melt extrusion can be defined as a process whereby a raw material is extruded through a 
die system under conditions of elevated temperature, mixing and pressure. As an effectively 
continuous process, high throughput rates are possible (Breitenbach, 2002). The extrusion 
system or the extruder consists of two main parts: a conveying system, where the material is 
massed, mixed and transported, and a die system which transform the material into the 
desired shape.  
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A review by Crowley et al. (2007) showed that hot melt extrusion compares favourably with 
traditional pharmaceutical processing techniques due to it being associated with fewer unit 
operations and greater product content uniformity, as well as offering a solvent-free process 
that is capable of solid-dispersion formation of poorly soluble drugs with improved 
bioavailability.  
 
1.2.1 Extrusion processing 
 
Generally, the HME technique is suitable for thermostable drugs and polymers which have 
appropriate thermoplastic behaviour. This technology usually comprises the following steps: 
(a) the drug and the polymer(s) are blended for content uniformity; (b) this mix is fed into 
the extruder, whereby parameters are adjusted according to the formulation prepared; and (c) 
the resultant extruded product (usually strands or films) need to be cooled by passing over a 
chilled roll, for example. In order to understand the melt extrusion itself, we can divide the 
process into the following steps in sequential order (Breitenbach, 2002): 
 
1-Feeding stage; 
2-Conveying of the mass (dispersive and distributive mixing); 
3-Flow through the die; 
4-Pumping outside into downstream processing (cooling, cutting or collecting the extrudate). 
These will be discussed in the context of the development of an HME process.  
 
Ever since HME first found its place in the pharmaceutical manufacturing operations, 
attention towards design issues, includes polymer type and amount, drug selection, 
processing conditions and parameters employed has become of immense importance for 
successful product development. Process parameters are divided up into monitoring and 
controlling parameters. Barrel temperature, feed rate and screw speed are controlling 
parameters; whereas motor load and melt pressure are monitoring parameters (Chokshi and 
Zia, 2004). To understand these processing parameters, it would be useful to have initially a 
brief overview of the extruder parts. Hot melt extrusion system or the extruder is typically 
composed of a feeding hopper, barrel(s), single or twin screws, and the die as exemplified in 
Figure 1.1. These parts are controlled and operated via connection to a central drive 
electronic control unit and a motor. Therefore, process control can be applied on the zone 
temperature, screw speed with optional monitoring devices of the pressure and extrusion 
torque.  
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Downstream equipment for the extruder is used for collection and cooling, such as a 
conveyer belt and cutting. Additional or auxiliary equipment for the extruder consist of on-
line or in-line process analytical technology (PAT) that is used for real time product quality 
evaluation. Examples include near infrared (NIR), Raman, ultrasound and laser systems 
(Maniruzzaman et al., 2012). 
 
 
 
Figure 1.1: Schematic side view of a twin-screw extruder set-up comprising a feed 
hopper, barrel heaters, twin screws connected to a drive unit and an outlet 
representing a die system. The solids are conveyed, melted and pumped into the die. 
Reproduced from www.polymerprocessing.com 
 
In hot melt extrusion, heat is applied to the material to enable its flow, hence a prerequisite 
of this material to be used in hot melt extrusion is thermal stability at the selected processing 
temperature. However, even thermally sensitive drugs can be processed using HME, if the 
process design is manipulated. For example, short processing times at low temperatures can 
solve the problem. During the extrusion, the barrel is heated at temperatures that allow 
melting or liquefaction of the conveyed solids. These temperatures are usually determined 
based on the glass transition (Tg) or melting temperature (Tm) of the polymer(s) and drug. 
The segmental mobility of the material is very high when the glass transition temperature 
(Tg) is below the set temperature. Therefore, a solid crystalline or a glassy system at 
temperature higher than its melting or glass transition temperature, respectively, is assumed 
to have better mixing ability due to high molecular mobility and lack of rigidity.  
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Another integral parameter in extrusion is a combination of the screw speed and feeding 
rate. The level of extruder filling is determined by this parameter. Constant feed rate and 
screw speed will mean a constant amount of material in the extruder. As a consequence, the 
applied mixing and residence time will remain constant. This means an efficient dispersive 
and distributive mixing as depicted in Figure 1.2. Dispersive mixing de-aggregates 
suspended particles in the molten mass, while distributive mixing, ideally, divides and 
recombines the material to ensure content uniformity (Chokshi and Zia, 2004). 
Alternatively, the main monitoring parameters which encompass motor load and melt 
pressure depend on the feed rate and screw speed, which depend on the viscosity and 
molecular weight of polymer and drug as well as polymer miscibility in binary mixtures 
(Breitenbach, 2002). For example, at constant temperature, as the viscosity and molecular 
weight of the material increase, lower feeding rate and faster rotation of the screw might be 
required to aid in the conveying, mixing and transportation of this material, resulting in a 
high motor amperage and barrel pressure. However, in some cases the melt viscosity is very 
high that the screw(s) will not be able to rotate. In this case, other avenues are used to 
improve processing conditions. Higher temperatures and/or incorporating plasticizers in the 
formulation can lower melt viscosities (Karl et al., 2011). 
 
 
 
Figure 1.2: A schematic diagram illustrating HME influence on achieving dispersive 
and distributive mixing 
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1.2.2 Extruder types 
 
Various types of extruders which are used for pharmaceutical purposes must meet regulatory 
requirements. Thus the contact parts must not be reactive, additive or absorptive with the 
product. Usually the processing units are made of stainless steel to resist abrasion, corrosion 
and adhesion (Ghebre-Selassie and Martin, 2003). In addition, the equipment is configured 
for cleaning and validation for pharmaceutical extrusion in accordance with Good 
Manufacturing Practices (cGMPs). 
 
These pharmaceutical grade extruders can be either ram extruders or screw extruders. Screw 
extruders operate with (a) rotating screw(s) inside a heated barrel. On the other hand, the 
ram extruders or piston-fed extruder works under the principle of high pressure ram 
displacement to push materials through the die. However, lack of temperature uniformity 
and limited melting capacity in this type usually generate products with lower homogeneity 
in comparison to the extrudate produced by screw extruders (Crowley et al., 2007; Ghebre-
Selassie and Martin, 2003). Therefore, screw extruders are more useful for pharmaceutical 
needs. 
 
Screw extruders can be classified as single-screw extruder and twin-screw extruders. The 
twin-screw extruder is the most widely used and preferred for pharmaceutical applications. 
Single-screw extruders consist of one screw, while twin-extruders utilize two screws that are 
usually arranged side by side. The use of two screws allows different configurations to be 
obtained. For example, as illustrated in Figure 1.3, a co-rotating design allows the rotation of 
the screws in the same directions, whereas in a counter-rotating configuration screws rotate 
in the opposite direction. In most cases, co-rotating design is primarily used in 
pharmaceutical manufacturing. This design allows high rotation speeds associated with high 
outputs while good mixing and conveying properties are maintained (Kolter et al., 2010). 
This type is associated with lower screw and barrel wear than counter-rotating extruders. 
However, counter-rotating design is useful when very high shear regions are needed, as the 
material can be squeezed through the gap between the two screws when they come together.  
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Overall, twin-screw extruders are commonly the extruders of choice in the pharmaceutical 
industry. These extruders have many advantages over single screw extruders such as 
versatility of the designs which allow convenient material feeding, better mixing, high 
capability of heat and mass transfer, shorter residence time with less tendency to overheat, 
which accounts for a decrease in the material degradation.  In addition to the “self-cleaning” 
property that is related to the self-wiping of the intermeshing design, presenting a clean 
environment required by GMP regulations for pharmaceutical extrusion (Hudson, 1995).  
 
 
 
Figure 1.3: Schematic of the cross section view of the different screws’ rotations in 
twin-screw extruder. Reproduced from www.iscrewbarrel.com 
 
1.2.3 HME formulation development 
 
Mixtures of active drug and functional excipients are commonly employed in HME 
applications to formulate various dosage forms and delivery system. Major ingredients of 
these excipients used in HME process may be generally classified as matrix carriers 
comprising polymeric carriers, release-modifying agents, plasticizers, and various additives 
such as antioxidants or thickening agents. The availability of materials of pharmaceutical 
grade that are eligible for extrusion is increasing steadily, with most of the materials used 
currently having been used previously for production of traditional dosage forms (Singhal et 
al., 2011). As mentioned previously, thermal stability is essential for any extrusion process, 
in addition to acceptable chemical and physical stability, low toxicity and, for the carrier 
systems it is usually required that they be pharmacologically inert. 
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1.2.3.1 Active ingredients 
 
The major drawback of the HME technology is relatively high shear forces and temperatures 
that restrict application to thermo-stable drug substances. However, thermolabile drugs can 
still be extruded if the processing time is short or the required processing temperature is 
reduced by incorporation of plasticizers. For example, thermosensitive p-amino salicylic 
acid (Verreck et al., 2006) and hydrocortisone (Repka et al., 1999) have been extruded 
successfully using plasticizers. In some cases, the drug itself may function as a plasticizer 
such as ibuprofen (Kidokoro et al., 2001; Siepmann et al., 2006), chlorpheniramine maleate 
(Wu and McGinity, 1999) and itraconazole (Rambali et al., 2003). 
 
Depending on the unique properties of the extruded drug and excipients formulated therein, 
the drug substance may be completely dissolved as a solid solution or dispersed as a solid 
dispersion or a combination. Performance as well as processability and stability can be 
influenced by the drug state in the extruded final dosage form. For example, solid 
dispersions may be more stable and easily processed in comparison to solid solution systems 
(Crowley et al., 2007). 
 
1.2.3.2 Carrier systems 
 
Hot melt extrudate production involves blending of the drug into carrier system comprised 
of one or more meltable substances. The selection of appropriate carrier(s) is critical factor 
in the design and development of HME formulation to impart the required properties to the 
final extruded product, such as obtaining the desired release profile of the drug substance or 
limiting the burst effect by incorporation of viscosity inducing agent.  
 
Investigation of the processing conditions and attributes of the raw materials is typically 
performed on the basis of the thermal properties, such as thermal stability, and the 
rheological properties, such as acceptable melt viscosity for processing. While thermal 
properties can be characterised using various thermoanalytical techniques, like differential 
scanning calorimetry and thermogravimetric analysis, melt viscosity can be measured 
indirectly from torque, melt pressure and motor amperage associated with the HME process.  
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The resistance of the viscous material to the shearing action of the melting process is 
measured by the torque, which is defined as the mechanical work needed to move material 
through an extruder. The energy consumed by the motor to transfer this material is measured 
by the drive motor amperage, and the pressure initiated from material compaction within the 
extruder, melting and pumping towards the die system is known as the melt pressure. These 
measures are proportional to the material viscosity and can be useful to reflect the 
processing environment. For instance, it may be used for comparative analysis of the torque 
between studied systems, thus their resistance for processing via the HME technique.  
 
However, the most important information to know is that all extruders have a limited 
operating window of a maximum operating temperature and rotational speed. Therefore, 
proper intervention is warranted in some cases, for example, plasticizer can improve the 
processing conditions by decreasing the melt viscosity and avoid improper conditions. 
Otherwise, the machine will be susceptible to physical damage and the used drug, excipient 
or additives to degradation (Coppens et al., 2005). 
 
Examples on the main categories of the commonly used carriers in the HME to prepare 
various dosage forms comprise polymeric carriers of polymethacrylates like Eudragit RS/RL 
(Zheng et al., 2004), Eudragit E (Qi et al., 2008a) and Eudragit S (Bruce et al., 2005), 
cellulosic derivatives such as ethylcellulose and hydroxypropylcellulose, polyethylene 
glycol, polyethylene oxide and their copolymers (Hall and Read, 2012). In addition to the 
non-polymeric carriers which include wide range of waxes like carnauba wax, 
microcrystalline wax (De Brabandera et al., 2000)and lipid carriers (Mehuys  et al., 2004) 
such as polyglycolised glycerides lipids (Gelucires®).  
 
1.2.3.3 Processing aids 
 
Processing aids are group of materials that offer remedies for the problems that might be 
encountered during the manufacturing of the extruded systems, thus enhancing HME 
processing condition. As for any pharmaceutical preparation, these additives should be of 
pharmaceutical grade and have good compatibility with other components of the formulation 
intended for extrusion. 
 
 
 
 
 
Introduction 
Chapter 1 
 
49 
 
1.2.3.3.1 Plasticizers 
 
Polymeric carriers employed in HME may require plasticizers to facilitate their extrusion 
and enhance processing conditions. Plasticizers are compounds that can decrease the glass 
transition temperature and melt viscosity of a polymer (Verreck, 2012). This could be 
attributed to increase free volume between polymer chains. Rigid and hard polymers have 
low free volume and the molecules cannot move past each other easily. Addition of small 
molecules such as plasticizers can separate the polymer molecules, increasing the free 
volume. Thus applying relatively lower temperature after incorporation of the plasticizers 
could supply the polymer molecules with enough energy to vibrate and move past each other 
rapidly, making the system more flexible. Other interventions which could increase free 
volume include modification of the backbone of the polymeric material by addition of side 
chains or end groups (Wilkes et al., 2005). 
 
Typically, plasticizers would reduce the need of excessive temperature to process hard 
polymers. In doing so, localized overheating, depolymerisation or oxidation of the polymers 
and thermal degradation can be avoided for both the drug and the polymer, thus a better 
quality of the product can be attained (Verhoeven et al., 2008). It has been also demonstrated 
that improving the conditions of HME processing by reducing required temperature, energy 
and torque for the material to melt and flow, can be reflected positively on the homogeneity 
of the mixing/dispersion of the drug in the polymeric matrix and content uniformity of the 
extruded product (Thumma et al., 2008). Plasticizers may also alter the drug release rate, so 
a judicious choice of the plasticizer type (hydrophobic vs. hydrophilic) and a balance 
between enough amount of plasticizer to facilitate extrusion, while maintaining the desired 
drug release profile are required (Coppens et al., 2005). 
 
Plasticizers are often low molecular weight compounds. Heinamaki and coworkers (1994) 
found that elongation percentage or ductility was mainly ascribed to the molecular weight of 
the plasticizer (polyethylene glycol), so the lower molecular weight and thus the size it has, 
the system will be more elastic. Table 1.1 lists plasticizers approved by the Food and Drug 
Administration (FDA) for use in pharmaceutical dosage forms. Moreover, the potential of 
pressurized carbon dioxide as a “temporary” plasticizer has been investigated. Efficient 
reduction of processing temperature was demonstrated (Verreck et al., 2006a) with its ability 
to work as a foaming agent, thereby increasing the porosity of the extruded formulations, 
resulting in their enhanced dissolution (Verreck et al., 2006b). 
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In some formulations, the active moiety (drug) can act as a plasticizer during processing 
(section 1.2.3.1).  Polymers themselves such as polyethylene oxide (PEO 100K) and poly (ε-
caprolactone) (PLC) have shown plasticizing effect (Lyon et al., 2008; Crowley et al., 2002). 
Additionally, some surfactants, such as Tween 80 and sodium lauryl sulphate, have been 
also reported to act as both plasticizers and solubilizers (Ghebremeskel et al., 2007). The 
existence of all-in-one ingredient or combining more than one property needed for effeicient 
formulation preparation is an integral factor in formulation design. Fewer ingredients in the 
formulation means less ingredient variability, better economic efficiency and less probability 
of adverse reactions or the need of elaborative compatibility testing.  
 
Type Examples 
Citrate esters Triethyl citrate, tributyl citrate,acetyl triethyl citrate, acetyl tributyl 
citrate 
Fatty acid esters Butyl stearate, glycerol monostearate, stearyl alcohol 
Sebacate esters Dibutyl sebacate 
Phthalate esters Diethyl phthalate, Dibutyl phthalate, dioctyl phosphate 
Glycol derivatives Polyethylene glycol, Propylene glycol 
Others Triacetin, mineral oil, castor oil 
Vitamin E TPGS D-α-tocopheryl polyethylene glycol 1000 succinate 
 
Table 1.1: Plasticizers used in pharmaceutical dosage forms (approved by FDA) and 
listed according to their chemical structures (Crowley et al., 2007) 
 
1.2.3.3.2 Other additives 
 
For systems prone to oxidation or light degradation, various materials can be added to 
improve their stability during storage or prevent their degradation during processing. 
Examples include light absorbers such as benzotriazole ultraviolet light absorber, preventive 
antioxidant like ascorbic acid, which undergoes oxidation preferentially, protecting by that 
other components from attack by oxygen (Singhal et al., 2011). 
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Other materials have been used in HME processing comprise, but not limited to, lubricants 
and pH modifying agents. Citric acid monohydrate, for instance, was found to act as a 
plasticizer and pH-modifying agent, facilitating HME processing and adjusting the system 
micro-environmental pH, which modulate drug release (Bruce et al., 2005). Thermal 
lubricants, like waxy glyceryl monostearate and triethyl citrate were found to lower melt 
viscosity and decrease both the glass transition temperature and the melt viscosity, 
respectively, thereby improving thermal processing during hot melt extrusion (Zhu et al., 
2004). 
 
1.2.4 Characterisation of the hot melt extrudate 
 
HME technology has been utilized for several applications in pharmaceutical field; however, 
a key application is the ability to produce solid molecular solution/dispersion of the active 
pharmaceutical ingredients in a matrix (Andrews and Jones, 2010) without being restricted 
by solvent concerns. The strategy for characterising extruded product containing an active 
pharmaceutical ingredient is usually dependent on the physical state of the drug in the 
extruded mix to differentiate between solid solution and solid dispersion systems. The 
formation of these systems is one of the important interventions in pharmaceutical 
applications to improve solubility and dissolution rate. Therefore, their characterisation is 
important for some impacts that they could have. For example, while dissolution rate can be 
improved by enhanced wetting behaviour of hydrophobic drugs with hydrophilic polymers 
in solid dispersion, solid solution systems can improve dissolution rate due to the amorphous 
nature of the product (Chokshi and Zia, 2004). 
 
Materials can be combined using HME to form broadly called “solid dispersions”. Solid 
dispersion systems refer to a group of solid products consisting at least two different 
components, e.g. drug and polymer (Patidari et al., 2011). While a number of classifications 
have been described in the literature of these systems, the most commonly used 
distinguishable feature is based on the molecular state of the drug in the carrier matrix. In 
pharmaceutical applications, the most encountered types are solid crystalline suspension, 
solid glassy suspension and solid glassy solution as presented in Figure 1.4. 
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Figure 1.4: Schematic presentation of incorporating modes of the drug in an 
amorphous carrier matrix (commonly polymeric material) using HME technology. (A) 
Refers to solid crystalline dispersion of crystalline drug particles with a polymeric 
carrier; (B) to solid glassy suspension of amorphous drug domains (clusters) with a 
polymeric carrier and (C) represents solid solution of amorphous drug molecularly 
dispersed between amorphous polymeric chains 
 
By definition, if the drug is dissolved at molecular level, thus the drug forms one phase 
system with polymer, it is referred to as a solid solution; whereas, if the drug is in a two 
phase system with polymer, it is referred to as a solid dispersion (Chokshi et al., 2007). The 
drug in this case is partly molecularly dispersed and exists as amorphous domains (clusters), 
giving rise to glassy solid suspension or found as crystalline particles and referred to as a 
solid crystalline dispersion (Kolter et al., 2010). The biggest challenge that might be 
encountered during characterisation of these systems is to ascertain how the drug is actually 
dispersed within the carrier at the molecular level (Craig, 2002). In recent years there has 
been growing interest in advancing research towards new approaches to meet these 
challenges. Qi and co-workers have conducted appreciable research on the use of micro- and 
nano-characterisation methods to identify the physical state of the drug in the HME 
formulations, such as microthermal analysis (Qi et al., 2008a) and localized nanothermal 
analysis using atomic force microscope with a thermal probe, photothermal Fourier-
Transform infrared microspectroscopy (Qi et al., 2011) and solid state proton nuclear 
magnetic resonance (NMR) relaxometry (Qi et al., 2010). 
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However, it is customary to rely on the absence of crystallinity to indicate that the drug is 
molecularly dispersed. Analytical methods that have been used to characterise hot melt 
extrudates are summarized in Table 1.2. The characterisation of hot melt extrudate using 
these techniques reveals many important aspects like their solid state structure, 
thermodynamic properties and changes such as phase separation, crystallization and 
structural relaxation.  
 
Thermoanalytical and gravimetric methods Differential scanning calorimetry 
Hot stage microscopy 
Microthermal analysis 
Thermogravimetric analysis 
Dynamic vapour sorption 
Dissolution testing In vitro and in vivo 
X-ray diffraction Powder X-ray diffraction 
Small angle X-ray scattering 
Spectroscopic Methods Infrared, Near infrared and  
Raman spectroscopy  
Solid-state nuclear magnetic 
resonance 
Microscopic Methods Polarized light microscopy 
Scanning electron microscopy 
Transmission electron microscopy 
Atomic force microscopy 
 
Table 1.2: Common physical and analytical techniques used for the characterisation of 
hot melt extruded formulations (Kolter et al., 2010; Li et al., 2013) 
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1.2.5 HME for transdermal drug delivery  
 
Hot melt extrusion is a versatile technique that has proven useful in the design and 
reformulation of different pharmaceutical preparations for various purposes that include 
enhanced dissolution rate, improved bioavailability, modification or controlling of the drug 
release and taste masking of  the bitter taste active drugs (Madana and Madanb, 2012; 
Williams et al., 2010). Whilst the main focus is placed on the production of solid 
solution/dispersion systems to enhance drug delivery for oral route, the utility of HME has 
also been extended as an attractive technique to produce different drug delivery systems for 
topical, transdermal and parenteral applications. 
 
The majority of the transdermal drug patches are prepared by the solvent cast method, 
whereby the adhesive polymer solution is coated over a backing membrane, and is dried to 
remove the solvent. Afterwards, a release liner is laid on the top of the adhesive and is 
laminated (Delgado-Charro and Guy, 2001). However, HME technology is currently being 
explored and used in the pharmaceutical field to produce transungual (Mididoddi et al., 
2006; Trey et al., 2007), transmucosal (Munjal et al., 2006; Palem et al., 2013) and 
transdermal films (Breitenbach et al. 2009; Crowley et al., 2004; Crowley et al., 2009; 
Repka et al., 1999) because it offers several advantages over traditional processing methods 
(Prodduturi et al., 2007). In particular, it avoids the usage of organic or aqueous solvents, 
offers a short processing time with continuous processing of products, and eliminates 
environmental concerns (Aitken-Nichol et al., 1996). In addition, preparation of transdermal 
films in a single processing step makes it economic wise technique. HME has also been 
shown to overcome decreased elongation or elasticity and increased film tensile strength 
after physical aging of the films produced by solvent casting approach (Gutierrez-Rocca and 
McGinity, 1993; Repka et al., 1999). 
 
In the hot melt procedure the molten polymers are mixed with the active ingredient without 
the use of any solvents, that could be hazardous, and the melts are spread over a backing 
layer. These materials should be “benign”, such as generally recognized as safe substances 
to decrease the risk of possible skin irritation and/or sensitization (Barry, 2001). Generally, 
substances used with proven safety in oral route can be used for investigations for potential 
transdermal delivery (Hadgraft et al., 2000).  
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Table 1.3 lists some advantages of using continuous HME as reviewed by Wolff (2000) in 
production of transdermal drug delivery systems, wherein coating and laminating unit is 
attached to the die system to combine the melt extrusion films with substrate for transdermal 
applications to provide single continuous manufacturing process.   
 
Characteristics  Positive impact on 
Solvent and water-free method Manufacturing costs (less) 
Physicochemical long-term stability 
Biocompatibility 
Environmental Compatibility 
Continuous process Processing time (shortened) 
Scale-up  
Manufacturing costs (less) 
Compact, small-sized equipment Floor space requirements (less) 
Capital costs (less) 
Automated process, electronically  
controlled and continuously monitored 
on-line 
Batch control 
Manufacturing costs (less) 
Capability of die coating Product yield 
 
Table 1.3: Main advantages of utilizing HME process (continuous with laminating and 
coating unit) for the manufacture of transdermal drug delivery systems (Wolff, 2000) 
 
1.3 Transdermal drug delivery systems (TDDS) 
 
Being the most expansive organ of the human body, the skin has been used as an 
administration site for pharmaceuticals. The drugs can be introduced for local and systemic 
action through dermal and transdermal route, respectively. However, the concept of 
delivering drugs through the skin for systemic treatment has been challenged over the past 
few years. This is because the skin and more specifically, the skin’s outermost layer - the 
stratum corneum - forms the main barrier to diffusion of the permeants through the skin. On 
the one hand this provides a protective shield against the entry of foreign material and 
possible invasion of pathogens, and on the other hand, it limits the transport of drugs. 
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However, the skin offers a tempting criteria of a large (1-2 m2) and potential accessible 
surface for drug delivery. Moreover, transdermal applications, relative to other routes, 
provide a variety of advantages inherent in the transdermal route, including: elimination of 
gastrointestinal absorption problems and the hepatic first pass effect, reduction of the 
frequent dosing, predictable and extended duration of activity, improved patient compliance, 
quick termination by simple removal of the system from the skin surface, and possible self-
administration (Delgado-Charro and Guy, 2001). So drug delivery across the skin can 
achieve the main objectives of (Cevec and Vierl, 2010): 
 
• minimal invasiveness, or non invasiveness of an application; 
• improved drug pharmacokinetics; 
• targeted drug delivery. 
 
On the other hand, limitations of transdermal drug delivery are posed by the skin’s barrier 
function. The factors which limit the success of transdermal drug delivery systems (TDDS) 
can be summarized in the following points (Barichello et al., 2006): 
 
• Local skin irritation related to certain drugs and formulation. 
• Limitation of the dose of the drug that could be delivered transdermally. 
• The lag time associated with delivery of the drug across the skin; resulting in a delay 
in the onset of action.   
• Variation of absorption rate, based on the site of application, skin type and patient 
age. 
 
Ideally, potent drug molecules with low molecular weights (<600 Dalton), low melting 
points, which is usually correlated with good ideal solubility, high but balanced partition 
coefficient as too large value could inhibit clearance by viable tissues, and a good solubility 
in both mineral oil and water (greater than 1mg/ml) can satisfy the requirements of efficient 
transdermal delivery, through effective penetration across the stratum corneum (Barry, 2001; 
Kusum et al., 2003). Today, there is a wide spectrum of conditions where the treatment is 
achieved by the use of transdermal drug delivery. Motion sickness, nicotine drug patches for 
smokers, Parkinson’s disease, angina pectoris, and contraception are a few examples of these 
conditions.  
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1.3.1 Skin drug delivery: topical versus transdermal drug delivery systems 
 
Topical delivery is the term used for localized treatment of the dermatological condition 
where the medication is not targeted for systemic delivery; examples include treatment of 
dermatological conditions like eczema or psoriasis by topical application. Examples of drugs 
delivered topically include corticosteroids, antifungals, antivirals, antibiotics, antiseptics, 
local anesthetics, and antineoplastics. Whereas, the terms for topical formulations containing 
drugs showing systemic action are transdermal delivery systems or transdermal therapeutic 
systems. Transdermal delivery may be defined as the delivery of a drug across intact skin, in 
which a direct access into the blood stream is achieved with a sufficient therapeutic amount 
(Sugibayashi and Morimoto, 1994). Transdermal delivery systems are also termed ‘patches’. 
These are defined as a self-discrete dosage, loaded with a certain amount of the medicine 
(drug) and when applied onto the skin surface, a specific dose will be delivered to the 
systemic circulation over a period of time (Wokovich et al., 2006). Scopolamine, 
nitroglycerin, clonidine, esrtadiol, fentanyl, nicotine and testosterone are examples of active 
agents delivered transdermally. 
 
1.3.2 Skin structure and anatomy 
 
In order to understand the mode of transdermal drug delivery action it is important to 
address some physiological aspects of the skin that are related to drug delivery. The skin is 
the largest organ of our body and macroscopically consists of two distinct layers:  the dermis 
which forms the bulk of skin, and overlying it avascular epidermis. The dermis is a layer 
with a high vascular structure that is made up of connective tissue elements, and includes the 
pilosebaceous units, sweat glands, dermal adipose cells, mast cells, and infiltrating 
leuckocytes. The epidermis composed primarily of keratinocytes (Menon, 2002). The 
dermal-epidermal junction is highly convoluted ensuring a maximal contact area (Delgado-
Charro and Guy, 2001). The structure of human skin is portrayed in Figure 1.5. 
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Figure 1.5: Cross section of the skin, highlighting the epidermis, dermis, hypodermis 
and stratum corneum. Reproduced from www.omnimedicalsearch.com 
 
1.3.2.1 Epidermis 
 
The epidermis is the uppermost layer of the skin. Epidermis is stratified and about 100-150 
µm thick. It comprises four distinct layers, namely the stratum basale, stratum spinosum, 
stratum granulosum and stratum corneum (Kulkarni, 2010). As it is a non-vascularised 
tissue, it receives its nutrition by diffusion from the capillary system of the dermis. The 
keratinocytes comprise the major cellular component and are responsible for the evolution of 
the barrier function. 
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The stratum basale, or basal layer, is responsible for progressive renewal of the epidermis. 
The cells that result from the mitotic activity of these epidermal stem cells, the 
keratinocytes, migrate in the direction of the stratum corneum. The next layer of the 
epidermis is the stratum spinosum, where the high number of desmosomes that connect 
adjacent cells accounts for the spiny appearance of these cells. In this layer an increased 
synthesis of proteins and lipids takes place in the cells. The layer above the stratum 
spinosum, the stratum granulosom, contains flattened cells with keratohyalin granules. 
Lamellar bodies which contain stacks of lipid vesicles are concentrated in the upper part of 
the granular cells (Menon, 2002). Epidermal cells undergo extensive differentiation, starting 
from the highly proliferative basal layer, until they form the stratum corneum. 
 
1.3.2.1.1 Stratum corneum 
 
The stratum corneum, with its unique architecture, is often compared to a wall made of 
bricks and mortar as described by Peter Elias (1983). With the fully differentiated 
corneocytes comprising the bricks, embedded in the intercellular lipids, which represents the 
mortar. This outermost layer of the skin, where it plays a critical role in barrier function, is a 
heterogeneous non-living structure, formed by keratinized cells, protein-rich cells, and 
intercellular lipid layers. The phospholipids are absent in the stratum corneum, wherein they 
are the usual components of the membrane of living cells. The lipids form bi-layers and their 
acyl chains can exist as gel and as liquid crystalline states. The transition between these two 
states occurs at certain temperatures, without loss of the bilayer structure (Curatolo, 1987). 
The principal lipids of the stratum corneum are ceramide, free fatty acids and cholesterol 
(Elias, 1991). The non-polar lipids are saturated, and the membrane structures formed by 
these lipids are less permeable than a typical plasma membrane, thus providing a formidable 
barrier to the diffusion of drug molecules (Ghosh and Jasti, 2005). Thus, the barrier function 
of stratum is usually linked directly to its structure and composition, which is highly 
organized and predominantly lipophilic (Delgado-Charro and Guy, 2001). Stratum corneum 
is covered by a thin film called “acid-mantle”, due to its acidic pH in the range between 4.2-
5.6, which is believed to result from lactic acid and carboxylic amino acids in sebaceous and 
eccrine sweat glands secretions (Washington et al., 2003). Therefore, the surface of the skin 
pH is around 5 (Hadgraft et al., 2000). 
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1.3.2.2 Dermis 
 
The dermis, the thickest skin layer, is mainly comprised of connective tissues that provide 
support for the epidermis and other appendageal structures, specifically the hair follicles and 
sweat glands (Menon, 2002). This layer incorporates blood and lymphatic vessels, where the 
resorption of the drugs that passed across the epidermis can take place. It therefore 
represents the access point for molecules transdermally absorbed to the systemic circulation 
(Flynn and Stewart, 1988). The hypodermis is the innermost layer of the skin and provides 
its thermal insulation. It consists of the subcutaneous tissue filled with fat cells, fibroblasts 
and macrophages (Kulkarni, 2010). 
 
1.3.3 Absorption pathways 
 
A drug can penetrate through the skin, before it reaches the systemic circulation, by 
transcellular route (across the cells), intercellular route (between the cells), or through 
“shunt” pathways across the skin provided by appendageal structures, such as hair follicles 
and sebaceous glands (Barry, 2001). However, these skin appendages occupy only ~0.1% of 
the total human skin surface, thus the contribution of this pathway is usually considered to 
be small, though it is important for transportation of polar molecules and peptides. In 
contrast, the transcellular pathway represents the major route for drug transport (Aulton, 
2007). Consequently, the lipid solubility of a molecule is vital for its transdermal delivery, 
since the extracellular space is concentrated with lipids. The different pathways of drug 
transport through the skin are shown in Figure 1.6.  
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Figure 1.6: Illustration of the possible pathways of molecules’ permeation throughout 
the skin (transverse section view). Reproduced from www.cdc.gov 
 
1.3.4 Transdermal drug delivery system design 
 
Simple passive transdermal systems are often known as ‘patches’ which are diversely 
referred to as a matrix system, a reservoir system, or a drug-in-adhesive system. The 
classification is usually based on the components and fabrication of the systems. In general, 
reservoir systems composed of the medicine in a liquid, high volatile solvent that facilitates 
drug permeation after applying to the skin. Whereas the drug-in-adhesive or matrix systems 
do not employ these volatile solvents. Instead, they use absorption enhancers that do not 
volatilize during the preparation process and would be solubilised with the components in 
the matrix (Grawe et al., 2005). Reservoir systems are multi-layered systems and usually not 
cost effective to produce due to its complicated architecture (Stricker, 1983). The matrix 
systems are simplest in concept, consisting only of a layer of the drug that may be embedded 
in the adhesive matrix (monolithic). Owing to its simplicity, it is the most commonly form of 
transdermal/transmucosal systems (Prodduturi et al., 2007). However, the main structural 
elements of transdermal patches are common to all transdermal system designs, and these 
elements as shown in Figure 1.7 are (Buskirk et al., 1997): 
 
• Backing material: the layer that provides integrity to the system. 
• Drug layer or reservoir: the layer or layers which contain the drug substance. 
• Protective liner (release liner): a removable film that protects the adhesive layer 
while the system is in the package. 
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• Adhesive system: materials (adhesives) that adheres the system to the skin or 
various layers in the transdermal system to each other. 
 
 
 
Figure 1.7: Common structural elements of simple transdermal drug delivery system 
(Scheindlin, 2004) 
 
In order to design a transdermal drug delivery system (TDDS), an understanding of the 
manufacturing attributes, as well as variables present in the formulation components of the 
product is important, because these factors may affect the reproducibility of release of the 
active drug substance to the stratum corneum and epidermis. This includes changes in the 
formulation composition involving adhesives, solvents, viscosity modifying agents that may 
have a significant effect on drug release. Therefore, adjustment in the levels of the patches’ 
components may be made in order to maintain proper drug release and/or product 
adhesion/wear characteristics while minimizing irritation. Adhesion in TDDS is of prime 
importance to the safety, efficacy and quality of these systems. For example, poor or lack 
adhesion can result in improper dosing of patients while fallen patches can be picked up by 
children with a risk of accidental dosing (Wokovich et al., 2006). 
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Proper design of the delivery system can also influence positively the control of the plasma 
profile of administered drugs, especially those which have a short half-life or a high 
elimination rate constant. In general, the main measures that control active substance 
permeation across the skin from a transdermal patch are (Grawe et al., 2005): 
  
• Particle size of the active substance-polymer. 
• Active substance concentration and thermodynamic activity.  
• Release surface area of the transdermal system. 
• Solubility of the active substance in the polymer. 
• Interaction of the active substance-polymer with the adsorbate water from the skin. 
• Crystallinity of the active substance in the polymer. 
 
Several techniques and tools have been developed to enhance the transdermal absorption of 
drugs. In general, they can be classified into two types. The first type is formulation-
oriented. In this approach, efficient permeation across the skin can be attained through 
proper selection of the drug and optimization of the type and/or amount of the carrier 
system. The second type is skin barrier function-oriented. There are two approaches of this 
type. The first one modifies the barrier properties of the skin using chemical enhancers or 
physical stimuli such as an electric pulse or ultrasound. Significant skin toxicity or irritancy 
sometimes limits the use of these techniques for clinical applications. The second approach 
utilizes the modification of the thermodynamic activity of drug molecules in the vehicle used 
to deliver the drug. This does not require physicochemical alteration of the skin barrier, and 
therefore will be safer than the former one. A method using supersaturation may be 
categorized in the second type. In a supersaturated system, the drug molecules are dispersed 
in a vehicle at a level greater than its solubility inside this matrix or vehicle, resulting in 
temporarily high thermodynamic activity thereby leading to high skin permeability (Inoue et 
al., 2005).  
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1.3.4.1 Permeation through the stratum corneum and its enhancement 
 
Drug molecules released from a transdermal delivery system first partition into the stratum 
corneum, then diffuse into the lower layer of the skin and are finally transported into the 
blood stream. The drug concentration in the plasma after transdermal delivery is determined 
by the balance between the permeation rate across the skin (input) and the elimination/ 
distribution rate in the body (Tojo, 1988). The thickness of the human stratum corneum, and 
the distance from the skin surface to the microcirculation, are 10-20 µm and 150-200 µm, 
respectively. Most drugs will penetrate the skin approximately proportionally to the 
concentration gradient between the upper and the lower side of the skin (Schaefer et al., 
1982). 
 
The basis for diffusion through membranes, such as the skin, is best described by Fick’s 
diffusion law. According to this law, permeation through membranes is determined by the 
concentration gradient of the diffusing substance along the cross section of the membrane. 
Thus, the flux ‘J’ of a drug through the stratum corneum is given in the following equation:  
 
J= (DmCs,m/L) . (Cv/Cs,v)                                                                                    (Eq.1.1) 
 
where Dm represents the diffusion coefficient of the drug in the membrane, Cs,m its solubility 
in the membrane, L the diffusion path length across the membrane, Cv the concentration of 
the drug dissolved in the vehicle and Cs,v  the solubility of the drug in the vehicle (Moser et 
al. ,2001). One of the strategies which may be postulated to improve permeation, based on 
this law, is via increasing the ratio Cv/Cs,v, i.e. the degree of saturation of the drug in the 
vehicle (the supersaturation approach). Supersaturated systems enhance the diffusive driving 
force for the drug delivery due to high thermodynamic activity or chemical potential of these 
systems. However, drug recrystallization from these metastable formulations makes this 
relationship short-lived.  
 
A permeation enhancer can also be used with the general recognition that an ideal 
permeation enhancer will be pharmacologically inert and devoid of any toxicity or irritancy 
to the skin with reversible action (Escobar-Chávez, 2010). But it is unlikely that any 
enhancer will be found that has all of these properties, and compromises will have to be 
made. Water is perhaps the ideal enhancer. Hydrated skin is generally more permeable, due 
to the decreasing cohesive strength of the stratum corneum (Hadgraft, 1999). Common 
enhancers are usually lipophilic, low-volatile liquids such as fatty esters, medium or long-
chain alcohols, emulsifiers, and terpenes. These additives generally improve skin resorption 
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properties (Horstmann et al., 1998), and their actions are mainly based on disturbing the lipid 
double-layers of the stratum corneum and weaken its diffusion-resistance structures.  
 
Ethanol, for example, is frequently used in many transdermal systems as a permeation 
enhancer. The most common mechanisms proposed for its penetration enhancing activity 
involve increase of the drug solubility in the used vehicle (Pershing et al., 1990), in the 
stratum corneum (Megrab et al., 1995b) and may also (at high concentrations or prolong 
exposure) disrupt stratum corneum through extraction of its lipids (Morrow et al., 2007; 
Williams and Barry, 2004). Another example is fatty acids, such as oleic acid and lauric 
acid, which have been used to enhance the permeation of hydrophilic and lipophilic 
molecules by inducing defects and disordering the lipid structure of the stratum corneum 
(Benson, 2005). 
 
1.3.4.1.1 Hydration as a skin absorption accelerator  
 
Normally the stratum corneum has a water content of approximately 20%, which lies 
primarily in the keratin layers between the horny cells (Repka and McGinity, 2001). The 
water content of the stratum corneum may attain equilibrium with the underlying tissues 
when the skin is soaked in water, exposed to higher humidity, or occluded without 
maceration. It is commonly believed that increased tissue hydration improves skin 
penetration of both hydrophilic and lipophilic drugs (Williams and Barry, 2004).   
 
The mechanism by which water enhances transdermal permeation is not yet fully 
understood. One proposed mechanism stated that the high water content due to occlusion 
might hydrate the polar head groups of the bilayer, causing them to swell and disrupt the 
lipid domains. Therefore, the stratum corneum becomes disorganized and less cohesive, and 
hence more permeable (Warner et al., 1999). In another embodiment, lacunar domains 
embedded in the stratum corneum might expand laterally, interconnect and form continuous 
pore pathway at sites of desomsomal dissolution (Elias et al., 2002). This might enhance 
transdermal drug delivery. Finally, water within the tissue that could exist under excessive 
hydration as a result of prolonged occlusion, for instance, would alter the solubility of the 
permeants in the stratum corneum and modify their skin partitioning (Benson, 2005).  
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1.4 Research objectives 
 
In pharmaceutical research there is a strong interest towards finding a novel formulation 
strategy that can synergize the concept of simplicity, safety and enhanced release program 
for transdermal applications. Therefore the aim of this thesis was to explore the concept of 
using hydration from the skin as a trigger for drug release from transdermal patches 
produced using hot melt extrusion. In this context, this work attempts to develop approaches 
to comprehensively characterise, understand and evaluate the formulated extruded 
transdermal patches, wherein described design issues such as carrier/drug optimization and 
understanding of the hydration influence as a modifying technique were discussed. Different 
methods and tools were employed for these investigations and ibuprofen was used as the 
model pharmaceutical drug throughout this work. General objectives were: 
 
• Prediction of drug-carrier miscibility and determination of processing parameters for 
hot melt extrusion. The aim was to realize adequate HME processing to form solid 
solutions or dispersions where the drug remains miscible to boost the efficiency of 
these systems for longer. This work was mainly described in Chapter 4 and Chapter 
6. 
 
• To characterise and understand the physicochemical properties, in vitro drug release 
and in vitro permeation behaviour associated with the developed melt embeddings’ 
patches in this study. The aim was to screen their potential for transdermal 
development. This work was detailed throughout the thesis. 
 
• To modify the carrier system for improved drug release through variation of the type 
and amount of the materials incorporated in the assessed formulations .This work 
was described in Chapter 6. 
 
• To examine the relationship between modified hot melt extruded products and 
hydration. The aim was to assess the hydration influence as a favourable approach to 
enhance permeation profiles in vitro. This work was outlined in Chapter 6, and led 
to the assessment of the most promising platform formulations.  
 
• To evaluate the potential of the carrier systems of the promising platform extruded 
formulations to become a novel approach of transdermal drug delivery under the 
influence of hydration in vitro and in vivo. This work was described in Chapter 7 
and Chapter 8. 
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2.1 Materials 
 
In order to explain the selection of the materials used to formulate extruded films in this 
work, a theoretical background is provided in this section, which in turn is subdivided into 
three parts that deal with the used model drug (section 2.1.1), carrier excipients (section 
2.1.2) and then the source of these materials (section 2.1.3). 
 
2.1.1 Model drug 
 
Ibuprofen is one of the most commonly used non-steroidal anti-inflammatory agents 
(NSAIDs). Due to its many interesting physicochemical and biochemical properties, 
ibuprofen is used regularly as a model drug (Cano et al., 2001). In this work, ibuprofen was 
also selected as a model drug. The following sections will attempt to review its main 
properties and the factors which led to its choice.  
 
2.1.1.1 Description 
 
Ibuprofen [2-(4-isobutyl-phenyl) propionic acid] molecule with an empirical formula 
C13H18O2 and a structural formula presented in Figure 2.1 has a molecular weight of 206.28 
and it is hydrophobic in nature. Its octanol-water distribution coefficient gave log D values 
of 3.7, 3.6, 2.1 and 1.2 at pH values of 1, 4, 6 and 7, respectively (Higgins et al., 2001). A 
partition coefficient (log P (n-octanol/water)) value was reported in the range between 3.51 -
3.72 (Hadgraft et al., 2000). Ibuprofen is a Biopharmaceutics Classification System (BCS) 
Class II drug, which has high permeability and pH-dependent solubility (Potthast et al., 
2005). Ibuprofen is a relatively weak organic acid with a pKa of 4.55 (Fini et al., 1995). This 
drug exists in the form of white or almost white, crystalline powder or colourless crystals. 
Ibuprofen has a melting point between 75-78°C and it is practically insoluble in water, freely 
soluble in acetone, methanol and in methylene chloride (British Pharmacopoeia 
Commission, 2011). 
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Figure 2.1: Chemical structure of ibuprofen 
 
2.1.1.2 Medical rationale 
 
Ibuprofen has two enantiomers S (+) and R (-). The pharmacodynamic activity resides 
mostly in the dextrorotatory isomer, with (S) configuration (Shen, 1972). Nevertheless, R (-) 
ibuprofen has been found to undergo extensive inversion into active S (+) upon metabolism 
(Oliary et al., 2005). However, the racemic mixture of the two enantiomers is usually used. 
Having analgesic, anti-inflammatory and antipyretic activity (Sheth et al., 1980), ibuprofen 
has been used widely as analgesic and antirheumatic drug. Moreover, its proven efficacy and 
tolerability make it “the drug of choice” for treatment of many mild to moderate painful 
conditions, such as pain associated with headache, migraine and dysmenorrhoea, as well as, 
management and treatment of osteoarthritis and rheumatoid arthritis and other muscle-
skeletal disorders (Rasenack and Müller, 2002; Valle-Jones et al., 1984). 
 
2.1.1.3 Selection of ibuprofen 
 
Despite being categorized as one of the safest NSAIDs available (Potthast et al., 2005), 
ibuprofen may produce gastrointestinal tract (GIT) adverse effects if administered orally. In 
addition to that, the short plasma half-life of almost 2.0±0.5 hours (Mäkelä et al., 1981; 
Davis, 1998) following the oral dosing requires frequent administration to maintain the 
desired steady state levels. With such frequent dosing regimens, patient compliance was 
found to be fairly poor (Sarkar et al., 1988). Therefore introduction of new NSAIDs or 
changing the route of administration to approaches such as the transdermal route would 
overcome these problems, through avoiding GIT pathway and to decrease the dose 
frequency using retard transdermal dosage form, thus a sustained and constant drug levels 
can be attained. Moreover, hepatic first-pass metabolism would be avoided using this route. 
However, the high doses (200-800 mg every 4-6 hours) needed to deliver therapeutic 
amounts of this drug is considered one of the main challenges to deliver it across skin. 
Materials and General methods 
Chapter 2 
 
70 
 
Hence, a novel strategy is required to improve its transport via transdermal route in enough 
amounts.  
 
As detailed in Chapter 1, for a drug to be successfully delivered into the blood stream 
transdermally, many requirements have to be fulfilled. As shown in Table 2.1, ibuprofen has 
many of the favourable properties that can be utilized to capture the benefits of its use in 
transdermal dosage forms, such as transdermal patches. In addition to that, Castelli et al. 
(2003) proposed ibuprofen ability to work as a lipid “fluidiser”, which is attributed to 
ibuprofen surface active properties (Fini et al, 1995), leading to its “self-permeation” and 
even permeation enhancement of other drugs across the skin as found by Al-Saidan (2004). 
 
Molecular property  aIdeal drug Ibuprofen 
Molecular weight (D) <400 206.28 
Melting point (°C) <200 b75-78 
Partition coefficient (logP(o/w)) Between-1.0 and 4 c 3.51-3.72 
Permeability coefficient (cm/h) >0.5x10-3 c4.36x10-2 
 
Table 2.1: Physicochemical properties of the ideal drug candidate for transdermal 
administration in comparison to the ibuprofen properties. a (Ghosh and Jasti, 2005),  
 
b
 (British Pharmacopoeia Commission, 2011), c (Hadgraft et al., 2000) 
 
It is worth to mention that since ibuprofen contains carboxylic acid, it can dissociate 
depending on the pH of the site of action and its pKa. Though unionized entities are 
suggested to be the main species that can pass readily across the lipid membrane (Aulton, 
2007), it has been found that ionized molecules of ibuprofen and other NSAIDs can also 
permeate effectively due to enhanced solubility which is directly related to the maximum 
flux into the skin (Hadgraft et al., 2000). Thus, it can be concluded that ibuprofen with all 
aforementioned features can be chosen for a potential delivery using transdermal route that 
can circumvent problems associated with its oral delivery. 
 
Several commercially available topical formulations contain ibuprofen, such as Ibuspray, 
Deep Relief Gel. However, the preparation of transdermal formulations containing ibuprofen 
is still growing. More recently, Strategic Science & Technologies, LLC (SST) has developed 
a method to successfully deliver ibuprofen transdermally. This product had the New Drug 
Application approval and it is in Phase III trials (http//www.ebdgroup.com, 2012).  
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Patches as transdermal drug delivery system are commonly prepared using the solvent 
casting method. Because of the low aqueous solubility of ibuprofen, the mode of preparation 
using this method necessitates the use of organic solvents. This is associated with 
environmental concerns, increased expenses and residual solvents that could elicit skin 
irritation. Therefore, it would be useful to develop these transdermal systems using another 
approach, such as hot melt extrusion (HME). As detailed in Chapter 1, HME is a solvent free 
method and, alongside other advantages, it has been used extensively in the recent years to 
disperse poorly water soluble drugs in polymers for enhanced delivery. The selection of 
ibuprofen in this study for processing via HME is also of particular interest. This drug can 
act as a plasticizer during processing (Kidokoro et al., 2001; Siepmann et al., 2006). Thus, 
association of plasticizing effect which can improve the processability, flexibility and 
elasticity of polymers and the active moiety in one agent i.e. ibuprofen, will limit possible 
side effects that could result otherwise from usage of many excipients for formulations 
intended for transdermal delivery. Therefore, ibuprofen is an ideal drug for evaluating the 
efficiency of extruded formulations for transdermal drug delivery designed as patches. 
 
2.1.2 Carrier excipients 
 
Several excipients in this section are described, wherein Eudragit RS PO was used as a basic 
component in the extruded formulations. Other excipients were chosen to tailor the release 
of ibuprofen from Eudragit RS PO extruded matrices as will be detailed in Chapter 6, with 
the aim to obtain delivery systems well accepted by the skin. Thermal stability for extrusion 
and physical characteristics of these materials will be evaluated in Chapter 3.   
 
2.1.2.1 Eudragit RS PO 
 
Eudragit RS is one type of the well known biocompatible polymethacrylate polymers 
(Josephine et al., 2011). Eudragit RS is a copolymer synthesized from acrylic acid and 
methacrylic acid esters with 5% of functional quaternary ammonium groups (Rowe et al., 
2009). The structural formula of this polymer is depicted in Figure 2.2. This cationic acrylic 
copolymer (Type B) is water insoluble (Perumal et al., 1999), yet able to swell and become 
permeable to solutes, due to the presence of the ionized hydrophilic ammonium groups 
(Pignatello et al., 2004). However, the presence of the ammonium groups as salts makes it 
permeable in a pH-independent manner (Rowe et al., 2009). Eudragit RS PO is the powder 
form of this polymer, which occurs as a fine white powder with amine-like odor. Eudragit 
RS PO is a glassy polymer with glass transition temperature of about 50-55°C (Fujimori et 
al. 2005; Kidokoro et al., 2001). The main feature of a glassy polymer is the transition from 
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largely brittle glassy behaviour at low temperature to a rubbery or viscoelastic state at high 
temperature. This polymer has been widely used in pharmaceutical delivery systems for 
sustained drug delivery (Oth and Moës, 1989), hot melt extrusion (Wu and McGinity, 2003), 
micro-encapsulation (Perumal, 2001), nanoparticles (Adibkia et al., 2011; Lopedota et al., 
2009), antiretroviral drug delivery (Khan et al., 2008), colon delivery (Kaur and Kim, 2009). 
It has also been used in transdermal drug delivery (Cilurzo et al., 2006; Gohel and Nagori, 
2009; Kusum et al., 2003), thanks to its biocompatibility and biological safety (Fujimori et 
al. 2005). 
 
 
 
Figure 2.2: Eudragit RS PO chemical structure (eudragit.evonik.com) 
 
As Eudragits are approved pharmaceutical materials for hot melt extrusion (Andrews et al., 
2009) and being described in the context of skin application with no known toxicity, 
Eudragit RS PO represents a good choice for preparation of the transdermal systems using 
hot melt extrusion. Moreover, its ability to provide sustained release depending on the 
applied concentration (Rapolu et al., 2012), Eudragit RS can provide appropriate dosing 
input for short-lived drugs as ibuprofen. However, it is worth mentioning that for ibuprofen, 
the design of formulation depends on the indication. For example, rapid release is required 
for acute onset pain, but rheumatoid arthritis treatment might require slow sustained release 
pattern to drive patient compliance of less frequent dosing. The relatively high viscosity of 
Eudragit RS (Kim et al., 2002) might contribute to enhance dispersive mixing during the 
extrusion as suggested by Kolter et al. (2010), especially when combined with a plasticizer 
such as ibuprofen to enhance processability during extrusion. Therefore, all these features 
might explain why Eudragit RS PO could be adequate parent polymer, used basically in this 
work as a vehicle or carrier for potential transdermal delivery of ibuprofen formulated by 
HME technology. 
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2.1.2.2 Sucrose 
 
Beet sugar or sucrose is β-D-fructofuranosyl-α-D-glucopyranoside with a chemical structure 
shown in Figure 2.3. It is one of the most widely used pharmaceutical excipients for oral 
formulations and generally considered as a safe material (Rowe et al., 2009). In skin 
preparations, this sugar has been used in both topical formulations (Repka et al., 2002) and 
wound dressings (Knutson et al., 1981). Utilizing the known ability of carbohydrate sugar 
carriers to enhance wettability of the drugs due to their polar heads (Das et al., 2011; 
Saharan et al., 2009), and because of its general safety in addition to availability and low 
cost (Polat and Linhardt, 2001), crystalline sucrose has been used in this work.  
 
 
 
Figure 2.3: Structural formula of sucrose (Rowe et al., 2009) 
 
2.1.2.3 Methyl cellulose 
 
Methyl cellulose (MC) is derived from cellulose in which the hydroxyl groups are 
substituted with methyl ether with different degrees (Kazuto et al., 1999). The grade used in 
this study (Methocel A4C Premium MC) has approximately 27.5 to 31.5 % methoxyl, 
yielding good water solubility (Colorcon, 2009), which occurs as white to off-white color 
powder. The structure of this polymer is presented in Figure 2.4. This water-soluble polymer 
is generally regarded as non-toxic, non-allergenic and non-irritant material that is widely 
used in oral, topical formulations (Rowe et al., 2009) and transdermal systems (Edwards, 
1998; Grawe et al., 2005). Due to the hydrophilicity of this polymer and its tolerable 
immunological properties, this polymer was investigated as an adjuvant that is capable of 
modulating release properties of the studied patches for potential transdermal application.  
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Figure 2.4: Structural formula of methylcellulose. R=CH3 or H (Kazuto et al., 1999) 
 
2.1.2.4 Xantural®75 
 
Xantural®75 is a cream colored free flowing fine powder with particle size of approximately 
75µm of xanthan gum (CPKelco, 2003). Xanthan gum is a natural gum obtained by 
microbial fermentation with Xanthomonas campestris. The term “gum” usually refers to a 
group of industrially useful polysaccharides (glycans) or their derivatives. Xanthan gum is a 
polysaccharide consisting D-glucose and D-mannose as the dominant hexose units, along 
with D-glucuronic acid which gives this polymer a negative charge (anionic material), and is 
prepared as sodium, potassium, or calcium salt (Zohuriaan and Shokrolahi, 2004). The 
structural formula is illustrated in Figure 2.5. 
 
As a hydrophilic polymer, xanthan gum can be used to tailor the drug release profile. This 
polymer can display a high degree of swelling due water uptake, polymer relaxation and 
possibility of pore formation which could contribute to the drug release (Mundargi et al., 
2007; Munday and Cox, 2000; Verhoeven et al., 2006). Xanthan gum is a non-toxic, 
biocompatible material which does not show any skin irritating or allergenic effect in rabbits 
or guinea pigs, respectively, following skin exposure (Rowe et al., 2009). It has been 
described in transdermal applications (Dezfuli et al., 2012; Masiz et al., 1998) and hot melt 
extruded formulations (Fukuda et al., 2006; Verhoeven et al., 2006). 
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Figure 2.5: Structural formula of xanthan gum (Rowe et al., 2009) 
 
2.1.2.5 Pluronic® F127 
 
Pluronic® F127 or poloxamer 407 is a non-ionic tri-block copolymer of polyoxyethylene 
(PEO)-polyoxypropylene (PPO)-polyoxyethylene (PEO) (Moore et al., 2000). It occurs as 
white, waxy, free-flowing flakes with a structural formula presented in Figure 2.6. It is the 
least toxic grade of the commercially available poloxamers (Hatefi and Amsden, 2002). This 
semi-crystalline polymer is believed to have crystalline domains of PEO and amorphous 
segments of PPO (Smithey et al., 2007; Yin et al., 2005). While the polyoxyethylene 
segments are hydrophilic, the polyoxypropylene segments are hydrophobic, giving rise to its 
amphiphilic character with HLB value of 22 (Cunha-Filho et al., 2012). Poloxamers are used 
as solubilising agents and vehicles for drug delivery systems and has been described in 
topical and transdermal systems, owing to their non-irritating and non-sensitising properties 
(Chi et al., 1996, Escobar- Chávez et al., 2006). 
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Figure 2.6: Structural formula of Pluronic® F127, a=101, b=56 (Rowe et al., 2009) 
 
2.1.2.6 Gelucire 44/14 
 
Gelucire 44/14 is a GRAS material that has been used for many years in oral delivery 
systems which belongs to the Lauroyl polyoxylglycerides (macroglycerides) family. It 
consists of a mixture of monoesters, diesters and triesters of glycerol, and monoesters and 
diesters of polyethylene glycols (Rowe et al., 2009). Gelucire 44/14 is manufactured by 
Gattefossé SA, Saint Priest, France, from the reaction of hydrogenated palm kernel oil with 
polyethylene glycol (PEG) 1500 or PEG 33. Its composition, thereof, is approximately: 20% 
mono-, di-, and triglycerides, 72% mono- and di-fatty acid esters of PEG 1500 and 8% free 
PEG 1500 (Gattefossé, 2000). The fatty acid distribution of this amphiphilic excipient is 
shown in Table 2.2. Gelucire 44/14 is inert semi-solid which occurs as a white to pale-
yellow waxy material. Gelucire 44/14 is mainly crystalline with less than 17% amorphous 
regions and some liquid glycerol (Svensson et al, 2004). It is identified by two values: a 
nominal melting point of approximately 44°C and the HLB (Hydrophilic-Lipophilic 
Balance) value of 14. It is surface active excipient (Kawakami et al. 2004), water-soluble 
(Ahuja et al., 2007), which does not absorb moisture or show limited water uptake at 
humidity levels below 80%RH, at room temperature (Gattefossé, 2000). This is thought to 
be brought about by assuming that each component of Gelucire 44/14 absorbs water 
independently. Thus, at low relative humidity levels up to 70%RH, a small amount will be 
absorbed corresponding to the low amount of liquid glycerol, followed by surge water 
uptake by PEG33 and PEG esters at RH values above 70% and 80%, respectively (Svensson 
et al., 2004). 
 
Because of its useful properties such as solubilising ability (Karatas et al., 2005; Kawakami 
et al., 2004), self-emulsifying properties (Chambin et al., 2004; Kale and Patravale, 2008; 
Kallakunta et al., 2013; Rowe at al., 2009), Gelucire 44/14 had a numerous pharmaceutical 
applications, such as improved drug release (Antunes et al., 2013) and bioavailability 
enhancement (Barker et al., 2003; Kale and Patravale, 2008; Yüksel et al., 2003). It has been 
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used to a limited extent for topical delivery (Li, et al., 2008; Mandawgade and Patravale, 
2008; Nicholas, and John, 2003) and there are no reports that we are aware of regarding any 
irritation or toxicity associated with application to the skin.   
 
Fatty acid distribution Percentage in Gelucire 44/14 
Caprylic acid (C8) 4-10 
Capric acid(C10) 3-9 
Lauric acid(C12) 40-50 
Myristic acid(C14) 14-24 
Palmitic acid(C16) 4-14 
Stearic acid(C18) 5-15 
 
Table 2.2: Fatty acid distribution in Gelucire 44/14 (Chambin et al., 2004) 
 
2.1.3 Sourcing of the used materials 
 
Model drug Ibuprofen Ibuprofen 25 US Quality 
Lot No.: IB1T0513 
BASF company 
Carrier excipients Eudragit RS PO Lot No.: G091038159 
Evonik Röhm Pharma polymers  
 Sucrose Lot No.: 0001434877 
SIGMA Life Science 
Sigma-Aldrich.com 
 Methylcellulose 
 
METHOCEL A4C PREMIUM  
Lot No.: DT319838 
Colorcon company 
 Xantural®75 Lot No.: 6g2349K 
CPkelco (A Huber Company) 
 Pluronic® F127 Lot No.:027K0033 
Sigma-Aldrich, BASF 
 Gelucire 44/14 Lot No.: 105656 
Gattefossé SA, Saint Priest, France 
 
Table 2.3: Materials’ sourcing  
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2.2 Methods 
 
An overview of the various experimental techniques used throughout this study is covered in 
this section. However, the methods used to assess in vitro release and in vitro permeation of 
the drug from the extruded formulations were detailed and described during corresponding 
chapter.  
 
2.2.1 Preparation of hot melt extruded transdermal patches 
 
Transdermal drug delivery systems as patches can be prepared by either solvent casting 
method or by hot melt extrusion technology. As detailed in Chapter 1, though solvent 
casting is widely used to produce these systems, doubts arise over its high costs, long 
processing times, environmental concerns and residual solvent that may cause some skin 
irritation (Aitken-Nichol et al., 1996). Hot melt extrusion method appears to overcome these 
problems and has found its place in pharmaceutical field for numerous applications such as 
production of topical and transdermal films (Breitenbach et al. 2009; Crowley et al., 2004; 
Crowley et al., 2009; Mididoddi et al., 2006; Repka et al., 1999 ;Trey et al., 2007). 
 
The hot melt extrusion method chosen in this work depends on the drug and the carrier 
excipients involved, hence the employed parameters might vary and will be discussed in 
Chapter 4 and 6. However, in a generic and basic sense this process involved the following 
steps: (a) Mixing of the drug and carrier excipients to form a powder blend. (b) Heating the 
barrel at the set temperature and determine the speed for screws’ rotation. (c) Feeding the 
extruder by the powder blend through a hopper. (d) Flushing the melt through a die after 
being cycled for appropriate time (residence time inside the extruder) to ensure good mixing. 
(e) Collecting the product (extrudate) from the outlet along customized conveyor belt, spread 
over a backing layer, such as aluminium foil, and to allow for cooling at room temperature. 
(f) Cutting the extrudate into the desired dimensions. In this work, the extrusion was 
performed using a co-rotating twin-screw extruder (Haake Minilab II Micro Compounder, 
Thermo Scientific), shown in Figure 2.7. This type of extruders is considered the most 
important type in industry, due to its ability to perform at high rotation speeds, allowing high 
outputs yet keeping good mixing and conveying properties (Kolter et al., 2010). For purging 
purposes before the production of each individual batch, a cleaning polymer (Asaclean U, 
Evonik industrial, Lot No. 07813) was fed into the extruder at 180°C and circulated for ten 
minutes as recommended by the manufacturer. 
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Figure 2.7: Thermo Scientific Haake Minilab II Micro Compounder. Insert showing 
magnification of the melting zone with twin screw assembly. Reproduced from 
www.thermo.com 
 
2.2.2 Characterisation methods used for the evaluation of hot melt extruded 
formulations for transdermal delivery   
 
2.2.2.1 Thermoanalytical techniques 
 
Thermoanalytical techniques are used to explore a range of chemical and physical 
properties. From pharmaceutical perspective, these techniques have been used extensively to 
characterise pharmaceutical materials from phase transitions to drug-excipient compatibility, 
in addition to the prediction of long-term behaviour such as physical stability (Craig and 
Reading, 2007). The findings of each technique are a valuable source of information; 
however, it is often more useful to have more than one technique to complete or confirm the 
characterisation of the material. In this work, differential scanning calorimetry (DSC) was 
used in its conventional and modulated modes, in addition to thermogravimetric analysis 
(TGA) and hot stage microscopy (HSM) techniques. 
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2.2.2.1.1 Differential scanning calorimetry (DSC) 
 
2.2.2.1.1.1 Basic principle and instrumentation 
 
Differential scanning calorimetry is a technique that measures the change of the difference in 
the heat flow to the sample and to a reference sample, as a function of time and temperature, 
while they are subjected to a controlled program in a specified temperature, time and 
atmosphere (Höhne et al., 1996), providing detailed information about both physical and 
energetic properties of a substance (Clas et al., 1999). There are two commercially available 
types of DSC operating systems: heat flux and power compensation. In brief, heat flux DSC 
performs using a single furnace, heat flows into two identical platforms, one contains the 
sample pan and the second for an empty reference pan. Thermocouples are positioned 
beneath the platforms in a back-to-back arrangement to measure the temperature difference 
between the sample and the reference as a function of the voltage developed from the 
thermocouples, allowing measurements of the heat flow. On the other hand, power 
compensation DSC has two individual furnaces, one for the sample pan and the second for 
an empty reference pan. The temperature difference between the sample and the reference is 
compensated for by varying the electrical power supplied to the two furnaces. Therefore, in 
this case heat flow is derived from direct measurements of electrical power required to 
sustain the heating of the two pans at a constant temperature.  
 
The TA Instruments DSC used during this thesis operated by heat flux and a basic schematic 
is shown in Figure 2.8. During DSC experiment the measurement of the differential heat 
flow can be explained by Ohm’s Law as follows:  
  = 	 																																																																																																				(Eq.2.1) 	   
where Q = heat, t = time, (dQ/dt represents the heat flow), ∆T = temperature difference 
between sample and reference and R is the thermal resistance in the heat flow path between 
the furnace and the pan (Craig and Reading, 2007). The reference pan is essential to 
eliminate influences that might affect the differential heat flow, such as the heat adsorption 
by the pan, allowing better measurements of the material properties. Furthermore, the ∆T 
signal requires calibration using high purity calibration standards to ensure that heat flow is 
a function of temperature as will be discussed in the following section.  
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Heat capacity of the studied material (Cp) determines the heat flow signal during the 
experiment, thus a DSC signal can be expressed as: 
  = 	
	  																																																																																														(Eq.2.2)		   
where dQ/dt represents the heat flow, dT/dt represents  the heating rate and Cp is the heat 
capacity defined as the amount of heat required to raise the temperature of one gram of the 
material by one degree Celsius (Craig and Reading, 2007). 
 
 
 
Figure 2.8: Schematic diagram of heat flux DSC 
 
2.2.2.1.1.2 Instrument calibration and sample preparation 
 
The reliability of the results obtained by DSC depends on proper instrument calibration. 
Defined calibration procedures are usually performed which involve the use of highly pure 
materials known as calibration standards with known enthalpies of melting and materials 
with known heat capacities.   
 
DSC calibration typically takes three steps. The first step is called baseline calibration, 
which records the instrument performance with an empty DSC cell over a temperature 
range, followed by using aluminium oxide (sapphire) disks to verify cell resistance and 
capacitance. The second step is used for cell constant/heat flow calibration. In this procedure 
indium is usually used, because it can be useful for both enthalpy and temperature 
calibrations. In this step the literature melting temperature is compared to the observed 
experimental value, from which cell constant is calculated and fed into the software of the 
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machine to correct the heat flow. Third step is usually recommended to ensure accurate 
measurements as close as possible to the studied transition temperatures. Therefore, 
temperature calibration is performed over the temperature range of interest, using standards 
with known transition temperatures, where their peak temperatures and peak areas are then 
determined and programmed into the instrument. In this work, these steps were conducted 
prior experimentation to achieve calibration of the conventional or standard DSC (cDSC) 
mode. Indium standard (Tm 156.6°C, Heat of fusion 28.6±0.2 J/g) was used to calibrate the 
DSC temperature and enthalpy scale. Other calibrants used were N-Octadecane (Tm 
28.2°C), Benzoic acid (Tm 122.4°C) and Tin (Tm 231.9°C) for temperature calibration over 
the temperature range used and experiment conditions.   
 
All experiments were carried out under inert atmosphere, using nitrogen to create 
reproducible atmosphere around sample and reference during the experiment, purged at a 
rate of 50 ml/min. The mass of each empty sample pan was matched to the mass of the 
empty reference pan within ±0.05 mg. Throughout this thesis, consistency of sample size 
and repeatability (n=3) were taken into consideration in attempt to provide reproducible 
results. Samples were loaded and crimped into TA standard aluminium pans. The flatness of 
the bottoms of the pans was checked before loading into the DSC cell to ensure good heat 
transfer between the DSC and the pan as recommended by Craig and Reading (2007). DSC 
of Q series (1000) equipped with a refrigerated cooling system (TA Instruments, United 
Kingdom) was used to obtain data. Further details about the methods developed and used are 
outlined in the relevant sections. Analyses were performed using TA Universal Analysis 
2000 software. 
 
2.2.2.1.1.3 Information derived from differential scanning calorimetry (DSC)  
 
DSC measures the total energy associated with a thermal event at any particular temperature 
or time interval and the data is usually presented as a plot of heat flow against temperature as 
illustrated in Figure 2.9. Ideally, the empty pans of sample and reference will result in the 
heat flow signal as a horizontal line known as the baseline. Changes of the heat capacity 
between the sample and the reference indicate the occurrence of thermal transition(s) 
accompanied by displacement of this baseline, such as the jump observed when the material 
goes through its glass transition region or the peaks during melting or crystallization events, 
etc., as shown in the DSC curve in Figure 2.9. Endothermic and exothermic thermal events 
are usually expressed as downward and upward peaks, respectively. The area under the 
curve is proportional to the total enthalpic change.  
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DSC is widely used in the pharmaceutical field to assess various materials through providing 
qualitative and quantitative information about the physicochemical properties of these 
materials. Examples include compatibility studies of drug with excipients (Mura et al, 1995; 
Mura et al., 1998; Pignatello et al., 2004), effect of moisture on glass transition and stability 
(Jain et al., 1998; Steendam et al., 2001), kinetic investigations (Macêdo and Nascimento, 
2002) and polymorphic transition (Marthi et al., 1992). 
  
 
 
Figure 2.9: Schematic of typical DSC curve includes commonly observed transitions 
 
2.2.2.1.2 Modulated temperature DSC (MTDSC) 
 
In thermal analysis techniques, conventional DSC is an integral tool to measure different 
samples’ response that is associated with temperature and energy change after application of 
a linear heating signal. An extent to this technique is the modulated temperature DSC 
(MTDSC). This method involves more complex temperature profile; however, represents a 
great potential in physical characterisations and general use in pharmaceutical sciences that 
yet to be further explored.   
 
2.2.2.1.2 .1 Principle of operation 
 
Modulated temperature DSC (MTDSC) is a technique which measures the difference in heat 
flow between a sample and an inert reference in the same heat flux cell design as the 
conventional DSC. However, this technique lies in a software modification whereby a 
different heating profile is applied to allow the superimposition of a modulation (oscillation) 
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on the underlying conventional linear signal as illustrated in Figure 2.10. This perturbation 
(a sinusoidal wave in most cases) of the temperature regimen is combined with mathematical 
procedures to yield a profile that allows the deconvolution of different sample behaviours. 
The resulting MTDSC heat flow can be expressed as: 
  = 	
	  + 	, 																																																																															(Eq.2.3)		   
where Q is the (heat) energy, Cp is the heat capacity, T= the absolute temperature, t = time, 
and , 	is some function of time and temperature that governs the response associated 
with the physical or chemical transformation (Coleman and Craig 1996). 
 
 
 
Figure 2.10: Temperature regimen as a function of time for conventional and 
modulated temperature DSC (Craig and Reading, 2007) 
 
In the MTDSC measurements, the heating rate is modulated as a result of modulating 
temperature. This allows separation of the reversing (heat flow associated with heat 
capacity) and non-reversing (heat flow associated with kinetically controlled chemical or 
physical process), because the sample’s response to the modulation is different from its 
response to the linear component of the heating program (Craig and Reading 2007). 
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Proceeding with the deconvolution or separation of these components, the following 
equations of the MTDSC temperature program is applied:  
 
 = 0 +  + 																																																																										(Eq.2.4) 
 
Where 0 is the starting temperature, = the heating rate, = the amplitude of the modulated 
temperature and ω is the frequency. Therefore the equation (2.3) can be rewritten as: 
  = 	
 + . cos +		,  		+ 	 sin 																				(Eq.2.5) 	
Where  ,  is the average underlying kinetic response, 	 = the amplitude of the kinetic 
response to the sine wave modulation, and the sinusoidal heating rate corresponds to	 +
. cos and equivalent to dT/dt (Coleman and Craig 1996).  
 
Therefore the reversing heat flow is obtained from the heat capacity component of the total 
heat flow (Cp .dT/dt). The reversing heat capacity can be derived by dividing the amplitude 
of the modulated heating flow by the amplitude of the modulated heating rate. This value 
can be multiplied by the linear component of the heating rate (b) to obtain reversing heat 
flow. This is associated with reversing transitions such as glass transition and most melting. 
The non-reversing heat flow is obtained by subtracting the reversing heat flow from the total 
heat flow. It is typically associated with the transitions that are non–instantaneous or 
reversible over the course of the time and temperature of their detection. It is associated with 
the kinetic components (, 	and involves transitions such as crystallization, enthalpy 
recovery, decomposition and loss of a volatile such as water.  
 
By way of example, Figure 2.11 shows the results of simple deconvolution for MTDSC heat 
flow signals of quench-cooled polyethylene terephthalate (PET). However, true sample 
modulation might not be achieved during a melting process. This is because uniform 
temperature within the sample during melting event, which is associated with large amount 
of enthalpy, is often difficult. Thus, reversing heat capacity would be frequency dependent 
during this event. Therefore, unless isothermal measurements are ensured, only qualitative 
assessment of melting is useful using MTDSC (Craig and Reading, 2007). 
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Figure 2.11: Thermoanalytical curve of quench-cooled PET showing the simple 
deconvolution (separation) of the MTDSC heat flow signals (Thomas, 2005) 
 
2.2.2.1.2.2 Instrumentation 
 
In order to maximize the quality of the results obtained by MTDSC measurements, there are 
three key experimental conditions that can be optimized, namely, the modulation period, the 
modulation amplitude and the underlying heating rate. A proper selection of these 
parameters has a profound influence on the measurements undertaken. In other words, the 
period of modulation must be sufficiently long to allow enough time for heat to flow 
between the sensor and the sample. Whereas the modulation amplitude should be chosen to 
provide a good sensitivity (large enough) to reveal the event with a sufficiently slow 
underlying heating rate to provide a number of modulation cycles over transitions of interest 
(at least six modulated cycles), thus better resolution. Normally, periods of 30 to 100 
seconds are used, the modulation temperature amplitude in the range of ±0.1°C to ±1.0°C 
and underlying heating rates between 1 to 5°C/min (Craig and Reading, 2007). 
 
MTDSC experiments were performed using the same DSC machine (TA Instrument DSC 
Q1000) and the sample preparation, DSC calibration (three steps) detailed for conventional 
DSC experiments are the same herein. However, MTDSC mode experiment necessitates a 
fourth set of calibration to calibrate heat capacity signals (heat capacity calibration). This 
calibration is required for more accurate quantification of the deconvoluted results, through 
reversing heat capacity calibration. For that purpose, clear disk of aluminium oxide was used 
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as a calibration standard, whereby the heat capacity constant determined by simply dividing 
the literature heat capacity of that standard by the measured heat capacity, both at the mid-
point of the studied temperature range. Further details regarding the parameters set for the 
MTDSC experiments are described within the relevant experimental section in Chapter 3. 
 
2.2.2.1.2 .3 Pharmaceutical applications 
 
MTDSC has lend itself as a well-established technique to characterise pharmaceutical 
systems, such as detection of phase separation (Six et al., 2003) and as a complementary 
technique to understand and investigate drug delivery systems, especially those based on 
polymeric materials (Wang et al., 2005). 
 
This technique is the method of choice to study glassy systems or amorphous materials, 
where an excellent detection of glass transitions can be made (Hill et al, 1998). It can 
enhance the resolution, through slow underlying heating rate, without affecting sensitivity. 
In fact it increases the sensitivity, through high rate of temperature change. This would result 
in generation of high heat capacity signal (and hence the reversing signal), where a signal to 
noise ratio is enhanced and subtle (weak) glass transitions are apparent. In addition to that, 
the measurements will not be effected by the shifting in the instrumental baseline, because 
the heat capacity will be calculated from the modulated amplitude. On the other hand, 
conventional DSC is better than MTDSC for melting measurements. As mentioned in earlier 
discussion, the melting event is a complex process to be truly modulated. The melting is a 
linear function of heating rate and in MTDSC technique this linear response may be lost. 
Hence, there is a limited applicability of MTDSC to study this event quantitatively.   
 
2.2.2.1.3 Thermogravimetric analysis (TGA) 
 
Thermogravimetric analysis (TGA) is one of the simplest and oldest thermal analysis 
techniques. This technique involves measurement of weight loss as a function of temperature 
in a controlled atmosphere or weight gain also as a function of time at a single temperature 
(Hunt and James, 1993). Thermogravimetric analysis (TGA) describes any experimental 
method whereby changes in mass are used to study physical or chemical process. In this 
work, TGA was used to investigate the thermal decomposition to assess thermal stabilities 
and to study water content of the samples. It is noteworthy to mention that mass loss 
measurements do not detect melting or other phase changes. 
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2.2.2.1.3.1 Instrumentation  
 
Common apparatus of thermogravimetry (TG) are depicted in Figure 2.12. Thermobalance is 
the main part of TG, it encompasses furnace equipped with a temperature control system, 
and thus the heat transferred to the sample is adjusted to a constant or programmed 
temperature. A thermocouple is placed close to the sample holder to measure and record 
sample temperature. Samples, which are usually contained in open light aluminium or 
platinum pans, are incubated in reaction container, which should be thermally stable and 
inert, under controlled atmosphere, usually inert gas. Taring of the empty sample pan is 
performed before the sample is loaded to ensure that the balance giving the accurate reading, 
therefore reference empty pan of the same size and type is used on the tare side for proper 
operation. The balance operates on a null position, which is usually restored using a 
magnetic force generated by an electric current acting on a magnetic material. Sample size 
should be small enough to avoid uncertainties associated with temperature variations within 
the sample yet representative of the bulk material and performing repeated identical 
experiments can verify the results.  
 
The modes of operation can be isothermal, wherein the sample temperature is held constant 
throughout the experiment or variation mode, thus the temperature is changed with time 
according to a specified program. A constant rate of temperature increase has been widely 
used (incremental variation mode). To optimize performance it may be necessary to perform 
calibration, which is usually for temperature and mass. Mass calibration is usually 
performed using standard weights. The temperature calibration is often obtained using the 
Curie point magnetic method with SRM Nickel described in American Society for Testing 
and Materials (E1582-93). In this work, TGA was operated in standard variation mode and 
isothermal mode using TA Instrument TGA Q5000 IR shown in Figure 2.13. Samples were 
placed in tared open aluminium pans on the sample holder. Experimental methods employed 
are detailed in the relevant sections. All TGA experiments were performed with a dry 
nitrogen gas purged at flow rates of 25 ml min-1 and 10 ml min-1 through the furnace and 
TGA head, respectively. Data were treated mathematically using TA Universal Analysis 
2000 software. 
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Figure 2.12: Schematic diagram of common TG apparatus 
 
 
 
Figure 2.13: TA Instruments TGA Q5000 IR. Reproduced from www.tainstruments. 
com 
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2.2.2.1.3.2 Pharmaceutical applications 
 
As aforementioned, thermogravimetry (TG) is an attractive experimental technique for 
investigations of processes that may cause a weight loss in a material. In pharmaceutical 
sciences, TGA has been used to characterise various drugs and excipients. Most studies 
using this method to measure the temperature range in which dehydration occurs and the 
quantity of water lost and determination of the material stability at high temperatures. The 
potential of using TGA in conjunction with complementary techniques such as X-ray 
diffraction (XRD) and differential scanning calorimetry (DSC) has been investigated in 
many works (Bettinetti et al., 1999; Dash and Tyle, 1996; Grisedale et al., 2012) to obtain 
more detailed analysis. During assessment of the glassy material, for example, water content 
determination by TGA appears as integral tool to supplement DSC analysis, whereby 
measured levels of water as a plasticizer can by correlated to the glass transition temperature 
changes.  
 
2.2.2.1.4 Hot stage microscopy (HSM) 
 
Hot stage microscopy is a unique analytical technique that combines the microscopy and 
thermal analysis to characterise the physical properties of the materials while being exposed 
to a controlled temperature program. This technique serves as a complementary tool to other 
pharmaceutical techniques such as DSC and TGA (Vitez et al., 1998), providing a balanced 
picture of the solid physical properties under investigation. The introduction of photographic 
equipment to this technique expanded its utility to capture on video or as digital images 
visualized thermal events. 
 
HSM used in this project was to allow visualisation of the dissolution of one component into 
another component melt, in attempt to predict compatibility of these materials (Forster et al., 
2001). HSM was also used as a conjunction tool to evaluate thermal transitions observed 
using MTDSC technique. The apparatus consists of a camera mounted above polarized light 
microscope (PLM), into which the sample is mounted on a glass slide and enclosed in the 
hot stage. PLM was also used without heating accessory (hot stage) as a supplementary 
technique to the SEM studies, due to its good ability of crystalline structure recognition.   
 
HSM studies were carried out using a Leica DML S2 polarized microscope (Wetzlar GmbH, 
Germany), connected to a Mettler Toledo FP82HT hot stage microscope and a FP90 central 
processor, equipped with a video capture system (JVC digital colour video camera) 
connected to a PC. Studio86Design Capture software (Version 4.1) was used to analyse 
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results. Full experimental details are given in the relevant sections of corresponding 
chapters. 
 
2.2.2.2 Dynamic vapor sorption (DVS) analysis 
 
Dynamic vapor sorption analysis (DVS) is a technique, whereby the effect of exposure to a 
controlled conditions of temperature and humidity on the materials is measured 
gravimetrically using a sensitive microbalance that detect weight changes of a sample and a 
reference. DVS has several applications that are used to investigate the moisture sorption 
behaviour of the materials, providing better understanding of the affinity and or interactions 
of water within these materials. This is of particular importance in pharmaceutical fields as 
the stability, performance and properties of the pharmaceutical material may be influenced 
by their moisture sorption.  
 
The DVS studies in this project were undertaken using TA Q5000 SA analyzer, consists of a 
vertical nulling microbalance in which the sample and reference hang-down wires and pans 
are enclosed in a humidity- and temperature-controlled chamber. A dry nitrogen gas is 
purged at a rate of 10 ml min-1 to assure the dryness of the balance housing. TA Instrument 
DVS used here and shown in Figure 2.14 has pair of mass flow controllers (MFCs), which 
are placed to purge the nitrogen gas to the humidity chamber, which contains the humidifier, 
sample and reference measurements chamber. Thereby these MFCs allow adjustment of the 
amount of wet and dry gas to obtain desired humidities. Temperature is also controlled to 
achieve consistent atmosphere for precise measurements. Sensors are located adjacent to the 
sample and reference holders to enable humidity and temperature regulation. The loss or 
uptake of moisture is therefore recorded gravimetrically in comparison to an empty reference 
using sensitive microbalance. This balance (thermobalance) is enclosed in well-insulated 
chamber, gas-purged and operates on a null position, allowing high sensitivity and accuracy 
of detection of weight changes, free from any interference such as vapour condensation or 
electrostatic forces, which could otherwise affect the accuracy and precision of the 
measurements.  
 
In this work, DVS experiments were performed in three different modes, namely, isotherm 
and isohume modes and as a function of time. In isotherm mode, the samples are exposed to 
a series of humidity step changes at a constant temperature. However, isohume mode 
operates in a series of temperature step changes at a constant humidity level. These modes 
are useful to give indication about physicochemical changes that can occur as a function of 
these variables (humidity or temperature at a given humidity level), such as the hydration 
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state changes of the tested sample. The third mode was maintaining the sample at a given 
humidity level and constant temperature for three hours. This experiment was used for 
preparatory purposes of the samples, thus a humidification is achieved under controlled 
conditions. Samples were placed in standard aluminium open pans (surface area of 
approximately 38.48 mm2) to unify the exposed surface area to the moisture and loaded into  
hemi-sphere quartz sample crucibles (180 µL). This assembly was tared prior each 
experimentation with matched empty reference hemi-sphere quartz crucible containing 
empty standard aluminium pan. However, in the preparatory experiment, the samples were 
placed directly into tared DVS crucibles. Experimental methods are detailed in the relevant 
sections. Analyses were performed using TA Universal Analysis 2000 software. 
 
 
 
Figure 2.14: TA Instruments Q5000 SA Dynamic Vapor Sorption Analyzer. 
Reproduced from www.tainstruments.com 
 
2.2.2.3 Attenuated total reflection-Fourier transform infrared spectroscopy (ATR-
FTIR) 
 
Infrared (IR) spectroscopy is a well-established technique and routine procedure in 
pharmaceutical field that can be used to acquire data quickly for characterising the 
composition and geometry of molecules and crystals. An electromagnetic wave in the 
infrared region (wavenumber between 4000 cm-1 and 400 cm-1) is passed through the sample 
and is absorbed by the bonds of the molecules in the sample causing them to stretch or bend. 
The wavelength of the radiation absorbed is characteristic of the bond absorbing it and the 
greater change in dipole moment during a vibration; the higher the intensity of absorption. In 
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a spectrometer, any remaining IR, not absorbed by the molecule is transmitted through the 
sample to a detector. The fraction of transmitted light allows determination of the 
frequencies at which the absorption of energy occurs in the infrared region of the 
electromagnetic spectrum. Because the frequencies and intensities of the modes are sensitive 
to physical and chemical structure, the observation of bands in well-defined ranges can 
indicate the presence of particular groups (fingerprinting) by applying the principle of group 
frequency correlations. This enabled many applications in pharmaceutical field, such as 
drug-polymer interaction studies and crystallinity investigations. The latter is usually 
monitored if the crystalline or amorphous materials give distinct vibration band(s). 
Therefore, changes can be correlated with the peak intensity, shape or position (Khanna and 
Khun, 1997). Moreover this technique can be used for quantification based on the principle 
of linear proportionality between IR absorbance and the number density of vibrating species 
(Hunt and James, 1993), thus the intensities of bands are related to the functional groups 
concentration producing them (Socrates, 2001). 
 
2.2.2.3.1 Instrumentation  
 
Fourier transform instruments are the most widely used instruments, wherein  the IR signal 
is produced as an interferogram which can be treated mathematically using equation called 
‘Fourier transform’ in order to extract the spectrum from a series of overlapping frequencies. 
The introduction of the attenuated total reflection (ATR) mode enabled FTIR to become 
valuable tool to characterise various polymeric matrices, drugs found in them and elucidate 
their interaction (Watson, 2005). ATR requires no special sample preparation and provides a 
non-destructive mean for evaluating solid or liquid samples. The sample is simply placed on 
the surface of the ATR crystal which is usually made of diamond or germanium. Infrared 
beam enters at an angle greater than the critical and is totally and internally reflected by the 
crystal, but attenuated by absorption from the sample contact layer as shown in Figure 2.15. 
The fraction of the light reaching into the sample is known as evanescent wave. At each 
reflection point the wave extends within the penetration depth (typically few microns) and 
existing beam will be analyzed to provide ATR-FTIR spectra of the studied material within 
this range. The most important consideration needed when testing a certain sample is to 
achieve high contact with the surface of refractive index and clean IR-transparent prism, to 
have better characterisation of the material under study (Hunt and James, 1993). 
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Figure 2.15: Schematic of a single reflection ATR system 
 
The ATR-FTIR studies were carried out using a Bruker optics IFS 66/S spectrometer 
(Coventry,UK) equipped with a Golden Gate ATR accessory from Specac Limited 
(Orpington, UK), shown in Figure 2.16, over a range of 4000-550 cm-1 with 32 scans at a 
resolution of 4 cm-1. Using the same parameters, ATR-FTIR spectra were also collected for 
heated samples utilising a Golden Gate heated diamond attenuated reflection top-plate with a 
3000 series high stability temperature controller with RS232 control from Specac Ltd. (Kent, 
UK). Analyses were performed using Omnic software (version 6.1a). 
 
 
 
Figure 2.16: Bruker IFS 66/S, Burker optics spectrometer (left side) equipped with a 
Golden Gate ATR accessory from Specac Limited (right side) 
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2.2.2.4 Powder X-ray diffraction (PXRD) 
 
PXRD is one of the primary techniques used in pharmaceutical solid state characterisation. 
Simplicity and non-destructive sample preparation led to the extensive use of this technique 
to trace crystallinity, to confirm the identity of mixed crystal phases and to detect amorphous 
regions in various materials. PXRD operates on the principle that the diffraction pattern for 
every crystalline phase is a unique as a fingerprint and determined by their individual 
uniform crystal structure. This fingerprint, when properly interpreted, allows for 
identification of the studied material. 
  
A typical X-ray diffractometer consists of three basic elements; X-ray tube (generator) in 
which copper is the  most commonly used, sample holder and X-ray detector as shown in 
Figure 2.17. The X-ray beam emitted from the tube and passed through the sample. When 
X-ray beam hits an atom in the molecule, the electrons around the atom oscillate with the 
same frequency as the incident beam. The atoms in the crystal have long range order and the 
leaving beam consists of large number of scattered rays. The intensity and position of these 
rays are recorded by a detector. The diffraction of X-ray by the crystal can be explained by 
Bragg’s diffraction (1918). In this model, crystal has a definite separation distance between 
its atomic or lattice planes called d-space. For a monochromatic X-ray beam with a 
wavelength λ, scattered from a crystal lattice, peaks of scattered intensity are observed only 
when the distance traveled by the ray reflected from successive atomic planes differs by a 
complete number (n) of wavelengths (Cullity, 1978). In Figure 2.18, this path length is (abc). 
The diffraction will occur when the path length difference is equal to an integer number of 
wavelengths (nλ). Geometrically, (ab) equals (bc) and both are equal to the distance (d) 
times the sine of the reflected angle Ө (dsin Ө). So Bragg's law is usually expressed as nλ = 
2 dsin Ө. The diffractogram, therefore, will be the intensity of the diffracted beam plotted 
against the angle of the leaving beam. The peaks in the diffractogram will correspond to the 
characteristic d-spacing sets of the atoms’ arrangements in the molecules within the sample.   
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Figure 2.17: Diagram of powder X-ray diffractometer (Morris et al, 2011) 
 
 
 
Figure 2.18: Diagram illustrating Bragg’s law reflection 
 
PXRD studies were carried out using X-ray powder diffractometer (ARL Xtra, 
manufactured by Thermo Fisher Scientific) equipped with X-ray tube (Copper, wavelength 
of 1.540562 Angstrom). Scanning speed of 1.2 °/min over the 2Ө range from 2 to 60 degrees 
was used with a step size of 0.01 degree and 0.5 second per step, using a 40 kV generator 
and a 20 mA stream. Smooth plane surfaces were ensured for the tested samples when 
packed or pressed into the sample holders. 
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2.2.2.5 Scanning electron microscopy (SEM) 
 
SEM is a type of electron microscopy that uses focused beam of high energy electrons to 
magnify the surface of the sample. Therefore information about surface topography, external 
morphology is produced with high magnification yet a good resolution, due to the great 
depth of the applied field. As seen in Figure 2.19, SEM operates using a fine beam of 
electrons which is scanned across the sample surface. The beam interacts with sample and a 
detector monitors the signals that result from the electron beam-sample interaction. The 
electrons emitted from the sample surface amplified to build up the SEM image from the 
detector signal. During SEM functioning, the beam current of the electrons penetrating the 
sample can generate heat. Therefore, heat damage can take place for susceptible sensitive 
samples. 
 
 
 
Figure 2.19: Schematic diagram of the main parts of a scanning electron microscope 
 
To increase the stability of the produced images and increase sample resolution, coating of 
the samples under vacuum sputter is essential. Therefore the surface become more 
conductive and static electric charges are dislodged from the specimen. A thin layer of 
conductive material is usually used to coat the samples, such as gold and silver. In this study, 
SEM studies were carried out using scanning electron microscope (JSM 5900LV, 
manufactured by JEOL, Japan), which was fitted with a tungsten (W) filament and an 
acceleration voltage of 20 kV with a 10 mm working distance, was used to obtain SEM 
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images. The samples were mounted onto stubs using double-sided tape and were gold coated 
by a Polaron SC7640 sputter gold coater manufactured by Quorum Technologies (UK), 
using Plasma current of 20 mA, Voltage: 2.1 kV for 30 seconds. 
 
2.2.2.6 Texture analysis (TA) 
 
Texture analysis is a penetrometry technique that is usually used to provide information 
about mechanical properties of the studied material through measurements of the material 
response to tension, compression, penetration and bending. Therefore, texture analyzers 
operate by applying controlled forces to the material and recording its response. Texture 
analyzer instrument consists typically of a probe, load cell and sample stage or platform, as 
shown in Figure 2.20. The sample is placed over the platform of the instrument. The probe is 
positioned above the sample and held by a load cell connected to a movable arm. The probe 
is usually placed close to the sample and is pushed into the sample and withdrawn away 
from it according to a control program. When the test starts, the probe is programmed to 
travel at a defined and constant speed to contact the sample and penetrates the sample up to a 
chosen depth. Then the probe detaches from the sample to its original position prior the test.   
 
 
 
Figure 2.20: TA-XT2 Texture Analyzer Stable Microsystems, Ltd. (Surrey, UK) 
equipped with a 5 kg load cell and fitted with a Perspex cylindrical probe 
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Many textural parameters can be analyzed in only one test using this technique. Therefore, 
texture analysis has been applied as a useful method to investigate mechanical properties of 
transdermal films such as hardness and adhesiveness (Abdul Rasool et al., 2011; Cilurzo et 
al., 2008; Repka et al., 2003; Yener et al., 2010). Generally, the texture profile analysis 
curve measures force as a function of time as shown in Figure 2.21. This curve provides 
several textural parameters as hardness, adhesiveness and cohesiveness. Hardness parameter 
can be defined as the peak force needed to reach a given deformation (Szczesniak, 1963) 
during the first compression cycle (here peak A). Adhesiveness is related to surface 
properties of the tested material and represents the work necessary to pull the probe away 
from the sample (negative force area, here area B). Cohesiveness represents the strength of 
the internal bonds making up the body of the material (Szczesniak, 1963) and can be defined 
as the ratio of the positive force area during the second compression portion to that during 
the first compression (here area C/ area A). 
 
 
 
Figure 2.21: A typical force-time curve obtained from two cycles texture profile 
analysis test, with the peak (A) resulting from first compression cycle and peak (C) 
from the second compression cycle 
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In this work, the hardness values as measured by the force of load (in grams and equals to 
9.8 mN) using TA technique was used to indicate flexibility of hot melt extruded Geluicre 
44/14/Eudragit RS PO films for transdermal delivery. Films were obtained after their 
application to the skin of healthy volunteers after occlusion. The hydration of these films 
was achieved by skin occlusion. The changes in hardness as a result of hydration, the 
relationship of these changes to the hydration times, as well as the correlation between the 
Gelucire 44/14 concentration and the hardness (with and without hydration) were 
investigated and detailed in Chapter 8. 
 
TA studies on the extruded films (in both dry and wet states) were carried out using TA-XT2 
Texture Analyzer (Stable Micro system, UK), shown in Figure 2.20, with a 5 kg load cell, a 
force measurement accuracy of 0.0025% and a distance resolution of 0.0025 mm. The 
penetration profiles of the probe were used to obtain the force of load required to compress 
the films (in grams), indicating their hardness. The probe used (Perspex cylindrical) with 
11.6 mm diameter was calibrated for height measurements, held above the sample by 4 mm 
of its original height. The pre-test speed was set up at 1 mm/second, the test speed at 0.5 
mm/second and the penetration depth of 60% of the film’s height. The study was carried out 
with two repeats obtained for each sample at room temperature. Texture Expert Exponent 
software was used to perform analyses. 
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3.1 Introduction 
 
For a compound that is intended to be used in hot melt extrusion for a design of a 
pharmaceutical product, an understanding of its characteristics is essential for at least two 
reasons. Firstly, to establish processing conditions (such as extrusion temperature and screw 
speed). Secondly, to provide understanding of the relationship between the raw material 
properties and the final product i.e. extrudate which can affect its performance and/or quality 
attributes. This chapter is provided to gain insight into the properties of the raw materials 
selected for performing hot melt extrusion in this work as detailed in Chapter 2 with the 
ultimate aim to formulate a drug delivery system for transdermal application. Extrudability 
of the raw materials appears to be influenced by two key features, which are thermal 
properties of the used drug or polymer and include thermal stability and their Tg or Tm, in 
addition to the melt viscosity (Chokshi et al., 2005). A characterisation program was 
provided in section 3.3 which is divided into two parts for the major constituents, namely, 
the drug and carrier excipients. Each part is further subdivided into two parts for each 
material. The first part is thermoanalytical investigations which describe thermal properties 
as probed using DSC and TGA techniques. The second part details some of the solid state 
characteristics of these materials, which are believed to be the most relevant for 
understanding the physical properties of the real extruded samples containing mixtures of 
the drug and carrier excipient(s). 
 
3.2 Methodology 
 
The basic research techniques and materials selection were explained in Chapter 2. In this 
section analytical methods which employed these techniques will be presented to 
characterise the selected materials. Methods included TGA and DSC in its conventional and 
modulated modes, which were used and developed to establish thermal properties of the 
main components. Standard DSC or conventional DSC (cDSC) was used at a heating rate of 
10°C min-1 to study both ibuprofen as a model drug and Eudragit RS PO as the parent main 
polymeric carrier. Samples (9.00-10.00 mg) of ibuprofen were initially subjected to two 
steps. Step1: equilibration at -70˚C, isothermal heating for 5 minutes, step2: heating to 
100˚C at 10˚C min-1 (Figure 3.2). The glass transition temperature and crystallization of 
ibuprofen were investigated using a second method of three steps or cycles. The first cycle: 
heating to 100°C at 10˚C min-1, cooling to -70°C (10˚C/min) in the second cycle followed by 
a reheating step (cycle 3) to 100°C (10˚C/min) as presented in Figure 3.3. Eudragit RS PO 
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(9.00-10.00 mg) samples were subjected to two steps; include equilibration at 30°C, 
isothermal heating for 5 minutes and then heating to 100˚C at10˚C min-1 (Figure 3.10).  
 
In the MTDSC experiments, the first method was applied to deconvolute the glass transition 
event of Eudragit RS PO with an underlying heating rate of 2˚C/min, a modulation period of 
40 seconds and amplitude of 0.212°C and included two steps. Step 1: equilibration at 30˚C 
and modulation ±0.212°C with a period of 40 seconds, isothermal heating for 5 minutes, step 
2: heating to 100˚C (2˚C/min), as shown in Figures 3.11 and 3.12. The second method was 
developed with the objective to enhance sensitivity of the measurements, using higher 
amplitude of 0.265°C and a period of 100 seconds, where the heating rate was 1˚C/min. The 
parameters of this MTDSC method were employed to characterise Eudragit RS PO, 
ibuprofen and the rest of tested materials in this work to provide finer analysis of their 
thermal transitions. Samples (9.00-10.00 mg) were subjected to two steps. Step1: 
equilibration at -70˚C and modulation ±0.265°C with a period of 100 seconds, isothermal 
heating for 5 minutes, step 2: heating to a final temperature (1˚C/min). The final temperature 
varies according to the tested material and in this chapter it was between 100-250°C. 
Conventional DSC and MTDSC measurements were carried out using TA Instrument DSC 
Q1000, equipped with a refrigerated cooling system (RCS) and calibration was performed 
prior each analysis as detailed in Chapter 2. Data were treated mathematically using TA 
Universal Analysis 2000 software and nitrogen was used as the purge gas through the DSC 
cell at a flow rate of 50 ml/min. TA instruments standard pans were used for all calorimetric 
studies; the mass of each empty sample pan was matched to the mass of the empty reference 
pan within ±0.05 mg and all the measurements were performed in triplicate. 
 
Thermal stability of the materials was studied using thermogravemetric analysis, which was 
performed using TGA Q5000 IR (TA Instruments, U.K). Samples (10.00-12.00 mg) were 
subjected to a single step of heating from 30°C to 300˚C at a heating rate of 10˚C min-1. All 
TGA runs were performed in open aluminium pans with a dry nitrogen gas purged at flow 
rates of 25 ml min-1 and 10 ml min-1 through the furnace and TGA head, respectively. Data 
were treated mathematically using TA Universal Analysis 2000 software to illustrate weight 
loss percentage and weight derivative loss signals. The latter is usually more sensitive for 
detection of the closely occurring multiple weight losses.  
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Other analytical techniques used to investigate physicochemical properties of the used 
materials were SEM, PXRD and ATR-FTIR. Scanning electron microscopy (SEM) was used 
to observe the morphological features of these materials. The samples were mounted onto 
stubs using double-sided tape and were gold coated, in order to increase conductivity of the 
electron beam, by a Polaron SC7640 sputter gold coater manufactured by Quorum 
Technologies (UK), using Plasma current of 20 mA, Voltage: 2.1 kV for 30 seconds. The 
photographs taken were obtained using scanning electron microscope (JSM 5900LV, 
manufactured by JEOL,Japan) fitted with a tungsten (W) filament, acceleration voltage of 20 
kV and 10 mm working distance.  
 
To investigate crystallinity of the ibuprofen and carrier excipients, qualitative PXRD 
analysis was performed using X-ray powder diffractometer (ARL Xtra, manufactured by 
Thermo Fisher Scientific) equipped with X-ray tube (Copper, wavelength of 1.540562 
Angstrom) over the 2Ө range from 2 to 60 degrees, scanning speed of 1.2˚/min (step: 0.01 
degree, 0.5 sec/step) using a 40 kV generator and a 20 mA stream. In addition, attenuated 
total reflectance-Fourier-transform infrared (ATR-FTIR) spectrometry (Bruker IFS 66/S, 
Burker optics equipped with a Golden Gate ATR accessory from Specac Limited) was used 
to investigate the most characteristic functional groups of the used materials which can aid 
in interpretation of molecular interactions, if any,  in the mixtures of these materials. Spectra 
of these components were collected over a range of 4000-550 cm-1, 32 scans at a resolution 
of 4 cm-1. Omnic software (version 6.1a) was used to analyze results. All weighing in this 
work was performed using XS205, Dual range analytical balance (Mettler Toledo). 
 
3.3 Results and discussion 
 
3.3.1 Model drug 
 
3.3.1.1 Thermoanalytical investigations 
 
Ibuprofen was chosen as a model drug for the reasons detailed in Chapter 2. TGA was used 
to estimate the onset of decomposition of this drug as a function of weight loss, thereby 
approximating its thermal stability. Figure 3.1 shows the percentage and derivative weight 
loss signals of ibuprofen heated at a rate of 10°C min-1. It can be seen from this figure that 
the decomposition starts approximately around 140°C and the sample disappeared after the 
finish of the run with a final temperature of 300°C, indicating complete decomposition. 
Thus, it could be inferred that extrusion temperature that can be employed should be less 
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than 140°C. However, it is expected to have extra heat generated from screw friction during 
the mixing process inside the extruder (Crowley et al., 2007). Therefore, it is believed that 
extrusion temperatures equal or below 120°C might be favourably selected to avoid or at 
least minimize this drug degradation while processing. At this temperature (120°C), less than 
0.1% of the ibuprofen weight loss was detected. 
 
 
 
Figure 3.1: TGA weight loss profile of crystalline ibuprofen heated at 10°C min-1 to 
300°C 
 
DSC experiments were performed in both its conventional and modulated modes to 
determine major thermal events of ibuprofen. Conventional or standard DSC (cDSC) 
measures heat flow of a sample providing information about its physicochemical properties 
qualitatively and quantitatively as detailed in Chapter 2. The initial cDSC experiments using 
a standard heating rate of 10°C min-1 and standard aluminium pans are demonstrated in 
Figure 3.2 to Figure 3.3. 
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Figure 3.2: Heat flow signal of ibuprofen heated at 10°C min-1 in standard aluminium 
pans 
 
 
 
Figure 3.3: Heat flow signal of ibuprofen cycled at 10°C min-1 (see text). Highlighted 
cycle after re-heating from -70°C is showing a magnified insert of the observed glass 
transition event 
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This crystalline drug give rises to an endothermic melting peak at 76.8±0.3°C measured as 
the peak temperature and at 75.5±0.3˚C as the extrapolated onset value (Tm
 (onset)) as 
presented in Figure 3.2. In order to study the amorphous form and subsequent 
recrystallization of this drug, supercooled ibuprofen was made inside DSC. Quench or rapid 
cooling of the melt is a well known approach to produce amorphous material or small 
crystallites. Therefore, the drug was heated till 100°C to ensure melting and then cooled to -
70 °C at 10°C min-1, followed by reheating till 100°C as highlighted in Figure 3.3. In this 
highlighted third cycle of this protocol an inclination in the DSC graph was observed 
between -45°C and -42°C, which is characteristic of an amorphous material passing through 
its glass transition temperature. A Mid-point temperature of this transition was found at -
43.4±0.2°C (n=3), which agrees well with the reported value for amorphous ibuprofen of 
approximately -45°C (Dudognon et al., 2008). The next thermal event seen in this cycle was 
an exothermic peak with a maximum at 36.7± 0.1°C, indicating rearrangement of molecules 
or recrystallization of the amorphous phase into the stable crystalline phase. Subsequent to 
this recrystallization exotherm, melting endotherm of crystalline ibuprofen was observed. 
 
MTDSC as explained in Chapter 2 is performed through application of temperature 
modulation over the underlying heating rate of standard DSC. This results in enhancement 
of both resolution and sensitivity. Therefore, weak or overlapped events can be distinguished 
effectively, wherein reversing heat flow signal shows heat capacity components while 
kinetic heat flow is detected in the non-reversing signal. The experimental procedure used 
for MTDSC in this characterisation was based on parameters developed for determination of 
the glass transition temperature of Eudragit RS PO as will be discussed in section 3.3.2. 
Though MTDSC is a useful technique, it is relatively complicated in comparison to the 
cDSC and it may also have limitations with respect to the melting characterisation (Chapter 
2), but since ibuprofen will be mixed primarily with Eudragit RS PO, their characterisation 
will be achieved using this method. Therefore, it would be useful to examine ibuprofen 
individually, to relate its fingerprints (thermal events) detected from the used parameters in 
this MTDSC method when examined as a mixture with this polymer.  
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Figure 3.4 shows the MTDSC profile of crystalline ibuprofen. A melting endotherm was 
observed in all the signals and determined from total heat flow signal at 75.7±0.2°C 
measured as the extrapolated onset value (Tm
 (onset)) and at 76.4±0.1°C as the peak 
temperature. Following the same aforementioned protocol of cooling the ibuprofen melt at 
10°C min-1, the third cycle was obtained using the applied MTDSC method with an 
underlying heating ramp rate at 1˚C min-1, a period of 100 seconds and amplitude of 
±0.265°C  to 100°C. This cycle is displayed in Figure 3.5 which shows reversing and non-
reversing heat flow signals for partially amorphized ibuprofen. A glass transition 
temperature was detected from the reversing heat flow signal at -43.4±0.2°C while non-
reversing signal revealed broad recrystallization exotherm at approximately 35.7±0.3°C 
(peak temperature).  
 
 
 
Figure 3.4: MTDSC heating scan of ibuprofen in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The signals have been offset for clarity 
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 (A) 
 
 
(B) 
 
 
Figure 3.5: MTDSC reversing heat flow signal (A) and non-reversing heat flow signal 
(B) of ibuprofen in standard aluminium pans. Underlying scan rate of 1°C min-1 with a 
modulation amplitude of ±0.265°C and a period of 100 seconds. Insert showing 
magnification of associated glass transition temperature (A) 
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3.3.1.2 Morphological and spectroscopic properties 
 
Ibuprofen occurs as a white crystalline material with a common crystal form of needle-shape 
habit with rough surface (Rasenack and Müller, 2002) as shown in the SEM micrograph in 
Figure 3.6. Using PXRD technique, each crystalline solid has a unique X-ray pattern. A 
diffractogram would result from X-ray interactions with electrons of the constituent 
molecules. For crystalline material, this diffractogram or PXRD profile is usually 
characterised with clearly defined peaks with varying intensities associated with uniform 
lattice spacing as seen in Figure 3.7 for crystalline ibuprofen.  
 
 
 
Figure 3.6: SEM image of crystalline ibuprofen 
 
 
 
Figure 3.7: PXRD diffractogram of crystalline ibuprofen 
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ATR-FTIR is also a valuable tool to derive information characteristic for studied sample 
through analyzing its molecular vibrations. The studied sample is usually described by 
treating it as a collection of individual functional groups, each of which corresponds to 
absorbance band assigned from group frequency correlation. This is illustrated in the ATR-
FTIR spectrum of ibuprofen in Figure 3.8, wherein major functional groups are assigned. It 
is worth to mention that hydroxyl O-H stretching broadness observed in this spectrum is a 
result of superimposition of the alkyl C-H stretching.  
 
 
 
Figure 3.8: ATR-FTIR spectrum of crystalline ibuprofen 
 
3.3.2 Carrier excipients 
 
3.3.2.1 Eudragit RS PO 
 
3.3.2.1.1 Thermoanalytical investigations 
 
The work in this study was made using the parent polymer Eudragit RS PO, which was 
selected to be a major constituent of the blend composition with ibuprofen (see Chapter 2). 
Therefore, characterisation of its properties can aid in understanding of its behaviour when 
blended with the drug and fabricated using HME technology.   
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TGA demonstrated three weight losses as detected from weight loss derivative curve in 
Figure 3.9. An initial weight loss was observed in the region between 45-115°C, indicating 
water loss. This polymer showed a thermal stability over the investigated temperature frame 
below 170°C with no signs of degradation. This agrees with Lin and Yu (2000) findings, 
whom employed DSC, TGA and ATR-FTIR/DSC microscopy techniques to investigate 
thermal stability of this polymeric grade. However after ~170°C, further two weight losses 
occurred, indicating decomposition. In comparison to ibuprofen, Eudragit RS PO is more 
stable thermally and thus extrusion temperature should be selected carefully with regard to 
the drug, wherein relatively low temperatures should be applied, preferably less than 120°C 
as aforeindicated.  
 
 
 
Figure 3.9: TGA weight loss profile of Eudragit RS PO heated at 10°C min-1 to 300°C 
 
As for ibuprofen, cDSC at 10°C min-1 was used to address thermal behaviour of Eudragit RS 
PO as shown in Figure 3.10. Being amorphous, no fusion peaks were detected for this 
polymer; however, a glass transition event was observed and complicated with a broad 
endotherm due to possible partial water loss around 55-60°C, supported by TGA findings. 
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Figure 3.10: Heat flow signal of Eudragit RS PO heated at 10°C min-1 in standard 
aluminium pans 
 
As previously stated, MTDSC is the technique of choice to separate out the kinetic 
components from those related to heat capacity components in non-reversing and reversing 
heat flow signals, respectively. Therefore, MTDSC was used to detect glass transition 
temperature of the Eudragit RS PO. The most commonly used MTDSC parameters of a 
modulation with an underlying heat rate of 2°C min-1, a period of 40 seconds and ±0.212°C 
amplitude were employed. Figure 3.11 shows that these parameters were able to produce 
more than six modulated cycles (approximately 10) through glass transition temperature of 
Eudragit RS PO as recommended by Craig and Reading (2007)  to allow better distinction of 
thermal events using MTDSC. The full MTDSC profile of Eudragit RS PO is shown in 
Figure 3.12.  
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Figure 3.11: Modulation heat flow signal over the reversing heat flow signal passing 
through Eudragit RS PO glass transition temperature. Underlying scan rate of 2°C 
min-1 with a modulation amplitude of ±0.212°C and a period of 40 seconds 
 
As seen in Figure 3.12, MTDSC traces of the reversing signal showed glass transition of 
Eudragit RS PO separated from water desorption endotherm, which appeared otherwise in 
the non-reversing heat flow signal as a broad peak. The glass transition temperature was 
determined as the Mid-point and equals approximately 53.5°C. Though deconvolution was 
achieved successfully in this method, the glass transition appeared as a weak signal. 
Consequently, this experimental method was amended with the objective to enhance 
sensitivity. Through application of relatively higher amplitude of ±0.265°C, a longer period 
of 100 seconds with an underlying heating rate of 1°C min-1, the glass transition temperature 
was more distinct and clearly seen around 53.3±0.5°C (Mid-point Tg, n=3) from the 
reversing heat flow signal as shown in Figure 3.13. The results of this method indicated its 
appropriateness for better distinguishing of Eudragit RS PO glass transition. 
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Figure 3.12: MTDSC heating scan of Eudragit RS PO in standard aluminium pans. 
Underlying scan rate of 2°C min-1 with a modulation amplitude of ±0.212°C and a 
period of 40 seconds. The signals have been offset for clarity 
 
 
 
Figure 3.13: MTDSC reversing heat flow signal of Eudragit RS PO in standard 
aluminium pans. Underlying scan rate of 1°C min-1 with a modulation amplitude of 
±0.265°C and a period of 100 seconds 
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3.3.2.1.2 Morphological and spectroscopic properties 
 
Eudragit RS PO occurs as a fine white powder and Figure 3.14 shows the shape of its 
particles under SEM. This amorphous polymer produced broad background signal with no 
defined peaks upon examination using PXRD (Figure 3.15). This is a result of the relative 
randomness of the molecular arrangements in the amorphous material; thereby a halo-pattern 
is usually manifested in the PXRD diffractogram. The absorption information derived from 
the ATR-FTIR spectrum of Eudragit RS PO in Figure 3.16 shows characteristic peaks at 
1723 cm-1 due to carbonyl stretching and at 1145 cm-1 which is related to (C-CO-C) 
stretching in the ester group, in addition to (CH2-) symmetric bending at 1450 cm-1. 
 
 
 
Figure 3.14: SEM image of amorphous Eudragit RS PO polymer 
 
 
 
Figure 3.15: PXRD diffractogram of Eudragit RS PO 
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Figure 3.16: ATR-FTIR spectrum of Eudragit RS PO 
 
3.3.2.2 Sucrose 
 
3.3.2.2.1 Thermoanalytical investigations  
 
As a function of temperature, TGA experiment indicated that a sign of sucrose weight loss 
started around 188-190°C as shown in Figure 3.17. This could be referred as the 
approximate onset of degradation, indicating thermal stability of sucrose below this 
temperature. In Figure 3.18,  the MTDSC traces of this sugar showed an endothermic peak 
detected from total heat flow signal related to sucrose melting at 175.2±1.8°C (Tm(onset)). 
Slightly above this melting peak, a decomposition exotherm was detected from the non-
reversing heat flow signal with a maximum approximately at 187°C. This is expected 
because of sucrose sensitivity for decomposition near its melting point (Feuge et al., 1973). 
Therefore, it would be recommended to perform hot melt extrusion of sucrose at 
temperatures below its melting temperature. This necessitates incorporation of plasticizer to 
lower required processing temperature and in this case it is the active moiety i.e. ibuprofen. 
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Figure 3.17: TGA weight loss profile of sucrose heated at 10°C min-1 to 300°C 
 
 
 
Figure 3.18: MTDSC heating scan of sucrose in standard aluminium pans. Underlying 
scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 
seconds. The signals have been offset for clarity 
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3.3.2.2.2 Morphological and spectroscopic properties 
 
Sucrose is crystalline material which appeared as crystalline blocks with oblong shape and 
slanted edges under SEM as depicted in Figure 3.19. This sugar exhibited sharp, intense and 
well-defined peaks in its PXRD profile displayed in Figure 3.20, implying highly ordered 
crystalline nature. In addition, Figure 3.21 shows major functional groups of sucrose 
assigned in its ATR-FTIR spectrum as suggested by Brizuela et al. (2012), whom combined 
theoretical and experimental approaches to characterise this complex sugar using IR 
spectroscopy. 
 
 
 
Figure 3.19: SEM image of crystalline sucrose 
 
 
 
Figure 3.20: PXRD diffractogram of crystalline sucrose 
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Figure 3.21: ATR-FTIR spectrum of crystalline sucrose 
 
3.3.2.3 Methyl cellulose 
 
3.3.2.3.1 Thermoanalytical investigations  
 
Thermal stability of methylcellulose, as for previous materials, was studied using TGA and 
the obtained weight loss pattern is shown in Figure 3.22 after heating to 300°C at 10°C min-1. 
One stage decomposition was detected, which started around 200°C. Before that, an early 
minor weight loss was detected between approximately 34-84°C. This event could be 
attributed to moisture desorption from the surface of this hydrophilic polymer. Further 
MTDSC examination of this polymer supported this observation as illustrated in Figure 
3.23. In this figure, traces of MTDSC signals permitted separation of three main thermal 
events. The first event was small endothermic peak, detected from total heat flow signal with 
an extrapolated onset at approximately -21.6°C. This endotherm was followed by broad 
endothermic peak, detected from non-reversing heat flow signal with extrapolated onset 
around 56°C.  The first event could be related to the melting of frozen water. Usually loosely 
bound water on the surface of hydrophilic polymer freezes at temperature lower than that of 
bulk water and melt before 0°C (Hatakeyama and Hatakeyama, 1998). The frozen form of 
this water melts at about -15° to -35°C (Joshi and Wilson, 1995). Therefore, water present in 
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methylcellulose is likely to be surface moisture. The second event is also believed to 
correspond to water desorption from this polymer and correlates well with TGA results. The   
third event is the glass transition temperature as determined from reversing heat flow signal 
at 103.0±0.1°C (Mid-point Tg, n=3) for this polymer grade (Methocel A4C Premium), 
indicating its amorphous structure. 
 
 
 
Figure 3.22: TGA weight loss profile of methylcellulose heated at 10°C min-1 to 300°C 
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Figure 3.23: MTDSC heating scan of methylcellulose in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The signals have been offset for clarity 
 
3.3.2.3.2 Morphological and spectroscopic properties 
 
As detailed in Chapter 2, methylcellulose is substituted from cellulose. In this substitution, 
hydroxyl groups of cellulose are replaced with methoxyl groups. The grade used in this 
study (Methocel A4C Premium) showed a fibrous-like shape of its particles under SEM 
(Figure 3.24) and exhibited a halo diffraction pattern in its PXRD diffractogram as seen in 
Figure 3.25, which is pertinent pattern to the amorphous material. Therefore, it could be 
inferred that the used grade of methylcellulose in this study is more likely to have 
amorphous nature as indicated by the absence of melting peaks and diffraction peaks in 
MTDSC and PXRD results, respectively. ATR-FTIR spectrum of this polymer showed three 
main characteristic bands. As seen in Figure 3.26, a typical hydroxyl stretching appeared at 
3500 cm-1, whereas alkyl stretching appeared at 2826 cm-1, which presents in the methyl 
ether groups (Babu et al., 2007). The C-O stretching vibration is assigned in the 1250-950 
cm-1 region (Buslov et al., 2008).   
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Figure 3.24: SEM image of methylcellulose 
 
 
 
Figure 3.25: PXRD diffractogram of methylcellulose 
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Figure 3.26: ATR-FTIR spectrum of methylcellulose 
 
3.3.2.4 Xantural®75 
 
3.3.2.4.1 Thermoanalytical investigations  
 
The TGA profile of Xantural®75 or xanthan gum shows an initial weight loss between 
approximately 34 and 125°C corresponds to the evaporation of the moisture content as seen 
from weight loss derivative curve (blue curve) in Figure 3.27. The extrapolated onset of the 
degradation for this polymer is almost at 235.2°C, where 14.6% (w/w) of decomposition 
took place. MTDSC scanning revealed broad endothermic peak between 39.9 and 150°C, 
which is likely related to the desorption of the moisture as indicated in the TGA results, and 
appeared in the total and non-reversing heat flow signals in Figure 3.28. In this figure, a 
single glass transition was detected around 37.7±2.6°C (Mid-point Tg, n=3), as determined 
from the reversing heat flow signals. Because of its natural origin, xanthan gum 
characterisation, such as glass transition temperature (Tg), might vary depending on the 
source of this material. For example, while Argin-Soysal et al. (2009) reported its Tg value 
at 143°C, Kocherbitov et al. (2010) estimated this value at 60°C.  
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Figure 3.27: TGA weight loss profile of Xantural®75 heated at 10°C min-1 to 300°C 
 
 
 
Figure 3.28: MTDSC heating scan of Xantural®75 in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The signals have been offset for clarity 
 
 
Characterisation of ibuprofen and the carrier excipients intended for hot melt extrusion 
Chapter 3 
 
126 
 
3.3.2.4.2 Morphological and spectroscopic properties 
 
SEM image depicted in Figure 3.29 shows that Xantural®75 powder exhibited irregular 
granular shape. PXRD profile of this polymer in Figure 3.30 did not show diffraction peaks, 
clearly indicating amorphous structure. This amorphicity is supported by MTDSC findings. 
The chemical structure of this polymer as studied using ATR-FTIR is displayed in Figure 
3.31. Hydroxyl stretching was detected at 3450 cm-1, carboxylic acid and C-O group at 1728 
cm-1 and 1157 cm-1, respectively (Lii et al.,2003). Other absorbance bands were 1615 cm-1 
related to carboxylate group, 1417 cm-1 due to C-H bending and 1023 cm-1 correlated with 
hydroxyl bending (Mundargi and Patil, 2007). 
 
 
 
Figure 3.29: SEM image of Xantural®75 
 
 
 
Figure 3.30: PXRD diffractogram of Xantural®75 
 
0
100
200
300
400
500
600
0 10 20 30 40 50 60 70
C
o
u
n
t 
ra
te
 (
C
P
S
)
Degrees (2 Theta)
Characterisation of ibuprofen and the carrier excipients intended for hot melt extrusion 
Chapter 3 
 
127 
 
 
 
Figure 3.31: ATR-FTIR spectrum of Xantural® 75 
 
3.3.2.5 Pluronic® F127 
 
3.3.2.5.1 Thermoanalytical investigations  
 
Pluronic® F127 or poloxamer 407 is a semi-crystalline polymer which exhibits its 
hydrophilicity due to the presence of polyoxyethylene segments as documented in Chapter 2. 
The moisture in this polymer liberated over a temperature range between approximately 31-
113°C in a step-wise fashion as seen clearly from the weight loss derivative curve in its TGA 
profile displayed in Figure 3.32. In this figure, decomposition started insignificantly around 
163.2°C with less than 0.1% (w/w) weight loss; however, the main degradation occurred 
after 185.9°C.  
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MTDSC profile of this polymer is illustrated in Figure 3.33. This profile showed a broad 
melting peak with a peak temperature at 56.7±0.3°C and Tm
 (onset) at 54.2±1.2°C, as 
measured from the total heat flow signals. Since semicrystalline polymers constitute a 
distribution of crystallites, it would be expected to have this relatively broad melting peak 
(Craig and Reading, 2007). Exothermic shoulders associated with the melting peak were 
detected in both total and non-reversing heat flow signals. This could be related to 
recrystallization of the amorphous fractions which undergo different degree of perfection. A 
small glass transition temperature was detected from the reversing heat flow signal at -63.5±    
0.7°C (Mid-point Tg, n=2). This temperature was found to be close to the reported glass 
transition temperature of amorphous polyoxypropylene (PPO) segments of poloxamer 
polymer, occurring approximately at -65°C (Smithey et al., 2007).   
 
 
 
Figure 3.32: TGA weight loss profile of Pluronic® F127 heated at 10°C min-1 to 300°C 
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Figure 3.33: MTDSC heating scan of Pluronic® F127 in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. Inset showing magnification of predicted glass transition 
temperature. The signals have been offset for clarity 
 
3.3.2.5.2 Morphological and spectroscopic properties 
 
SEM image of the white flaky Pluronic® F127 in Figure 3.34 shows particles with different 
shapes, mostly as spheres and rods. PXRD diffractogram in Figure 3.35 distinguished two 
diffraction peaks of this polymer, indicating crystalline material presence. This PXRD 
profile matches polyoxyethylene (PEO) diffraction pattern for this polymer as reported by 
Yin et al. (2005), thereby supporting possible presence of the other main component of this 
polymer i.e. PPO as amorphous material. Three characteristic bands of this poloxamer were 
indicated in the ATR-FTIR spectrum, as presented in Figure 3.36. Hydroxyl stretching at 
3505 cm-1, alky C-H stretching at 2975 cm-1 and an intense band at 1103 cm-1, which is 
related to C-O-C ether stretching (Zhang and Lam, 2005). 
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Figure 3.34: SEM image of Pluronic® F127 
 
 
 
Figure 3.35: PXRD diffractogram of Pluronic® F127 
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Figure 3.36: ATR-FTIR spectrum of Pluronic® F127 
 
3.3.2.6 Gelucire 44/14 
 
3.3.2.6.1 Thermoanalytical investigations  
 
Gelucire 44/14 is amphiphilic multi-component excipient with a lipidic nature and polymeric 
constituents as detailed in Chapter 2. TGA examination of this lipid gave two stages of 
decomposition preceded by initial weight loss ascribed to moisture desorption as shown in 
Figure 3.37. The first stage of decomposition starts around 152.4°C followed by the second 
major decomposition stage that starts around 170.6°C. Therefore, thermal stability of this 
material can be maintained below 150°C. As previously mentioned in Chapter 2, part of this 
lipid denotes the melting point, which is 44°C. However, the melting of Gelucire 44/14 
occurs at a range of temperatures, which despite being relatively narrow range (Gattefossé, 
2007) is reasonably expected due to many components in this excipient which exhibit 
different melting points. This broad melting peak was detected from MTDSC traces in 
Figure 3.38. As determined from the total heat flow signal, this peak seems to have two 
fractions. The one which has higher melt ∆H (larger peak) will be called primary melting 
endotherm which occurs at 39.5±0.8°C (Tm
 (onset)) while  the secondary melting fraction 
corresponds to the small leading shoulder-like endotherm at 32.1±1.4°C (Tm
 (onset)).  
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Figure 3.37: TGA weight loss profile of Gelucire 44/14 heated at 10°C min-1 to 300°C 
 
 
 
Figure 3.38: MTDSC heating scan of Gelucire 44/14 in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The signals have been offset for clarity 
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3.3.2.6.2 Spectroscopic properties 
 
Using SEM technique documented in Chapter 2, the beam current of electrons flow will hit 
the sample and a heat can build up on the sample. For low-melting point materials as 
Gelucire 44/14, the tested samples can melt under examination which will affect the results 
through contamination of the secondary electrons emitted from the surface of these samples 
after being dislodged by a focused electron beam moving across their surfaces. Therefore, 
SEM was not used to characterise Gelucire 44/14. PXRD profile illustrated in Figure 3.39 
for Gelucire 44/14 showed two main diffraction peaks, indicating the presence of crystalline 
material. Figure 3.40 shows ATR-FTIR spectrum of Gelucire 44/14, wherein recognizable 
peaks were assigned as: hydroxyl stretching around 3479 cm-1 from free PEG 1500 found in 
its structure, 2885 cm-1 due to alkyl group C-H stretching, carbonyl stretching around 1729 
cm-1 from ester groups and peaks around 1145, 1107 and 1058 cm-1 from C-O stretching, 
which are related to either primary or secondary alcohol groups as suggested by Siripuram et 
al. (2010).  
 
 
 
Figure 3.39: PXRD diffractogram of Gelucire 44/14 
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Figure 3.40: ATR-FTIR spectrum of Gelucire 44/14 
 
3.4 Conclusions 
 
The aim of the work described in this chapter was to characterise the behaviour of the 
materials prior actual processing via HME. This could explain two objectives, one for 
optimisation the temperature of extrusion as main experimental condition through 
understanding of the thermal properties of these materials. The second objective represents 
an attempt to construct a small library of the main physical features of these materials that 
could be used as fingerprints to separate superimposed data obtained in the future, from 
characterisation of their blends of more than one component. This objective was covered 
under sections of morphological and spectroscopic properties for the model drug i.e. 
ibuprofen and carrier excipients. SEM, PXRD and ATR-FTIR appeared as suitable 
techniques to supplement the characteristics of these materials with one exception for 
Gelucire 44/14. This lipid with its waxy nature, low melting point was not suitable for 
examination under SEM due to sample damage from generated heat during the test.  
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On the other hand, TGA and DSC techniques were essential to understand decomposition 
and major thermal transition(s), respectively, of the studied samples. This was detailed under 
sections of thermoanalytical investigations. With regard to the DSC experiments, MTDSC 
permits the separation of overlapping phenomena and allowed greater detection of thermal 
events using developed method of ±0.265°C amplitude with a period of 100 seconds and 
underlying heating rate of 1°C min-1. As shown in Table 3.1, the temperatures below which 
these materials were thermally stable are high enough to perform extrusion above 
characterised Tg or Tm of these materials. It was recommended therefore that temperature of 
extrusion for these mixes to be selected far below the decomposition temperature of the 
component with the lowest thermal stability. This temperature could be suggested between 
10-20°C below the degradation onset. In this range of extrusion temperature, it would be still 
higher than glass transition temperature (Tg) or melting temperature (Tm) of the used 
constituents, ensuring proper mixing of the liquefied or melted components, respectively. 
Moreover, unpredicted thermal degradation due to rise of the set extruder temperature due to 
generated heat from the extruder screws’ friction would be minimized. In addition, less 
energy would be wasted. For mixes contain ibuprofen, the required processing temperature 
could be set lower than decomposition temperature of the suggested range and a bit lower 
than glass transition temperature or melting point of the used components, because of  
ibuprofen ability to act as a plasticizer (Kidokoro et al., 2001; Siepmann et al., 2006).  
 
Tested material  Estimated thermal 
stability range (°C) 
Estimated melting 
point temperature 
(Tm(onset),°C) 
Estimated glass transition 
temperature  
(Mid-point Tg,°C) 
Ibuprofen <140 75.7±0.2 -43.4±0.2 
Eudragit RS PO <170 - 53.3±0.5 
Sucrose <187 175.2±1.8 - 
Methyl cellulose <200 - 103.0±0.1 
Xantural®75 <235 - 37.7±2.6 
Pluronic® F127 <163 54.2±1.2 -63.5±0.7 
Gelucire 44/14 <150 32.1±1.4* - 
 
Table 3.1: Summary of the thermal properties of the raw materials (as received) 
intended for processing via HME, as estimated from the used TGA and MTDSC 
techniques. *: corresponds to the onset of the leading endothermic peak (see section 
3.3.2.6.1) 
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4.1 Introduction 
 
The previous chapter detailed characterisation of the constituent materials that were used 
throughout this study in the hot melt extrusion. This is of immense practical importance as 
the way in which pharmaceutical formulations act depends mainly upon the physicochemical 
properties of the components used. However, in order to have a better understanding of the 
formulation performance, it is essential to characterise the formulation as a whole. In this 
context attention was placed on providing comprehensive characterisation of hot melt 
extruded formulation of ibuprofen in Eudragit RS PO using a multi-disciplinary approach 
combining DSC, PXRD, SEM and ATR-FTIR techniques.  
 
This chapter is divided into four sections dealing with three objectives. The first objective is 
subdivided into finding suitable parameters to embed ibuprofen in Eudragit RS PO using 
HME and then examination of the drug solubility in this polymer. HME was selected as 
being an attractive approach for production of films intended for transdermal delivery, 
mainly due to avoidance of the use of organic solvents as detailed in Chapter 1. Thus, in a 
first step section 4.3.1 examines suitability of the selected extrusion temperature on thermal 
stability of ibuprofen-Eudragit RS PO blends. This is followed by section 4.3.2 which 
discusses theoretical and experimental approaches to predict miscibility between Eudragit 
RS PO and ibuprofen and how they correlate with the hot melt extrusion process. This is 
essential, as characterisation of drug solubility within a transdermal drug delivery system 
(TDDS) is one of the key parameters to understand and predict its performance, since flux is 
a function of solubility equilibrium (Ahmad et al., 2004). The second objective is to 
approximate equilibrium saturation solubility of the drug in the Eudragit RS PO extruded 
formulations via monitoring the phase separation in real time at high and low relative 
humidities as will be detailed in section 4.3.3. While assessment of the saturation 
concentration is non-trivial, there is uncertainty regarding how the solubility in a matrix 
alters on exposure to moisture. Indeed, while care may be taken to prevent product exposure 
to moisture during storage, this will not preclude sorption when that product is applied to the 
skin. Therefore, it is of interest to assess the saturation solubility of the TDDS in the dry 
state and in presence of moisture, thereby providing a better prediction of performance in 
situ. The third objective is to elucidate the tendency of ibuprofen-Eudragit RS PO extruded 
formulations for physical ageing through fragility assessment as will be discussed in section 
4.3.4. This can be taken into account when stabilization strategies are designed for the final 
product to ensure consistency of the mechanical properties and/or performance which could 
be affected by drug recrystallization. 
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4.2 Methodology 
 
4.2.1 Preparation of physical mixtures 
 
Physical mixes of ibuprofen and Eudragit RS PO were prepared for at least two major 
purposes. One of the purposes is to compare with the respective hot melt extruded systems, 
where known amounts of crystalline ibuprofen were physically mixed with Eudragit RS PO 
using pestle and mortar. This method was also used to prepare these blends for hot melt 
extrusion. A second purpose was estimation of the miscibility between ibuprofen and 
Eudragit RS PO using melting point depression approach. In this study, the physical 
mixtures of Eudragit RS PO containing 1%-90% by weight of ibuprofen were prepared and 
weighed (10 mg) in aluminium standard DSC pans. These pans were placed in desiccators 
containing phosphorous pentoxide at room temperature (~25°C) for one day to dry them and 
then taken out and crimped with aluminium lids for analysis.  
 
4.2.2 Preparation of hot melt extruded ibuprofen in Eudragit RS PO 
 
Hot melt extrusion process has a number of parameters to be optimized to allow proper melt 
embedding of the drug in polymeric carrier(s) as described in Chapter 1. The method used 
ultimately in this work was based mainly on selecting extrusion temperature which allows 
rotation of the screws with acceptable torque values. Torque values were considered 
acceptable when a homogenous extrudate is obtained with the minimal possible residence 
time of extrusion at the selected mixing speed. More importantly, the temperature was 
chosen below degradation temperatures of ibuprofen and Eudragit RS PO, which were 
determined using TGA in Chapter 2. The temperature was also selected from the 
recommended temperature range of performing extrusion as reviewed by Crowley et al. 
(2007), wherein a temperature of 15-60°C above the melting or the glass transition 
temperature is usually set to achieve proper mixing. Therefore, physical mixes of ibuprofen-
Eudragit RS PO  were  compounded in a co-rotating twin screw extruder (Haake Minilab  II 
Micro Compounder) using a temperature of 100˚C from the feed to the die end and a screw 
speed of 100 rpm for four minutes. The resulted extrudates were prepared at different drug 
loadings until opaque extrudate was produced. Therefore, a concentration range of 1-40% 
(w/w) of ibuprofen was used. These extrudates were collected and cooled along a 
customised conveyer belt and kept in polyethylene bags for further evaluation.  
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4.2.3 General methods 
 
A wide variety of techniques were used in this chapter to perform characterisation of the 
physical mixes with corresponding extruded systems of ibuprofen in Eudragit RS PO. TGA 
was used to estimate thermal stability as a function of weight loss of ibuprofen-Eudragit RS 
PO physical mixes. For this purpose, isothermal heating mode of a TA Instruments TGA 
Q5000 IR was employed to obtain the thermogravimetric analysis curves. Samples (10-12 
mg) were held at 100°C for four minutes and the percentage weight loss was recorded. The 
samples were heated at a rate of 100°C/min to reach the desired isothermal temperature. This 
technique was also used to determine water content of the extruded samples during the 
storage study (60%RH/25°C). The stored samples (~10 mg) were taken out from humidity 
chambers and were heated at 10°C/min from 30°C to 250°C. All TGA runs were performed 
in open aluminium pans with a dry nitrogen gas purged at flow rates of 25 ml min-1 and 10 
ml min-1 through the furnace and TGA head, respectively. 
 
Conventional DSC and MTDSC measurements were carried out using TA Instrument DSC 
Q1000, equipped with a refrigerated cooling system (RCS) and calibration was performed 
prior each analysis as detailed in Chapter 2. Data were treated mathematically using TA 
Universal Analysis 2000 software and nitrogen was used as the purge gas through the DSC 
cell at a flow rate of 50 ml/min. TA instruments standard pans were used for all calorimetric 
studies and the mass of each empty sample pan was matched to the mass of the empty 
reference pan within ±0.05 mg and all measurements were performed in triplicate. In the 
MTDSC experiments, the method developed in Chapter 3 was employed. Using amplitude 
of ±0.265 °C, period of 100 seconds and underlying heating rate of 1°C/min, samples were 
subjected to two steps in this method. The first step was equilibration at -70˚C, isothermal 
heating for 5 minutes followed by a second step of heating to 100˚C. The standard mode of 
this method (without modulation) was applied to estimate miscibility between Eudragit RS 
PO and ibuprofen using melting point depression approach. Thus, samples of their physical 
mixtures of approximately 10 mg at different ibuprofen loadings were prepared as described 
in section 4.2.1 and examined accordingly. The slow heating rate in this method (1°C min-1) 
is believed to provide enough time for mixing through the timescale of the experiment, 
therefore to provide good approximation to the efficient mixing provided in hot melt 
extrusion technology. However, the MTDSC of this method was used to study thermal 
transition of the extruded samples throughout this study and the detected glass transition 
temperatures were in all cases taken at the midpoint of the transitions from the reversing heat 
flow signals. All measurements were performed in triplicate. 
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Standard (conventional) DSC was also used to estimate fragility of the fresh extruded 
samples using a protocol of cooling at various rates, followed by heating at a constant rate 
through the glass transition region of these samples. Therefore, fresh extruded samples 
(4.00-6.00 mg) of Eudragit RS PO loaded with ibuprofen 10-30% (w/w) were subjected to 
three steps using 10˚C/min as the reheating rate and on the range which covers glass 
transition temperature region for the tested extrudates, determined previously using 
MTDSC. The first step was equilibration at 70˚C, isothermal heating for 5 minutes and then 
a second step of cooling to -20˚C at different rates for each cycle: 2, 5, 10 and 20 ˚C/min. In 
each individual cooling rate experiment, isothermal condition was maintained for 5 minutes 
at -20˚C. The third step involved reheating to 70˚C (10˚C/min). cDSC was also used to 
amorphize crystalline ibuprofen by a quench from its melt, as one of the most widely used 
strategy to produce amorphous material. Therefore, crystalline ibuprofen in open standard 
aluminium pan was heated at 10°C/min to 100°C, then cycled rapidly to -70°C at 20°C/min 
followed by heating at 10°C/min to 100°C. 
 
Attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) spectrometry (Bruker 
IFS 66/S, Burker optics equipped with a Golden Gate ATR accessory from Specac Limited) 
was used to investigate the molecular interactions between ibuprofen in Eudragit RS PO in 
the extruded formulations. Therefore spectra of the physical mixes of these components 
were compared to the corresponding extruded systems over a range of 4000-550 cm-1, 32 
scans at a resolution of 4 cm-1. Furthermore, this method was utilized to confirm 
recrystallization of ibuprofen in the extruded samples, qualitatively. Omnic software 
(version 6.1a) was used to analyze results and perform comparison.  
 
Using methods documented in Chapter 3, qualitative PXRD was used to detect crystalline 
ibuprofen in the extruded samples as compared to the respective physical mixes, whereas 
SEM was used to visualise crystalline ibuprofen of the extruded samples and thus detecting 
any sign of phase separation on that basis. For that purpose, morphological features of the 
surface and cross sections of the extruded formulations were examined. Storage studies of 
extruded ibuprofen-Eudragit RS PO films with drug loadings of 1-40% (w/w) were 
performed under different humidity levels for one month. The extruded films were stored at 
0%RH and 60%RH, both at room temperature (24±1°C). Airtight jars were used as humidity 
chambers with phosphorus pentoxide to achieve dryness (0%RH), and saturated salt 
solutions of sodium bromide in distilled water to control relative humidity to a level of 
~60%RH at room temperature (O’Brien, 1948). These chambers were prepared two days 
before sample storage to enable equilibrium to be achieved. Humidity strips were incubated 
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in these chambers to check the relative humidity values. All weighing in this work was 
performed using XS205, Dual range analytical balance (Mettler Toledo). 
 
4.3 Results and discussion 
 
4.3.1 Investigation into thermal stability of the ibuprofen-Eudragit RS PO physical 
mixes for processing via hot melt extrusion 
 
Temperature used for hot melt extrusion is important processing parameter, which is 
selected and optimized on the basis of uniform extrudate formation and avoiding thermal 
decomposition. The first condition was met using 100°C during extrusion of ibuprofen-
Eudragit RS PO blends with acceptable torque values, which will be discussed in the 
following section. The second condition; however, can be evaluated through addressing of 
the thermal degradation of these materials. Thermal degradation of the ibuprofen and 
Eudragit RS PO was detailed in Chapter 3 using TGA and showed that these materials 
would be stable at relatively high temperature as 100°C. However, in this study the 
isothermal mode of thermogravimetric analysis was used to gain insight into thermal 
stability of the used ibuprofen-Eudragit RS PO blends with respect to HME processing 
temperature and time. Therefore, these blends were held at 100°C for the selected dwelling 
time inside the extruder (4 minutes), with the objective of mimicking the used hot melt 
extrusion conditions. 
 
Figure 4.1 and Figure 4.2 show the comparative TGA results as a function of drug loading of 
the examined ibuprofen-Eudragit RS PO physical mixes. It was noted that weight loss is 
increased with increasing Eudragit RS PO content in these mixes. This is likely to be due to 
moisture desorption from this polymer as shown previously in Chapter 3. However, the 
relative thermal stability after four minutes of heating at 100°C for all these mixes can be 
considered acceptable, due to insignificant observed weight losses (less than 1% (w/w)) at 
all the studied drug loadings. This supports the use of these parameters during extrusion of 
ibuprofen and Eudragit RS PO with minimal concerns of thermal instability.  
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Figure 4.1: TGA weight loss profiles of ibuprofen-Eudragit RS PO physical mixes at 
different drug loadings (w/w %) 
 
 
 
Figure 4.2: Total weight loss percentages of ibuprofen-Eudragit RS PO physical mixes 
with different drug loadings (w/w %) measured at 100°C for four minutes using TGA 
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4.3.2 Assessment of the miscibility and compatibility of ibuprofen-Eudragit RS PO hot 
melt extruded systems 
 
Miscibility behaviour of the drug with the polymer and possible solubility in solid 
dispersions can be estimated using solubility parameters, which are directly related to the 
cohesive energy density of a molecule (Greenhalgh et al., 1999). The solubility parameters 
of the ibuprofen and Eudragit RS PO were correlated with the Hansen (partial) solubility 
parameter model. This model was proposed to approximate total cohesive energy density 
(Savova et al., 2007) and can be utilized to predict the compatibility of pharmaceutical 
materials (Mohammad et al., 2011). In this model, the total energy is divided into individual 
components, namely, dispersion, polar and hydrogen bonding. On the basis that “like 
dissolves like”, the similarity of the relative strengths of these forces that present in the 
studied materials relates to possible good solubility (Stefanis and Panayiotou, 2008). This 
can be estimated through calculation of the total solubility parameter (δt) as follows 
(Hansen, 1967): 
 
δt	= (δd2+δp2+δh2)0.5   																																																																					(Eq.4.1) 
 
where δd is the dispersion Hansen solubility parameter, δp is the polar Hansen solubility 
parameter and δh is the hydrogen-bonding Hansen parameter solubility parameter. Using 
group contributions of the structural groups of the studied materials as complied with 
Krevelen and Hoftyzer (1976), these solubility parameters can be predicted as follows: 
 
	δd		=  ∑Fdi
V
 																																																																																		(Eq.4.2) 
	δp = 			!∑	Fpi^2
V
																																																																										(Eq.4.3) 
δh		=			#∑Ehi
V
																																																																																(Eq.4.4) 
 
where (i) is the structural group within the molecule, (Fdi) is the group contribution to the 
dispersion forces, (Fpi) is the group contribution to the polar forces, (Ehi) is the group 
contribution to the hydrogen bonding energy, and (V) is the molar volume. 
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Accordingly the overall value of solubility parameters (δt) for ibuprofen and Eudragit RS 
PO were calculated based on the group contributions of their structural components, which 
were depicted in Chapter 2. These values were found equal to 19.26 and 17.45 (J/cm3)1/2 for 
ibuprofen and Eudragit RS PO polymer, respectively. Therefore a good miscibility between 
these two components is predicted as difference less than ± 6.3 (J/cm3)1/2 indicates good 
miscibility (Sears and Touchette, 1982). An example of the solubility parameter calculation 
is provided in Table 4.1. 
 
 (A) 
Structural group Fdi 
(J1/2.cm3/2.mol-1) 
Fpi 
(J1/2.cm3/2.mol-1) 
Ehi 
(J/mol) 
3(CH3) 1260 0 0 
1(CH2) 270 0 0 
2(CH) 160 0 0 
1(COOH) 530 420 10000 
1Phenylene 1270 110 0 
 
(B) 
Equation (4.2) δd  
(J1/2.cm3/2) 
δp  
(J1/2.cm3/2) 
δh 
(J1/2.cm3/2) 
 17.76 2.21 7.13 
Equation (4.1)                                  δt = 19.26 J1/2.cm3/2 
 
Table 4.1:  Example of the solubility parameter calculation (δt) using component group 
contributions of ibuprofen (A) (Krevelen and Hoftyzer, 1976) according to Equations 
4.1 to 4.2 (B) 
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In recent years, a melting point depression thermodynamic model has also been 
demonstrated as a feasible approach to predict miscibility of pharmaceutical materials 
(Djuris et al., 2013; Marsac et al., 2006; Papageorgiou et al., 2011; Yang et al., 2013). 
Marsac et al., (2006) suggested application of the Flory-Huggins theory to estimate drug-
polymer miscibility through determination of the interaction parameter “χ”. In this work, “χ” 
was determined experimentally from melting point depression data using DSC and the 
following equation:  
 
(1/TMmix) – (1/TMpure) = (-R/∆Hfus) [ lnΦdrug +  (1- 1/m) Φpolymer + χ Φ2polymer]            (Eq.4.5) 
 
where  TMmix is the melting temperature of the drug in the presence of the polymer, TMpure is 
the melting temperature of the drug in the absence of the polymer, ∆Hfus  is the heat of fusion 
of the pure drug, and m is the ratio of the volume of the polymer to that of the lattice site 
(defined here by the volume of the drug), Φdrug  is the volume fraction of the drug, Φpolymer  is 
the volume fraction of the polymer, χ is the Flory-Huggins interaction parameter and R is the 
universal gas constant. This equation provides an estimate of the interaction parameter at 
temperatures close to the melting point of the drug and requires that there is enough physical 
interaction between the drug and the polymer for melting point depression to be manifested, 
in addition to thermal stability over the temperature range of interest.  
 
The melting point depression of crystalline ibuprofen blended with amorphous Eudragit RS 
PO was observed with increasing the volume fraction of this polymer as shown in Figure 4.3 
(A) and (B). The temperature reduction is predicted to be caused by the decrease of the 
chemical potential of the drug by the addition of a miscible diluent (Papageorgiou et al., 
2011). The occurrence of the melting point depression of the ibuprofen can be explained by 
the ease of possible interaction or mixing between the molten drug and the polymer at the 
used temperature (100°C). This temperature is higher than the melting point of ibuprofen 
(74.7˚C as the extrapolated onset value and 76.4˚C “offset value”, Chapter 3) and glass 
transition temperature of Eudragit RS PO (53.3±0.5°C, Mid-point Tg, Chapter 3), thus 
molten drug is believed to equilibrate with the “liquid-like” polymer, wherein the melting 
point depression is kinetically favourable to be manifested. 
 
 
 
 
 
Formulation development and physicochemical characterisation of hot melt extruded 
ibuprofen-Eudragit RS PO films for transdermal delivery 
Chapter 4 
 
146 
 
(A) 
 
 (B) 
 
 
Figure 4.3: Exemplary DSC thermograms (heating rate of 1°C min-1) of ibuprofen-
Eudragit RS PO physical mixtures compared to the pure ibuprofen (A). Extrapolated 
onset of melting of ibuprofen as a function of volume fraction of Eudragit RS PO (Each 
data point represents the mean±S.D. of three measurements), measured at a scan rate 
of 1°C min-1(B) 
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The resultant equilibrium melting temperatures can be then analyzed using Equation (4.5) 
and plotted as shown in Figure 4.4 to estimate Flory-Huggins interaction parameter “χ”. The 
value of this parameter can be derived from the slope of this plot and was (-0.6559). This 
negative value predicts miscibility (Marsac et al., 2006) based on the data from the volume 
fraction of the polymer that yielded linear relationship (R2 value of 0.9794 was obtained). 
Furthermore, this interaction parameter was used to estimate the drug miscibility limit based 
on the following equation: 
 
Lnγ
 drug = ln (Φdrug/x drug) + (1-(1/m)) Φ Polymer + χ Φ2Polymer                                       (Eq.4.6) 
 
where γ (drug) is the activity coefficient of the drug in the polymer at solubility limits, m is the 
ratio of the volume of the material to the lattice site, x is the drug solubility mole fraction, χ 
is the Flory-Huggins interaction parameter and Φ is the volume fraction of the material as 
modelled by Marsac et al. (2006). With the assumption that the activity coefficient is the 
same at the solubility limit of the drug in the polymer (Marsac et al., 2009), the solubility 
limit of ibuprofen in Eudragit RS PO was calculated and was found to be around 47% (w/w). 
 
 
 
Figure 4.4: Estimation of Flory-Huggins interaction parameter between ibuprofen and 
Eudragit RS PO based on Eq. (4.5). Each data point represents the mean±S.D. of three 
measurements 
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Annex 13, EMA/CHMP/ICH/405290/2010), the molecular weight of ibuprofen, which 
equals 206.28 g/mol and molecular weight of Eudragit RS PO (assuming 100 repeat units in 
the polymer; Evonik, n.d.), which equals 35000 g/mol. 
 
At this point, solubility parameter calculations (theoretical approach) and interaction 
parameter (experimental approach) indicated good miscibility between ibuprofen and 
Eudragit RS PO. The latter approach predicted ibuprofen miscibility up to a certain limit in 
Eudragit RS PO (~47% w/w). The question therefore arises as to how does this agree with 
the solubility or dispersibility of the hot melt extruded ibuprofen in Eudragit RS PO, and 
what types of molecular interactions, if any, exist between these two components. 
 
To address these issues, the hot melt extruded systems of ibuprofen in Eudragit RS PO were 
prepared and characterised using MTDSC, PXRD, SEM and ATR-FTIR techniques. For the 
hot melt extrusion process, the aforementioned parameters in section 4.2 were suitable to 
produce translucent hot melt extrudates of Eudragit RS PO containing 1-35% by weight of 
ibuprofen. However at 40% (w/w) drug loading the opacity was higher compared to other 
extrudates as shown in Figure 4.5. It was also observed that torque values inside the extruder 
were decreased gradually as a function of increased drug loading as illustrated in Figure 4.6. 
This parameter is directly proportional to the viscosity of the molten material. This implies 
that ibuprofen decreased the melt viscosity and could be explained by the ability of this drug 
to work as a plasticizer (Kidokoro et al., 2001; Siepmann et al., 2006), facilitating the 
movement of the mixture inside the extruder towards the die system. 
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Figure 4.5: Photographs of freshly prepared hot melt extruded ibuprofen in Eudragit 
RS PO produced at different drug loadings between 1-40 % (w/w) 
 
 
 
Figure 4.6: Variation of the observed torque values during hot melt extrusion as a 
function of changing ibuprofen loadings (w/w %) in Eudragit RS PO. Each data point 
represents the mean±S.D. of three observations 
 
These extrudates were characterised by single glass transition temperatures over a 
concentration range of 1-35 % (w/w) drug loading as indicated in the MTDSC 
measurements shown in Figure 4.7. In this figure, the reversing heat flow signals were used 
to help in the correct assignment of the glass transitions of these extrudates, as detailed in 
Chapter 2. The presence of single glass transition temperature implies single phase system, 
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which refers as to solid solution system with the drug molecularly dispersed in the interstitial 
spaces between the amorphous polymer chains (Crowley et al., 2007). Moreover, the glass 
transition temperature of these extruded systems decreased with increasing drug loading as 
indicated in the shift of the arrows in Figure 4.7. This clearly shows that the ibuprofen is 
acting as efficient plasticizer for Eudragit RS PO. In contrast to these systems, hot melt 
extruded systems at 40 %(w/w) drug loading showed a broad melting endotherm in the 
MTDSC measurements (Figure 4.8), thereby a binary-phase system was formed or solid 
dispersion. This system is characterised with a glass transition temperature at 23.2 ±1.9°C 
(n=3, Mid-point Tg), representing the amorphous phase. In addition, this system showed an 
endothermic peak related to the melting of the surplus ibuprofen with a depressed 
extrapolated onset melting temperature of 57.4±0.5°C (n=3), which represents the crystalline 
phase.  
 
 
 
Figure 4.7: MTDSC reversing heat flow signals of ibuprofen-Eudragit RS PO 
extrudates with different drug loadings (w/w%) in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. Arrows indicate the assigned Mid-point glass transition 
temperatures 
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Figure 4.8: MTDSC heating scan of hot melt extruded 40% (w/w) ibuprofen in 
Eudragit RS PO in standard aluminium pans. Underlying scan rate of 1°C min-1 with a 
modulation amplitude of ±0.265°C and a period of 100 seconds 
 
The compositional variation of the glass transition temperature of the previously described 
extruded systems of ibuprofen and Eudragit RS PO was further studied using Gordon-Taylor 
(G-T) equation. This equation is used most often in the amorphous pharmaceutical materials 
due to its simplicity and reliability (Zografi and Hancock, 1997). Assuming ideal behaviour 
of no specific interactions and perfect volume additivity during mixing of the studied 
mixtures, this equation can be used to predict glass transition temperature of these mixes 
with small positive or negative deviations. These deviations might indicate drug-polymer 
interaction as reviewed by Qian et al. (2010).  
 
To start with the first implication of this equation, it can be represented as follows (Gordon 
and Taylor, 1952): 
 
Tgmix= (Tg1w1+Tg2w2K)/ (w1+Kw2)                                                                      (Eq.4.7)  
 
where Tg1 and Tg2 are the glass transition temperatures of components 1 and 2, respectively, 
whereby  Tgmix is the predicted glass transition temperature of their mixture, w1 and w2 are 
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the weight fractions of  component 1 and 2 in the mixture. K is a sample-specific parameter 
which can be estimated using the popular Simha-Boyer rule (Simha and Boyer, 1962): 
 
K ≅ ρ1Tg1/ρ2Tg2                                                                                                   (Eq.4.8) 
 
where ρ1 is the density of component 1 and ρ2 is the density of component 2. Using 
Equations 4.7 and 4.8, the predicted theoretical values of glass transition temperatures of the 
binary extruded systems of ibuprofen (component 1) and Eudragit RS PO (component 2)  
with varying compositions is shown in Figure 4.9. As can be seen from this Figure, the 
experimental data deviate negatively from the theoretical values obtained from the G-T 
equation up to 35% (w/w) drug concentration. This could be ascribed to the aforementioned 
plasticizing effect of the ibuprofen, wherein the glass transition temperature of these blends 
was lowered with increasing drug load. However, at 40% (w /w) ibuprofen loading, excess 
drug recrystallized which may limit the sliding motion of the materials in the mix and results 
in the observed increase of the glass transition temperature that almost meets with the 
predicted or theoretical value derived from G-T model. 
 
 
 
Figure 4.9: Theoretical glass transition temperature values predicted by G-T equation 
of the ibuprofen-Eudragit RS PO mixes in comparison to the experimental values 
obtained from reversing heat flow signals of the MTDSC measurements (1°C min-1) of 
their equivalent hot melt extruded systems (Figure 4.7 and 4.8) 
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The Gordon-Taylor equation can also be used to evaluate random miscibility of the 
pharmaceutical binary glass systems at a segmental level (Fukuoka et al., 1989), or as a 
conjunction tool to the ATR-FTIR measurements  to investigate possible interaction between 
the studied components (Fujimori et al., 2005) through the following  rearrangements: 
 
Tgmix = -k [(Tgmix-T2) w2/w1] + T1                                                                                                                                (Eq.4.9)  
 
where subscripts 1 and 2 denote components 1 and 2, respectively, w1 and w2 are the weight 
fractions of component 1 and 2. T1 and T2 are the Tg values of components 1 and 2, and k is 
a coefficient defined by k= ∆β1/∆β2, where ∆β expresses the difference of the expansion 
coefficient below and above Tg. Considering component 1 as Eudragit RS PO (E) and 
component 2 as ibuprofen (IBU), the resulted plot of the glass transition temperatures of the 
ibuprofen-Eudragit RS PO systems according to Equation 4.9 is depicted in Figure 4.10. It 
can be observed that a linear relationship was established using the theoretical glass 
transition temperatures of the binary mixtures of ibuprofen and Eudragit RS PO. This 
complies with the assumption of the G-T equation of the “ideal” behaviour of no orienting 
interaction and volume additivity (Moustafine et al., 2006). However, using the experimental 
or observed glass transition of these mixes, a large negative deviation was observed from the 
“ideal” behaviour and the linearity was lost. This indicates that the randomness of the 
mixing between these components is less likely to occur, with a possibility to have specific 
interaction(s). The latter could be further explored in the coming discussion using ATR-
FTIR measurements. 
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Figure 4.10: Analysis of the ibuprofen-Eudragit RS PO system according to the G-T 
Equation (4.9). Theoretical glass transition temperatures of these systems (Tgmix) were 
predicted according to G-T model whereas the observed Tgmix were obtained from 
reversing heat flow signals of the MTDSC measurements at 1˚C/min of their equivalent 
hot melt extruded systems (Figure 4.7 and 4.8 ) 
 
Overall, the miscibility of the hot melt extruded systems of ibuprofen in Eudragit RS PO 
exhibiting single glass transition temperatures up to 35% (w/w) drug loading might not be 
infallible indicator of the miscibility of the drug as molecular dispersion within these 
matrices. Thus, further characterisation using techniques like PXRD, SEM and ATR-FTIR 
can add more details to assess the possible one-phase solid solution formation, as will be 
demonstrated in this discussion. Figure 4.11 shows an overlay of the X-ray powder 
diffraction profiles (diffractograms) of the hot melt extruded systems of ibuprofen in 
Eudragit RS PO at different drug loadings in comparison to their equivalent physical mixes. 
The diffraction peaks appeared in the physical mixtures over the concentration range 1-35 
%( w/w) of ibuprofen were absent in all diffractograms of the equivalent extrudates, which 
showed alternatively broad halos, indicating amorphicity of the extruded systems. However, 
at higher ibuprofen content of 40% (w/w), extruded system showed clear diffraction peaks 
related to the crystalline ibuprofen. Nevertheless, in comparison to the corresponding 
physical mixture, the diffractogram shows a visible decrease in the resolution of the 
ibuprofen characteristic peaks, suggesting a decrease in the structural uniformity and an 
increase in the presence of the amorphous drug in the extruded system. 
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(A) 
 
 
(B) 
 
 
Figure 4.11: PXRD diffractograms of ibuprofen, Eudragit RS PO, physical mixtures of 
ibuprofen-Eudragit RS PO systems at different drug loadings (w/w %) (A) and fresh 
hot melt extruded systems equivalent to the studied physical mixes (B)                                  
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Microscopic examination using SEM of the fresh hot melt extruded systems of ibuprofen 
and Eudragit RS PO is shown in Figure 4.12 (I) and (II). The surfaces and cross sections of 
these extruded systems up to 35% (w/w) drug loading were observed with no visible drug 
crystals, supporting drug miscibility within the Eudragit RS PO matrices. However, 
ibuprofen crystals were visible on both the surface and the cross section of the extruded 
system at 40 %(w/w) drug loading, suggesting that ibuprofen content exceeded the drug 
solubility in the polymer (i.e. supersaturation). Less importantly, the effect of increasing 
drug loading was shown to enhance the smoothness of the examined surfaces and observed 
elasticity during the cut of the extruded systems for SEM examination up to 35% (w/w) drug 
loading, which could be ascribed to ibuprofen plasticizing effect. 
 
 (I) Surfaces 
     
    
    
                                      
Figure 4.12: SEM micrographs illustrating the surface morphologies of fresh hot melt 
extruded ibuprofen in Eudragit RS PO (I) at different drug loadings (A-F), whereby A 
= 1%(w/w), B = 5%(w/w), C = 10%(w/w), D = 15% (w/w), E = 20%(w/w), F = 25 %   
(w/w), G = 30 %(w/w), H = 35 %(w/w) and I = 40 %(w/w) 
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 (II) Cross sections 
     
   
   
                                      
Figure 4.12 (Contd.): SEM micrographs illustrating the cross sections of fresh hot melt 
extruded ibuprofen in Eudragit RS PO (II) at different drug loadings (A-F), whereby A 
= 1%(w/w), B = 5%(w/w), C = 10%(w/w), D = 15% (w/w), E = 20%(w/w), F = 25 %   
(w/w), G = 30 %(w/w), H =35 %(w/w) and I = 40 %(w/w) 
 
In summary, MTDSC analysis, PXRD results and SEM images revealed that a molecular 
dispersion as solid solution is formed in the studied hot melt extruded systems when the 
content of ibuprofen does not exceed 35% (w/w) in the Eudragit RS PO. These extrudates 
were translucent, characterised by a single glass transition temperature (which decreased 
with drug loading from 53.3°C to 7.2°C for 0 to 35% loaded systems) and the absence of 
crystalline diffraction pattern observed using PXRD, supported by SEM images which 
revealed clarity from visible ibuprofen crystals. On the other hand, higher content of 
ibuprofen at 40%(w/w) drug loaded extrudate represents the supersaturation level, 
characterised by  a broad endothermic peak in MTDSC measurements, diffraction peaks in 
PXRD results related to surplus crystalline ibuprofen. Drug recrystallization was visible in 
the SEM images of these extrudates. In the light of these results, it could be also inferred that 
performed solubility parameter calculations together with the used thermodynamic model of 
melting point depression approach elucidated good correlation with the experimental 
findings of the solubility of ibuprofen in Eudragit RS PO hot melt extrudates, which might 
suggest their usefulness for prediction of drug-polymer miscibility  prior setting-up HME 
A B C
D E F 
G H I 
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process. However, it is worth pointing out that observed overestimation of the solubility 
from melting point depression predictive model is likely due to estimation at higher 
temperatures close to the melting of the drug. 
 
The preliminary investigation of the possible interactions between ibuprofen and Eudragit 
RS PO using G-T model is now evaluated using ATR-FTIR spectroscopy. Thus the nature 
and the extent of possible interaction(s) between ibuprofen and Eudragit RS PO at different 
drug loadings can be investigated. Therefore spectra of Eudragit RS PO, crystalline 
ibuprofen, amorphous ibuprofen, physical mixtures of them at different drug loadings in 
comparison to their equivalent extruded systems are shown in Figure 4.14 and Figure 4.15. 
 
As described in the methodology (section 4.2), amorphous ibuprofen was prepared in DSC 
pans by quenching of its melt. As illustrated in Figure 4.13 the crystalline ibuprofen 
underwent melting in the first heating cycle. In the second cycle, the melt was rapidly cooled 
(quenched) and crystallization was avoided (absence of exothermic peak in the DSC 
thermogram). On subsequent heating the glass transition of ibuprofen was clearly seen in the 
third cycle with no melting endotherm. Thus it was concluded that ibuprofen was 
amorphized and tested immediately using ATR-FTIR. Amorphous material can be 
differentiated from crystalline material using ATR-FTIR technique. While crystalline 
material is usually characterised by sharp absorbance bands, the amorphous state can result 
in band broadening or disappearance in a definite broadening case. This is attributed to the 
non-specific intermolecular bonding in comparison to the crystalline material. 
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 (I) 
 
(II) 
 
(III) 
 
 
Figure 4.13: Amorphous ibuprofen production using cDSC method. Highlighted green 
cycle represents: (I) first cycle of the heating at 10°C/min, (II) second cycle of rapid 
cooling (quenching) at 20°C/min and (III) third cycle of reheating at 10°C/min 
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The reference spectra of the ibuprofen in Figure 4.14 (A) showed that peaks in the region of 
900-550 cm-1, due to the bending vibrations of aromatic ring, can be used to mark the 
differences between the amorphous and crystalline state of this drug. In particular 
absorbance band around 779 cm-1, due to the (=C-O-bending) of carboxylic acid (Bhende 
and Jadhav, 2012). As seen in Figure 4.14 (A) this band can be used as a characteristic peak 
corresponding to the crystalline ibuprofen due to its marked sharpness compared to the 
amorphous ibuprofen. In addition, it does not overlap with the Eudragit RS PO bands 
observed in Figure 4.14 (B).  
 
(A) 
 
(B) 
 
 
Figure 4.14: Reference ATR-FTIR spectra of the crystalline, amorphous ibuprofen (A) 
and Eudragit RS PO (B) 
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In the ATR-FTIR spectrum of crystalline ibuprofen carboxylic acid appears around  1708 
cm-1, hydroxyl stretching vibration in the 3100-2950 cm-1 region, aromatic stretch (C=C)  in 
the 1507-1510 cm-1 region and bending peaks of aromatic ring in the 900-550 cm-1 region 
(Figure 4.14(A)). On  the other hand Eudragit RS PO spectrum shows characteristic peaks 
around 1723 cm-1 (carbonyl stretching ), at 1145 cm-1 due to (C-CO-C) stretching in the ester 
group and (CH2-) symmetric bending at 1450 cm-1(Figure 4.14 (B)). The ATR-FTIR spectra 
of the physical mixtures of crystalline ibuprofen in Eudragit RS PO and their equivalent 
extrudates are presented in Figure 4.15. It is noteworthy that spectra of the surfaces of the 
extruded systems are effectively identical to their cross sections (data not shown here) at all 
drug loadings, indicating possible homogeneity of the extruded formulations (Qi et al., 
2008a).  
 
The carbonyl stretch modes appear around 1722-1717cm-1 in all the physical mixtures, 
which associate the stretching of the carboxyl group of the drug and the ester group of the 
polymer (Figure 4.15 (A)). These modes did not change in the corresponding extrudates 
(Figure 4.15 (B)). Notably, the Eudragit RS PO bands hid most of the peaks of ibuprofen in 
the extruded systems in comparison to their physical mixes in the 1450-550 cm-1 region. 
However, the breadth (bandwidth) of these bands was slightly more relative to the Eudragit 
RS PO, suggesting the presence of diffused (broadened) amorphous ibuprofen bands. This 
hypothesis is supported by the appearance of characteristic crystalline peak of ibuprofen at 
40 %( w/w) drug loading in these extrudates as highlighted in Figure 4.15 (B). Thus, when 
the concentration of the drug exceeded the miscibility in the polymer, the ibuprofen 
recrystallized and its bands become more distinguished (sharpened) and appeared in this 
region (1450-550 cm-1) similar to the physical mix, which otherwise contains crystalline 
ibuprofen. Overall, these observations ruled out the possibility of chemical interaction 
between ibuprofen and Eudragit RS PO after being extruded but supported previous results 
obtained by MTDSC, PXRD and SEM findings  that maximum drug load for the production 
of glassy solid solution of the extruded ibuprofen-Eudragit RS PO systems is 35% (w/w). 
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 (A) 
 
(B) 
 
 
Figure 4.15: ATR-FTIR spectra of ibuprofen-Eudragit RS PO physical mixtures at 
different drug loadings (w/w %) (A) and their corresponding fresh hot melt extruded 
systems (B). Absorption intensities of these spectra vary. Used “marker” region for 
crystalline ibuprofen is enclosed in orange rectangle 
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4.3.3 Influence of the relative humidity on the saturation solubility of ibuprofen in 
Eudragit RS PO extrudates  
 
The previous section revealed what can be considered as the “apparent” solubility of the 
ibuprofen in Eudragit RS PO extrudates on freshly basis. This is because the complexities 
associated with the estimation of the actual degree of the solid solubility of these extruded 
systems. For example, this parameter is expected to be influenced by the phase behaviour of 
the extruded systems with time, after removal of the experienced intense mixing and 
subsequent stress during the HME process. In addition, the meta-stability of the amorphous 
material and tendency towards recrystallization as a function of time and other perturbation 
factors such as elevated temperatures or exposure to moisture. Thus, the following 
discussion will focus on defining the approximate equilibrium saturation solubility of the 
drug in the Eudragit RS PO extruded systems in terms of their physical stability. In other 
words, the solid saturation solubility value will represent the drug loading in the extruded 
system before any inclination to phase separation or drug recrystallization after storage at the 
chosen condition. 
 
4.3.3.1 Investigations into the saturation solubility of hot melt extruded ibuprofen in 
Eudragit RS PO after storage study at 0% relative humidity 
 
After storage under dry conditions (a relative humidity of 0% at ~25°C) for one month, the 
aged samples of ibuprofen-Eudragit RS PO extrudates up to 35% (w/w) drug loading were 
transparent. Furthermore, they were characterised by only single glass transition 
temperatures as assigned from the MTDSC reversing heat flow signals in Figure 4.16. These 
observations were similar to the fresh samples (previous section), suggesting that aged 
samples remained as solid solutions. However, opaque extrudate at 40% (w/w) ibuprofen 
loading converted into white colour. In addition, the drug melt enthalpy (ΔHmelt) was 
relatively higher than fresh samples as illustrated in the MTDSC total heat flow signals in 
Figure 4.17. These observations indicate increased crystallinity at this drug loading after 
ageing, which is reasonably expected in the light of known meta-stability associated with 
supersaturated systems. 
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Figure 4.16: MTDSC reversing heat flow signals of ibuprofen-Eudragit RS PO 
extrudates with different drug loadings (w/w%) after ageing for one month at 
0%RH/25°C. Underlying scan rate of 1°C min-1 with a modulation amplitude of 
±0.265°C and a period of 100 seconds. Arrows indicate the assigned Mid-point glass 
transition temperatures 
 
 
 
Figure 4.17: Representative MTDSC heat flow signals (total and reversing) of 
ibuprofen-Eudragit RS PO extrudate at 40% (w/w) drug loading measured for fresh 
samples and after ageing for one month at 0%RH/25°C. Underlying scan rate of 1°C 
min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds 
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Figure 4.18 compares the measured glass transition temperatures of the studied aged 
extrudates with those observed just after extrusion (fresh extrudates). This figure illustrates a 
slight increase of the glass transition temperature after ageing under dry conditions over the 
concentration range of 1-35% (w/w) ibuprofen loading. Conversely, a clear increase was 
observed at 40% (w/w) drug loading. This reflects the dynamic of these systems while they 
are trying to equilibrate after the stress experienced during the extrusion process. On the 
other hand, increased ibuprofen recrystallization at 40% (w/w) concentration after ageing 
was associated with higher Tg value than fresh extruded system. This could be explained by 
possible limited plasticizing effect contributed by ibuprofen on the glass transition 
temperature of Eudragit RS PO after its separation as a crystalline phase. 
 
 
 
Figure 4.18:  Comparison  between glass transition temperatures (Mid-point Tg) of the 
fresh samples and samples stored for one month at 0%RH/25°C of the hot melt 
extruded ibuprofen in Eudragit RS PO systems  at different drug loadings (w/w%). Tg 
values were obtained from reversing heat flow signals of the MTDSC measurements at 
1˚C/min. Each data point represents the mean±S.D. of three measurements 
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The PXRD results supported MTDSC results. Figure 4.19 shows an overlay of PXRD 
diffractograms (profiles) of the aged extruded samples at different ibuprofen loadings. 
Compared to the fresh samples studied in the previous section (Figure 4.11), the PXRD 
patterns over the concentration range of 1-35% (w/w) drug loading gave a similar 
characteristic amorphous halo, thus no indication of crystallinity. However, extruded 
samples at 40% (w/w) ibuprofen loading showed a visible increase in the resolution of the 
characteristic ibuprofen peaks, indicating an increase in the structural uniformity and 
crystalline material.   
 
 
 
Figure 4.19: PXRD diffractograms of hot melt extruded ibuprofen-Eudragit RS PO 
systems at different drug loadings (w/w %) after storage for one month at 0% RH/25˚C 
 
Furthermore, the aged samples were examined under SEM. Interestingly, there were no 
visible crystalline ibuprofen in these samples similar to the fresh samples (see Fig.4.12) only 
up to 30% (w/w) drug loading. Conversely, at 35% (w/w) drug loading, micro-crystallites 
were detected on the surface of these aged extrudates as shown in Figure 4.20. ATR-FTIR 
was also used to investigate this observation as shown in Figure 4.21. This figure indicates 
the presence of crystalline ibuprofen mainly on the surface of these samples as visualized 
from sharpening of the characteristic (marker) absorbance band of crystalline ibuprofen 
around 779 cm-1. Therefore, ATR-FTIR confirmed SEM observation, clearly implying that 
ibuprofen had been recrystallized in the aged extruded system at 35% (w/w) drug loading. 
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Figure 4.20: SEM images of the surface (left side) and cross section (right side) of hot 
melt extruded ibuprofen in Eudragit RS PO at 35% (w/w) drug loading after ageing 
for one month at 0%RH/25°C 
 
 
 
Figure 4.21: ATR-FTIR spectra of surface and cross section of ibuprofen-Eudragit RS 
PO extrudate at 35% (w/w) drug loading aged for one month at 0%RH/25°C. Used 
“marker” region for crystalline ibuprofen is enclosed in orange rectangle 
 
Overall, the findings in this section gave insight into how hot melt extruded systems of 
ibuprofen in Eudragit RS PO equilibrate, in terms of their physical stability, in a low 
humidity environment after one month. A combined analytical approach was used to 
ascertain the drug dispersion in a solid solution in these extrudates after ageing. Ibuprofen 
appeared to remain molecularly dispersed up to 35% (w/w) drug loading, similar to the fresh 
samples, as indicated from MTDSC and PXRD studies. However, SEM investigations 
showed a presence of crystalline ibuprofen on the surface of 35% (w/w) drug loading 
extrudate, which was also detected by ATR-FTIR measurements. Therefore, it is reasonably 
to consider that solid saturation solubility of the extruded ibuprofen-Eudragit RS PO after 
one month of storage at 0%RH/25°C corresponds to 30 %( w/w) ibuprofen loading. This is 
surprising given the low values of Tg observed (Figure 4.18). Therefore, it is suggested that 
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the reported high viscosity of Eudragit RS (Kim et al., 2002) is responsible for limiting the 
collision of ibuprofen molecules and subsequent crystallization. Additionally, the polymer 
viscosity increases with the decrease in the temperature during the cooling of the extrudate 
(Crowley et al., 2007). 
 
4.3.3.2 Investigations into the saturation solubility of hot melt extruded ibuprofen in 
Eudragit RS PO after storage study at 60% relative humidity 
 
The objective of this study was to understand how water will affect the extent of solid state 
miscibility of ibuprofen-Eudragit RS PO extruded systems. These extrudates were allowed 
to equilibrate with a surrounding humidity level of 60% RH at room temperature for one 
month.   
 
Representative reversing heat flow signals of MTDSC data of these aged samples are given 
in Figure 4.22 (A), (B) and (C). The glass transition temperature was assigned accordingly 
from these signals and notably it was lowered to values from 31.7± 0.1˚C and 9.6±0.2°C of 
10-30% ibuprofen loaded systems to 25.1±0.4˚C and 3.2±0.2˚C before any recrystallization 
was detected. The water content of these samples was measured using TGA, where broad 
single step weight loss of the tested samples was observed from 30°C to 120°C, indicating 
water loss (Figure 4.23). Water contents of approximately 1.14 wt. % and 0.84 wt. % for the 
10% and 30% loaded systems, respectively, were measured after one month of storage at 
60% RH/25°C. This would imply the powerful role of water as a plasticizer for these 
extruded samples, because even small amounts of water were enough to depress the glass 
transition temperatures of these glassy systems. 
 
Furthermore, it was observed that melting endotherm of ibuprofen, indicating recrystallizat-
ion, appeared at drug loadings higher than 10% (w/w) after ageing for 20 days and 30 days 
of 30% (w/w) and 20%(w/w) drug loaded extrudates, respectively. This could be explained 
by further reduction of the glass transition temperatures of these extruded systems due to 
moisture uptake. Consequently, as the Tg of the extruded system becomes sufficiently lower 
than the storage temperature due to plasticization by water, enhanced molecular mobility of 
ibuprofen molecules would be expected with subsequent recrystallization.  
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(A) 
 
(B) 
 
 
Figure 4.22: MTDSC reversing heat flow signals of hot melt extruded ibuprofen-
Eudragit RS PO systems at 10% (w/w) drug loading (A) and 20% (w/w) drug loading 
(B), examined on 0 day (fresh) and after 10, 20, 30 days of storage at 60% RH/ 25°C, 
measured at 1°C/min underlying heating rate with a modulation amplitude of ±0.265°C 
and a period of 100 seconds 
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(C) 
 
 
Figure 4.22 (Contd.): MTDSC reversing heat flow signals of hot melt extruded 
ibuprofen-Eudragit RS PO systems at 30% (w/w) drug loading (C), examined on 0 day 
(fresh) and after 10, 20, 30 days of storage at 60% RH/ 25°C, measured at 1°C/min 
underlying heating rate with a modulation amplitude of ±0.265°C and a period of 100 
seconds 
 
 
 
Figure 4.23: TGA weight loss profiles of hot melt extruded ibuprofen-Eudragit RS PO 
systems at different drug loadings (w/w %) after ageing for one month at 60%RH/25°C 
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PXRD was also used to monitor ageing of these extruded systems and excepting extrudates 
at 40% (w/w) drug loading (data not shown here), there was no indication of crystallinity 
with the PXRD patterns remained halo as shown in Figure 4.24. This could be attributed to 
low levels of crystallinity in these aged extrudates below detection limits of this technique. 
 
However, in agreement with the MTDSC experiments, ibuprofen crystals were visible under 
the SEM of the aged extruded systems with drug loading higher than 10% (w/w) as 
illustrated in Figure 4.25. In this figure, few drug crystals appeared mainly on the surfaces of 
these extrudates and increased with increasing drug loading. Overall, this section indicates 
that the solubility of ibuprofen in Eudragit RS PO extrudate had been reduced to circa 10% 
(w/w) after one month. While crystallization on water uptake is well known, it is surprising 
that the effect was so marked with such a small decrease in Tg and may reflect equilibrium 
solubility changes.  
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(A) 
 
(B) 
 
 (C) 
 
 
Figure 4.24: PXRD diffractograms of hot melt extruded ibuprofen-Eudragit RS PO 
systems  at different drug loadings of:  (A) 10% (w/w), (B) 20% (w/w) and  (C) 30% 
(w/w), examined on 0 day (Fresh) and  after 10, 20, 30 days of storage  at 60% RH/ 
25°C 
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Figure 4.25: SEM images of the surfaces (left side) and cross sections (right side) of hot 
melt extruded ibuprofen in Eudragit RS PO at different drug loadings (w/w %) after 
ageing for one month at 60%RH/25°C 
 
4.3.4 Fragility assessment of ibuprofen-Eudragit RS PO extruded systems 
 
In the previous section the equilibrium saturation solubility of the extruded mixtures of 
ibuprofen in Eudragit RS PO was characterised and approximated for specified storage 
conditions at room temperature with two relative humidity levels (0%RH and 60% RH). 
These systems showed good stability and maintained high solid solubility after ageing at dry 
conditions (up to 30% (w/w) drug loading), though storage temperature was around or 
higher than their glass transition temperature. With the knowledge that some glassy systems 
may show good kinetic stability around Tg but may have the potential to collapse into 
crystals below their glass transition temperature due to structural relaxation (Qi et al., 
2008b), it was useful to examine fragility parameter of the binary extruded systems of 
ibuprofen in Eudragit RS PO in this study. This parameter can be correlated to the molecular 
mobility behaviour of the studied glassy (amorphous) system, giving a complementary 
indirect measure to understand its physical stability.  
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This work was performed on the extruded Eudragit RS PO systems loaded with 10-30% 
(w/w) ibuprofen to estimate their fragility parameters, with a goal to identify qualitatively 
the propensity of their physical ageing. This ageing measured by fragility usually refers to 
the tendency of the system to decrease its glass transition temperature at lower temperatures, 
which enhances molecules mobility and increases the chance for crystallization to occur. 
Using fictive temperature approach, conventional DSC (cDSC) can be used to determine 
fragility parameter depending on the scanning rate as suggested by Robertson et al., (2000). 
Fictive temperature concept was first proposed by Tool (1953), who described it as the 
temperature at which the liquid structure is frozen in. The fictive temperature is defined as 
the extrapolated intersection of the pre-transition and post-transition DSC heat flow 
baselines transposed to enthalpy units that is related to the contribution of the structural 
relaxation process to the properties of the glass (Cassel, 2002). This temperature depends 
only on the previous cooling rate through the glass transition temperature (thermal history), 
regardless the heating rate used for its measurement (Yue et al., 2004). Therefore, Equation 
4.10 can be used to correlate the fragility parameter with the fictive temperature (Robertson 
et al., 2000) as follows: 
 
m∆h = - (d log βc)/(d(Tf,ref/Tf))                                                                                (Eq.4.10) 
 
where βc is the prior cooling rate, Tf is the fictive temperature measured in the heating cycle, 
Tf,ref is the reference fictive temperature and m∆h is the fragility parameter. Wherein the value 
of Tf,ref should be obtained from the fictive temperature of the cooling rate equivalent to 
reheating rate used, because the value of the fictive temperature would be very close to the 
glass transition temperature and thus called limiting fictive temperature (Yue et al., 2004).  
 
By cooling at various rates: 2, 5, 10 and 20˚C/min, followed by heating at a constant 
(arbitrary) rate of 10°C/min through the glass transition region of the studied extruded 
systems, the variation of the Tf with the cooling rate was used to define an enthalpic fragility 
parameter, m∆h (Hodge, 1994). The fictive temperatures measured for these extrudates using 
cDSC are summarized in Table 4.2. Values in this table were used in Eq.4.10 to obtain plots 
shown in Figure 4.26, whereby the fragility parameters can be estimated from the slopes of 
the resulted lines, determined using a least squares best fit, from these fragility plots (Cassel, 
2002). As clear from this figure, the estimated fragility parameters fall below 100 (around 
89.9, 70.2 and 32.0 for 10%, 20% and 30% (w/w) drug loaded extrudates, respectively), 
resembling behaviour of strong, non-fragile systems (Borde et al, 2002). Therefore, it is less 
likely for the studied extruded systems to show physical relaxation of their glassy state and 
Formulation development and physicochemical characterisation of hot melt extruded 
ibuprofen-Eudragit RS PO films for transdermal delivery 
Chapter 4 
 
175 
 
ultimately crystallization of the drug, if they stored at temperatures below their glass 
transition temperatures.  
 
Drug Loading (w/w %) 10% (w/w) 20% (w/w) 30% (w/w) 
cooling rate  Tf ± s.d./°C Tf ± s.d./°C Tf ± s.d./°C 
2°C/min 19.6±0.5 16.7±0.5 9.3±1.1 
5°C/min 21.7±0.2 17.8±0.3 12.0±0.2 
10°C/min 22.1±0.1 19.5±0.2 16.5±0.6 
20°C/min 22.6±0.4 20.3±0.7 16.9±0.2 
 
Table 4.2: Summary of the cDSC results of the fresh hot melt extruded ibuprofen-
Eudragit RS PO films at different drug loadings 
 
  
                                       
 
Figure 4.26: Fragility plots of fresh hot melt extruded ibuprofen-Eudragit RS PO films 
at drug loading of: (A) 10 %( w/w), (B) 20 %( w/w) and (C) 30% (w/w) 
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4.4 Conclusions 
 
The aim of the work described in this chapter was to continue characterising the ibuprofen 
and Eudragit RS PO for miscibility and interactions as a whole formula produced by hot 
melt extrusion. Hot melt extrusion technology was utilized successfully for the development 
of solid solutions of ibuprofen at high loading (up to 35% w/w) incorporated in Eudragit RS 
PO. The theoretical approaches of miscibility estimation using solubility parameters and 
melting point depression provided relatively good prediction of the practical solubility found 
for the studied extruded systems. Ibuprofen and Eudragit RS PO did not exhibit significant 
interactions but appeared to form compatible blends, supported by the one phase system 
existence of these systems i.e. solid solutions.  
 
Section 4.3.1 detailed the initial characterisation of the physical mixes of ibuprofen and 
Eudragit RS PO for thermal stability before extrusion. TGA results demonstrated minimal 
weight losses after thermal treatment of these mixes at the extrusion temperature for the 
intended mixing time, indicating low degradation and thermal stability at these conditions.  
 
Section 4.3.2 elucidated the potential use of solubility parameter and melting point 
depression thermodynamic model as tools to predict compatibility and miscibility of 
ibuprofen in Eudragit RS PO and correlated this with the solubility of this drug in Eudragit 
RS PO hot melt extrudate. This included the use of various techniques such as DSC, PXRD, 
SEM and ATR-FTIR for characterisation of the dispersibility of ibuprofen-Eudragit RS PO 
extruded systems. The glass transition temperatures of these systems were decreased with 
increasing drug loading due to the presence of the plasticizer i.e. ibuprofen, which aided in 
the extrudability of ibuprofen-Eudragit RS PO blends. Composition range within which the 
drug-polymer miscibility may be regarded as the solubility of the drug in the polymer was 
35% (w/w) as confirmed by aforementioned techniques. 
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Section 4.3.3 detailed the use of DSC, PXRD, ATR-FTIR, and SEM techniques for 
approximation of the extent of solid state miscibility or equilibrium saturation solubility 
under two relative humidity levels for one month. This achieved through monitoring of the 
phase behaviour of the selected solid solutions of ibuprofen-Eudragit RS PO extrudates. It 
was noted that the equilibrium solubility composition of the extruded mixture without phase 
separation or drug recrystallization slightly dropped under dry conditions (0%RH/25°C) to 
30% (w/w) drug loading. However, a significant decrease in the miscibility was noted on 
storage at 60% RH/25°C despite the water uptake being relatively low, indicating extra 
molecular mobility resulting from the strong plasticizing effect of water, wherein the drug is 
also poorly soluble.  This part also provides insight into the physical stability of these drug-
polymer mixtures under selected storage conditions and recommended storage under dry 
conditions to maintain high solubility of ibuprofen in Eudragit RS PO extrudate. The results 
of MTDSC and PXRD showed some agreement with each other, especially in 0%RH/25°C 
storage study for detection of ibuprofen crystals, thus indicating phase separation. However, 
ATR-FTIR and SEM appeared as viable techniques for detection and visualization, 
respectively, of low amounts or small crystallites of ibuprofen undetected by PXRD or 
MTDSC techniques. 
 
Section 4.3.4 provides prediction of the tendency of miscible extruded ibuprofen-Eudragit 
RS PO systems towards physical relaxation (ageing) using the fragility parameter. The 
results revealed strong glassy systems, from which we can infer that storage of the studied 
solid solutions under temperatures less than their glass transition temperatures might not 
affect their stability in terms of drug recrystallization. 
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Chapter 5: In vitro ibuprofen release and permeation studies from 
hot melt extruded Eudragit RS PO films 
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5.1 Introduction 
 
In vitro performance testing of transdermal films with respect to drug release and skin 
permeation can be achieved using dissolution apparatus and Franz-type diffusion cells, 
respectively. In vitro dissolution test for transdermal delivery systems is referred to drug 
release or in vitro release study (Siewert et al., 2003), which concerns the evaluation of the 
release of the drug in a dissolution medium, wherein the drug is generally dissolved. 
However, in the case of transdermal pharmaceutical systems, it is also important to 
understand to which degree the tested formulation or the used product design may affect the 
drug permeation through the skin by in vitro permeation testing. Therefore the ultimate goal 
of the in vitro permeation studies is analogous to that of in vitro release studies, as a valuable 
measure of product quality, reflecting the thermodynamic activity of the drug substance in 
the pharmaceutical product. Consequently, the data derived from both experiments can be 
utilized together to evaluate the drug release behaviour of delivery systems and define 
biopharmaceutical characteristics to ensure that the developed formulations can be used or 
otherwise optimised to achieve the delivery of the therapeutic levels of drug to the site of 
action. Therefore, the aim of the present chapter is to assess relative suitability of Eudragit 
RS PO-based hot melt extruded films to deliver ibuprofen transdermally in terms of their 
contribution to the in vitro drug release and in vitro permeation profiles. Section 5.2 
comprehensively outlines the theory and set up of the in vitro dissolution/release and Franz 
diffusion cells system techniques and describes the kinetic modelling that can be used to 
assess mechanism(s) of drug release and permeation. Section 5.3 subsequently details the 
results obtained from these two experiments with the kinetic modelling of the obtained 
permeation profiles to explain the release kinetics of ibuprofen from the tested films. 
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5.2 Experimental methodologies 
 
5.2.1 In vitro drug release studies 
 
For transdermal drug delivery systems, drug release studies are usually performed using 
different compendia apparatus (PhEur, 2005; USP31, 2008) and generally they are paddle 
over disk method (USP apparatus 5/PhEur 2.9.4.1), rotating cylinder method (USP apparatus 
6/PhEur 2.9.4.3), reciprocating disk method (Apparatus 7) and paddle over extraction cell 
method (PhEur 2.9.4.2). However, several different and appropriate apparatuses can be used 
for the drug release testing and in our case the best approach proposed was the use of the 
paddle and vessel assembly with the addition of a stainless steel basket. The design of this 
hybrid basket-paddle system, as illustrated in Figure 5.1, was adapted from Grundy et al. 
(1997), thereby the advantage of high agitation from the paddle apparatus can be combined 
to the benefit of sample floating prevention using the basket apparatus.   
 
 
 
Figure 5.1: Modified dissolution apparatus for characterising in vitro release of the hot 
melt extruded films 
 
In vitro dissolution/release testing in this study was utilized to estimate drug release from the 
formulations prepared by hot melt extrusion using a Copley Scientific DIS8000 dissolution 
bath attached to a Copley Scientific FH16-D heating unit (Figure 5.2). This experiment can 
indirectly reflect the amount of the drug that can be available for absorption to systemic 
circulation, thus aiding selection of the appropriate formulation candidate for in vitro 
permeation testing or correlation. Concerning the dissolution medium, many studies employ 
a phosphate buffer system with pH = 7.2 to 7.4, due to similarity with the blood or plasma 
compartment (Mitu et al., 2011). Consequently, a phosphate buffer system (PBS) was 
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prepared with a pH = 7.2 (section 5.2.1.1) to account for physiological relevance of the 
systemic pool wherein the drug will be delivered (Gavali et al., 2010; Itoh et al., 1990). In 
addition, it has been reported that saturation solubility of ibuprofen in this medium (PBS, pH 
= 7.2) is almost 3.74±0.14 mg/ml (Dabbagh and Taghipour, 2007). Consequently it may be 
expected that dissolution will not be limited by the ibuprofen solubility in this medium, 
allowing reasonable dissolution time windows which in turn provide a convenient test 
framework.  
 
 
 
Figure 5.2: Copley dissolution bath 
 
The term sink condition usually refers to situations whereby the volume of the medium is 
three times or more (five or even ten) times the volume required to form saturated solution 
of a drug substance in this medium (Rohrs, 2001). However, these conditions can be 
acceptable if the drug concentration in the dissolution medium does not exceed 10 to 20% of 
the saturation concentration or solubility of the solute, as suggested by Hoa and Kinget 
(1996). Therefore, it was important to ensure that saturation solubility of the ibuprofen is 
determined experimentally in our dissolution medium rather than simply to use the reported 
value (section 5.2.1.2). In this work, a volume of 900 ml of the dissolution medium was used 
as usually specified in the pharmacopoeias and the samples’ weights were determined 
accordingly, using the following equation (Gowthamarajan and Singh, 2010): 
 
The maximum dissolvable dose of the drug = (V x Cs) / (Cs/CD)            (Eq.5.1) 
 
Where V is the dissolution medium volume, Cs is the saturated solubility of the drug in the 
medium and CD is the concentration of the drug in the bulk medium. (Cs/CD) should be 
greater than or equals 3 to achieve sink condition. 
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5.2.1.1 Preparation of phosphate buffer solution (pH =7.2) 
 
The dissolution media were prepared by weighing individual buffer components into tared 
weighing boats. 34.02 g of potassium dihydrogen orthophosphate was transferred into a 
clean 5 L volumetric flask and a quantity of deionized water was added (~2 L), then the 
mixture was stirred until all the solids were dissolved. Then 0.2M sodium hydroxide was 
prepared by dissolving 7.99 g of sodium hydroxide into 1 L volumetric flask through 
addition of sufficient deionized water to produce 1000 ml and then stirred for enough time 
(~20 minutes) to ensure that they are fully dissolved. Afterwards 875 ml of 0.2M sodium 
hydroxide was mixed into the 5 L volumetric flask mixture and a further amount of water 
was added to produce a final volume of 5 L. The pH of the solution was checked using a pH 
meter, and when necessary adjusted using small quantities of NaOH or HCl as needed. 
 
5.2.1.2 Equilibrium saturation solubility 
 
Saturation solubility of ibuprofen in phosphate buffer solution (pH = 7.2) was estimated 
through weighing excess amounts of crystalline powdered ibuprofen. Each sample of 0.50 g 
was introduced separately into 10 ml conical flask containing 5 ml of phosphate buffer 
solution (pH 7.2). The sealed flasks were stirred on a magnetic stirrer for 72 hours at 37°C 
and equilibrated for 2 hours. Then the solutions (supernatant) were filtered through 0.20 µm 
membrane filters (Sartorious stedim biotech Minisart®), and the filtrates were suitably 
diluted and analyzed using UV spectrophotometer at 223 nm (PerkinElmer, Lambda XLS). 
Determinations were carried out in triplicate. 
 
5.2.1.3 Evaluation of drug release  
 
Hot melt extruded films based on Eudragit RS PO and formulated with different ibuprofen 
loadings (10-40%w/w) were prepared as described in Chapter 4. The films were cut 
manually and the dimensions were measured with an electronic digital caliper (MS092 
Toolzone Vernier Caliper, UK). The tested films had similar dimensions of approximately 
6mmx4mmx1mm (length, diameter, thickness) and of a total weight of not less than 2500 
mg. The weighing was performed using a XS205 dual range analytical balance (Mettler 
Toledo). The prepared hot melt extruded films with 10% (w/w) ibuprofen loading 
corresponds to the saturation solubility of ibuprofen in Eudragit RS PO extruded matrices 
after equilibration or ageing at 60%RH/25°C for one month as detailed in Chapter 4. 
Therefore, the inclusion of water at this storage conditions did not compromise the physical 
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stability of these films at this drug loading, because the solid solution of ibuprofen in 
Eudragit RS PO matrix was maintained. Consequently, these aged films were evaluated to 
elucidate the possible role of conserved water molecules in their structure on the in vitro 
release behaviour. Ground hot melt extruded samples were obtained at this drug loading and 
compared to their equivalent physical mixtures and crystalline ibuprofen. On the other hand, 
equilibration at 0%RH/25°C for one month indicated that higher drug loading (30% w/w) 
were physically stable (Chapter 4) as the ibuprofen was molecularly dispersed in Eudragit 
RS PO. To further assess the impact of ageing on these films at 30% (w/w) ibuprofen 
loading, aged samples under these conditions were compared to the fresh fabricated samples.  
 
In all the experiments, the dissolution medium consisted of 900 ml phosphate buffer (pH 
7.2) was maintained at 37.0 ±0.1°C using a dissolution bath (Copley Apparatus, UK), and 
the stirring rate was set at 100 rpm. A volume of 5 ml of sample was withdrawn at specified 
time intervals and replaced immediately with the same volume of fresh dissolution medium, 
which was maintained at 37.0 ±0.1°C. The samples then filtered using a 0.20 µm filter 
(Sartorious stedim biotech Minisart®) and analyzed using an appropriate method, either by 
UV spectrophotometer (PerkinElmer, Lambda XLS) at λmax determined for ibuprofen (223 
nm) or by high performance liquid chromatography (reversed phase) using  HPLC (Perkin-
Elmer) instrument equipped with an ODS-Hypersil C18 column (5µm, 150x4.6 mm I.D.) 
and a degasser unit. The mobile phase (HPLC grades) consisted of a 50:50:1 (v/v) mixture 
of acetonitrile: deionized water: phosphoric acid and the flow rate was set at 1ml/min. The 
UV detector was set at 225 nm, at which ibuprofen showed maximum absorbance using this 
mobile phase. Chromatography was performed at 25°C; the injection volume was 100µl. 
Under these conditions, the retention time for ibuprofen was approximately 9.87 min as 
shown in Figure 5.3. 
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Figure 5.3: Chromatogram of ibuprofen in acetonitrile: deionized water: phosphoric 
acid (50:50:1, (v/v)) mobile phase at flow rate of 1ml/min detected at 225 nm 
 
5.2.1.3.1 Preparation of calibration standard 
 
Calibration standard serves as an indication of the linear correlation between absorbance and 
drug concentration over the required range, in which the wavelength of maximum 
absorbance can be determined. Hence, a series of drug solutions were prepared with suitable 
concentrations using phosphate buffer (pH 7.2) and scanned from 200 to 400 nm using UV 
spectrophotometer (PerkinElmer, Lambda XLS) to detect λmax, at which ibuprofen showed 
the maximum absorbance and it was 223 nm. Phosphate buffer solution (pH 7.2) was used as 
analytical blank to zero the spectrophotometer prior each measurement. Consequently a 
calibration curve was constructed, as shown in Figure 5.4, to perform necessary calculations 
of the drug amount released or dissolved in different samples. In addition to that, a 
calibration curve by HPLC was constructed through preparation of series of drug solutions 
with suitable concentrations using the mobile phase that was set to flow at a rate of 1ml/min 
wherein the elution was monitored at 225 nm (Figure 5.5). As indicated by the regression 
equations in Figure 5.4 and 5.5, these calibration standards had good correlations between 
the studied drug concentrations and responses (UV absorbance or area under the retention 
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peak of ibuprofen) as detected by the used method in UV spectrophotometer or HPLC, 
respectively.  
 
 
 
Figure 5.4: Calibration curve of ibuprofen in phosphate buffer solution (pH 7.2) 
measured at 223 nm 
 
 
 
Figure 5.5: Calibration curve of ibuprofen by HPLC measured at 225 nm, flow rate of 
1ml/min and using acetonitrile: deionized water: phosphoric acid (50:50:1, (v/v)) 
mobile phase 
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5.2.1.3.2 Measurements of drug content 
 
Each tested batch of the different formulations was assayed for the ibuprofen content prior to 
each in vitro release and permeation study. Approximately 450 mg sample of the films were 
dissolved with 50 ml of methanol with 0.4 ml phenolphthalein solution. The resultant 
solution was titrated with 0.1M sodium hydroxide until a faint pink colour obtained (end-
point). The volume of the titre (0.1M NaOH) used to produce this colour change was 
corrected by means of a blank titration, which alternatively was performed each time and 
consumed 0.1-0.2 ml of the titre volume. The calculations  of  the content of each sample 
was conducted on the basis that each ml of 0.1M sodium hydroxide is equivalent to 20.63 
mg of C13H18O2 (British Pharmacopoeia Commission, 2010) and the titration was repeated 
three times. 
 
5.2.2 In vitro permeation (diffusion) studies 
 
In vitro drug permeation testing is an important tool for the characterisation of transdermal 
systems and has been shown, in some cases, to provide a good correlation with biological 
response. Thus, it can be used as a surrogate option for in vivo studies which are often 
expensive to perform and obtaining ethical approval can be limiting for their progress (Pellet 
et al., 1997a). In order to empower this correlation (in vitro/in vivo), it is recommended to 
design the experiment with in vitro conditions that mimic or simulate anatomical site and 
physiological conditions at the site of application, such as the skin for topical and 
transdermal drug delivery systems (TDDS), and site of drug release, such as systemic 
circulation for TDDS, and in other words, to model in vivo performance i.e. bioavailability.  
 
A Franz Cell diffusion system composed of six diffusion cells with identical characteristics 
were used to measure the release of ibuprofen from different formulae through silicone 
membranes (Figure 5.6). Jacketed Franz cells were connected to a water bath maintained at 
37°C as depicted in Figure 5.7. However, the measured temperature in the donor chambers 
was approximately 32±1°C, mimicking normal skin temperature (Green et al., 1979). The 
receptor chambers were filled with 5ml phosphate buffer (pH 7.2). The silicone membranes 
(SSP®, 102 µm thickness) were cut into suitable sizes to cover the diffusion areas of the 
diffusion cells (0.7854 cm2), and were placed between donor and receptor chambers. 
Silicone membranes were selected because of their rate limiting characteristics akin to those 
of skin (Pellett et al., 1997b). These membranes were soaked previously in isopropyl 
myristate (IPM) for 1 hour, because the latter has bipolar properties that tend to mimic the 
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biochemical composition of the skin (Megrab et al., 1995a; Raghavan et al., 2000). 
Therefore, they can be used as skin model membranes.  
 
 
 
Figure 5.6: A 6-station PermeGear Franz Cell diffusion system with a V-Series 
magnetic stirrer 
 
 
 
Figure 5.7: Compartments of a 9mm jacketed vertical Franz Cell (PermeGear) with a 
5ml receptor volume 
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Eudragit RS PO hot melt extruded films loaded with ibuprofen at different levels (10-40% 
w/w) were tested. Each sample had approximate dimensions of 6mmx4mmx1mm (length, 
diameter, thickness) and weighed out individually before loading using a XS205 dual range 
analytical balance (Mettler Toledo). Details of the preparation process have been given in 
previous chapter and each batch was assayed prior testing (see section 5. 2.1.3.2). The donor 
chambers of the Franz system were secured by the clamps and the tested samples were 
placed on the top of the silicone membranes. The sampling ports and the donor chambers 
were covered with double layers of Parafilm® to minimise evaporation from the openings.  
The receptor solution was maintained in sink conditions with respect to the drug and stirred 
at a fixed speed of 500 revolutions per minute. Aliquots of 0.2 ml were taken of the receptor 
phase, at specified time intervals, and evaluated spectrophotometrically at a wavelength of 
223 nm that was unaffected by other components that might be released together with the 
drug (section 5.2.1.3.1). To best characterise the permeation properties of ibuprofen in the 
used experiment design without vehicle influence i.e. Eudragit RS PO,  a saturated solution 
of ibuprofen in PBS medium (pH 7.2) was run in a similar procedure to the extruded films 
using a volume of 0.3 ml to fill the donor chamber.  
 
Extruded samples with the highest drug loading and showed best physical stability after 
storage at 0%RH/25°C for one month were around 30%w/w drug loading (see Chapter 4). 
These samples can be considered the prototype to deliver high doses of ibuprofen and thus, 
in like manner to the in vitro release studies, the permeation studies were used as a quality 
control tool to indicate if any deviation of the permeation profiles of these aged samples 
from those obtained immediately after fabrication. Cumulative percentage drug permeated 
was established for each test set of not less than three tested samples. At the end of each 
permeation experiment, the silicone membranes were immersed for 36 hours in 10 ml 
diethyl ether under constant stirring (200 rpm) at room temperature to extract the drug in 
case it was deposited or retained in these membranes. The extraction solutions were filtered 
through 0.45 µm membrane filters (HT Tuffryn® membranes, Acrodisc® syringe filters), 
and the filtrates were suitably diluted and analyzed using UV spectrophotometer at 222 nm 
(PerkinElmer, Lambda XLS) wherein a calibration standard was constructed in the same 
manner as detailed in section 5.2.1.3.1, using series of ibuprofen solutions prepared with 
suitable concentrations in diethyl ether (Figure 5.8). 
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Figure 5.8: Calibration curve of ibuprofen in diethyl ether measured at 222 nm 
 
5.2.3 Modelling of in vitro permeation profiles 
 
One important element for the scientific development of any new solid dosage is to 
recognize the manner by which the drug is dissolved or released from that pharmaceutical 
delivery system, hence its applicability for the intended use. This is usually described by 
kinetic models in which the dissolved /released amount of the drug is a function of the test 
time. The drug release from a polymeric matrix-type transdermal film can be defined as the 
process of the exposure of drug solutes from the polymeric system to the release medium. 
This might be a simple definition of a more complex process, in which many factors can 
contribute to the drug release kinetics. For example, drug crystallinity, particle size and 
solubility, the structural properties of the polymeric system, and the release environment 
(Grassi and Grassi, 2005). 
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In this work, the principal mechanism of ibuprofen release will be elucidated as a function of 
the in vitro kinetics of release and permeation of ibuprofen, chosen as model drug, from 
Eudragit RS PO hot melt extruded transdermal films (patches). The choice of the 
mathematical models was evaluated considering the most relevant and commonly used 
mathematical models to describe the TDDS. The curve fitting and thus the applicability of 
the kinetic models employed was judged using the linear correlation coefficient, R2. The 
following models were employed to study the permeation (diffusion) profiles: 
 
1. Zero order kinetics: 
This model can be represented by the following equation: 
 
Wt
W∞
=	K° t       																																																																																																																										(Eq.5.2)	
 
In this relation, the plotted fraction of the dissolved/released drug ( Wt
W∞
) against time (t) will 
be linear as the same amount of the drug is released within a unit of time. K° is the zero 
order release constant. This pattern of release is, in theory, the method of choice to achieve a 
steady-state release for a prolonged pharmacological action (Costa and Lobo, 2001).  
 
2. First order kinetics: 
This model can be expressed by the following relation: 
 
Wt
W∞
= 1- e&K1 t     																																																																																																																					(Eq.5.3) 
 
The drug released amount is assumed to follow exponential decline over time, manifesting a 
decrease in rate with time. Hence, a graphic of natural logarithm of the fraction of the drug 
to be released (1-( Wt
W∞
)) versus time (t) will be linear. K1 is the first order release constant. 
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3. Higuchi model (Square Root Law): 
This model in its simplified form can be described in the following manner: 
 
Wt
W∞
=	KH t1/2  																																																																																																																											(Eq.5.4)	
 
where the fraction of dissolved/released drug ( Wt
W∞
 is a linear function of square root of time 
(t1/2), if the release process is diffusion dependent. KH is the Higuchi release constant. This 
equation is valid with the assumptions that the diffusivity of the drug is constant during the 
release and the polymer system(s) should not dissolve or swell when exposed to the release 
medium (Perrie and Rades, 2010). 
 
4. Korsmeyer-Peppas model (Power Law): 
This model is commonly used for pharmaceutical polymeric dosage forms to have insight 
into a multi or even unknown release mechanism(s). Korsmeyer et al. (1983) derive the 
following equation: 
 
Wt
W∞
=	a tn     																																																																																												 																															(Eq.5.5) 
 
This equation describes systems with Fickian (diffusion controlled) and Non-Fickian 
(anomalous) behaviour, where (a) is a constant incorporating the properties of the 
macromolecular polymeric systems and the drug (Reza et al., 2003) and (n), known as the 
release exponent, is used to characterise different kinetics and release mechanisms as 
follows: 
 
1. If the diffusion is the main drug release mechanism, n=0.5.  
2. Anomalous transport will be followed for system of n values between 0.5 and 1.0, as 
well as for low values of n (n <0.5) as reported by Gao (2011). This case is usually 
associated with the drug release that is governed by both diffusion and swelling 
(Perrie and Rades, 2010). 
3. Case-II transport, which is assumed to be mainly swelling controlled release, will 
have a value of n=1.0.  
4. Values of n higher than 1.0 will describe a super case-II transport, which is 
controlled by the swelling and relaxation of the polymer(s). 
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However, n value will depend on the geometry of the studied system. The above proposed 
mechanisms will fit with slab or plane sheets, whereas in case of cylinder-shape system n = 
0.45 instead of 0.5 and 0.89 instead of 1. For spheres, n will be 0.43 instead of 0.5 and 0.85 
instead of 1. In addition to that, this value can be used to express the kinetics of the release 
mechanisms as shown in Table 5.1. It is important to mention that determination of the 
exponent n should be based on the first 60% of the fractional release (Ritger and Peppas 
1987), although Rinaki et al. (2003) suggested the applicability of this model to the whole 
drug release profile. This model can be useful as well to validate the applicability of Higuchi 
models, which holds only for system controlled by pure diffusion mechanism. These models 
can aid understanding the release mechanism of the embedded drug and will potentially 
allow the operator to identify if that mechanism will vary from different systems according 
to the composition or the conditions of the application. If the kinetics of these systems vary, 
they still can be compared in a non-model approach, such as the time necessary to the 
release of higher than or equal to 80% of the drug,	t	≥	80%).  
 
Release Exponent (n) Rate as a function of time 
0.5 t-0.5 
0.5<n<1.0 tn-1 
1.0 Zero order release 
Higher than 1.0 tn-1 
 
Table 5.1: Expected release rate kinetics according to the power model (Korsmeyer et 
al., 1983) 
 
5.3 Results and discussion 
 
The saturated solubility of ibuprofen in the phosphate buffer solution (pH 7.2) at 37°C was 
determined as 4.49±0.29 mg/ml. This value correlated relatively well with the reported value 
of 3.74±0.14 mg/ml obtained by Dabbagh and Taghipour (2007). Accordingly the weight of 
drug used in the in vitro release/dissolution experiments and for permeation studies could be 
considered to represent sink conditions. Table 5.2 lists the assayed drug loadings of different 
formulations, which reflected a good loading efficiency. The percent loading efficiency is 
defined as the experimental drug loading over the theoretical value expressed as a 
percentage. Therefore, it could be inferred that possible drug loss during preparation of the 
formulation was minimal and therefore will not be expected to account for less than 100% in 
vitro release or permeation profiles of the tested films.  
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Drug loading 
(Theoretical)  
 
(w/w %) 
Drug loading 
(Actual)  
 
±SD* (w/w %) 
Drug loading 
efficiency  
 
± SD* (%) 
10 9.93±0.26 99.33±2.65 
20 19.87±0.26 99.33±1.32 
30 29.80±0.46 99.33±1.53 
40 39.27±0.26 98.18±0.66 
 
Table 5.2: Calculated (actual) percent drug loadings of hot melt extruded samples of 
Eudragit RS PO at different ibuprofen loadings and loading efficiencies using hot melt 
extrusion technique. *Average ± S.D. of three determinations has been reported 
 
5.3.1 In vitro release studies 
 
Hot melt extruded films of ibuprofen at different loadings in Eudragit RS PO were evaluated 
for their release behaviour over 24 hours. The release studies were performed for freshly 
prepared films up to 40%w/w drug loading, which represents the supersaturation level of 
ibuprofen in Eudragit RS PO extrudates (Chapter 4). The drug release quantification was 
performed using HPLC, to ensure that only ibuprofen is considered in the measurements and 
that no degradation products are interfering with the detection signal. These values were 
then compared to the UV absorbance values obtained spectrophotometerically, which 
showed no significant difference (data not shown) and thus UV data were adapted for the 
remainder of the study. 
 
In vitro cumulative percent ibuprofen released from the extruded films increased as a 
function of increased drug loading as shown in Figure 5.9. The following formula was used 
to calculate the relative cumulative percent drug released (RCDR %) of the extruded 
formulations for each drug loading: 
 
RCDR % at time (n) = 
Cumulative percent drug released at time (n) 
Drug loading percentage 
 X 100         (Eq.5.6) 
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The amount of ibuprofen released (expressed as cumulative percentage drug release) from 
these extruded films increased with the increase of drug loading. However, all the tested 
formulations with different drug loadings were associated with slow rate and poor release 
(Figure 5.9). This low percentage of drug release can be ascribed to the thermal treatment of 
the water-swellable Eudragit RS PO during extrusion. Azmari et al. (2005) and Hasanzadeh 
et al. (2009) found that drug release can be retarded from Eudragit RS matrix when it is 
thermally treated to temperatures above its glass transition temperature (53.3±0.5°C, Chapter 
3) possibly due to rearrangement of its network into more coalesced structure as indicated 
from less porous matrix. Hence, this is believed to create extra physiological stress needed to 
be broken prior drug release.  
 
 
 
Figure 5.9: Comparative release profiles of ibuprofen from hot melt extruded films at 
different drug loadings in phosphate buffer solution (pH 7.2) at 37.0±0.1°C. Each data 
point represents the mean±S.D. of three measurements 
 
Extrudate with a drug load of 10% w/w represents the equilibrium saturation solubility of 
ibuprofen in Eudragit RS PO after one month of incubation under ambient conditions of 
60%RH/25°C (Chapter 4). Therefore, water coexists in its structure under these conditions 
without affecting the physical stability. As seen in Figure 5.10, these extruded films with 
only 1.14% (w/w) water content showed higher amount of dissolved ibuprofen in the 
dissolution medium compared to those aged for the same duration but at dry conditions 
(0%RH/25°C). This might indicate a possible role of water in this release enhancement, 
though not significant (~5% increase in the cumulative amount of the dissolved drug). This 
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may suggest that the drug remained entrapped in extruded films can be liberated using 
advents that improve its partitioning into the elution medium to achieve a reasonable rate 
and extent of release. It was also noticed that these formulations provided retarded release 
pattern compared to the fast immediate dissolution profiles of crystalline ibuprofen and 
equivalent physical mixture.   
 
 
 
Figure 5.10: Comparative dissolution profiles of ibuprofen from crystalline drug, 
physical mixture and Eudragit RS PO-based extrudate at 10% w/w drug load in 
phosphate buffer solution (pH 7.2) at 37.0±0.1°C. Each data point represents the 
mean±S.D. of three measurements 
 
As the ibuprofen release was found to be a function of drug loading for these extruded films, 
it is recommended to continue the development stages of these systems with the films at 
high drug content that lie within solubility limits of the ibuprofen in the Eudragit RS PO 
matrices. Therefore, films at 30% w/w drug loading were selected and investigated for their 
proposed physical stability (Chapter 4) in terms of any potential change in their in vitro 
release profiles. As depicted in Figure 5.11, the films aged for one month at 0%RH/25°C 
showed superimposable release profiles to the ones tested on freshly basis, supporting their 
physical stability.  
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Figure 5.11: Comparative release profiles of ibuprofen from Eudragit RS PO extruded 
films  at 30% w/w drug load  tested on freshly basis (Fresh) and after ageing for one 
month at 0%RH/25°C (Aged) in phosphate buffer solution (pH 7.2) at 37.0±0.1°C. Each 
data point represents the mean±S.D. of three measurements 
 
5.3.2 In vitro permeation (diffusion) studies 
 
For skin-mimicking membranes such as the silicone-based membranes used here, it is 
appropriate to ask to what extent these membranes control the drug permeation. This is 
important as unnecessary proliferation of method design or formulation fabrication can be 
avoided if the drug physicochemical properties limited or prevented its diffusion across 
these membranes. Therefore, saturated solutions of ibuprofen in PBS (pH 7.2) were 
examined and, as shown in Figure 5.12, the permeation of the total amount of the ibuprofen 
was almost completed after 6 hours with circa 97.8% cumulative percent permeation. This 
indicates that ibuprofen diffusion per se across the silicone membrane does not necessitate 
permeation enhancement.   
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Figure 5.12: Diffusion profile of ibuprofen from saturated solutions in phosphate 
buffer solution (pH=7.2) tested approximately at 32°C and permeated across silicone 
membrane into phosphate buffer solution (pH=7.2) at 37°C. Each data point represents 
the mean±S.D. of three measurements 
 
For the extruded films tested in the permeation experiments we have two interfaces, the 
extrudate-membrane interface and the membrane-receptor solution interface. Therefore, the 
ibuprofen molecules have to get out from the extruded films into the silicone membrane. 
Thereafter the molecules will be available to partition into the second interface and dissolve 
in the receptor phase. In Figure 5.13, the hot melt extruded films of ibuprofen in Eudragit RS 
PO showed poor penetration into the receptor phase. This was predicted as the release was 
limited by the extrudates themselves as indicated earlier in the in vitro release studies. 
Again, data here came to confirm that the drug release with subsequent measured 
permeation is a function of drug loading. Relative percent of drug permeated was calculated 
using Formula (5.6). Drug recovered from retention in the silicone membranes after the 
diffusion experiment was less than 0.5 mg for all tested films at different ibuprofen loading 
as indicated in Table 5.3. This implies that certain amount of the drug was needed to 
equilibrate with the membranes, and such disposition could impart, though not mainly, in the 
observed low percent of ibuprofen permeation.  
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22 24 26
C
u
m
u
la
ti
v
e
 %
 P
e
rm
e
a
te
d
Time (Hours)
In vitro ibuprofen release and permeation studies from hot melt extruded Eudragit RS PO 
films 
Chapter 5 
 
198 
 
 
 
Figure 5.13: Comparative diffusion  profiles of ibuprofen from hot melt extruded films 
with Eudragit RS PO tested approximately at 32°C and permeated across silicone 
membrane into phosphate buffer solution (pH=7.2) at 37°C. Each data point represents 
the mean±S.D. of no less than three measurements 
 
Drug loading (w/w%) Amount recovered (mg)* Percentage of the drug recovered in 
relative to the loaded dose (%)* 
10 0.27±0.01 12.44±0.31 
20 0.30±0.13 6.93±0.67 
30 0.36±0.04 5.54±0.38 
40 0.38±0.34 4.43±0.45 
 
Table 5.3: Quantification of the drug recovered in the silicone membranes after the end 
of the permeation experiments (over seven days) for examined Eudragit RS PO 
extruded films formulated with different ibuprofen loadings. *Average ± S.D. of three 
determinations has been reported 
 
In a diffusion experiment, the test duration is usually set to achieve 85% of the drug 
permeation or until the plateau is reached. Therefore, the experiments were extended over 
seven days until a plateau was reached. However, overall drug released and permeated were 
low. Therefore, these films can be used but with modulation appropriate to deliver 
ibuprofen, which is used in high doses (200-800 mg every 4-6 hours). Thus, modifications 
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can be applied to enhance drug release in reasonable amounts. In order to achieve that, a 
prototype is needed. As shown in the in vitro release assessment section, 30% w/w drug 
loaded formulation appears to be the most suitable choice as a prototype at this stage. A 
further permeation experiment of the aged films at this drug loading was conducted to check 
if the performance of these films will keep up as the fresh samples, in terms of the in vitro 
permeation behaviour. The diffusion profiles of the aged samples were approximately the 
same as fresh samples after seven days, with mean deviations less than 2% between the two 
observed profiles (Figure 5.14), indicating good physical stability under the used ageing 
conditions which supported previous findings of the same in the previous chapter and 
section herein. 
 
 
 
Figure 5.14: Comparative diffusion profiles of ibuprofen from Eudragit RS PO-based 
extrudates at 30% (w/w) drug loading (fresh vs. aged samples stored for one month at 
0%RH/25°C), tested approximately at 32°C and permeated across silicone membrane 
into phosphate buffer solution (pH=7.2) at 37°C 
 
5.3.3 In vitro permeation studies model fitting 
 
Through interpretation of the kinetics of drug release from the studied systems, the release 
mechanism can be explained. Data of the in vitro permeation was fitted to the zero-order 
equation, the first-order equation and the Higuchi and Korsemeyer-Peppas (power) models. 
The correlation coefficients of different applied mathematical models are included in Table 
5.4. On the basis that the higher the correlation coefficient the better the model, the first 
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order equation was most suitable to explain the observed profiles. The power model also 
fitted these profiles well, predicting anomalous transport of the ibuprofen from the matrices. 
This indicates that a combination of diffusion and swelling are the possible dominant 
mechanisms to control the drug release from these systems. 
 
 (A) 
Used Kinetic model  First order model Zero order model Higuchi square-root of 
time model 
Drug loading of the 
tested samples 
(w/w%) 
R2 R2 R2 
10 0.9870 0.6277 0.8200 
20 0.9653 0.7373 0.9004 
30 0.9805 0.7382 0.8997 
30 (Aged) 0.9426 0.8638 0.9466 
40 0.9695 0.7707 0.9501 
 
(B) 
Kinetic model  Korsmeyer-Peppas model (Power law) 
 
Drug loading of the 
tested samples 
(w/w%) 
R2 Release exponent 
(n) 
Expected release mechanism 
 
10 0.9457 0.36 Anomalous transport 
20 0.9498 0.39 Anomalous transport 
30 0.9591 0.46 Anomalous transport 
30 (Aged) 0.9816 0.41 Anomalous transport 
40 0.9548 0.55 Anomalous transport 
 
Table 5.4: (A) Fit correlation coefficients (R2) of different applied kinetic models and 
(B) possible interpretation of the measured release exponents from the power law 
model and their correlation coefficients (R2), both for the permeation profiles of 
ibuprofen formulated with different levels (loads) in hot melt extruded Eudragit RS 
PO films. Aged samples under 0%RH/25°C for one month with 30 %( w/w) drug 
loading were also evaluated 
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5.4 Conclusions 
 
The potential of Eudragit RS PO based hot melt extruded films to deliver ibuprofen at a 
reasonable rate and extent is yet to be achieved. Characterisation of the in vitro release 
properties of these films showed a low release from these films due to possible coalescence 
of the used Eudragit RS PO matrices after thermal treatment using hot melt extrusion 
technology. The release found to be dependent on the drug load and water inclusion in these 
films might facilitate drug liberation. Thus, adjustments of these formulations to achieve 
desired release may involve judicious choice of hydrophilic components, enabling fluid 
access into these extruded films. With respect to the in vitro permeation behaviour, the 
controlling (retarding) role of the Eudragit RS PO matrices on the drug permeation was 
evident in comparison to the diffusion of the ibuprofen from its saturated solution across the 
silicone membranes. Films at 30% w/w drug loading were chosen as a prototype to introduce 
further advents to optimise and establish usefulness of these formulations. Good physical 
stability of these films addressed in Chapter 4 was shown here as comparable in vitro release 
and in vitro permeation profiles between aged samples under dry conditions for one month 
and fresh samples. By fitting the in vitro permeation data of all the tested films into zero 
order, first order, Higuchi and power model, it was concluded that the ibuprofen release 
from Eudragit RS PO films followed first order kinetics and was diffusion and swelling 
mediated. Both in vitro release/dissolution and in vitro permeation studies aided in better 
understanding of the release of the ibuprofen from the tested films and directed the need of 
modification.  
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6.1 Introduction 
 
In the previous chapter the performance of the developed Eudragit RS PO extruded matrices 
with ibuprofen was discussed. In spite of their promising properties in terms of solubility 
and stability, problems related to retarded release and concomitantly poor permeation 
profiles were encountered. These ‘poor’ profiles can limit the efficiency to deliver non-
potent active substances such as ibuprofen, whereby higher doses are needed to achieve 
therapeutic levels. However, these systems present a viable option to deliver drug 
transdermally if the challenge of delivering sufficient amounts of the ibuprofen can be met. 
Therefore, this chapter aims to realize the potential of using these systems through 
investigation of some enhancement techniques through variation of design parameters.  
Section 6.2 details the first design parameter based on drug/carrier optimisation through 
introduction of various classes of hydrophilic polymers, in particular considering 
processability, solid state characteristics, in vitro release and permeation profiles. Section 6.3 
explores hydration as another design parameter and the use of this enhancement strategy for 
selected vehicles to attain optimal drug permeability. 
 
6.2 Effects of vehicle formulations  
 
The previous chapter indicated that Eudragit RS PO matrices, when extruded with 
ibuprofen, provide a controlling role that influences the rate and amount of ibuprofen 
release, although optimisation is needed to achieve the desired release of the drug. 
Therefore, this section is devoted to discuss the formulation influence on the in vitro 
ibuprofen release and permeation from modified hot melt extruded films (matrix-type 
patches).  
 
6.2.1 Methodology 
 
Physical mixtures of the drug and the carrier blend of Eudragit and other hydrophilic 
excipients were prepared by simple mixing in a pestle and mortar. The mixes were fed into a 
co-rotating twin screw extruder (Haake Minilab II Micro Compounder) equipped with a 
sheet-shaped die.  Determination of the minimum ratio between these components was based 
on 30% w/w ibuprofen loading, which represents the solubility limit of this drug in the 
parent polymer i.e. Eudragit RS PO. Each batch size was formulated with total weight of 10 
grams. Temperatures of 90-100˚C from the feed to the die end were used according to the 
formulation prepared and a screw speed was set at 100 rpm for four  minutes, which was 
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found to be suitable for the extrusion of these mixtures. The resultant extruded films were 
cooled along a customised conveyer belt to room temperature, where the melts spread out 
over aluminium foil. These films were separated into unit doses of roughly equal size 
(approximately 24 mm3). The films were measured for thickness using a Vernier caliper. 
The films were stored between aluminium sheets, except for the ones containing Gelucire® 
44/14, which were stored between silicone sheets due to their high stickiness. The films 
were labelled and stored in desiccators at room temperature until further evaluations. 
 
The extrudable mixtures obtained as described above were characterised using techniques of 
MTDSC, PXRD and SEM and compared when appropriate with the equivalent physical 
mixes. These experiments were the same as detailed in Chapter 3. The in vitro drug release 
experiment (dissolution test) and in vitro permeation studies were also carried out for the 
selected optimised formulations in the same procedure described in Chapter 5. Ibuprofen 
retained in the silicone membranes in permeation studies was extracted with diethylether as 
detailed in Chapter 5. Each membrane was placed in 10 ml diethylether, stirred at 200 rpm 
for 36 hours. The extraction solutions were filtered through 0.45µm membrane filters 
(Acrodisc® syringe filters), and the filtrates were suitably diluted and analyzed using UV 
spectrophotometer at 222 nm (PerkinElmer, Lambda XLS). All the reported values were 
measured as mean±S.D (n=3) unless otherwise mentioned in the relevant section. 
 
6.2.2 Results and discussion 
 
6.2.2.1 Fabrication and development of hot melt extruded Eudragit RS PO-based films 
loaded with ibuprofen and intended for transdermal drug delivery 
 
In the initial part of this investigation, the key consideration was the addition of a third 
excipient, with hydrophilic properties to modify drug release, to the Eudragit RS PO and 
ibuprofen, which could be extruded effectively. Therefore, it is reasonable at this stage to 
aim for the necessary adjustments on the ratios of these excipients (modifiers) that will 
permit processing with acceptable yield characteristics, these being flexibility without high 
fluidity and suitable robustness of the cooled product. The scope of the specifications for the 
use of these excipients for transdermal drug delivery system and their thermal stability for 
extrusion process were covered in Chapter 2 and Chapter 3, respectively.  
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Among the key factors that were considered relating to the processing, the extrusion 
temperature was of principal interest with its subsequent influence on acceptable torque 
values that permits efficient material transfer towards the outlet of the extruder. During the 
extrusion process, the system needs to be at the minimum temperature that is required to 
allow rotation of the screws; inclusion of a plasticizer can further improve processing 
conditions via reducing the torque needed. Because ibuprofen can be an efficient plasticizer 
(Kidokoro et al., 2001), it is expected to enhance the processability and film flexibility. As 
illustrated in Table 6.1, temperatures of 90-100°C were found to be suitable to perform 
extrusion of the combinations studied with average torque values range between 5-26 Ncm, 
except for formula with the code of FM4 (high level of methylcellulose), whereby a torque 
value of 150±5 (n=2) Ncm was required, indicating high viscosity. It is noteworthy that both 
Pluronic® F127 and Gelucire 44/14 melt at comparatively low temperatures (see Chapter 3) 
and showed low viscosities which collectively permitted their extrusion at 90°C. 
 
Carrier system(s) with 
drug loading of 30% w/w 
Carrier blend(s) 
(% w/w) 
Extrusion 
temperature 
(°C) 
Formula code 
Eudragit RS PO 70 100 FM0 (Control) 
Eudragit RS PO/ Sucrose 
ratios 
60:10 100 FM1 
50:20 100 FM2 
Eudragit RS PO/ Methyl 
cellulose ratios 
60:10 100 FM3 
10:60 100 FM4 
Eudragit RS PO/ Xantural® 
75 ratios 
60:10 100 FM5 
10:60 100 FM6 
Eudragit RS PO/ Pluronic® 
F127 ratios 
60:10 90 FM7 
50:20 90 FM8 
Eudragit RS PO/ Gelucire 
44/14 ratios 
60:10 90 FM9 
50:20 90 FM10 
 
Table 6.1: Formulation and extrusion temperatures for hot melt extruded films of 
ibuprofen with different carriers 
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The amount of modifier added to the parent polymer i.e. Eudragit RS PO to make the carrier 
blend for ibuprofen was selected at two levels for each system. The first level involved the 
addition of a relatively small amount of this excipient, in attempt not to affect established 
high miscibility of ibuprofen in Eudragit RS PO at the used drug loading (30%w/w). 
Therefore the carrier blend was formulated with the ibuprofen in a ratio of 1:6:3 (new 
material: Eudragit RS PO: ibuprofen). The second level, which is the higher amount of the 
excipient, is almost a complete step into exchange the Eudragit RS PO carrier system with 
the newly introduced material in  a ratio of 6:1:3 (new material: Eudragit RS PO: ibuprofen). 
This strategy worked well only for methyl cellulose and Xantural® 75. The second level was 
not achievable in sucrose, Pluronic® F127 and Gelucire 44/14 as the extruded material was 
liquid and could not stream into the outlet. Thus the higher level possible was for a ratio of 
2:5 of the new material (hydrophilic excipient): Eudragit RS PO and was only feasible with 
Gelucire 44/14 (FM10). Extrudates produced using sucrose (FM2) and Pluronic® F127 
(FM8) at this high ratio lacked a definite shape and were difficult to collect and spread over 
the aluminium foil for a uniform film production as depicted in Table 6.2. Apart from these 
formulations (FM2, FM8), films listed in this table were considered as successful to move 
into the following stages of this study.  
 
As shown in Table 6.2, films produced with Pluronic® F127 (FM7) and Gelucire 44/14 
(FM9-FM10) were translucent clear strands similar to the control films, which contain only 
Eudragit RS PO and ibuprofen, coded as FM0. However, the films extruded with methyl 
cellulose were either golden clear extrudates (FM3) or like flat breads cream-coloured films 
(FM4). Yellowish extrudates were also produced with the formulations containing 
Xantural® 75, which appear to be translucent at FM5 composition and opaque in FM6 
formula. These discolorations are believed to be related to the colour of the raw material of 
methylcellulose or Xantural® 75 which occur as yellowish-white powders. Their onset 
temperatures for decomposition as detailed in TGA measurements in Chapter 3 were far 
higher than the used extrusion temperature; therefore, they are not expected to degrade. The 
extruded films with sucrose, coded as FM1, exhibited an almost white colour as the melting 
of sucrose was not completed at the selected extrusion temperature, which was not increased 
in order to avoid ibuprofen degradation. 
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Carrier system(s) with 
drug loading of 30% w/w 
Carrier blend(s) 
(% w/w) 
Photos (macroscopic 
appearance) 
Formula 
code 
Eudragit RS PO 
70 
  
FM0 
(Control) 
Eudragit RS PO/ Sucrose 
ratios 
60:10 
  
FM1 
50:20 
  
FM2 
Eudragit RS PO/ Methyl 
cellulose ratios 
60:10 
  
FM3 
10:60 
  
FM4 
Eudragit RS PO/ 
Xantural® 75 ratios 
60:10 
  
FM5 
10:60 
  
FM6 
Eudragit RS PO/ 
Pluronic® F127 ratios 
60:10 
  
FM7 
50:20 
  
FM8 
Eudragit RS PO/ Gelucire 
44/14 ratios 
60:10 
  
FM9 
50:20 
  
FM10 
 
Table 6.2: Eudragit RS PO-based hot melt extruded films loaded with ibuprofen: 
composition and their visual appearance 
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The visual examination and measured thickness of the successfully extruded films are 
described in Table 6.3. The level of stickiness or tackiness was assessed qualitatively by 
holding these films between thumb and index finger. Extruded films which contained 
Gelucire 44/14 were found to have the highest observed stickiness, whereas films containing 
Pluronic® F127, sucrose or low level of Xantural® 75 (FM5) showed medium stickiness 
profiles. This is an important feature to address, especially at the last steps of final product 
development, as “stickiness” would allow the film to adhere to the skin. Good adhesion of 
the patch to skin is a prime element for safety and efficiency of TDDS as detailed in Chapter 
1. 
 
Carrier system(s) with 
drug loading of  
30% w/w 
Carrier 
blend(s) 
(% w/w) 
Formula 
code 
Appearance Thickness 
(±0.02mm) 
Eudragit RS PO 
70 FM0 
(Control) 
Smooth, no cracks, 
low stickiness. 
1 
Eudragit RS PO/ 
Sucrose ratio 
60:10 FM1 Smooth, no cracks, 
medium stickiness. 
1 
Eudragit RS PO/  
Methyl cellulose ratios 
60:10 FM3 Rough, no cracks, 
low stickiness. 
1 
10:60 FM4 Rough, cracked, no 
stickiness. 
2 
Eudragit RS PO/ 
Xantural® 75 ratios 
60:10 FM5 Smooth, no cracks, 
medium stickiness. 
1 
10:60 FM6 Smooth, sporadic 
cracks, low 
stickiness. 
2 
Eudragit RS PO/ 
Pluronic® F127 ratio 
60:10 FM7 Smooth, no cracks, 
medium stickiness. 
1 
Eudragit RS PO/ 
Gelucire 44/14 ratios 
60:10 FM9 Smooth, no cracks, 
high stickiness. 
1 
50:20 FM10 Smooth, no cracks, 
high stickiness. 
2 
 
Table 6.3: Overview of the descriptions of the Eudragit RS PO-based hot melt 
extruded films loaded with ibuprofen 
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Furthermore, the film thicknesses with compositions of FM4 (high level of methylcellulose), 
FM6 (high level of Xantural® 75) and FM10 (high level of Gelucire 44/14) were higher than 
predicted as the extruded materials leaves the equipment through an orifice or die with an 
approximate opening of 1 mm, hence there is an expected film thickness of almost 1 mm.  
This could be explained by the die-swelling phenomenon sometimes encountered with the 
extrusion process (Zhang and McGinity, 1999). The material inside the extruder will be 
exposed to mechanical stress induced by rotating screws. Once it moves out the equipment, 
and depending on its viscoelastic properties, it may recover or swell with resultant increase 
in its thickness. Though this high thickness did not exceed 2 mm, an intervention was made 
to unify its value with other extrudates. Thus a roller was used to spread these films to 
approximate thickness of 1 mm. This was feasible only for FM6 and FM10 compositions as 
their extruded melt remained semisolid for appreciable time and were relatively easy to 
control, whereas FM4 films containing high level of methylcellulose were stiff (non elastic) 
and brittle, thereby limiting their adjustments.  
 
As part of the design, the second stage of this work focused on the ability of the acceptable 
extruded samples (i.e. extrudable from the first stage; see Table 6.3) to form soluble mixes, 
so the drug is dissolved in the solid state without phase separation. Therefore the phase 
behaviour of these extruded films was investigated through solid state characterisation using 
MTDSC and PXRD while the morphological features of these extrudates were assessed 
using SEM. Dealing with multi-component systems such as these extruded films 
necessitated the application of MTDSC, thereby enabling the deconvolution of complex and 
overlapping thermal events. In particular, the thermal events were complicated by water 
interactions, as observed in Chapter 3 for the raw materials owing to their hydrophilicity.  
 
The MTDSC profiles of representative samples are shown from Figure 6.1 through to Figure 
6.6. The reversing heat flow signals were used to assign the glass transition temperature 
(Midpoint-Tg), whereas the melting endotherm was identified from the total heat flow 
signals. Crystallization and water dehydration were drawn from the non-reversing signals. 
The dehydration led to broad endothermic peaks over an approximate temperature range of 
30 to 90°C, while crystallization was manifested as exothermic peak described in the 
relevant discussion.  As shown in Figure 6.1, FM0 formula (Eudragit RS PO and ibuprofen) 
represents the control extruded sample that is characterised with a single glass transition 
temperature at 9.6±0.2°C, implying a one phase system. However, the addition of sucrose at 
the FM1 composition led to separation of ibuprofen, as demonstrated from the melting 
endotherm observed in these films (Figure 6.1). This endothermic peak was observed in both 
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reversing and total heat flow signals, confirming that it is related to ibuprofen melting rather 
than water loss. Nevertheless, the extent of separation is not complete, as the melting peak of 
the ibuprofen is depressed (Tm (onset) at 51.2±1.2°C) in comparison to the pure ibuprofen 
(Chapter 3, Tm (onset) 75.7±0.2˚C), indicating a possible involvement in a certain interaction 
or miscibility (Abdul-Fattah and Bhargava, 2002). This is supported by the recorded glass 
transition temperature of approximately 35.6± 0.3°C (n=2), which is lower than the reported 
Tg of Eudragit RS PO (Chapter 3, 53.3±0.5°C), thereby representing the ibuprofen-Eudragit 
RS PO miscible phase as the sucrose is still crystalline due to extrusion temperature (100°C) 
far below its melting point (Chapter 3, Tm (onset) at 175.2±1.8°C), thus it is unlikely to be 
involved in this amorphous phase. 
 
  
  FM0                                                                 
 
FM1 
Figure 6.1: MTDSC heating scans of different hot melt extruded films (see Table 6.3) in 
standard aluminium pans. Underlying scan rate of 1°C min-1 with a modulation 
amplitude of ±0.265°C and a period of 100 seconds. The traces have been offset for 
clarity 
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In Figure 6.2, the extruded system at FM3 composition (low level of methylcellulose) 
exhibited two amorphous phases. The first one was characterised with a low glass transition 
temperature (Mid-point Tg = -3.5±1.6°C), that is highly likely to result from a combination 
of the amorphous ibuprofen (Mid-point Tg = -43.4±0.2°C, Chapter 3) and Eudragit RS PO 
(Chapter 3, 53.3±0.5°C). The second glass transition temperature at 87.0±1.7°C (Mid-point 
Tg) might indicate a methylcellulose rich phase as this value close to the glass transition 
temperature of this polymer (Mid-point Tg = 103.0±0.1°C, Chapter 3), lowered due to 
plasticization effect of ibuprofen (Kidokoro et al. 2001). Increasing the level of methyl 
cellulose as the major polymeric constituent in FM4 films resulted in a three-phase system 
(Figure 6.2). In comparison to the FM3 films, the first amorphous phase was shifted to a 
lower glass transition temperature indicating amorphous drug rich-phase, while the second 
amorphous phase was shifted to a higher glass transition temperature almost equals 
aforementioned Tg value of the raw methylcellulose polymer. The third phase obtained was 
crystalline ibuprofen indicated by its melting endotherm.  
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FM3   
 
FM4 
 
Figure 6.2: MTDSC heating scans of different hot melt extruded films containing 
methylcellulose, Eudragit RS PO and ibuprofen (see Table 6.3) in standard aluminium 
pans. Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The traces have been offset for clarity 
 
Replacing methylcellulose by Xantural® 75 (xanthan gum) resulted in a one phase system at 
FM5 composition with a low glass transition temperature occurring around -6.7±0.9°C (Mid-
point Tg), as shown in Figure 6.3. However, at higher loaded amounts of xanthan gum found 
in FM6 films a three-phase system was manifested (Figure 6.3). At this composition, the 
ibuprofen was partially solubilised in the liquefied polymeric phase(s) and a melting peak 
was detected, though associated with a depressed onset in comparison to the pure ibuprofen, 
indicating partial miscibility. The remaining two phases were amorphous with glass 
transition temperatures at -20.4±0.3°C and 47.4±0.4°C, possibly related to amorphous 
ibuprofen rich- phase and xanthan gum rich-phase, respectively. This was inferred based on 
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the proximity of values to the estimated glass transition temperature (Mid-point) of 
ibuprofen (-43.4±0.2°C) and xanthan gum (37.7±2.6°C) reported in Chapter 3. An exotherm 
was observed in the non-reversing heat flow signal of FM6 films with an extrapolated onset 
temperature at 43.0±0.4°C (n=2). This event is highly related to recrystallization of 
ibuprofen because it was followed by the endothermic peak characteristic of the melting of 
the conventional crystalline phase of this drug.  
 
  
FM5    
 
FM6 
 
Figure 6.3: MTDSC heating scans of different hot melt extruded films containing 
Xantural® 75, Eudragit RS PO and ibuprofen (see Table 6.3) in standard aluminium 
pans. Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The traces have been offset for clarity 
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As illustrated in Figure 6.4, phase separation was evident in the FM7 solid composition of 
ibuprofen in the hydrophilic poloxamer polymer (Pluronic® F127) and Eudragit RS PO; 
however, it is believed that the Pluronic® F127 is separated not the drug. This polymer is 
known to have a good solubilising capacity (Escobar-Chávez et al., 2006) and this was 
demonstrated in the formation of amorphous phase system with a glass transition 
temperature at -5.4±1.5°C which is expected to consist of amorphous fraction of this 
polymer (Mid-point Tg =-64.2±0.3°C) and the dissolved amorphous ibuprofen therein along 
Eudragit RS PO. A melting transition was also observed with an extrapolated onset 
temperature at 47.4±2.9°C and peak temperature at 56.2±1.9°C which correlated well with 
the values obtained from the melting of this semi-crystalline polymer (Pluronic® F127) in 
the physical mix of FM7 as seen in Figure 6.5 (extrapolated onset temperature at 49.5±0.8°C 
and peak temperature at 53.5±0.1°C). The hypothesis  presented herein of these phases is 
consistent with the observations of Smithey et al. (2007) who found that the amorphous drug 
will primarily resides in amorphous segments of the poloxamer i.e. PPO domains, wherein 
the glass transition temperature of this dispersion will be dependent on the amount of the 
amorphous drug and PPO regions. However, PEO segments of poloxamer will generally 
recrystallize. These segments or domains of poloxamer were described earlier in Chapter 2. 
 
  
 
Figure 6.4: MTDSC heating scan of FM7 hot melt extruded film containing Pluronic® 
F127 Eudragit RS PO ibuprofen ratio of (1:6:3) in standard aluminium pans. 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The traces have been offset for clarity 
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Figure 6.5: MTDSC total heat flow signal of the FM7 physical mix Pluronic® F127 
Eudragit RS PO ibuprofen ratio of (1:6:3) in standard aluminium pans. Underlying 
scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 
seconds   
 
The films formulated with Gelucire 44/14 showed two different MTDSC profiles according 
to the level of Gelucire incorporation as seen in Figure 6.6. At low level of this lipid as 
represented by FM9 films, the system showed one phase characterised by a single glass 
transition temperature at 1.5±0.7°C (Mid-point Tg). This might suggest homogenous 
dissolution of the amorphous drug in the used carrier blend of Gelucire 44/14 and Eudragit 
RS PO. The effect of increasing the amount of Gelucire 44/14 was shown at FM10 
composition and resulted in two-phase system formation. The first phase was amorphous 
characterised by a glass transition at 21.8±0.4°C (Mid-point Tg) while the second phase was 
associated with an exotherm having an extrapolated onset temperature around 5.4±1.1 and 
peak temperature at 17.6±0.2, followed by endothermic peak which starts at 29.3±1.5°C 
(extrapolated onset temperature). This peak might suggest melting of either crystalline 
ibuprofen or Gelucire 44/14. This might be more understood using PXRD technique to relate 
this transition. 
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  FM9 
  
FM10 
 
Figure 6.6: MTDSC heating scans of different hot melt extruded films containing 
Gelucire 44/14, Eudragit RS PO and ibuprofen (see Table 6.3) in standard aluminium 
pans. Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds. The traces have been offset for clarity 
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In summary, changes of the molecular distribution of the drug took place with different 
compositions. Control extruded films (FM0) were described as solid solutions of the 
amorphous ibuprofen dissolved at molecular level in Eudragit RS PO as detailed in Chapter 
4. The addition of sucrose (FM1) resulted in a decrease of ibuprofen miscibility and 
therewith the drug recrystallized from the extruded matrix. However, in methylcellulose-
Eudragit RS PO FM3 extruded films, two Tg’s were observed, indicating fully amorphous 
‘glassy’ solid dispersion system (see Chapter 1). One Tg is highly likely to result from a 
combination of the amorphous ibuprofen and Eudragit RS PO, whereas the other Tg was 
attributed to a methylcellulose-rich phase. Attempts to replace the Eudragit RS PO using 
high proportion of the methylcellulose in FM4 films resulted in a phase separation and 
ibuprofen crystallization. Xanthan gum (Xantural® 75) showed a similar behaviour when 
incorporated at high level (FM6), indicating that a relatively high concentration of Eudragit 
RS PO was necessary in both cases to maintain and/or enhance the ibuprofen miscibility, 
which was previously discussed in Chapter 4. However, at low level of Xnatural® 75 as in 
FM5 films, one phase system was formed similar to the control films but with lower Tg.  
 
Films formulated with Pluronic® F127 (Poloxamer 407) in the FM7 composition showed 
interesting behaviour. It is believed that the amorphous drug was dissolved in the amorphous 
fraction of this polymer in addition to Eudragit RS PO, whereas the crystalline part of this 
poloxamer was shown to be highly likely to cause the observed melting endotherm. This 
behaviour is well documented for semi-crystalline polymers wherein some drugs are 
concentrated in the amorphous regions of these polymers (Delahaye et al., 1997).  
 
Gelucire 44/14 has a lipidic nature while also containing polymeric constituents; the 
presence of the lower concentrations of this material appeared to facilitate solubilisation of 
the drug in the mixed films (FM9). These films were characterised by a single glass 
transition temperature at 1.5±0.7°C (Mid-point Tg) which is indicative of solid solution 
formation. However, the drug seems to be only partially miscible at higher levels of this 
lipid, as indicated by the detection of melting peaks which could correspond to the 
crystalline ibuprofen. However, given the crystalline nature of the Gelucire 44/14 it was not 
certain whether these endothermic events might be attributable to the carrier rather than the 
drug. In order to clarify this, and other anomalous results from the MTDSC studies, PXRD 
studies were employed to identify the nature of the crystalline material detected using the 
thermal approach. The X-ray powder diffraction profiles (diffractograms) are shown from 
Figure 6.7 through to Figure 6.11. Overlay of these diffractorgrms were obtained for the 
fresh extruded films and compared to their equivalent physical mixes and raw materials of 
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crystalline ibuprofen and newly introduced hydrophilic excipient. Eudragit RS PO is glassy 
(amorphous) polymer that exhibits halo PXRD pattern as described in Chapter 3. 
 
As shown in Figure 6.7, PXRD pattern of fresh FM1 (Eudragit RS PO 60% (w/w) and 
sucrose 10% (w/w) as carriers) film gave characteristic peaks of both ibuprofen and sucrose 
indicating their recrystallization. The diffractograms of fresh FM3 (low level of 
methylcellulose) and FM4 (high level of methylcellulose) films are displayed in Figure 6.8. 
While FM3 films exhibited a fully amorphous halo pattern, FM4 films revealed diffraction 
peaks of the crystalline ibuprofen. Films containing xanthan gum at FM5 composition 
showed broad halos in their diffractograms, indicating amorphous systems (Figure 6.9). 
Alternatively, diffraction peaks of crystalline ibuprofen were detected in the films with 
higher level of xanthan gum (FM6) as seen in Figure 6.9, indicating phase separation in 
these films. All these data were consistent with the foregoing MTDSC results. 
 
 
 
Figure 6.7: X-ray powder diffraction profiles of raw materials, physical mixture 
(sucrose, Eudragit RS PO and ibuprofen) and the corresponding hot melt extruded 
films of FM1composition 
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Figure 6.8: X-ray powder diffraction profiles of raw materials, physical mixtures 
(methylcellulose, Eudragit RS PO and ibuprofen) and the corresponding hot melt 
extruded films of FM3 (low level of methylcellulose) and FM4 (high level of 
methylcellulose) compositions 
 
 
 
Figure 6.9: X-ray powder diffraction profiles of raw materials, physical mixtures 
(Xantural® 75, Eudragit RS PO and ibuprofen) and the corresponding hot melt 
extruded films of FM5 and FM6 compositions 
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The PXRD pattern of the FM7 extruded sample identified both Pluronic® F127 and 
ibuprofen crystals as shown in Figure 6.10. However, the melting endotherm detected by 
MTDSC experiment in this extruded system was very close to the melting endotherm of the 
Pluronic® F127 in the equivalent physical mix. It is therefore believed that low glass 
transition temperature of this FM7 extruded system (-5.4±1.5°C, Mid-point Tg) facilitated 
recrystallization of ibuprofen over the timescale of the PXRD scan (almost one hour), and 
thus the detection of ibuprofen crystals. This can be understood in the light of amorphous 
material stability. The metastable nature of the amorphous materials results in them having a 
great tendency to assume stable crystalline form. Enhanced molecular mobility of the 
amorphous system at and above its glass transition temperature often results in 
recrystallization. Thus, at room temperature (~25°C), which is far above the Tg of this FM7 
system, it is expected that the molecular mobility was enhanced to the degree of ibuprofen 
crystallization during PXRD examination. 
 
 
 
Figure 6.10: X-ray powder diffraction profiles of raw materials, physical mixture 
(Pluronic® F127, Eudragit RS PO and ibuprofen) and the corresponding hot melt 
extruded films of FM7 composition 
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Interestingly, the diffractogram of FM9 films containing low level of Gelucire 44/14 showed 
halo pattern typical for amorphous material though having relatively low Tg (Figure 6.11). 
This conforms with the MTDSC results and suggests enhanced stability in comparison to the 
FM5 or FM7 films containing Xantural® 75 and Pluronic® F-127, respectively. 
Alternatively, higher level of Gelucire 44/14 in FM10 extruded films showed principal peaks 
of ibuprofen crystals in their PXRD traces as shown in Figure 6.11. Thus, it could be 
inferred that the phase separation of the FM10 extruded films resulted in drug crystallization 
rather than the lipid itself with subsequent melting endotherm observed in its MTDSC 
profile (Figure 6.6). 
 
 
    
Figure 6.11: X-ray powder diffraction profiles of raw materials, physical mixtures 
(Gelucire 44/14, Eudragit RS PO and ibuprofen) and the corresponding hot melt 
extruded films of FM9 (low level of Gelucire 44/14) and FM10 (high level of Gelucire 
44/14) compositions 
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MTDSC and PXRD techniques were also supplemented with SEM of the extruded films as 
illustrated in Figure 6.12 and Figure 6.13. Analysis by scanning electron microscopy showed 
that phase separation was evident in all tested films except FM5 (low level of xanthan gum) 
and FM9 (low level of Gelucire 44/14) films, through indication of their morphological 
features. SEM images of the extruded film containing sucrose, Eudragit RS PO and 
ibuprofen (FM1) as depicted in Figure 6.12, showed lines of crystals coating the surface 
whereas the cross section was full of these crystals but in less organized manner. This 
conforms to MTDSC and PXRD results which stated the presence of crystalline materials of 
sucrose and ibuprofen, indicating phase separation. The formulation of FM3 films (low 
levels of methylcellulose) showed fine granules which might be related to ibuprofen crystals 
whereas the cross sections were free from crystals. However, drug recrystallization in these 
samples was undetected using MTDSC or PXRD, suggesting that the small amount of 
crystalline material present may be below detection limits of these methods. The lower limit 
of quantification of crystalline material in amorphous dispersion by these techniques has 
been reported to be approximately 5% (Shah et al., 2006). However, for films comprising 
higher levels of methylcellulose (FM4), the structure was less compact (see photo in Table 
6.2)  and the ibuprofen crystals were more developed protruding from the surfaces and cross 
sections of these extruded films. This indicates a high extent of phase separation in 
comparison to the FM3 films containing lower levels of methylcellulose.  
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(A)                                                       (B)                 
FM1   
FM3   
FM4   
FM5   
FM6   
 FM7   
 
Figure 6.12: SEM morphological features of the surfaces (column A) and cross sections 
(column B) obtained for different fresh extruded films loaded with ibuprofen (see text 
or Table 6.3 for their compositions) 
 
 
The effect of variation of design parameters on the release and permeation properties of 
ibuprofen from hot melt extruded carriers 
Chapter 6 
 
224 
 
The surface and cross section features of the FM5, FM6 and FM7 films are also shown in 
Figure 6.12. FM5 extruded films containing low level of xanthan gum did not show crystals 
on their surfaces or cross sections, complying with both MTDSC and PXRD results. At 
higher levels of xanthan gum, the resulting FM6 films showed agglomeration of ibuprofen 
crystals mainly on the surface, while the cross section exhibited a leaf-like texture. The FM7 
(10% (w/w) Pluronic® F127) extruded films showed granular-shaped crystal formations 
only on their surfaces. These findings are consistent with previous MTDSC and PXRD 
results which indicated the presence of crystalline materials in these extruded films and 
hence phase separation. 
 
For the films containing Gelucire 44/14, the surface morphology of the low lipid loaded 
films (FM9) did not indicate the presence of any crystallinity (Figure 6.13), while needle-
shape crystals appeared for the higher lipid content (FM10) films. It was noted that the SEM 
imaging process itself did appear to cause damage to the lipid-loaded film surfaces, as 
evidenced by visible macroscopic changes; such effects are well known and are a result of 
the heating effects generated by the use of the electron beam (see Chapter 2). Therefore, 
SEM is not suitable to detect morphological features of these samples.   
 
(A)                              (B)                                (C) 
FM9    
FM10    
 
Figure 6.13: SEM images of the surfaces (column A) and cross sections (column B) for 
fresh FM9 and FM10 extruded films. Column C: photographs illustrating the 
deformations of the tested films post SEM scanning 
 
 
The effect of variation of design parameters on the release and permeation properties of 
ibuprofen from hot melt extruded carriers 
Chapter 6 
 
225 
 
In summary, the results obtained from MTDSC, PXRD and SEM methods were relatively 
comparable and complementary to each other. Overall, these techniques showed that multi-
component extruded systems of ibuprofen, Eudragit RS PO and the newly introduced 
hydrophilic excipients were not forming complete solid solutions except at FM5 (low level 
of xanthan gum) and FM9 (low level of Gelucire 44/14) compositions. Separation of the 
drug phase as crystallites can be observed in all other formulations, which seems to be 
extensive in FM1 (with sucrose), FM4 (high level of methylcellulose) and FM6 (high level 
of xanthan gum) films. 
 
6.2.2.2 In vitro release of ibuprofen from the viable hot melt extruded formulations 
 
As discussed in the previous section, the decision regarding which of the formulations to 
select initially focussed on the attributes to the manufacturing variables. The extrudable or 
processable samples were then investigated for their solid state characteristics, knowledge of 
which is essential for understanding the subsequent release performance. Given the basic 
hypothesis that the addition of these hydrophilic modifiers can enhance fluid access into the 
films and this might enhance drug release, this section of the study examines the efficiency 
of the drug release from the ‘extrudable’ carrier systems in comparison to the control films 
of ibuprofen and Eudragit RS PO (FM0). This was performed using in vitro drug release 
testing (dissolution test) in phosphate buffer (pH 7.2) at 37°C over 24 hours and the resultant 
release profiles for these formulations are shown from Figure 6.14 through to Figure 6.17 in 
addition to Figure 6.19 and Figure 6.20. 
 
The release profile of ibuprofen from FM1 system (10% (w/w) sucrose and 60% (w/w) 
Eudragit RS PO as carriers) is shown in Figure 6.14. The inclusion of sucrose in this 
extruded formulation had no significant effect on decreasing the retardation influence of 
Eudragit RS PO on the drug release. This was indicated from similar release profile to the 
control films (FM0) containing Eudragit RS PO alone as a carrier. Thus the expected 
increased wettability or water influx due to sucrose polarity was not achieved in these 
matrices (Saharan et al., 2009).   
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Figure 6.14: Ibuprofen release profiles from hot melt extruded films of FM0 (Eudragit 
RS PO as a carrier) and FM1 (Eudragit RS PO and sucrose as carriers) formulations 
in phosphate buffer solution (pH=7.2) at 37.0±0.1°C. Each data point represents the 
mean±S.D. of three measurements 
 
The 10% w/w methylcellulose system (FM3) also released ibuprofen to the same extent as 
the control films as seen in Figure 6.15. However, in this figure the increased level of methyl 
cellulose in FM4 extruded films resulted in a fast complete overall release of the drug after 
24 hours. These extruded films were less compact or less consolidated that the ibuprofen 
crystals were observed easily; macroscopically (Table 6.2) and using SEM (Figure 6.12). 
Thus it is believed that the crystalline ibuprofen was readily exposed to the dissolution 
medium which resulted in a complete release over a relatively short time.  
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Figure 6.15: Ibuprofen release profiles from hot melt extruded films of FM0 (Eudragit 
RS PO as a carrier), FM3 (10% (w/w) methylcellulose and 60% (w/w) Eudragit RS PO 
as carriers) and FM4 (60% (w/w) methylcellulose and 10% (w/w) Eudragit RS PO as 
carriers) formulations in phosphate buffer solution (pH=7.2) at 37.0±0.1°C. Each data 
point represents the mean±S.D. of three measurements 
 
Similarly, films formulated with xanthan gum (FM5-FM6) were evaluated for the alteration 
of ibuprofen release profiles as illustrated in Figure 6.16. These extruded films demonstrated 
enhanced release profile, especially at higher level of xanthan gum (Xantural® 75). 
Ibuprofen release from FM6 films (60%(w/w) xanthan gum and 10%(w/w) Eudragit RS PO 
as carriers) was rapid with almost complete release after 24 hours while the drug release 
from FM5 films (10%(w/w) xanthan gum and 60%(w/w) Eudragit RS PO as carriers) was 
slower with approximate 83% drug release after the same period. This suggests that a little 
change in the concentration of this hydrophilic polymer could result in a desired release 
profile with reasonable amount and extent (sustained release). Therefore, extruded films 
formulated with the compositions listed in Table 6.4 and using the same processing 
parameters of FM5 and FM6 were tested to assess this point.   
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Figure 6.16: Ibuprofen release profiles from hot melt extruded films of FM0 (Eudragit 
RS PO as a carrier), FM5 (10% (w/w) xanthan gum and 60% (w/w) Eudragit RS PO as 
carriers) and FM6 (60% (w/w) xanthan gum and 10% (w/w) Eudragit RS PO as 
carriers) formulations in phosphate buffer solution (pH=7.2) at 37.0±0.1°C. Each data 
point represents the mean±S.D. of three measurements 
 
Carrier system(s) 
with drug loading 
of 30% w/w 
 
Carrier 
blend(s) 
(%w/w) 
Photos Formula 
code 
Appearance Thickness 
(±0.02mm) 
Eudragit RS PO/ 
Xantural® 75 ratios 
67.5:2.5 
 
FM-I Smooth,  
no cracks,  
low 
stickiness. 
1 
65:5  
 
FM-II Smooth,  
no cracks, 
medium 
stickiness. 
1 
 
Table 6.4: Description of Eudragit RS PO-based hot melt extruded films loaded with 
ibuprofen and different amounts of Xantural® 75 polymer 
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As can be seen in Figure 6.17, the decrease of the amount of added xanthan gum in the FM-
II films (5%(w/w) xanthan gum and 65%(w/w) Eudragit RS PO) modulate the drug release 
to be slow yet higher than control films (FM0). On the other hand the lowest concentration 
of xanthan gum in FM-I films resulted in a non-remarkable increase in the ibuprofen release 
as compared with FM0 films (Eudragit RS PO as a carrier). It was therefore concluded that 
extrudates with FM-II composition might provide a suitable vehicle to deliver ibuprofen 
from these films at a reasonable amount and extent. These variations can be related to the 
swelling properties as a function of the level of incorporation of the hydrophilic polymer 
xanthan gum (Figure 6.18). Verhoeven et al. (2006) and Mundargi et al. (2007) suggested 
that this polymer will swell upon exposure to the aqueous medium; thereby the structure of 
the matrices will be disrupted, resulting in pore formation. Therefore, it is believed that these 
pore channels in the extruded carrier matrices (Eudragit RS PO and xanthan gum) facilitated 
drug release into the dissolution medium. Moreover, these findings indicate that the release 
from these extruded formulations is directed by xanthan gum concentration, thus adjusting 
the used ratio of this polymer can result in the desired release profile. 
 
 
 
Figure 6.17: Ibuprofen release profiles from hot melt extruded films of FM0 (Eudragit 
RS PO as a carrier), FM-I (2.5% (w/w) xanthan gum and 67.5% (w/w) Eudragit RS 
PO), FM-II (5% (w/w) xanthan gum and 65% (w/w) Eudragit RS PO) and FM5 (10% 
(w/w) xanthan gum and 60% (w/w) Eudragit RS PO) formulations in phosphate buffer 
solution (pH=7.2) at 37.0±0.1°C. Each data point represents the mean±S.D. of three 
measurements 
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Figure 6.18: Photographs of  hot melt extruded films  of ibuprofen with Eudragit RS 
PO and different proportions of xanthan gum after 24 hours of dissolution in 
phosphate buffer solution (pH=7.2) at 37±0.1°C 
  
Being a non-ionic surfactant and with the hydrophilic polyoxyethylene chains, Pluronic® 
F127 or poloxamer 407 in FM7 extruded films achieved an increase of the drug release as 
indicated in Figure 6.19. More than 40% of the ibuprofen was released from these films in 
comparison to approximately 20% release of ibuprofen from the parent control extrudates 
(FM0); both after 24 hours.  
 
 
 
Figure 6.19: Ibuprofen release profiles from hot melt extruded films of FM0 (Eudragit 
RS PO as a carrier) and FM7 (Eudragit RS PO and Pluronic® F127 as carriers) 
formulations in phosphate buffer solution (pH=7.2) at 37.0±0.1°C. Each data point 
represents the mean±S.D. of three measurements 
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On the other hand, the most rapid and complete drug release was obtained from films 
containing Gelucire 44/14 in FM10 films, while the lower level of this lipid gave an 
intermediate release profile from FM9 extruded films (Figure 6.20). Gelucire 44/14 can act 
as a surfactant and self-emulsifying agent (Chambin et al., 2004; Kale and Patravale, 2008; 
Kallakunta et al., 2013; Rowe at al., 2009), providing a significant increase in the total 
amount of the released ibuprofen. As depicted in Figure 6.20, FM9 produced not less than 
60% of ibuprofen release after 24 hours, whereas FM10 resulted in a complete release of the 
ibuprofen after 4 hours of the test. One of the interesting changes observed for the FM10 
films was almost complete disappearance of these films after the test, transforming the 
dissolution medium into milk-like liquid. This suggests possible emulsification which might 
be responsible on the fast-dissolving immediate release observed amongst other tested 
formulations. 
 
 
 
Figure 6.20: Ibuprofen release profiles from hot melt extruded films of FM0 (Eudragit 
RS PO as a carrier), FM9 (10% (w/w) Gelucire 44/14 and 60% (w/w) Eudragit RS PO 
as carriers) and FM10 (20% (w/w) Gelucire 44/14 and 50% (w/w) Eudragit RS PO as 
carriers) formulations in phosphate buffer solution (pH=7.2) at 37.0±0.1°C. Each data 
point represents the mean±S.D. of three measurements 
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In an attempt to consider the relative strengths and weakness of each tested formulation up 
to this stage of development, Table 6.5 was constructed. The extruded system(s) that can 
satisfy most of the favourable criteria, namely which, exhibit enhanced drug release and 
achieved homogenous drug distribution without phase separation might be considered as a 
good candidate for the transdermal delivery. The latter would be further verified using in 
vitro permeation studies in the following section. As seen in Table 6.5, phase separation 
extent was defined by the number of the phases formed as indicated previously in the 
MTDSC findings. The presence of crystalline drug at the stage of fabrication of the fresh 
films might indicate significant tendency of more recrystallization during equilibrium which 
could alter drug release properties from these extruded formulations. Thus, utilization of 
matrix wherein the active substance inclusion is contained in the dissolved non-crystalline 
form is preferable.  
 
Formulation 
Code 
Number of 
observed 
phases  
Physical Appearance Detected 
crystalline 
ibuprofen 
Ibuprofen 
release at 24 
hours (w/w %) 
 
Translucency Elasticity 
FM1 Three x x √ 21.84±0.29 
FM3 Two √ √ √ 25.46±0.07 
FM4 Three x x √ 98.97±0.22 
FM5 One √ √ x 82.73±0.08 
FM6 Three x x √ 94.40±0.74 
FM7 Two √ √ √ 42.89±2.51 
FM9 One √ √ x 58.21±3.02 
FM10 Two √  √ √ At 4 hours: 
98.11±1.24 
 
Table 6.5: Ibuprofen extruded formulations, extent of phase separation (number of 
observed phases) and physical appearance along with drug crystalline state and in vitro 
release (see text or Table 6.3 for their compositions) 
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As is evident from Table 6.5, formulations of FM1 (10% (w/w) sucrose and 60 %(w/w) 
Eudragit RS PO as carriers), FM3 (10% (w/w) methylcellulose and 60 %( w/w) Eudragit RS 
PO as carriers) and FM6 (60%(w/w) xanthan gum and 10 %(w/w) Eudragit RS PO as 
carriers) lack homogenous drug distribution with a high extent of phase separation and 
crystalline drug, indicating poor compatibility and miscibility. Moreover, these films lack 
appealing transparency with poor flexibility and, as described in Table 6.3, they have low 
stickiness. Therefore, their physical appearance is not appealing, not suitable for handling 
due to hardness of FM1(sucrose) films and brittleness of FM3 (methylcellulose) and FM6 
(xanthan gum) films; in addition to their low stickiness means that they can impart limited 
adherence to the site of action i.e. the skin. Thus, it was decided not to progress these films 
to the next stages of development as drug delivery systems for ibuprofen. 
 
In accordance with the requirements mentioned previously, FM5 films (10% (w/w) xanthan 
gum and 60% (w/w) Eudragit RS PO as carriers) and FM9 films (10% (w/w) Gelucire 44/14 
and 60% (w/w) Eudragit RS PO as carriers) appear to be the most encouraging formulations. 
However, FM7 films with 10% (w/w) Pluronic® F127 and FM10 films with 20% (w/w) 
Gelucire 44/14 present a potential for ibuprofen delivery. In spite of the fact that these 
formulations contain crystalline ibuprofen as predicted from PXRD results, there are still 
opportunities to investigate their permeation properties. This is partially due to their 
acceptable physical appearance and enhanced drug release in vitro. Furthermore, a key 
observation was that relatively fast release of ibuprofen from FM10 formulation. This result 
demonstrates that various indications can be obtained from these formulations. While slow 
controlled release of ibuprofen is desired to relieve pain in cases such as osteoarthritis and 
rheumatoid arthritis, a fast ibuprofen release can be advantageous for indications required 
rapid onset of analgesic effect that is maintained for a reasonable extent.  
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In summary, in vitro drug release (dissolution testing) undertaken for different ibuprofen 
extruded formulations revealed the effect of assortment of the hydrophilic release promoters.  
It is believed that retardation influence of Eudragit RS PO was decreased after the addition 
of xanthan gum (FM5), Pluronic® F127 (FM7) and Gelucire 44/14 (FM9-FM10) due to 
possible increase of fluid access into the extruded films as a result of hydrophilic properties 
of these promoters. Other speculated mechanisms for increase drug release are reported 
ability of xanthan gum to swell with subsequent pore formation for drug release, and 
possible emulsifying effect after inclusion of Gelucire 44/14. A comparative study between 
the extruded compositions here based on their solid state characteristics, appealing physical 
appearance and enhanced in vitro release properties showed that extruded formulations of 
FM5, FM7, FM9 and FM10 can be further explored in terms of their in vitro permeation 
properties.  
 
6.2.2.3 In vitro permeation studies of the selected formulations 
 
The transdermal patch development in this work continues with the analysis of the interplay 
between the selected extruded films and their enhancing effect on the permeation of 
ibuprofen. Therefore, these formulations were evaluated using an in vitro model of Franz 
diffusion cells fitted with silicone membranes. Ibuprofen permeation was shown in the 
diffusion profiles in Figure 6.21 and Figure 6.22 from these selected films.  
 
As previously addressed in Chapter 5 the films based only on Eudragit RS PO matrices 
showed poor ibuprofen permeability through the silicone membranes due to the very low 
release from the extruded films themselves. Therefore, it is expected that formulations which 
have shown improved drug release in the previous section to affect the permeation of the 
ibuprofen positively. However, in contrast to the observed enhanced release behaviour, the 
ibuprofen permeation profile from the FM5 extruded films (10% (w/w) xanthan gum and 60 
% (w/w) Eudragit RS PO as carriers) was even lower than control films containing Eudragit 
RS PO alone (FM0) as illustrated in Figure 6.21 (A). This can be explained by swelling 
characteristics of the xanthan gum polymer included in these films. It is believed that this 
hydrophilic polymer requires enough amount of water to swell and enhance drug release. 
However, the only available water to be absorbed herein is the evaporated water from the 
receptor medium in the Franz cells, which seems to be not enough for this swelling to take 
place. Therefore, it is expected that if we decrease the amount of this polymer, the diffusion 
profiles can be enhanced. This approach has been examined as shown in Figure 6.21 (B) and 
revealed that the highest overall permeation was achieved using the lowest level of xanthan 
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gum at FM-I composition; however, the permeation profile was poor as that of the control 
films (Eudragit RS PO as a carrier). This can be related to the limited ability of these films to 
provide sufficient drug release in the first place (Figure 6.17).   
 
 (A) 
 
(B) 
 
 
Figure 6.21: Comparative diffusion profiles of ibuprofen from (A) FM0 (Eudragit RS 
PO as a carrier) and FM5 (10% (w/w) xanthan gum and 60%(w/w) Eudragit RS PO as 
carriers) extruded films and (B) from FM-I (2.5% xanthan gum), FM-II (5% xanthan 
gum) and FM5 films, tested approximately at 32°C and permeated across silicone 
membrane into phosphate buffer solution (pH=7.2) at 37°C. Each data point represents 
the mean±S.D. of no less than three measurements 
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For Pluronic® F127 loaded films (FM7), the permeation profile was enhanced with circa 
26% drug permeation after three days in comparison with a total of about 9% drug 
permeated after the same period from the control films (FM0) as seen in Figure 6.22. The 
inclusion of Gelucire 44/14 in Eudragit RS PO films showed a maximum of circa 22% of the 
total drug permeated after three days from FM9 films which contained the lower lipid 
content (10% w/w). However, a remarkable increase in the permeation was detected using 
FM10 formulation (higher lipid content) as compared to other formulations tested here. 
More specifically, these films showed a permeation of nearly 45% of the loaded ibuprofen 
after four days (Figure 6.22). 
 
However, the drug permeation was not completed over the course of the experiment i.e. five 
to seven days. This can be a major spur to investigate other factors that can control active 
substance permeation from these films. Among these factors or measures, as cited in Chapter 
1 (Grawe et al., 2005), crystallinity of the active substance,  as well as the interaction of the 
active substance and polymer with the water adsorbed from the skin can affect the 
permeation of the active constituent across the skin from transdermal patches. The first 
factor will be explored in this section, whereas the second one will be discussed in the 
following section since it is more related to the performance properties at the level of the site 
of action rather than vehicle formulation effects.  
 
 
 
Figure 6.22: Ibuprofen diffusion profiles from hot melt extruded films of  FM0, FM7, 
FM9 and FM10 formulations tested approximately at 32°C and permeated across 
silicone membranes into phosphate buffer solution (pH=7.2) at 37°C. Each data point 
represents the mean±S.D. of no less than three measurements 
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The percentage crystallinity was calculated from MTDSC total heat flow signals of the 
samples and based on the following equation:  
 
		Crystallinity		% = .∆Hm	of		the	Extruded	sample∆Hm	Ibuprofen ×W : 	x	100																																		(Eq.6.1) 
 
Where, ‘∆Hm of the Extruded sample’ represents the melting enthalpy of the ibuprofen in 
the extruded system (J/g). For this term, difficulty arose with the films containing crystalline 
ibuprofen and crystalline or semi-crystalline constituents as Gelucire 44/14 and Pluronic®F-
127. The integration range used to measure the area of their melting endotherms was 
associated with some uncertainty, due to broadness of these peaks as illustrated from Figure 
6.24 through to Figure 6.26. However, for the same kind of samples the same ranges were 
used.  
 
Moreover, the observed melting peak of the FM10 films was mainly ascribed to ibuprofen, 
as per PXRD findings, but this does not preclude the existence of crystalline Gelucire 44/14. 
This suggestion is consistent with the location of the broad peak in the extrudate as 
compared to its respective physical mixture as seen in Figure 6.26. The melting range of the 
peak in the extruded film seems to embrace both constituents (ibuprofen and Gelucire 44/14) 
which were otherwise observed individually in the equivalent physical mix. Therefore, the 
estimated values of the percent crystallinity in this work are understood to be indicative 
rather than quantitative. Furthermore, it is recommended that the melting peak magnitude 
approach to be used for intra-comparison purposes for the same material constituents or 
formulations rather than inter-comparison between different formulations.  
 
Other terms in Equation 6.1 are ‘W’ and ‘∆Hm Ibuprofen’. The first one is defined as the 
weight fraction of ibuprofen in the extruded sample. It should be pointed out that this weight 
fraction of ibuprofen will be less after the permeation experiment due to diffusion of 
ibuprofen into the receptor medium and its retention in the used silicone membrane. On that 
basis the calculations were performed. Therefore the amounts of the drug recovered in the 
silicone membranes and permeated into the receptor medium were subtracted from the 
original assayed amount (before the permeation study). The resultant weight was used in this 
equation to represent ibuprofen amount in the films examined via MTDSC after the 
permeation experiment. The results were recorded as ‘relative’ percent crystallinity to allow 
for better comparative results (Table 6.6).  The ‘∆Hm Ibuprofen’ is the melting enthalpy of 
the ibuprofen standard, which is assumed to represent full crystallinity (100%). 
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The extruded films removed after the end of the diffusion experiments and assessed for any 
signs of ibuprofen recrystallization using MTDSC measurements are displayed from Figure 
6.23 through to Figure 6.27. It was noted that the ibuprofen recrystallized within these 
matrices after the permeation study, thus melting endotherms were detected in FM5 (10% 
(w/w) xanthan gum) and FM9 films (10% (w/w) Gelucire 44/14)  as shown in Figure 6.23 
and Figure 6.24, respectively, or increased in size (melt ΔH) as in FM7 films (10% (w/w) 
Pluronic® F127) shown in Figure 6.25, and in the case of FM10 films (20% (w/w) Gelucire 
44/14), two melting peaks were observed (Figure 6.26). One of these two peaks has a similar 
melting range to the one detected in the fresh samples and is preceded with a second peak 
that is similar to the melting range of the secondary melting endotherm of the Gelucire 44/14 
(see Chapter 3). This can explain the contradiction of the relative percent crystallinity 
observed for these films as seen in Table 6.6. In other words, the fresh films were estimated 
to have about 10% crystalline ibuprofen, whereas the films after the experiment had almost 
half this value. This might indicate that melting endotherm used in the calculation of this 
percentage in the fresh samples was in fact a function of both Gelucire 44/14 and ibuprofen 
crystals rather than only ibuprofen. This suggests the possibility of obtaining a lower relative 
percent crystallinity of ibuprofen in these fresh samples, if we take into account contribution 
of the crystalline Gelucire 44/14. The broad melting endotherm observed for FM9 (10% 
(w/w) Gelucire 44/14) extruded films after the permeation experiment might also follow the 
same behaviour. As depicted in Figure 6.25, the range of this melting peak occurs within the 
range of the melting events of both Gelucire 44/14 and ibuprofen as compared to their 
equivalent physical mix. Thus the calculated drug percent crystallinity in this case might be 
overestimated. 
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 Relative Percent Crystallinity 
Formula code Fresh extruded film (before the test) Extruded films after the test 
FM0 Not applicable 2.95±0.62 
FM5 Not applicable 13.65±0.35 
FM7 1.82±0.28 22.18±0.89 
FM9 Not applicable 12.66±0.92 
FM10 10.08±0.66 5.74±0.88 
 
Table 6.6: Estimated relative percentage crystallinity of ibuprofen from different hot 
melt extruded formulations before and after the end of the permeation experiments 
(see text or Table 6.3 for their compositions) 
         
 
 
Figure 6.23: Observed melting endotherm in the MTDSC total heat flow signals of 
FM5 (10% (w/w) xanthan gum and 60% (w/w) Eudragit RS PO as carriers) extruded 
film examined before (fresh) and after the permeation experiment. Underlying scan 
rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds   
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Figure 6.24: Observed melting endotherms in the MTDSC total heat flow signals of 
FM7 (10% (w/w) Pluronic® F127 and 60% (w/w) Eudragit RS PO as carriers) 
extruded film before (fresh) and after the permeation experiment in comparison to its 
equivalent physical mixture. ‘A’ and ‘B’ symbols denoted for peaks related to 
ibuprofen and Pluronic® F127, respectively. Underlying scan rate of 1°C min-1 with a 
modulation amplitude of ±0.265°C and a period of 100 seconds    
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Figure 6.25: Observed melting endotherms in the MTDSC total heat flow signals of 
FM9 (10% (w/w) Gelucire 44/14 and 60 % (w/w) Eudragit RS PO as carriers) extruded 
film examined before (fresh) and after the permeation experiment in comparison to its 
equivalent physical mixture. ‘A’ and ‘B’ symbols denoted for peaks related to 
ibuprofen and Gelucire 44/14, respectively. Underlying scan rate of 1°C min-1 with a 
modulation amplitude of ±0.265°C and a period of 100 seconds    
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Figure 6.26: Observed melting endotherms in the MTDSC total heat flow signals of 
FM10 (20% (w/w) Gelucire 44/14 and 50% (w/w) Eudragit RS PO as carriers) 
extruded film before (fresh) and after the permeation experiment in comparison to its 
equivalent physical mixture. ‘A’ symbol denoted for peak related to ibuprofen whereas 
‘B-I’ and ‘B-II’ symbols denoted for peaks related to Gelucire 44/14. Underlying scan 
rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds    
 
Although the aforementioned limitations could affect the estimated relative percent 
crystallinity, the approach represents a simple means of assessing the occurrence of drug 
recrystallization as well as giving some indication of its extent. In the control films (FM0), 
containing 30% (w/w) ibuprofen in 70% (w/w) Eudragit RS PO, recrystallization took place 
as shown in Figure 6.27. This can be understood with reference to the equilibrium saturation 
solubility study after incubation at 60%RH/25°C (Chapter 4). This earlier study, in brief, 
stated that water adsorbed under these conditions for one month dropped down the solubility 
of the ibuprofen in Eudragit RS PO matrices to almost 10% (w/w). A certain relative 
humidity can be generated inside Franz cells because they were occluded using parafilm to 
prevent water loss. The crystallization in the permeation studies took place within a shorter 
time in comparison to the films incubated under 60%RH/25°C. Therefore, it could be 
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inferred that a higher relative humidity conditions exist in this experiment (inside Franz 
cells) and/or the effect of high temperature employed (~32°C compared to 25°C) which in 
either case, drove a faster crystallization. As known, storage at temperatures higher than the 
glass transition of the amorphous material, along with possible water plasticization, can 
enhance mobility of the amorphous compound and speed up its conversion to the stable 
crystalline state. Accordingly, it could be speculated that in response to these conditions, the 
recrystallization took place or increased in other tested formulations during the permeation 
studies. It was with hindsight performing water content measurements of the samples after 
permeation study that would have indicated if the water amount in these samples differed to 
the samples stored under 60%RH/25°C. 
 
                                               
 
Figure 6.27: Observed melting endotherm in the MTDSC total heat flow signals of the 
control extruded FM0 film (Eudragit RS PO as a carrier) examined before (fresh) and 
after the permeation experiment. Underlying scan rate of 1°C min-1 with a modulation 
amplitude of ±0.265°C and a period of 100 seconds    
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Overall, as shown in Table 6.6, the estimated fraction of the drug that has been recrystallized 
after the permeation experiment is minimal; which alone might not be enough to account for 
the observed poor diffusion from the studied systems. Nevertheless, it can be argued that the 
observed recrystallization within the tested films could decrease the drug release and the 
permeation thereof would be low.  
 
In summary, ibuprofen permeation was limited from the FM5 (10% (w/w) xanthan gum), 
FM7 (10% (w/w) Pluronic® F127), FM9 (10% (w/w) Gelucire 44/14) and FM10 (20% 
(w/w) Gelucire 44/14) formulations. Possible factors contributing to the poor diffusion 
profiles were lack of sufficient hydration, which was clearly demonstrated in the films 
formulated with the xanthan gum (FM5), in addition to the recrystallization of ibuprofen. It 
was therefore decided to investigate other approaches for enhancement of the ibuprofen 
permeation from the selected films. This will be discussed in the following section and 
concerns the influence of hydration as a possible means of permeation enhancement. This 
technique corresponds to one of the most common design modifications that are applied at 
the level of the application site rather than optimisation of the drug-vehicle formulation 
(Benson, 2005). For that purpose, two categories of films were selected from the optimized 
formulations. Firstly, films whereby the ibuprofen is not crystalline in the fresh samples 
were selected (FM5 (10% (w/w) xanthan gum) and FM9 (10% (w/w) Gelucire 44/14)). The 
second type of film chosen is the one that achieved the maximum permeation of the drug, 
namely, the FM10 (20% (w/w) Gelucire 44/14) films.   
 
6.3 Effects of hydration 
 
In the previous section we have defined some elements important for designing feasible 
formulations for extrusion with improved release profiles. However, poor permeation 
profiles of these selected systems steer the discussion on the possible reasons behind that, 
including drug recrystallization and lack of proper hydration. Therefore, the main objective 
of this section is to explore how hydration may influence permeation from selected films. 
The study will examine the issue of the relationship between drug permeation and hydration 
level inside the Franz cells, as measured by the relative humidity level established in these 
cells. The relationship between ibuprofen permeability from the optimized selected matrices 
and the approximate hydration level that can be produced by skin occlusion will also be 
addressed. 
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6.3.1 Methodology 
 
A Franz Cell diffusion system composed of six diffusion cells with identical characteristics 
were used to measure the release of ibuprofen from FM5 (10% (w/w) xanthan gum), FM9 
(10% (w/w) Gelucire 44/14) and FM10 (20% (w/w) Gelucire 44/14) films through silicone 
membranes in a similar procedure to Chapter 5. However, to probe the influence of 
hydration on the enhancement of ibuprofen release from the tested films thereafter its 
penetration across the silicone membranes, two conditions were applied, namely, Test 1 and 
Test 2.   
 
In Test 1, the extruded films in the donor phase were immersed with 0.3 ml (maximum 
capacity of the donor chamber) of the phosphate buffer medium (pH=7.2), which is also 
used in the receptor phase. The second condition (Test 2) was exposing fresh films to a 
controlled relative humidity of 95% at 25°C using DVS machine (see Chapter 2) and the 
films were held at this humidity level for 3 hours to achieve near equilibrium at this 
condition prior application to the Franz Cell diffusion system. TGA was used to measure the 
water content as documented in Chapter 4. The level of the relative humidity that could be 
established inside the Franz cells was monitored through setting up the diffusion 
experiments as described in Chapter 5, but without any tested films. Humidity indicator 
cards were assembled with the donor chambers of the Franz cells in order to give an 
approximation on that humidity level as depicted in Figure 6.28. Gelucire 44/14 containing 
films, coded as FM9 (10% (w/w) Gelucire 44/14) and FM10 (20% (w/w) Gelucire 44/14) 
were also probed for their permeation behaviour in a similar procedure with the Test 1, but 
using 0.14 ml volume of the PBS (pH=7.2) in attempt to mimic hydration established after 
skin occlusion. MTDSC experiments, as described in Chapter 3, were carried out to study 
the changes in film integrity after the drug permeation following hydration.  
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Figure 6.28: PermeGear Franz Cell diffusion system includes six jacketed Franz cells; 
securely located to a stirrer. The receptor chambers were filled with phosphate buffer 
solution (pH=7.2) maintained at 37°C and covered with silicone membranes. Humidity 
indicator cards were mounted on the top of each donor chamber and all openings were 
sealed with double layers of Parafilm® 
 
6.3.2 Results and discussion 
 
6.3.2.1 Hydration dependence of the in vitro permeation of ibuprofen from hot melt 
extruded films 
 
Due to the enhanced in vitro release (dissolution test) behaviour of the FM5 (10% (w/w) 
xanthan gum), FM9 (10% (w/w) Gelucire 44/14) and FM10 (20% (w/w) Gelucire 44/14) 
films compared to the films with no hydrophilic additives, understanding the influence of 
hydration is necessary in order to understand the in vitro permeation properties. Figure 6.29 
shows to what extent the permeation profiles of the ibuprofen depends on these films’ 
hydration. The permeation profiles of these samples were firstly compared to the samples 
hydrated using 0.3 ml of the phosphate buffer (pH=7.2) in ‘Test 1’. This level of hydration is 
the maximum volume can be added in the donor chamber of each cell of the Franz diffusion 
system. It is clearly seen that this hydration provoked a significant enhancement in the 
permeation profiles as compared with the control samples of the same compositions but 
without hydration. The maximum drug permeation was 85.44% after 72 hours from FM5 
films (xanthan gum), 98.91% after 96 hours from FM9 films (low level of Gelucire 44/14) 
and around 94.26% after 5 hours from FM10 films (higher level of Gelucire 44/14).  
 
The effect of variation of design parameters on the release and permeation properties of 
ibuprofen from hot melt extruded carriers 
Chapter 6 
 
247 
 
Additionally the samples were conditioned at a controlled level of humidity using the DVS 
at 95%RH/25°C for three hours and examined for their in vitro permeation behaviour 
(Figure 6.29, Test 2). The water content of these samples was measured using TGA and 
compared to the non-hydrated samples as shown in Figure 6.30. This increase in the water 
content resulted in a profound change of the drug permeation in comparison with non-
hydrated samples (control) as depicted in Figure 6.29. An increase in the percent of the drug 
permeated was noticed but in a slower rate than samples exposed to the hydration level in 
‘Test 1’. This was illustrated in Figure 6.31 using the time parameter which is required to 
attain 80 percent or higher of the cumulative drug permeation.  
 
 (A) 
 
 
Figure 6.29: Ibuprofen diffusion profiles from hot melt extruded films of (A) FM5 
(60% (w/w) Eudragit RS PO and 10% (w/w) xanthan gum as carriers) tested 
approximately at 32°C and permeated across silicone membrane into phosphate buffer 
solution (pH=7.2) at 37°C. Control: samples without hydration. Test 1: each sample 
was placed in 0.3 ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Test 2: 
samples were moistened at 95%RH/25°C for three hours prior testing in the Franz 
cells. Each data point represents the mean±S.D. of no less than three measurements 
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(B) 
 
(C) 
 
 
Figure 6.29 (Contd.): Ibuprofen diffusion profiles from hot melt extruded films of (B) 
FM9 (60% (w/w) Eudragit RS PO and 10% (w/w) Gelucire 44/14 as carriers) and (C) 
FM10 (50% (w/w) Eudragit RS PO and  20% (w/w) Gelucire 44/14 as carriers)  tested 
approximately at 32°C and permeated across silicone membrane into phosphate buffer 
solution (pH=7.2) at 37°C. Control: samples without hydration. Test 1: each sample 
was placed in 0.3 ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Test 2: 
samples were moistened at 95%RH/25°C for three hours prior testing in the Franz 
cells. Each data point represents the mean±S.D. of no less than three measurements 
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Figure 6.30: Summary of the measured percentage water contents of different hot melt 
extruded films (see text for their compositions) determined by TGA on freshly basis 
immediately after extrusion (before treatment) and after incubation at 95%RH/25°C 
for three hours in the DVS (after treatment) 
 
 
 
Figure 6.31: The time corresponding to 80% or higher of the cumulative percentage 
permeation of the ibuprofen from hot melt extruded films of Eudragit RS PO-based 
films containing Xantural® 75 (FM5 composition), Gelucire 44/14 (FM9 and FM10 
compositions) tested approximately at 32°C and permeated across silicone membrane 
into phosphate buffer solution (pH=7.2) at 37°C. Test 1: each sample was placed in 0.3 
ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Test 2: samples were 
moistened at 95%RH/25°C for three hours prior testing in the Franz cells   
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Furthermore, the permeation kinetics of the in vitro drug permeation from these films was 
explored with and without hydration under different conditions. Zero order, first order and 
Higuchi equation models were used to study the effect of hydration on the permeation 
kinetics from these films as shown in Table 6.7, whereas the power model was used to 
explain the possible release mechanism as seen in Table 6.8. As detailed in Chapter 5, the 
correlation coefficient, R2, was used to assess the fit of a model equation. The model with 
the highest R2 will be considered to be the best fit to describe the kinetics of the permeation.  
FM5 (10% (w/w) xanthan gum), FM9 (10% (w/w) Gelucire 44/14) and FM10 (20% (w/w) 
Gelucire 44/14) films, studied at different hydration conditions and compared to the non-
hydrated samples exhibited non-linear ibuprofen permeation with time wherein the first 
order release kinetics was the best model to describe these profiles (Table 6.7). This 
indicates that hydration level did not alter these profiles kinetically and that the permeation 
rate will decrease with time. Consequently, these systems can act as matrices that control the 
permeation profile of the drug. This control can be advantageous for enhanced 
reproducibility of the transdermal drug delivery because inter- and intra-subject variations 
can be minimized (Hillery et al., 2001). 
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Used Kinetic model  First order 
model 
Zero order 
model 
Higuchi square-root of 
time model 
Tested sample R2 R2 R2 
(A) FM5 Films    
Control 0.9655 0.8895 0.9491 
Test 1 0.9756 0.9238 0.9557 
Test 2 0.9902 0.8701 0.9523 
(B) FM9 Films    
Control 0.9823 0.9553 0.9787 
Test 1 0.9741 0.8156 0.9108 
Test 2 0.9845 0.9587 0.9811 
(C) FM10 Films    
Control 0.9831 0.8419 0.9384 
Test 1 0.9742 0.2198 0.4133 
Test 2 0.9916 0.9543 0.9741 
 
Table 6.7: Fit correlation coefficients (R2) of different applied kinetics models for the 
permeation profiles of the FM5 (10% (w/w) xanthan gum), FM9 (10% (w/w) Gelucire 
44/14) and FM10 (20% (w/w) Gelucire 44/14) films tested under different hydration 
conditions. Control: samples without hydration. Test 1: each sample was placed in 0.3 
ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Test 2: samples were 
moistened at 95%RH/25°C for three hours prior testing in the Franz cells 
 
In Table 6.8 the power model was used to predict the involved release with subsequent 
permeation mechanism(s) from these films. As mentioned in Chapter 5, the measured 
release exponent can be used to describe these mechanisms. The permeation profiles from 
FM5 films (10% (w/w) xanthan gum) showed anomalous transport in all the tested samples 
regardless of the applied hydration condition. This means that diffusion and swelling were 
the main mechanisms involved in the ibuprofen release from these films and permeation 
through the silicone membranes. However, it could be argued that hydrated samples can also 
follow case-II transport, because their release exponents are almost approaching 1. In this 
case it would be assumed that drug release is mainly controlled by swelling of these 
matrices. On either way, it is believed that swelling is a feasible prediction of the release 
mechanism herein, because it is characteristic of the xanthan gum contained in these films to 
allow drug release and permeation. These films were swelled after being hydrated in Test 1 
and in Test 2 assuming the shape of the diffusion area (circular) of the Franz cells. 
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 Kinetic model  Korsmeyer-Peppas 
model (Power law) 
 R2 Release exponent 
(n) 
Expected release 
mechanism 
(A) FM5 Films    
Control 0.9480 0.45 Anomalous transport 
Test 1 0.9676 0.97 Anomalous transport 
Test 2 0.9776 0.95 Anomalous transport 
(B) FM9 Films    
Control 0.9820 0.67 Anomalous transport 
Test 1 0.9253 1.00 Case-II transport 
Test 2 0.9833 0.93 Anomalous transport 
(C) FM10 Films    
Control 0.9779 0.79 Anomalous transport 
Test 1 0.9538 2.52 Super case-II transport 
Test 2 0.9698 1.18 Super case-II transport 
 
Table 6.8: Interpretation of the measured release exponents from the power law model 
and their correlation coefficients (R2) for the permeation profiles of the FM5 (10% 
(w/w) xanthan gum), FM9 (10% (w/w) Gelucire 44/14) and FM10 (20% (w/w) Gelucire 
44/14) films tested under different hydration conditions. Control: samples without 
hydration. Test 1: each sample was placed in 0.3 ml of PBS (pH=7.2) in the donor 
chamber of the Franz cells. Test 2: samples were moistened at 95%RH/25°C for three 
hours prior testing in the Franz cells  
 
The release exponent determined in the FM9 films (10% (w/w) Gelucire 44/14) revealed that 
matrix swelling is expected to control the faster permeation of these films achieved by 
hydration in Test 1. Conversely, the slower permeation obtained after being hydrated at low 
levels in Test 2 is believed to be controlled by combination of matrix swelling and diffusion, 
resembling the mechanism of control samples (non-hydrated). The films hydrated in Test 2 
had a release exponent close to 1, so we could also assume that swelling would be the main 
mechanism of drug release from these films (case-II transport). 
 
The swelling in the FM9 films could take place as a function of the swelling of Gelucire 
44/14 in these systems as expected after contact with aqueous medium as other Gelucires 
(Sutananta et al., 1995). This was further supported by the appearance of these films. In like 
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manner to the FM5 films, the films exposed to hydration in Test 1 and 2 were swelled and 
jellified adapting the shape of the diffusion area (circular) of the Franz cells.  
 
Incorporation of higher level of Gelucire 44/14 in the FM10 films demonstrates an alteration 
of the predicted mechanism after being hydrated in both Test 1 and Test 2. The control 
systems (non-hydrated) changed from anomalous transport controlled by swelling and 
diffusion into super case-II transport that is controlled by swelling and relaxation 
mechanisms. However, films tested under Test 2 have a release exponent close to 1, so it 
could also be speculated that drug release is controlled mainly by swelling (case-II 
transport). The control samples herein retained their normal rectangular shape after the 
permeation study whereas the films hydrated in Test 2 swelled and jellified as FM9 films. 
Surprisingly samples in Test 1 transferred into homogenous liquid-like emulsion. Figure 
6.32 is set forth to exemplify the shape deformation of different films after permeation 
experiment or otherwise after being hydrated externally under glass slides to illustrate 
mainly the liquid-like formation of FM10 films similar to Test 1 condition.   
 
   
(I) FM5                      (II) FM9 or FM10 
  
(III) FM9                    (IV) FM10 
   
Figure 6.32: Representative photographs of shape and consistency changes of  hot melt 
extruded films removed from Franz cells post testing (top row) and exposed to 0.3 ml 
PBS (pH=7.2) at 32°C to imitate  Test 1 condition over three hours and under glass 
slides (bottom row). (I) FM5 films (10% (w/w) xanthan gum) after Test 1 and Test 2. 
(II) FM9 films after Test 1 and Test 2 or FM10 after Test 2. (III) FM9 films (10% 
(w/w) Gelucire 44/14). (IV) liquid-like emulsion of hydrated FM10 films (20% (w/w) 
Gelucire 44/14). Images of these films before the tests were captured in Table 6.2 
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From earlier discussion it is evident that hydration left appreciable impact on the observed 
permeation profiles of ibuprofen from the studied films. Therefore, humidity level was 
further evaluated inside Franz cells, which is assumed to closely mimic in vivo skin 
conditions. It is believed that these measurements would be useful to get insight into the 
suggested relation between the onset of maximum permeation from the studied systems and 
applied humidity condition. Using the same conditions employed in the used permeation 
studies the humidity levels were estimated. Figure 6.33 shows the experimentally 
determined relative humidity values over five days. It is noted that the relative humidity 
levels increased over time. However, the water accumulated in these cells does not meet the 
threshold to enhance the drug liberation from the studied films as reflected by poor 
permeation profiles, but rather it is expected to facilitate drug recrystallization as suggested 
in section 6.2.  
 
 
 
Figure 6.33: Variation of the percent relative humidity (%RH) over 120 hours inside 
the donor chambers of Franz Cell diffusion system encompasses receptor chambers 
covered with silicone membranes and filled with phosphate buffer solution (pH=7.2) 
maintained at 37°C. Each measurement recorded from humidity indicator card 
represents the mean±S.D. of six measurements 
 
Notably, the maximum percentages of the drug permeated from the FM5 (xanthan gum), 
FM9 (low level of Gelucire 44/14) under control conditions (without hydration) and used 
hydration levels of Test 1 and Test 2 were achieved at the times which correspond to the  
humidity levels higher than 80%RH inside Franz cells as seen in Figure 6.34. This reinforces 
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the role of the water taken from the surrounding environment (Franz cells) in achieving 
maximum permeation from the studied films. This also conforms to the observed permeation 
behaviour of FM10 films under control conditions and at Test 2 conditions (humidification 
at 95%RH/25°C for 3 hours prior test).  
 
However, using higher hydration condition in Test 1, the maximum permeation achieved in 
FM10 films was not correlated with the high humidity level inside Franz cells. This may 
likely be attributable to some observed aspects of this formulation. At this hydration level, 
profound changes of the solid state consistency took place wherein a liquid-like emulsion 
formed. This may suggest possible emulsion formation with subsequent enhanced 
solubilisation and permeation of ibuprofen. This would be expected by knowing the good 
solubilisation (Karatas et al., 2005; Kawakami et al., 2004), permeation enhancement (Li et 
al., 2008) and self-emulsifying (Chambin et al., 2004; Kale and Patravale, 2008; Kallakunta 
et al., 2013; Rowe at al., 2009) properties of Gelucire 44/14. Another possibility is formation 
of supersaturated systems after immersion in the buffer solution. These systems are known 
to have high chemical potential that can drive significant increase of the active substance 
permeation as evident here from the significant increase of the percent ibuprofen permeated.  
 
 
 
Figure 6.34: Relative humidity values as recorded from Franz cells (from Figure 6.33) 
at the time point corresponding to the maximum total permeation from formulations of 
FM5 (10% (w/w) xanthan gum), FM9 (10% (w/w) Gelucire 44/14) and FM10 (20% 
(w/w) Gelucire 44/14), tested at different hydration levels  
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Overall, the hydration was essential to achieve improved drug permeation from the studied 
systems. Thus, the application of these films looks as innovative approach to deliver the 
ibuprofen transdermally due to simple matrix design and the safety of employing water to 
activate drug permeation (Hadgraft, 1999). Moreover, different permeation programs in the 
same type of the system were created depending on the applied hydration level.  
 
Therefore, variation of either  the vehicle used or the applied hydration level will result in a 
different permeation program. As the permeation profiles from vehicles containing Gelucire 
44/14 were notably conditioned and improved even at low levels of hydration in comparison 
to the FM5 formula contating xanthan gum, it was decided to continue with these 
formulations, coded as FM9 and FM10. However, the need of high hydration of FM5 films 
to release the ibuprofen can be solved if we use this system, for example, for wound 
dressings when inflammation is present and where an excess of fluid is coming from 
exuding wounds. Therafter, the exudate will be  removed or absorbed by this system and 
simultaneously the anti-inflmmatory agent i.e. buprofen will be released.  
 
For FM9 (10% (w/w) Gelucire44/14) and FM10 (20% (w/w) Gelucire44/14) films, it is 
believed that the  hydration produced by skin occlusion might be enough to activate them. 
Skin occlusion is a common therapy approach that is usually utilized to improve permeation 
of the drugs into the skin (Warner et al., 1999; Williams and Barry, 2004). This approach 
relies mainly on the profound hydration it can produce, wherein water can act as “absorption 
acceleator”  through the proposed  mechanisms detailed in Chapter 1. However, in our case 
the hydration will not only be useful to modulate the skin barrier function per se and 
facilitate drug permeation, but also to improve drug release from the used formulations. 
  
To get insight into the performance of these formulations under skin occlusion, the Franz 
cells were used and a volume of 0.14 ml of the PBS (pH=7.2) was used to hydrate the 
samples. This volume is expected to approximate the water volume that might accumulate 
after 48 hours of the human skin occlusion over the used diffusional cell area (0.785 cm2) 
based on the  transepidermal water loss rate measurements performed by Roskos and Guy 
(1989) after skin occlusion with polypropylene chambers. Figure 6.35 set forth aspects of the 
permeation behaviour of ibuprofen from the FM9 and FM10 films on the assumption that 
they were hydrated under occlusion conditions.  
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Figure 6.35: Ibuprofen diffusion profiles from hot melt extruded Eudragit RS PO-
based films which contain 10% (w/w) and 20% (w/w) Gelucire 44/14 in FM9 and FM10 
systems, respectively, tested at approximately 32°C and permeated across silicone 
membrane into phosphate buffer solution (pH=7.2) at 37°C. Each sample was hydrated 
with 0.14 ml of PBS (pH=7.2) in the donor chamber of the Franz cells. Each data point 
represents the mean±S.D. of no less than three measurements 
 
In similar manner to the previous experiments performed under hydration conditions, Figure 
6.35 showed that the permeation of the drug was enhanced in both FM9 and FM10 films as 
compared to their permeation profiles without hydration (see Figure 6.22) and the rate of 
ibuprofen permeation was faster in the FM10 films which contain higher level of Gelucire 
44/14. In link with Figure 6.29,  the maximum percent of ibuprofen permeated was obtained 
at slower rate than the samples examined in Test 1 but faster than Test 2, supporting the 
suggestion of permeation dependence on the applied level of hydration. On the other hand 
the proposed kinetics and mechanism(s) of drug release and permeation from FM10 films 
showed same behaviour at different hydration levels (Table 6.8 and Table 6.9).  
 
However, FM9 films, as seen in Table 6.9, demonstrated for the first time fitness to zero-
order model after being hydrated with 0.14 ml of the buffer solution. Alternatively, this 
opens another door for the usefulness of using this system, wherein concentration 
independent release may be attained with steady-state release. The proposed mechanism of 
the release from these systems was ‘anomalous transport’, based on the power model. This 
indicates possible  role of swelling and diffusion to control the release from these matrices.   
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 (A) 
Used Kinetic model  First order model Zero order model Higuchi square-root of 
time model 
Tested sample R2 R2 R2 
FM9 Films 0.9691 0.9769 0.9685 
FM10 Films 0.9850 0.7374 0.9048 
 
(B) 
Kinetic model  Korsmeyer-Peppas model (Power law) 
 
 R2 Release exponent 
(n) 
Expected release mechanism 
 
FM9 Films 0.9704 0.76 Anomalous transport 
FM10 Films 0.8876 1.21 Super case-II transport 
 
Table 6.9: (A) Fit correlation coefficients (R2) of different applied kinetics models and 
(B) possible interpretation of the measured release exponents from the power law 
model and their correlation coefficients (R2), both for the permeation profiles of the 
FM9 and FM10 films under the condition of hydration with 0.14 ml of PBS (pH=7.2) in 
the donor chambers of the Franz cells  
 
In Figure 6.36 and Figure 6.37, the MTDSC was used to get further insight into possible 
changes on these films while being tested in Franz cells under the applied hydration level 
(0.14 ml of PBS, pH=7.2). Though these samples were blotted onto filter papers to dry them 
prior the MTDSC experiment, these samples kept some water. Therefore, the changes were 
observed from the reversing heat flow signals rather than the total heat flow signals, as the 
latter were distorted with overlapped broad dehydration peaks. Thus and due to quantitative 
limitations associated with using reversing heat flow signal (see Chapter 2), the relative 
trend of changes in the ‘apparent’ melting peaks will be discussed herein. For the FM9 films 
(Figure 6.36), an endothermic peak started to appear with a peak temperature around 51.8°C 
(n=2) after 15 minutes of the permeation experiment, this peak sharpened (higher melt ∆H) 
after one hour, indicating possible recrystallization due to possible perturbation of moisture 
and temperature found inside Franz cells. Afterwards, this peak was shifted to lower 
temperatures, indicating possible solubilisation. This peak almost disappeared after the end 
of the experiment (48 hours) with a very broad and subtle endotherm detected around 41.1°C 
(Tm (peak), n=1).  
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Figure 6.36: MTDSC reversing heat flow signals for fresh hot melt extruded FM9 
(10% (w/w) Gelucire 44/14) removed at different times from the permeation 
experiment in the Franz-type diffusion cells. The tested samples were hydrated with 
0.14 ml of PBS (pH=7.2) in the donor chambers of the Franz cells at approximately 
32°C. Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and 
a period of 100 seconds 
 
By the same token, FM10 films (Figure 6.37) showed a shifting of its melting endotherm 
towards a lower temperature with a relative decrease in the observed ∆H of the melt 
transition, which again indicates possible solubilisation or even involvement in a certain 
interaction (Abdul-Fattah and Bhargava, 2002). However, the monitoring of these samples 
was extended up to 5 hours after which the samples were transformed into liquid-like 
emulsion. These observations corroborate the addressed improvement of the performance of 
these films under the used hydration level, which is believed to approximate the level 
initiated after skin occlusion. Therefore, what is decisive for the possible usefulness of these 
films as  promising drug delivery systems is depending on the presence of the safest and 
efficient penetration enhancer i.e. water (Aulton, 2007; Escobar-Chávez, 2010; Hadgraft, 
1999) that can be accumulated under occlusive conditions.  
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Figure 6.37: MTDSC reversing heat flow signals for fresh hot melt extruded FM10 
(20% (w/w) Gelucire 44/14) films removed at different times from the permeation 
experiment in the Franz-type diffusion cells. The tested samples were hydrated with 
0.14 ml of PBS (pH=7.2) in the donor chambers of the Franz cells at approximately 
32°C. Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and 
a period of 100 seconds 
 
6.4 Conclusions 
 
The objectives of the work described in this chapter were to highlight the significance of 
formulation composition (polymer type and ratio used) for fabrication of hot melt extruded 
films with enhanced release properties and to determine the influence of  hydration on 
further improvement of ibuprofen release and permeation from the studied hot melt extruded 
matrices. The aim of this work is to investigate feasibility of Eudragit RS PO-based films to 
deliver ibuprofen using various modification techniques of increasing ibuprofen release and 
permeability in vitro. 
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Section 6.2 detailed the compositions and ratios of hydrophilic additives in the drug-loaded 
carriers that demonstrated acceptable processing features i.e. whether they produced 
extrudable formulations. MTDSC, PXRD and SEM were used as solid state characterisation 
tools to investigate the compatibility and miscibility of the extrudable matrices loaded with 
ibuprofen. Changes of the molecular distribution of the drug took place with different 
compositions. Although Eudragit RS PO and ibuprofen were found to be completely 
miscible in the solid-state (Chapter 4), addition of small amounts (10% (w/w)) of sucrose or 
Pluronic® F127 or methylcellulose to this system led to phase separation. This separation 
was also observed using large amounts (60% (w/w)) of methylcellulose or xanthan gum 
(Xantural® 75) or higher level of ‘extrudable’ Gelucire 44/14 (20% (w/w)). However, 
multiple component systems made up of Eudragit RS PO, ibuprofen and small amounts 
(10% (w/w)) of xanthan gum (FM5) or Gelucire 44/14 (FM9) maintained the miscibility.   
 
The results obtained from MTDSC, PXRD and SEM methods were relatively comparable 
and complementary to each other, suggesting a multi-disciplinary approach for investigating 
the solid state characteristics of these extruded films. Both PXRD and MTDSC were found 
to be less sensitive for tracing low crystallinity as compared to visually determined 
crystallites using SEM. PXRD aided in identification of crystalline species in the mixtures 
containing more than one crystalline type.  
 
In vitro release studies (dissolution testing) revealed the effect of inclusion of the 
hydrophilic release promoters. It is believed that retardation influence of Eudragit RS PO 
was decreased after the addition of xanthan gum (FM5), Pluronic® F127 (FM7) and 
Gelucire 44/14 (FM9-FM10) due to possible increase of fluid access into the extruded films 
as a result of hydrophilic properties of these promoters. It was also concluded that 
formulations with the xanthan gum (Xantural® 75) were correlated with polymer 
concentration and proper adjustment of the ratio used of this polymer can result in the 
desired release profile. Information derived from solid state characterisation, physical 
appearance and in vitro release properties were used to decide the encouraging formulations 
for further exploration of their in vitro permeation properties. Formulations which 
completely dissolve the drug as FM5 (10% (w/w) xanthan gum) and FM9 (10% (w/w) 
Gelucire 44/14) together with formulations showed superior release profile with acceptable 
physical features were selected i.e. FM7 (10% (w/w) Pluronic® F127) and FM10 (20% 
(w/w) Gelucire 44/14) films. Diffusion or permeation profiles improvement was limited 
from these selected films. Drug recrystallization as indicated by MTDSC measurements and 
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lack of proper hydration, as clearly evident in formulations with the xanthan gum (FM5), 
appeared as possible factors that contributed to the poor diffusion (permeation) profiles.  
 
Section 6.3 detailed the use of two major types of films from the optimized formulations to 
investigate the influence of hydration as a possible enhancement technique. The first type 
encompassed the samples wherein the ibuprofen is not crystalline in the fresh samples until 
they are tested in the Franz cells and involved FM5 (10% (w/w) xanthan gum) and FM9 
(10% (w/w) Gelucire 44/14) extruded films. The second type was the one achieved the 
maximum permeation of the drug amongst other tested formulations and this complies with 
the FM10 films (20% (w/w) Gelucire 44/14). Drug overall permeation profiles from the 
studied matrices were described mainly with first order kinetics and hydration influence was 
manifested on changing the drug release mechanism for the most systems. It was also 
concluded that variation of either  the vehicle used or the applied hydration level will result 
in a different permeation program. Hydration, especially in films containing Gelucire 44/14 
was notably influential and appeared as effiecient technique to enhance ibuprofen 
permeation profiles, in terms of the amount permeated and extent. It is therefore preferable 
to use these films under occlusive conditions.  
 
A simulative study of the hydration  under occlusion conditions augments the usefulness of 
films conatining Gelucire 44/14 in formulations coded as FM9 (10% (w/w) Gelucire 44/14) 
and FM10 (20% (w/w) Gelucire 44/14). MTDSC experiment of these hydrated films 
indicated possible solubilsation during the permeation experiment. Swelling and swelling 
with polymer relaxation were found to be the most relevant  mechanisms of drug release  
from these hydrated FM9 and F10 films, respectively, as predicted from the used power 
model. FM10 film, which contains higher level of Gelucire 44/14 (20% (w/w)) showed 
interesting behaviour upon hydration and depending on the applied level, its consistency  
changed into  liquid-like emuslion, which is believed to be the reason which led to the 
maximum permeation enhancemnet through either emulsification or oversaturation. Overall, 
what was decisive for the possible usefulness of these films as promising drug delivery 
system (patches) was depending on the presence of water that can be accumulated under 
occlusive conditions. Thus, it is concluded that with such affordable smart drug delivery 
design activated by hydration, further studies can be carried out using the carrier blends of 
Eudragit RS PO and Gelucire 44/14 as promising vehicle to deliver drugs transdermally.  
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transdermal delivery  
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7.1 Introduction 
 
On the basis of improving the amount of the ibuprofen liberated from Eudragit RS PO based 
matrices, the optimisation of the choice of the vehicle or carrier was discussed in Chapter 6. 
Among these carriers, inclusion of Gelucire 44/14 resulted in enhancement of in vitro drug 
release and significant improvement of the in vitro ibuprofen permeation from these 
extruded matrices which changes with hydration level. To reap the potential of using these 
Gelucire 44/14 in Eudragit RS PO extruded carriers in transdermal delivery with 
concomitant extended implications for different applied medicines, this Chapter was 
introduced. These carrier systems were extruded using two concentrations of Gelucire 44/14 
in Eudragit RS PO. A physicochemical characterisation of these systems was performed 
using various techniques, followed by exploration of possible interactions between Eudragit 
RS PO and Gelucire 441/14 using ATR-FTIR. As hydration played a major role in achieving 
the maximum drug enhancement from these vehicles, it was vital to assess its influence on 
these vehicles without the drug to understand the possible mechanism(s) involved in the 
release. Furthermore, the aged systems of these carriers were evaluated in the light of the 
influence of temperature and relative humidity. Bringing together what has been learnt from 
these aged carrier systems without the drug; a link to the ageing studies of the corresponding 
systems containing the drug was established. Franz-type diffusion cells  in this chapter were 
not only useful to perform in vitro permeation studies of the  ibuprofen from these carrier 
systems but  were also used as a valuable in vitro model to provide a predictive simulation of 
the possible changes on the “non-medicated” Eudragit RS PO/Gelucire 44/14 carrier devices 
under hydration.  
 
7.2 Characterisation of the Eudragit RS PO/Gelucire 44/14 hot melt extruded 
films 
 
This section is devoted to the solid state characteristics of the carrier matrix system or the 
vehicle based on Eudragit RS PO at two levels of Gelucire 44/14; in particular we study 
drug-free films so as to allow comparison with the loaded systems. This was performed 
through bringing some useful common characterisation techniques, such as cDSC, MTDSC, 
PXRD and SEM.  
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7.2.1 Methodology 
 
The films were prepared via hot melt extrusion as described in Chapter 4. The parameters of 
extrusion were selected to exert tolerable torque values. A speed of 100 rpm was set for five 
minutes, with a temperature of 120°C from feed to the die end. These parameters allowed for 
the extrusion of the formulations shown in Table 7.1. The hot melt extruded films were cut 
neatly into units with roughly equal dimensions and then sandwiched between two pieces of 
aluminium foil. The hot melt extruded films were evaluated using techniques of MTDSC, 
PXRD and SEM. These experiments were the same as detailed in Chapter 3. Physical 
mixtures equivalent to the studied extrudates in this section were prepared through mixing of 
Gelucire 44/14 and Eudragit RS PO with pestle and mortar, for five minutes and were also 
characterised using PXRD and MTDSC. Conventional DSC (cDSC) experiments were also 
performed for both physical mixes and freshly extruded films, similar to the experimental 
method developed in Chapter 3. A heating rate of 1°C min-1 was also used in the 
conventional mode with the appropriate calibrations, at the same rate as was used for sample 
analysis. The purpose of using this heating rate was to compare results with those obtained 
by the MTDSC method at the same heating rate. The amounts of the pure Gelucire 44/14 
used in the comparative cDSC and MTDSC studies on the physical mixtures, were 
equivalent to its amounts in these mixes. These physical mixtures were prepared inside DSC 
pans and shown to be comparable to those produced with pestle and mortar based on 
similarity of the results obtained by DSC measurements. All the reported values were 
measured as mean±S.D (n=3) unless otherwise mentioned in the relevant section. 
 
 
 
 
 
 
 
 
 
 
 
 
Investigation into Eudragit RS PO/Gelucire 44/14 hot melt extruded films as promising 
carrier systems for ibuprofen transdermal delivery 
Chapter 7 
 
266 
 
Gelucire 44/14: 
Eudragit RS PO  
ratio 
Extrusion 
temperature 
(°C) 
Appearance Formula 
code 
Photos 
1:6 120 Translucent, smooth, 
no cracks,  
low stickiness and rigid. 
FM-A 
 
2:5 120 Translucent, smooth, 
 no cracks,  
 low stickiness and flexible. 
FM-B 
 
 
Table 7.1: Formulation and description of the placebo Eudragit RS PO/Gelucire 44/14 
hot melt extruded films 
 
7.2.2 Results and discussion 
 
7.2.2.1 Investigation into thermal properties using conventional DSC (cDSC) and modulated 
temperature DSC (MTDSC)  
 
7.2.2.1.1 Analysis of the physical mixes 
 
Analysis using conventional DSC (cDSC) with a heating rate of 10°C min-1, revealed two 
dominant melting endotherms of Gelucire 44/14 at 29.3±1.4°C (secondary) and 39.4±0.5 °C 
(primary), measured as the Tm(onset). Physical mixtures of Gelucire 44/14 and Eudragit RS 
PO were prepared inside DSC pans. In these mixes, when the Eudragit RS PO was 
incorporated in a ratio of 6:1 (Eudragit RS PO:Gelucire 44/14), identified as FM-A system, a 
marked reduction in the Gelucire 44/14 melt ∆H of both melting peaks took place to what is 
expected to pure Gelucire 44/14 (15.4 Jg-1). This was associated with a small variation in the 
Tm
 (onset) of the observed primary or secondary endotherms which instead occurred at 
40.3±1.3 and 30.5±2.0°C, respectively, as seen in Figure 7.1 and determined as the Tm
 (onset). 
This could imply miscibility and a possible interaction between the two components (Abdul-
Fattah and Bhargava, 2002). At higher loading of Gelucire 44/14 in the ratio of 2:5 (Gelucire 
44/14:Eudragit RS PO), the physical mixture coded as FM-B showed similar behaviour as 
illustrated in Figure 7.2. A significant reduction was detected in the melt ∆H with respect to 
the pure Gelucire 44/14 (30.7 Jg-1). The onset temperatures of the melting peaks of the 
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Gelucire 44/14 therein were observed at 39.3±0.4°C (primary peak) and at 28.5±0.3°C 
(secondary peak). 
 
 
 
Figure 7.1: Heat flow signal for Gelucire 44/14 and FM-A physical mixture heated at 
10°C min-1 in standard aluminium pans. See Table 7.1 for composition 
 
A further investigation was performed using MTDSC with an experimental method which 
was developed in Chapter 3. The samples were heated from -70°C to 100°C with an 
underlying heating rate of 1°C min-1, modulation amplitude of ±0.265°C and a period of 100 
seconds. The reversing and the total heat flow signals are displayed in Figure 7.3 and Figure 
7.4 for FM-A and FM-B physical mixtures, respectively (see Table 7.1 for their 
compositions), in comparison to pure Gelucire 44/14. Table 7.2 summarises the MTDSC 
results of the FM-A and FM-B physical mixtures. 
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Figure 7.2: Heat flow signal for Gelucire 44/14 and FM-B physical mixture heated at 
10°C min-1 in standard aluminium pans. See Table 7.1 for composition 
 
 
 
Figure 7.3: MTDSC heating scans (total and reversing heat flow signals) of Gelucire 
44/14 (closed circles) and FM-A physical mixture (open squares) in standard 
aluminium pans. Underlying scan rate of 1°C min-1 with a modulation amplitude of 
±0.265°C and a period of 100 seconds 
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Figure 7.4: MTDSC heating scans (total and reversing heat flow signals) of Gelucire 
44/14 (closed circles) and FM-B physical mixture (open squares) in standard 
aluminium pans. Underlying scan rate of 1°C min-1 with a modulation amplitude of 
±0.265°C and a period of 100 seconds 
 
Sample Tg (Mid-point)* Tm (onset) ** 
Primary peak 
Tm (onset)** 
Secondary peak 
FM-A-Physical 
mix 
53.3±0.5°C 40.5±0.4°C 33.8±0.4°C 
FM-B-Physical 
mix 
53.1±0.4°C 40.6±0.6°C 31.5±0.6°C 
*Measured from the reversing heat flow signal. 
**Measured from the total heat flow signal. 
Table 7.2: Summary of the MTDSC experiment with the underlying heating rate 1°C 
min-1, modulation amplitude of ±0.265°C and period of 100 seconds. Values were 
measured as mean±S.D (n=3). (See Table 7.1 for composition) 
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The results in Table 7.2 showed that detected glass transition temperatures of these mixes 
and related to Eudragit RS PO were either equal to or slightly less than the range of values 
observed for glass transition temperature of Eudragit RS PO alone, which was reported in 
Chapter 3 as 53.3±0.5°C (Mid-point Tg). Therefore it could be concluded that there is no 
appreciable change in the Tg. In the same way as in previous conventional DSC results, the 
MTDSC total heat flow signals revealed slight variation of the onset melting peaks’ values 
yet a significant decrease in the melt ∆H, with respect to the  pure Gelucire 44/14. Again, 
this decrease in the melt ΔH might indicate miscibility and a possible interaction between 
Gelucire 44/14 and Eudragit RS PO (Abdul-Fattah and Bhargava, 2002). 
 
For comparative purposes, the amount of crystalline Gelucire 44/14 (G44/14) detected in 
these physical mixtures was calculated after heating at the selected rate and methods, using 
the following equation: 
 
		Crystallinity		% = .∆Hm	of		the	G44/14	in	the	Physical	mix∆Hm	of	the	pure	G	44/14 ×W : 	x	100															(Eq.7.1) 
 
Where ‘∆Hm of the G44/14 in the Physical mix’, is the total melting enthalpy of the 
Gelucire 44/14 in the physical mix (J/g) of the primary and secondary melting endotherms to 
obtain more reliable enthalpy value as the peaks overlap. ‘W’ is the weight fraction of 
Gelucire 44/14 in the physical mixture. ‘∆Hm of the pure G44/14’ is the melting enthalpy of 
the Gelucire 44/14 standard, assumed to represent full crystallinity (100%). Hence all 
crystallinity levels reported in this work are relative to the original Gelucire 44/14 sample.  
 
Sample Crystallinity (%) Method Comments 
Physical mix FM-A 52.93±0.06 10°C min-1, cDSC Fig.7.1 
Physical mix FM-A 72.87±0.61 1°C min-1, MTDSC Total heat flow signal, 
Fig.7.3 
Physical mix FM-B 31.00±0.03 10°C min-1, cDSC Fig.7.2 
Physical mix FM-B 46.53±0.46 1°C min-1, MTDSC Total heat flow signal, 
Fig.7.4 
 
Table 7.3: Summary of the calculated percent crystallinity of Gelucire 44/14 in the 
physical mixtures of FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-B 
(Gelucire 44/14 Eudragit RS PO ratio of 2:5) from cDSC and MTDSC experiments  
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The results in Table 7.3 showed that there is a decrease in the percentage crystallinity of 
Gelucire 44/14 in the physical mixture with Eudragit RS O after heating in situ in the DSC 
pans. This suggests that simple contact between these components results in miscibility 
during heating. A further intriguing observation is the difference in the percent crystallinity 
measured using the MTDSC method with slower heating rate of 1°C min-1 in comparison to 
the cDSC method with a higher heating rate of 10°C min-1 for each studied physical mix. 
Though we cannot compare these two methods for this reason and due to the different 
principle of the techniques, but it is speculated that a use of a faster heating rate results in a 
greater difference in the measured heat input; therefore the investigated thermal event will 
be observed largely over the experiment time. This was contrary to our case, where the use 
of a slow heating rate of 1°C min-1 in the MTDSC led to sharper, larger, defined melting 
peaks of the Gelucire 44/14 and subsequent higher calculated percentage crystallinity. This 
can be related to the Gelucire 44/14 properties which is a multi-component heterogeneous 
system with complex crystallization behaviour (Sutananta et al., 1994). The longer time 
offered by the MTDSC experiment with an underlying slow heating rate of 1°C min-1 is 
believed to give enough time for Gelucire 44/14 to rearrange into a better packed crystalline 
structure to yield the melting profiles of its components. This behaviour is very common for 
broad-melting polymers. In these polymers, enough time provided during ‘characterisation’ 
experiment, for example, can lead to so-called secondary crystallization after the spherulitic 
space filling of primary crystallization is complete and thus there are larger melting 
enthalpies in the DSC curve (Hunt and James, 1993). 
 
7.2.2.1.2 Analysis of the extruded films 
 
Upon DSC analysis of the extruded films of the 1:6 ratio of Gelucire 44/14: Eudragit RS PO 
(FM-A system), a single glass transition was detected with the absence of the Gelucire 44/14 
melting endotherms. As shown in Figure 7.5, this single glass transition temperature was 
observed at 43.1±1.1°C (Mid-point, n=3), using a cDSC experiment (10°C min-1). This glass 
transition temperature is far less than the glass transition temperature of the Eudragit RS PO 
alone, which was detected in Chapter 3 around 50.4°C. This indicates that the Gelucire 44/14 
has contributed to the reduction of this glass transition temperature and formed a one phase 
system with Eudragit RS PO. cDSC, at a heating rate of 1°C min-1 was also used to 
characterise these samples as shown in Figure 7.6. Based on the investigations in the 
previous section, MTDSC measurements resulted in a better distinction of the Gelucire 
44/14 peaks. This was attributed to the use of a slow heating rate. Therefore, using this 
specific heating rate of 1°C min-1 in the conventional mode of DSC is for the purpose of 
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allowing better detection of the Gelucire 44/14 melting peaks, if any, regardless of the used 
technique. The heat flow signals using this technique in Figure 7.6 showed only a single 
(Mid-point) glass transition temperature at 33.3±0.9°C (n=3), confirming the absence of any 
melting endotherm(s). To allow better detection of this glass transition event, the MTDSC 
technique was used.  
 
 
 
Figure 7.5: Heat flow signal for FM-A hot melt extruded film  (Gelucire 44/14 Eudragit 
RS PO ratio of 1:6) heated at 10°C min-1 in standard aluminium pans 
 
The MTDSC profile of these samples using an underlying heating rate of 1°C min-1 is shown 
in Figure 7.7. A broad endotherm in the non-reversing heat flow signals was detected with 
an extrapolated onset temperature around 30.3±2.1°C. This event could be ascribed to either 
water desorption or associated endothermic relaxation at this point of analysis. The reversing 
heat flow signal allowed measurements of the glass transition temperature of the FM-A 
extruded system without the effect of this accompanying endothermic event, which was 
detected around 37.1±0.5°C (n=3, Mid-point Tg). All these findings indicated that FM-A 
extruded system exhibits a single glass transition over the entire composition range, and 
could be described as a miscible single phase. This demonstrates solid solution system 
formation. 
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 It is noteworthy that the obtained Tg values were different according to which 
characterisation method was used, which is related to the Tg dependence on the heating rate 
(Höhne et al., 1996), its occurrence over broad temperature intervals and any overlapping 
with the endothermic peak as observed from the MTDSC experiment. Therefore, it is 
recommended to use one method for further comparison, which would be the MTDSC 
method, because of its great advantage in determining the glass transition from the reversing 
heat flow signal as detailed in Chapter 2.  
 
 
 
Figure 7.6: Heat flow signal for FM-A hot melt extruded film (Gelucire 44/14 Eudragit 
RS PO ratio of 1:6) heated at 1°C min-1 in standard aluminium pan 
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Figure 7.7: MTDSC heating scans of FM-A hot melt extruded film (Gelucire 44/14 
Eudragit RS PO ratio of 1:6) in standard aluminium pans. Underlying scan rate of 1°C 
min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds 
 
The FM-B hot melt extruded films were characterised in a similar approach to the FM-A 
extruded films using either cDSC or MTDSC as shown in Figure 7.8 through to Figure 7.10. 
The FM-B system contains Gelucire 44/14 at a higher level than in the FM-A system (see 
Table 7.1). In the conventional DSC method at a heating rate of 10°C min-1, a broad melting 
endotherm was detected with a Tm
 (onset) of 35.9°C (n=3) as illustrated in Figure 7.8. This 
melting peak is closely related to the primary melting fraction of the Gelucire 44/14, 
reported in section 7.2.2.1.1. In addition, a glass transition temperature was detected at 
17.4±0.2°C (n=3, Mid-point Tg). At a lower heating rate of 1°C min-1, a sharper melting 
endotherm with a larger melt enthalpy was observed as displayed in  Figure 7.9, consistent 
with our discussions in the previous section. This melting peak could be ascribed to the 
primary melting fraction of the Gelucire 44/14 with a Tm
 (onset) value of 35.4±0.1°C (n=3). A 
glass transition temperature was also detected (Mid-point) around 15.9±1.7°C. In the 
MTDSC scan as seen in Figure 7.10, this melting endotherm was assigned from the total 
heat flow signal with a Tm
 (onset) of  37.1±1.4°C (n=3) and a glass transition (Mid-point) was 
measured from the reversing heat flow signal at 20.8±1.0°C (n=3).  
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Figure 7.8: Heat flow signal for FM-B hot melt extruded film (Gelucire 44/14 Eudragit 
RS PO ratio of 2:5) heated at 10°C min-1 in standard aluminium pans 
 
 
 
Figure 7.9: Heat flow signal for FM-B hot melt extruded film (Gelucire 44/14 Eudragit 
RS PO ratio of 2:5) heated at 1°C min-1 in standard aluminium pans 
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Figure 7.10: MTDSC heating scans of FM-B hot melt extruded film (Gelucire 44/14 
Eudragit RS PO ratio of 2:5) in standard aluminium pans. Underlying scan rate of 1°C 
min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds 
 
In summary, a melting transition was detected in the FM-B extruded films (Gelucire 44/14 
Eudragit RS PO ratio of 2:5) in all the methods used with more defined aspects using a slow 
heating rate of 1°C min-1. The Tm
 (onset) of the melting peak of Gelucire 44/14 in these 
extruded films occurred at a lower temperature i.e. depressed with marked reduction in the 
melt ∆H compared to the pure Gelucire 44/14. This suggests a possible interaction and 
miscibility (Abdul-Fattah and Bhargava, 2002). This system also exhibits a glass transition 
temperature (~21°C) that occurs at a lower temperature than the FM-A (Gelucire 44/14 
Eudragit RS PO ratio of 1:6) extruded film single Tg (~37°C) does. This would suggest that 
a higher amount of Gelucire 44/14 in the FM-B extruded system has led to greater reduction 
in the observed glass transition temperature with respect to the glass transition temperature 
of the Eudragit RS PO alone (~53°C). Therefore, FM-B system is better described as a solid 
dispersion system which contains a crystalline Gelucire 44/14 phase and an amorphous 
Eudragit RS PO/Gelucire 44/14 phase.  
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7.2.2.2 Characterisation by X-ray powder diffraction (PXRD) and scanning electron 
microscopy (SEM) 
 
An overlay of the diffractograms obtained for the fresh hot melt extruded films of FM-A 
(Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-B (Gelucire 44/14 Eudragit RS PO 
ratio of 2:5) is illustrated in Figure 7.11. In this figure, the studied extrudates showed halo-
patterns in their diffractograms, typical for amorphous materials, in comparison to the 
crystalline peaks observed for their equivalent physical mixtures. This suggests the presence 
of a solid solution system for formulation of extruded FM-A and FM-B compositions, based 
on the absence of crystalline peaks related to the Gelucire 44/14. However, the combination 
of the previous cDSC, MTDSC findings from the previous section with the current PXRD 
results supports the formation of a solid solution system only for the FM-A extrudate (low 
Gelucire 44/14 level), characterised by a single Tg. For the FM-B extruded system (high 
Gelucire 44/14 level), the detected melting endotherm indicates the presence of Gelucire 
44/14 crystallites and the system was described as a solid dispersion. Therefore, the lack of 
diffraction peaks in the PXRD profile of the extruded FM-B system is not ascribed to the 
absence of crystalline Gelucire 44/14, but rather can be related to the small crystalline traces 
found in this extruded system that fall below the detection limits of the PXRD experiment. 
 
 
 
Figure 7.11: X-ray powder diffraction profiles of the raw materials, physical mixtures 
and their corresponding hot melt extruded films of Gelucire 44/14 and Eudragit RS  
PO of FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-B (Gelucire 44/14 
Eudragit RS PO ratio of 2:5) systems 
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The SEM images of the surfaces of the studied fresh extrudates and their cross sections are 
shown in Figure 7.12 and Figure 7.13. The surface of the FM-A film with a ratio of 1:6 
(Gelucire 44/14: Eudragit RS PO) was smooth with no visible crystals. Conversely, the FM-
B film had a few granules scattered on its surface. These granules were approximately 
between 0.4-2.6 microns in diameter. There is therefore a visible indication of phase 
separation within the FM-B extruded system. These findings are in agreement with the 
MTDSC and cDSC results mentioned earlier. This suggests formation of an amorphous one 
phase solid solution between the Eudragit RS PO and Gelucire 44/14 in the FM-A extruded 
system (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and formation of two phases solid 
dispersion between these components in the FM-B extrudate (Gelucire 44/14 Eudragit RS 
PO ratio of 2:5). 
 
 (A-I) 
 
(A-II) 
 
 
Figure 7.12: Morphological features of the surface (A-I) and cross section (A-II) of the 
fresh extrudate of FM-A system (Gelucire 44/14 Eudragit RS PO ratio of 1:6) 
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(B-I) 
 
 
 
 
 
 
 
 
(B-II) 
 
 
Figure 7.13: Morphological features of the surface (B-I) and cross section (B-II) of the 
fresh extrudate of FM-B system (Gelucire 44/14 Eudragit RS PO ratio of 2:5) 
 
7.2.2.3 A note on the decomposition of Gelucire 44/14 and Eudragit RS PO using the 
selected temperature of the extrusion 
 
The temperature of the extrusion of the FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) 
and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems was set to achieve adequate 
mixing of the materials used, through efficient transfer of these materials and tolerable 
torque values. In addition, this temperature was selected below the point of their thermal 
degradation. In this case a temperature of 120°C was chosen in an attempt to satisfy these 
requirements. This temperature is also higher than 15-60°C above the melting or the glass 
transition temperature of the used materials, which is the usual range for extrusion 
temperatures as reviewed by Crowley et al. (2007). A further experiment using the MTDSC 
method up to 200°C was used to analyse the onset of the decomposition of these materials 
more closely. 
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 As shown in Figure 7.14 (A) and (B), possible degradation peaks appeared in the non-
reversing heat flow signal with a Tm(onset) of approximately 142.2±0.1°C (n=2) and 
140.7±0.7°C (n=2), for Gelucire 44/14 and Eudragit RS PO, respectively. These results 
agree with the findings of their TGA decomposition profiles shown in Chapter 3, which 
demonstrate that 120°C is well below their thermal degradation onset temperatures. 
 
(A) 
  
 
Figure 7.14: MTDSC heating scans of Gelucire 44/14 in standard aluminium pans (A). 
Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a 
period of 100 seconds 
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(B) 
 
 
Figure 7.14 (Contd.): MTDSC heating scans of Eudragit RS PO in standard aluminium 
pans (A). Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C 
and a period of 100 seconds 
 
7.3 ATR-FTIR assessment of the Eudragit RS PO/Gelucire 44/14 hot melt 
extruded films 
 
The study of the molecular state and presence of any specific interaction in the drug delivery 
systems can aid in the understanding of their mechanism of delivery and therefore their 
efficiency. ATR-FTIR was used to explore these aspects for FM-A (Gelucire 44/14 Eudragit 
RS PO ratio of 1:6) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems and 
provide more information about their stated miscibility and potential as novel drug delivery 
devices. 
 
7.3.1 Methodology 
 
In this section we have used both physical mixes and the extrudates of FM-A and FM-B 
compositions as detailed in section 7.2.1, in addition to the pure components (Gelucire 44/14 
and Eudragit RS PO). The evaluation using ATR-FTIR experiment was documented in 
Chapter 3. Using the same parameters, the ATR-FTIR spectra were also collected for heated 
samples, to mimic the temperature applied during the extrusion, utilising a Golden Gate 
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heated diamond attenuated reflection top-plate with a 3000 series high stability temperature 
controller with RS232 control (Specac Ltd., Kent, UK). Samples were placed on a preheated 
ATR diamond at the extrusion temperature of 120°C. Cooling of the samples was achieved 
at room temperature (~25°C) until they were solidified. ATR-FTIR was also used 
quantitatively to assess the relative concentration of the functional groups on the basis that 
the intensities of the absorbance bands are related to the concentrations of the functional 
groups producing them (Socrates, 2001). To determine if there is an appreciable change on 
the studied samples ‘quantitatively’, the values of the integrated areas under the ATR-FTIR 
spectra which fall outside the range of experimental error as determined by mean±S.D of the 
undertaken measurements will be considered a significant change. A further tracking of any 
distinct vibrational bands that can be correlated with crystallinity changes was addressed 
(Khanna and Khun, 1997). Omnic software (version 6.1a) was used to analyze the obtained 
results and to perform a comparison. As a supportive technique, hot stage microscopy 
(HSM) was used to visualize the effect of the thermal treatment on the studied physical 
mixtures as will be detailed in section 7.3.3. 
 
7.3.2 Results and discussion 
 
The ATR-FTIR spectra of the extruded systems were collected for FM-A (Gelucire 44/14 
Eudragit RS PO ratio of 1:6) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) fresh 
films. An overlay of the ATR-FTIR spectra of the surface and cross section of the tested 
films were superimposable as shown in Figure 7.15. Therefore their surfaces’ spectra were 
used for comparison and further analysis.  
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 (A) 
 
(B) 
 
 
Figure 7.15: Overlay of superimposable ATR-FTIR spectra of the surface and cross 
section of hot melt extruded films of system FM-A (A) and system FM-B (B). See text 
for their compositions 
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The ATR-FTIR spectra related to the extruded films were then compared to their equivalent 
physical mixtures as shown in Figure 7.16. The absorbance bands which correspond to the 
vibrations of specific functional groups within the structure of Eudragit RS PO and Gelucire 
44/14 were determined in Chapter 3. Therefore, each tested spectrum in Figure 7.16 can be 
divided generally into three regions as follows: 
 
-Region I:  3172-2702cm-1: This region is indicative of the changes that could be related to 
the alkyl C-H groups of both components i.e. Gelucire 44/14 and Eudragit RS PO. 
 
-Region II: 1857-1605 cm-1: This region presents changes in the C=O stretching of the ester 
groups in both Gelucire 44/14 and Eudragit RS PO. 
 
-Region III: 1547-885 cm-1: This region is associated with the changes mainly in the C-O 
stretch of alcohols (primary or secondary) of Gelucire 44/14 and C-CO-C stretching in 
Eudragit RS PO. 
 
It is worth mentioning that band assignment to these regions was based on characteristic 
absorption bands of these materials while these regions in the acquired spectra contained 
bands from other vibrational modes. The relative areas integrated under these three regions 
were used to give an idea about the possible changes of the samples under investigation. For 
comparative purposes, relative percentage area region was calculated as the percentage of 
the normalized integrated area of the total region with respect to the total integrated area of 
the studied spectrum. 
 
In this study, collection of the spectra was also performed for the pure components and 
studied physical mixtures after thermal treatment in situ at the extrusion temperature, using a 
built-in heating accessory in the ATR-FTIR, followed by cooling to room temperature. This 
allows the tracking of possible changes in these systems during heating and after thermal 
treatment and to observe the trend of intensity changes in comparison to the hot melt 
extruded films of these materials. 
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 (A)
 
(B) 
 
 
Figure 7.16: Overlay of the ATR-FTIR spectra of the physical mixtures and 
corresponding hot melt extruded films of FM-A (Gelucire 44/14 Eudragit RS PO ratio 
of 1:6) system (A) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) system (B). 
See text for composition 
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The quantitative data of the integrated areas of the ATR-FTIR spectra of the Gelucire 44/14 
and Eudragit RS PO are presented in Figure 7.17. The changes in the relative percentage 
areas with respect to control samples were as follows: 
 
1. The absorption in region I, between 3172 and 2702 cm-1, has essentially increased 
only in Gelucire 44/14 after thermal treatment. 
 
2. The absorption in region II, between 1857 and 1605 cm-1, arises mainly from C=O 
stretching mode of the ester groups, which has increased after thermal treatment in 
both Gelucire 44/14 and Eudragit RS PO. 
 
3. The absorption in region III, between 1547 and 885 cm-1, has decreased only in 
Gelucire 44/14 after thermal treatment. 
 
These observations were not appreciably significant except in region I of Gelucire 44/14. It 
is believed that thermal treatment of this lipid might be associated with a possibility of 
reorientations in the alkyl groups therein or changes in the transition dipole of these groups. 
As the infrared absorbance is due to interaction between the electric field vector and the 
molecular dipole transition moments due to molecular vibration, the orientations can be 
observed. Thus, differences in the molecules’ alignment could result in changes in the band 
intensities. An alternative idea of change in transition dipole is the hypothesis that thermal 
treatment of these samples might change their optical properties. It is expected that as the 
material is heated, the sample will have better contact with the ATR crystal, thus enhancing 
contact with the evanescent wave (see Chapter 2). The resulting spectrum will therefore 
provide information within this range of more penetration depth. 
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Figure 7.17: Histograms of the integrated relative percentage areas of Eudragit RS PO 
(a) and Gelucire 44/14 (b), of the alkyl C-H group stretching (3172-2702 cm-1), C=O 
stretching of the ester groups (1857-1605 cm-1) and C-O stretch of alcohols (primary or 
secondary) of Gelucire 44/14 and C-CO-C stretching in Eudragit RS PO (1547-885 cm-
1). Samples were examined as the following sets: Control (no thermal treatment). At the 
temperature of extrusion (120°C). The cooled samples to the room temperature after 
thermal treatment (solidified samples). Average values of three spectra of each set were 
calculated and S.D. error bars were estimated accordingly 
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Similarly, the ATR-FTIR spectra of the thermally treated physical mixtures and their 
equivalent extrudates were analyzed as shown in Figure 7.18 and Figure 7.19. The analysis 
of these data revealed the following main changes with respect to the controls (untreated 
equivalent physical mixes) of these samples: 
 
• In region I, the heat-cooled physical mixture of FM-B (higher content of Gelucire 
44/14) showed a decrease in the absorption. 
 
• In the same region, related to C-H alkyl group stretching, the extruded systems of 
FM-A (lower content of Gelucire 44/14) and FM-B (higher content of Gelucire 
44/14) showed a decrease in the absorption. This complies with FM-B heat-cooled 
physical mixture behaviour.  
 
• In region II, heat-cooled physical mixtures and the extruded films of both FM-A and 
FM-B systems showed the same trend of increased absorption in the region  
associated with the C=O stretching mode, especially for the FM-B systems which 
contained a higher level of Gelucire 44/14. 
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Figure 7.18: Histograms of the integrated relative percentage areas of FM-A system (1: 
6 ratio of Gelucire 44/14: Eudragit RS PO), for both physical mixture (PM) and 
equivalent fresh extruded film. The alkyl C-H group stretching related to the region 
between 3172 and 2702 cm-1,C=O stretching of the ester groups (1857-1605 cm-1) and 
C-O stretch of alcohols (primary or secondary) of Gelucire 44/14 and C-CO-C 
stretching in Eudragit RS PO (1547-885 cm-1). Samples were examined as the following 
sets: Control (no thermal treatment). At the temperature of extrusion (120°C). The 
cooled samples after thermal treatment at the room temperature (solidified samples). 
Average values of three spectra of each set were calculated and S.D. error bars were 
estimated accordingly 
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Figure 7.19: Histograms of the integrated relative percentage areas of FM-B system (2: 
5 ratio of Gelucire 44/14: Eudragit RS PO), for both physical mixture (PM) and 
equivalent fresh extruded film. The alkyl C-H group stretching related to the region 
between 3172- 2702 cm-1, C=O stretching of the ester groups (1857-1605 cm-1) and C-O 
stretch of alcohols (primary or secondary) of Gelucire 44/14 and C-CO-C stretching in 
Eudragit RS PO (1547-885 cm-1). Samples were examined as the following sets: Control 
(no thermal treatment). At the temperature of extrusion (120°C). The cooled samples 
after thermal treatment at the room temperature (solidified samples). Average values 
of three spectra of each set were calculated and S.D. error bars were estimated 
accordingly 
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These observations (Figure 7.18 and 7.19) can be rationalized by the proposal that extrusion 
of Gelucire 44/14 in Eudragit RS PO in the ratio of 1:6 and 2:5 in FM-A and FM-B systems, 
respectively, in addition to the thermal treatment of the FM-B physical mix might result in 
migration of alkyl groups. Thus, absorption bands associated with the hydrophobic alkyl 
groups in region I were decreased, whereas an increase of the absorption was detected in the 
carbonyl group in region II.  
 
Consequently, it is hypothesized that the interior of these samples is enriched with the C-H 
groups, in which hydrophobic side chains would be expected to be more involved in 
interactions (a decrease in the detected absorption), whereas the remaining hydrophilic 
functional groups will be “expelled” or readily available on the surface for these samples (an 
increase of their measured absorptions). The formation of such construct is consistent with 
the properties of Gelucire 4/14 as reported by Wehrung et al. (2012) and supported by the 
formation of a new shoulder, appearing around 1177 cm-1 (C-O stretch) in both studied 
extrudates as shown in Figure 7.20. This trend of group rearrangements could be facilitated 
by intimate mixing provided during hot melt extrusion (HME) or the availability of more 
Gelucire 44/14 in the thermally treated physical mix (FM-B system).  
 
However, it could be argued that if the interior of the extruded samples is enriched with C-H 
groups this will be mirrored as an increase of the  measured absorption of these groups from 
the cross sections of these extrudates. This was not the case in these samples because the 
surfaces were superimposable to the cross sections. Nonetheless this hypothesis can hold 
true because the ATR-FTIR technique offers a limited depth of penetration into the sample, 
typically around the values from <0.2 micron to >1 micron (Tang et al., 2007). Therefore, it 
could be speculated that the alkyl groups are embedded deeply in these systems and that 
examination of the cross sections will not detect them. 
 
In summary, the changes associated with the relative percentage areas of the acquired 
spectra from thermally treated or extruded samples can be explained by three possible 
hypotheses, namely, change in transition dipole, change in optical properties or migration of 
the alkyl groups. Further explanation as to these changes is beyond this thesis, because at 
present there is insufficient evidence to decide which effect is operating. 
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Figure 7.20: ATR-FTIR spectra of hot melt extruded films of (A) FM-A (Gelucire 
44/14 Eudragit RS PO ratio of 1:6) system and (B) FM-B (Gelucire 44/14 Eudragit RS 
PO ratio of 2:5) system (absorption intensities of these spectra vary) 
 
To probe the molecular state of Gelucire 44/14 inside the extruded systems of FM-A and 
FM-B using ATR-FTIR, the Eudragit RS PO spectra were subtracted from the spectra of the 
extruded systems (Gelucire 44/14 in Eudragit RS PO). The resultant subtraction spectra are 
shown in Figure 7.21 and Figure 7.22. These spectra were compared to the Gelucire 44/14 
spectra that had also been extracted from the equivalent physical mixes without thermal 
treatment (control) through subtraction of Eudragit RS PO spectra. In addition, Gelucire 
44/14 spectra collected during heating at the extrusion temperature (assuming that the 
molten Gelucire 44/14 is behaving like amorphous material) and after cooling at room 
temperature (solidified) were shown for further comparison.   
 
In Figure 7.21, the Gelucire 44/14 spectrum stripped from the physical mixture was 
superimposable to the raw pure Gelucire 44/14 spectrum described in Chapter 3 (data not 
show here), indicating a good subtraction. Furthermore, the subtraction is justified because 
the Eudragit spectrum does not change with temperature and the subtraction does not result 
in any misshaped peaks which would occur if shifts in the Eudragit spectrum had occurred. 
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As illustrated in this figure (7.21), four characteristic peaks were assigned in this spectrum 
(Gelucire 44/14). These peaks will be named peak (A) at 1347 cm-1 related to C-O 
stretching, peak (B) at 1145 cm-1, peak (C) at 1107 cm-1 and peak (D) at 1058 cm-1. Peak 
(B), (C) and (D) are mainly due to the PEG 1500 C-O-C stretching vibration (Feng et al., 
2011). As illustrated in this figure, these peaks were the most changed bands after thermal 
treatment of the Gelucire 44/14 at the extrusion temperature (molten Gelucire 44/14) and to 
a lesser extent the peak around 1347 cm-1 (peak (A)). 
 
 
 
Figure 7.21: ATR-FTIR spectra of (1) Eudragit RS PO-subtracted spectrum of 
physical mixture containing Eudragit RS PO Gelucire 44/14 in a ratio of 6:1, without 
thermal treatment (control), (2) molten Gelucire 44/14 at the extrusion temperature 
(120°C), (3) solidified Gelucire 44/14 after thermal treatment at extrusion temperature 
and (4) Eudragit RS PO-subtracted spectrum of extruded film containing Eudragit RS 
PO Gelucire 44/14 in a ratio of 6:1 (FM-A system) 
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As illustrated in Figure 7.21, the previously mentioned peaks (B-D) were overlapped or 
merged into one peak with the apex of band (C) around 1107 cm-1 at the extrusion 
temperature (120°C) in the molten Gelucire 44/14. In addition, new peaks appeared around 
1039 and 994 cm-1. These new bands occur at similar locations of glycerol C-O stretching 
bands (Calvino-Casilda et al., 2011), suggesting a hydrolysis of the ester structure in the 
Gelucire 44/14. After cooling of Gelucire 44/14 to the room temperature (solidified 
samples), the characteristic peaks (B), (C) and (D) appeared again at their locations at 1145, 
1107 and 1058 cm-1, respectively. However, a newly detected peak around 1039 cm-1 
remained, suggesting hydrolysis at a certain extent. Furthermore, the sharpness (intensity) of 
peak (A) at 1347 cm-1 became similar to the control crystalline Gelucire 44/14. It is therefore 
concluded that solidified samples underwent recrystallization and this peak (at 1347 cm-1) is 
sensitive to the crystallinity of Gelucire 44/14.  
 
In the amorphous state (like molten Gelucire 44/14 herein), the less ordered molecules in 
comparison to the crystalline structure can result in a greater distribution of the molecular 
frequencies due to non-specific intermolecular bonding. This will be viewed as broader 
absorbance (less intense) bands  in the ATR-FTIR spectrum, which in some cases can spread 
over a large extent and thus the absorbance peaks will be flattened, because it can be 
smeared with the baseline of the spectrum. Peak (A) around 1347 cm-1, for example, can be 
used as a marker to correlate with the crystallinity changes of Gelucire 44/14. This is 
because it has been broadened in the molten state (which is assumed to resemble the 
amorphous state) and then changed into a more defined shape peak in the solidified sample, 
similar to the crystalline Gelucire 44/14 in the control samples.   
 
In Figure 7.21, this marker peak (A, 1347 cm-1) was flattened in the Gelucire 44/14 spectrum 
extracted from the FM-A extrudate (after subtraction of Eudragit RS PO spectrum), whereas 
it has been elevated in the Gelucire 44/14 spectrum extracted from FM-B extrudate in Figure 
7.22. In conjunction with the previous findings using MTDSC, cDSC and SEM, which 
indicated that Gelucire 44/14 recrystallization was inhibited only in the FM-A system (lower 
content of Gelucire 44/14) upon extrusion, it could be reasonably concluded that the 
distinction of this peak in the FM-B extrudate (higher content of Gelucire 44/14) is related to 
the presence of crystalline Gelucire 44/14.  
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Figure 7.22: ATR-FTIR spectra of (1) Eudragit RS PO-subtracted spectrum of 
physical mixture containing Eudragit RS PO Gelucire 44/14 in a ratio of 5:2, without 
thermal treatment (control), (2) molten Gelucire 44/14 at the extrusion temperature 
(120°C), (3) solidified Gelucire 44/14 after thermal treatment at extrusion temperature 
and (4) Eudragit RS PO-subtracted spectrum of extruded film containing Eudragit RS 
PO Gelucire 44/14 in a ratio of 5:2 (FM-B system) 
 
Furthermore, an overlay of the Gelucire 44/14 spectra from FM-A (lower content Gelucire 
44/14) and FM-B (higher content Gelucire 44/14) extrudates was obtained after subtraction 
of Eudragit RS PO spectra as displayed in Figure 7.23. This figure shows the spectral region 
of the most changing peaks of Gelucire 44/14 after thermal treatment. It can be seen that 
Gelucire 44/14 spectra (extracted from the extruded samples) retain the evolved new 
shoulder detected in these extrudate around 1177 cm-1 (see Fig.7.20), and denoted here as 
(I). This shoulder appears as a more distinct peak in the Gelucire 44/14 spectrum extracted 
from FM-B extruded system (higher content of Gelucire 44/14). In this Figure (7.23), peak 
around 1107 cm-1, denoted here as (III) and related to C-O-C stretching, appeared as a 
shoulder in FM-A system and sharpened as a distinct peak in the FM-B system, indicating 
crystalline Gelucire 44/14 in the latter. To conclude, the bands related to the peak at 1347 
cm-1 and peak at 1107 cm-1 can be used as bench marks for the amorphous Gelucire 44/14 
inside the extruded systems of FM-A and FM-B compositions. Crystalline Gelucire 44/14 
will exhibit sharper or more distinct peaks in these locations. 
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Figure 7.23: ATR-FTIR Eudragit RS PO-subtracted spectra of extruded films 
containing Eudragit RS PO Gelucire 44/14 in the ratios of 6:1 (FM-A system) and 5:2 
(FM-B system) 
 
7.3.3 A note on the observed behaviour of Eudragit RS PO/Gelucire 44/14 physical 
mixtures under thermal treatment by hot stage microscopy (HSM) 
 
The HSM technique, described in Chapter 2, can be used in conjunction with the previous 
characterisation techniques to provide visual evidence of the affinity or miscibility between 
Gelucire 44/14 and Eudragit RS PO in the FM-A (Gelucire 44/14 Eudragit RS PO ratio of 
1:6) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems, during heating of their 
physical mixes. The HSM experiment involved a video capture microscope while exposing 
the samples to a controlled temperature program heating from 30°C to 120°C at 5°C min-1. 
Photos of these blends were taken immediately after cooling to the room temperature (~ 
25°C). The approximate cooling rate was 2°C/min.   
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Figure 7.24 and 7.25 showed a series of images captured during the heating of the physical 
mixtures of FM-A and FM-B systems, respectively. As can be seen from Figure 7.24 the 
melting of Gelucire 44/14 was apparent from 40°C and more visible for the higher content of 
Gelucire 44/14 in the FM-B system, as indicated in Figure 7.25. Above 60°C, which is 
higher than the glass transition of the Eudragit RS PO, we can find that more material is 
involved in the liquefied-molten zone as illustrated in both figures. Finally at the extrusion 
temperature (120°C), one phase system was observed for FM-A and FM-B composition with 
a clear appearance after cooling at room temperature, suggesting good miscibility. It is 
noteworthy that this one phase system was formed at approximately 118°C for FM-A and 
around 111°C for the higher ratio of Gelucire 44/14 at FM-B composition. Therefore, this 
technique is supplementary to the MTDSC, cDSC and ATR-FTIR techniques. All these 
techniques indicated that there is miscibility and possible interactions between Eudragit RS 
PO and Gelucire 44/14 at the studied compositions even after simple heating of their 
physical mixes.  
 
   
30°C                                      40°C                                     50°C 
 
   
60°C                                       120°C                                after cooling at room temperature 
 
Figure 7.24: Hot stage microscope images captured at specific temperatures for 
physical mixture of FM-A composition (Gelucire 44/14 Eudragit RS PO ratio of 1:6) 
while being heated at 5°C per minute 
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30°C                                      40°C                                    50°C 
 
   
60°C                                          120°C                              after cooling at room temperature 
 
Figure 7.25: Hot stage microscope images captured at specific temperatures for 
physical mixture of FM-B composition (Gelucire 44/14 Eudragit RS PO ratio of 2:5) 
while being heated at 5°C per minute 
 
7.4 Hydration behaviour of Eudragit RS PO/Gelucire 44/14 hot melt extruded 
films 
 
In order to design an effective transdermal patch dosage form, it is recommended to 
recognize and investigate the main factors contributing to its success. Among these factors, 
hydration appears to be essential to achieve the desired drug release from these extruded 
films as detailed in Chapter 6. Therefore this section explores the water sorption features of 
these carrier systems followed by a deep investigation of the changes that may associate 
hydration of these films and contribute to their delivery mechanism. 
 
7.4.1 Investigation into water sorption properties of Eudragit RS PO/Gelucire 44/14 
hot melt extruded systems 
 
In this section an attempt to elucidate some aspects of the sorption behaviour was carried out 
for the pure components of Gelucire 44/14 and Eudragit RS PO, their physical mixtures and 
equivalent extruded systems at FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-
B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) compositions.  
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7.4.1.1 Methodology 
 
Samples of the basic ingredients of Gelucire 44/14 and Eudragit RS PO were examined for 
their moisture sorption behaviour using dynamic vapor sorption technique (DVS) 
documented in Chapter 2. In this part, two DVS experiments were carried out. The first 
experiment will be termed here ‘method A’. In this method a general procedure of stepping 
the humidity (%RH) over a range of 0%RH-95%RH at 25°C was performed. In this method 
the humidity was raised in steps of 5%RH, where the sample is held in each step for one 
hour, to enable equilibrium prior the next humidity level. The second experiment will be 
termed ‘method B’. This method involved exposure to a single high relative humidity of 
95%RH at 25°C for 24 hours. In this experiment, the pure components, the physical mixtures 
of FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-B formulae (Gelucire 44/14 
Eudragit RS PO ratio of 2:5), described in section 7.2.1, and their equivalent extruded 
systems were tested. The basic ingredients and the tested physical blends were further 
divided into two groups based on the thermal treatment. The first group involves the controls 
of untreated samples, whereas the second group consists of the heated samples at the 
extrusion temperature (120°C) followed by solidification at room temperature. In the first 
step of all the experiments, the samples were held for three hours at 0%RH at 25°C to allow 
drying. The program in method A and B was set to advance the humidity or the holding 
time, respectively, when weight percentage is less than 0.01 in five minutes. Samples were 
spread evenly to fill standard aluminium open pans (surface area of approximately 38.5 
mm2) in an attempt to unify the exposed surface area of these samples to the moisture; 
thereby a direct comparison can be made between different tested samples. 
 
7.4.1.2 Results and discussion 
 
The resulting sorption isotherms of Gelucire 44/14 and Eudragit RS PO from method A are 
shown in Figure 7.26 (A) and (B), respectively. The isotherm of Eudragit RS PO seems to 
level out at low relative humidity values, approaching a maximum (plateau). On the 
contrary, the moisture sorption isotherm of Gelucire 44/14 could not achieve that 
equilibrium at any studied humidity level. This suggests that the more hydrophobic nature of 
Eudragit RS PO allows for faster equilibrium moisture content in comparison to the 
amphiphilic nature of the Gelucire 44/14 (Svensson et al., 2004). This inferred that the time 
for the latter should be long enough to ensure moisture or humidity equilibrium. 
Furthermore in Figure 7.27, it can be seen that Eudragit RS PO begins to take up water 
earlier than Gelucire 44/14, though very small amount (less than 0.05 %( w/w)). However, 
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after 53%RH, Gelucire 44/14 began to hydrate with an abrupt increase in the moisture 
uptake curve after 75%RH at 25°C. This behaviour is consistent with the manufacturer’s 
specifications of Gelucire 44/14, whereby little or no moisture absorption is detected below 
80%RH at room temperature (Gattefossé, 2000). However, the water uptake by Gelucire 
44/14 above approximately 70%RH/25°C is higher than Eudragit RS PO as illustrated in 
Figure 7.27. For example, at 95%RH/25°C, the total water content of Gelucire 44/14 exceeds 
16% (w/w) in comparison to the Eudragit RS PO with around 3.72% (w/w) moisture 
content. Therefore this confirms that Gelucire 44/14 is the main component in absorbing 
water when combined with the Eudragit RS PO especially at high relative humidities 
(~≥70%RH) at room temperature. 
 
(A) 
 
 
Figure 7.26: Weight percent versus time signal for Gelucire 44/14 at 25°C with an RH 
ramp from 0 to 95% (A) 
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(B) 
 
 
Figure 7.26 (Contd.): Weight percent versus time signal for Eudragit RS PO at 25°C 
with an RH ramp from 0 to 95% (B) 
 
 
 
Figure 7.27: Overlay of the moisture content of Gelucire 44/14 (open squares) and 
Eudragit RS PO (filled circles) according to the relative humidity at 25°C 
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Based on the findings of method A, the parameters of the second experiment were set 
(method B). This method was performed using high relative humidity of 95% RH at 25°C, 
which corresponds to the highest water uptake of the studied ingredients (Gelucire 44/14 and 
Eudragit RS PO). Samples were held for one day at this condition to enable equilibrium of 
moisture content. As presented in Figure 7.28 (A) and (B), the water uptake ability for 
Eudragit RS PO was decreased by thermal treatment, while being increased for the Gelucire 
44/14. When these components are combined in the ratio of 1:6 and 2:5 (Gelucire 44/14: 
Eudragit RS PO) in FM-A and FM-B systems, respectively, the resulting moisture isotherms 
are illustrated in Figure 7.29 (A) and (B). It can be seen from these figures that samples of 
the FM-A system (Fig. 7.29 A) absorbed less water in comparison to the FM-B system (Fig. 
7.29 B) as a function of Gelucire 44/14 loading. Alternatively, the general trend of the 
moisture uptake by the physical mixtures after thermal treatment follows the Eudragit RS 
PO behaviour, because of its high proportion in both systems. Therefore, thermally treated 
samples of the physical mixes took up less water than untreated ones and approached a 
maximum earlier or achieved a faster humidity equilibration. Azarmi et al. (2005) and 
Hasanzadeh et al. (2009) found that thermal treatment of Eudragit RS PO above its glass 
transition temperature results in increase of the coalescence of matrices made from this 
polymer, rendering it less accessible to the aqueous medium. This is consistent with our 
findings, wherein thermal treatment of the systems composed mainly of Eudragit RS PO 
results in less water uptake in comparison to the equivalent untreated samples.  
 
The extruded samples showed an increase in moisture uptake in comparison to the 
equivalent thermally treated physical mixes. This observation could support our previous 
FT-IR-ATR spectroscopic hypothesis of the migration of alkyl groups. In other words, it was 
speculated that the interior of the extrudate is enriched with hydrophobic alkyl groups 
whereas the hydrophilic side branches are more available on its surface, thereby allowing 
more moisture or water uptake. However, this increase was barely significant in the FM-A 
extruded systems but was more evident in the FM-B extruded system (higher content of 
Gelucire 44/14), as shown in Table 7.4. The moisture uptake of the FM-B extrudate was 
even higher than the equivalent untreated physical mix (control). This can be explained by 
the existence of free Gelucire 44/14 or solid dispersion at this composition as indicated in 
the previous sections, in addition to the assumption of concentrated hydrophilic regions on 
the surface of these samples. Table 7.4 summarizes the moisture content values obtained 
from method B that was represented in Figure 7.28 (A and B) and Figure 7.29 (A and B). 
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(A) 
 
(B) 
 
 
Figure 7.28: Moisture uptake of Eudragit RS PO (A) and Gelucire 44/14 (B) expressed 
as percentage of weight change versus time, both tested at 95%RH/25°C. Samples were 
examined as the following sets: untreated (no thermal treatment), at the temperature of 
extrusion (120°C) followed by solidification at room temperature (treated) 
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(A) 
 
 
Figure 7.29: Moisture uptake for the samples of FM-A (Gelucire 44/14 Eudragit RS PO 
ratio of 1:6) system (A) expressed as percentage of weight change versus time tested at 
95%RH/25°C. Samples were examined as the following sets: untreated physical 
mixtures (filled circles), treated physical mixtures at the temperature of extrusion 
(120°C) followed by solidification at room temperature (open squares) and samples 
prepared via hot melt extrusion (filled stars) 
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Figure 7.29 (Contd.): Moisture uptake for the samples of FM-B system (Gelucire 44/14 
Eudragit RS PO ratio of 2:5) system (B) expressed as percentage of weight change 
versus time tested at 95%RH/25°C. Samples were examined as the following sets: 
untreated physical mixtures (filled circles), treated physical mixtures at the 
temperature of extrusion (120°C) followed by solidification at room temperature (open 
squares) and samples prepared via hot melt extrusion (filled stars) 
  
Sample  Untreated Treated Hot melt extruded 
Eudragit RS PO 4.70±0.45 2.11±0.32 - 
Gelucire 44/14 46.01±0.18 47.04±0.27 - 
FM-A physical mixture 11.02±0.23 9.432±0.35 10.08±0.31 
FM-B physical mixture 12.06±0.37 11.97±0.31 14.11±0.36 
 
Table 7.4: Summary of the water content (w/w %) of different samples determined at 
the apparent moisture equilibrium level of 95%RH/25°C (method B) and measured by 
DVS (n=2, mean±SD)  
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7.4.2 Investigation into the influence of hydration on the properties of Eudragit RS 
PO/Gelucire 44/14 hot melt extruded systems  
 
This section aims to define the structural and microscopic appearance changes associated 
with the water uptake by the hot melt extruded FM-A (Gelucire 44/14 Eudragit RS PO ratio 
of 1:6) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems, using an in vitro 
model i.e. Franz cells under occlusive conditions, and dissolution bath. This is important for 
at least two reasons. First, to understand the changes of the matrix system without the drug. 
Second, to extrapolate the likely behaviour with a drug loaded system. Therefore, the basis 
of the process by which the drug was released can be established.  
 
7.4.2.1 Methodology 
 
In this section we have used the extruded films of FM-A (Gelucire 44/14 Eudragit RS PO 
ratio of 1:6) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems, described in 
section 7.2.1. These films were characterised for any change in their properties outlined in 
section 7.2, after being tested in two conditions. The first condition is testing in the 
dissolution bath in a similar way to the in vitro drug release studies described in Chapter 5. 
This test will be termed herein as dissolution testing or a dissolution study. The second 
condition is testing in the Franz-type diffusion cells. These cells were used to model in vitro 
behaviour of the tested films when applied to the skin under occlusive conditions. This 
modelling, utilized the same conditions detailed in Chapter 5, with the added parameter of 
occlusion. The latter was achieved through hydrating the films, each with a 0.07 ml volume 
of the used receptor medium of the PBS (pH=7.2). This value was chosen to approximate the 
films’ behaviour under skin occlusion, in a similar assumption mentioned in Chapter 6 for 
the medicated films. However, in this case the experiment was conducted only for 24 hours, 
thus a volume of 0.07 ml rather than 0.14 ml was used to hydrate the samples. 
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The films were cut manually and their dimensions were measured using an electronic digital 
caliper (MS092Toolzone Vernier Caliper, UK). In the dissolution study, the films of system 
FM-A and FM-B were tested with similar dimensions and of a total weight of not less than 
2500 mg. The applied samples in the dissolution test were evaluated after 24 hours. In the 
Franz cells, six films of size (24.12 ±1.31 mm3) were mounted for each studied system. In 
which the average weight of (24.94 ± 1.17 mg) and (25.85 ± 1.45 mg) corresponds to the 
used dimensions of FM-A and FM-B films, respectively. These films were removed after 
0.25, 1, 2, 3, 4 and 24 hours and placed in sealed containers for further evaluation. The 
samples in the dissolution bath and Franz cells were weighed before and after testing at the 
scheduled intervals using a XS205, Dual range analytical balance (Mettler Toledo).  
 
After removal of each sample from the test, the films were blotted gently by applying filter 
paper (Fischer brand, Fischer Scientific, Whatman No.1 70mm diameter) for 30 seconds. 
After blotting, the weight measurements were performed for the film to a constant weight. 
Then, the water absorption capacity measurements were calculated with respect to the initial 
weight of the films as follows: 
 
Water absorption capacity (w/w%) = @(Wnh-W0 
W0
A x 100%      																				(Eq.7.2) 
 
Where W ((n) h) is the weight of the films removed at (n) hour(s) and W0 is the initial weight 
of the films before the test. These measurements indicate the percentage increase in the 
weight of the film over its initial weight, after the testing time in hour(s). 
 
Furthermore, the swelling ratio percentages were found for these films using the following 
equation: 
 
Swelling ratio (%) = B(Volume((n)h)-Volume (t0)Volume (t0) C x 100%                           (Eq.7.3) 
 
Volume ((n) h) and Volume (t0) are the volumes of the films after (n) hour(s) and films 
before the test (t=0 hour), respectively. 
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The films tested in the dissolution bath were stored under phosphorous pentoxide (P2O5) at 
room temperature (0%RH/RT) for one week to achieve efficient drying after this test. The 
weight loss percentage was calculated using the following formula: 
 
Weight loss percentage = B(W0-WdW0 C x 100%                               																				(Eq.7.4) 
 
Where W0 is the initial weight of the films before immersion in the dissolution bath and Wd 
is the weight of the films after immersion for 24 hours and dried for one week (0%RH/RT).  
 
The characterisation of these tested hot melt extruded films (FM-A and FM-B systems) was 
performed using MTDSC to assess thermal properties, SEM for morphological aspects and 
TGA to measure the water content as documented in Chapter 4. Other techniques include 
PXRD for the films studied in the dissolution bath, while further evaluation was performed 
for films studied in the Franz cells using ATR-FTIR and polarized light microscopy (PLM) 
techniques. A Leica DML S2 polarized microscope (Wetzlar GmbH, Germany) equipped 
with a video capture system was used to take the sample photos with a 10x (optical zoom) 
lens. This is the same microscope used in the HSM studies and described in Chapter 2, but 
without the heating accessory. The rest of the experimental techniques and the used methods 
were outlined in Chapter 3.  
 
7.4.2.2 Results and discussion 
 
Thermogravimetric analysis (TGA) of the FM-A and FM-B extruded samples was used to 
determine the water content as water loss from the region between approximately 100°C and 
120°C. This region is the common range of water loss. The hydrated samples tested using 
dissolution bath or inside Franz cells were associated with significant water loss in this 
region as indicated from the peaks of the percentage and temperature derivative weight loss 
in Figure 7.30 (B) and (C), respectively. This is not to be confused with the decomposition 
profiles obtained for Eudragit RS PO and Gelucire 44/14 using TGA in Chapter 3, wherein 
the onset temperatures of degradation were detected above 150°C. This weight loss was 
preceded with a much broader derivative weight change for all the samples and occurred 
with an onset at approximately 38.7±0.8°C for the control samples. This event could be the 
responsible for the observed endothermic peak in the non-reversing signal of the FM-A fresh 
extruded sample shown previously in section 7.2.2.1.2. Thus, it is more likely to be 
attributed to water desorption rather than endothermic relaxation event.  
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(A) 
 
(B) 
 
 (C) 
 
 
Figure 7.30: Representative TGA weight loss profiles of (A) control extruded film while 
(B) for tested extruded films in dissolution bath and (C) for tested extruded films in 
Franz-type diffusion cells. All heated at 10°C min-1 to 150°C 
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The measurements of the water absorption capacity, water content (Wc), swelling ratio (%) 
and the percent weight loss of the films after dissolution testing are given in Table 7.5. 
These results demonstrate increased water absorption capacity and subsequent swelling as 
the amount of Gelucire 44/14 increased, thus higher values for FM-B (Gelucire 44/14 
Eudragit RS PO ratio of 2:5) extruded films in comparison with FM-A (Gelucire 44/14 
Eudragit RS PO ratio of 1:6) films. However, it is believed that swelling is a function of both 
components. While Gelucire 44/14 aid in the aqueous medium penetration and ease the 
Eudragit RS PO swelling, it may swell when in contact with aqueous media as is the case 
with other Gelucires (Sutananta et al., 1995), which is also one proposed mechanism for its 
self-emulsification ability (Chambin et al., 2004; Craig et al., 1995).   
 
Extruded 
sample 
Swelling 
ratio (%) 
Water absorption 
capacity (w/w %) 
Wc1  
(w/w %) 
Wc2 
 (w/w %) 
 
Weight loss 
(w/w %) 
 
FM-A 
System 
45.92±0.79 54.51±0.43 16.36±0.13 0.27±0.03 3.17±0.5 
FM-B 
System 
109.45±0.52 76.16±0.80 17.26±0.08 0.27±0.02 5.47±0.2 
 
Table 7.5: The water uptake properties and weight loss measurements of the hot melt 
extruded films of FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-B 
(Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems after dissolution testing in 
phosphate buffer solution (pH=7.2) at 37±0.1°C. Wc represents the water content 
measured via TGA immediately after the test (Wc1) and after drying under 0%RH/RT 
for one week (Wc2). Values represent mean ± S.D (n=2) 
 
Furthermore, the water content measurements did not show a large difference between FM-
A and FM-B extruded systems. This feature could be related to removal of the residual water 
at the time of the testing and evaporation prior to thermal treatment, suggesting poor water 
holding capacity. Weight loss would be expected in these samples, mainly due to washing of 
the Gelucire 44/14 into the dissolution medium, because Eudragit RS PO as mentioned in 
Chapter 2 is not water soluble. According to the small values of the weight loss percentage, 
a strong association between Gelucire 44/14 and Eudragit RS PO is suggested. 
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These samples were tested by MTDSC as recommended in section 7.2.2.1. The changes 
were observed from the reversing heat flow signals and shown in Figure 7.32 without using 
the total heat flow signals to detect the melt observed in FM-B extruded system. This is due 
overlapping with broad dehydration peaks as seen in Figure 7.31. Though these samples 
were blotted onto filter papers to dry them prior to the MTDSC experiment, these samples 
retained water. Therefore, the reversing heat flow signals were used, detecting the glass 
transition temperatures mainly and only to show the relative trend of changes in the melting 
peaks due to the limitations mentioned in Chapter 2.   
 
  
 
Figure 7.31: Representative MTDSC profiles of tested FM-A (left) and FM-B (right) 
films in the dissolution experiment showing the dehydration (water-desorption) event 
in the non reversing and total heat flow signals. Underlying scan rate of 1°C min-1 with 
a modulation amplitude of ±0.265°C and a period of 100 seconds 
 
Samples of the FM-A extruded system (solid solution, Gelucire 44/14 Eudragit RS PO ratio 
of 1:6) showed a decrease in the glass transition temperature after testing in the dissolution 
bath with a Mid-point Tg of 32.4±1.8°C (n=3) as illustrated in Figure 7.32 A. This 
corresponds to an almost 13% reduction from the Tg of the control samples (37.1±0.5°C). 
Water can act as a plasticizing agent, resulting in a depression of the glass transition 
temperature and a more flexible film. After drying of these tested samples for one week, the 
glass transition temperature showed an approximately 9% increase in comparison to the 
fresh control samples with a Mid-point Tg of 40.8±1.8 (n=3). However, in order to account 
for ageing effect, these samples were further compared to the untested samples (control) that 
were stored using the same conditions for one week. The Mid-point Tg of the aged control 
samples was 39.0±1.2 (n=3). Therefore, the glass transition temperature of the efficiently 
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dried tested samples is not significantly higher than the Tg of the aged control samples. In 
summary, the glass transition temperature of the FM-A extruded films was depressed after 
the dissolution test as a result of being hydrated. The absence of water after drying resulted 
in an unplasticized glass transition. 
 
The effect of immersion in the dissolution bath on the FM-B extruded system (solid 
dispersion, Gelucire 44/14 Eudragit RS PO ratio of 2:5) using MTDSC experiment (Fig. 
7.32 B) was also addressed (Table 7.6). To begin with, the melting endotherm disappeared 
after the test. This infers removal of the excess Gelucire 44/14 into the dissolution medium, 
resulting in weight loss after the test. Additionally, the glass transition temperature 
depressed by approximately 33% from the original value detected for the control samples, 
giving softer films and demonstrates again, the profound effect of water as a plasticizing 
agent. After the storage of these samples under dry conditions for one week, the melting 
endotherm reappeared besides unplasticized Tg. However, the melt ∆H of this peak is 
markedly less than the corresponding control as shown in Figure 7.32. This is more likely to 
be associated with formation of new crystals, rather than any remaining portion of the 
original crystals in the fresh sample. For the original crystals, they were mainly detected on 
the surface of these extrudates as revealed by SEM images previously. Therefore, it would 
be the first candidate to leave the films upon contact with the dissolution medium and if any 
melt will be detected later, is expected to result from new crystal formation that would 
increase as a function of storage time. This ageing effect was confirmed from the sharper 
fusion peak with higher melt ∆H observed for the control films stored for one week in 
comparison to the fresh control films (Figure 7.32 B). 
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(A) 
 
 
(B) 
 
 
Figure 7.32: MTDSC reversing heat flow signals of fresh hot melt extruded (A) FM-A 
(Gelucire 44/14 Eudragit RS PO ratio of 1:6) and (B) FM-B (Gelucire 44/14 Eudragit 
RS PO ratio of 2:5) films examined after testing  in the dissolution bath for 24 hours 
(t=24 hrs), followed by drying at 0% relative humidity/25°C for one week 
(0%RH/25°C/1wk) and compared to the controls of:  fresh films (t=0 hr) and after 
ageing for one week at the same storage conditions (0%RH/25°C/1wk). Underlying 
scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 
seconds 
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Sample Tg (Mid-point, °C)  Tm(onset) (°C) 
Control (t=0 hr) 20.8±1.0 37.0±1.2 
Test      (t=24 hrs) 13.9±0.3  - 
Control (0%RH/25°C/1wk) 20.8±0.8 36.7±1.0 
Test      (0%RH/25°C/1wk) 23.5±0.9 36.0±0.4 
 
Table 7.6: Summary of the MTDSC results derived from the reversing heat flow 
signals of the hot melt extruded FM-B films examined as shown in Figure 7.32 (B). 
Values represent mean ± S.D (n=2) 
 
Figure 7.33 (A) and (B) illustrate PXRD profiles of the FM-A (lower content of Gelucire 
44/14) and FM-B (higher content of Gelucire 44/14) extruded systems, respectively, after 
immersion in the dissolution bath and after drying of these tested samples. These profiles 
showed that samples of these films were completely amorphous after testing using the 
dissolution bath and after storage under dry conditions for one week. However, these data 
conflict with the conclusions drawn from the MTDSC results for the FM-B hot melt 
extruded system. A dried sample of FM-B extruded system showed a melting endotherm, 
indicating crystalline Gelucire 44/14. However, the small amount of the crystalline Gelucire 
44/14 might fall below the detection limit of the PXRD technique. 
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(A) 
 
 
(B) 
 
 
Figure 7.33: X-ray powder diffraction profiles of the raw materials, physical mixtures 
and their corresponding hot melt extruded films of Gelucire 44/14 Eudragit RS PO 1:6 
ratio (FM-A composition, A) and 2:5 ratio (FM-B composition, B). The films were 
examined after testing in the dissolution bath for 24 hours (t=24 hrs), followed by 
storage under dry conditions for one week at 0% relative humidity, 25°C to allow 
drying (0%RH/25°C/1wk) and compared to the controls of fresh extruded films (t=0 
hr) 
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To show the real morphology changes of these tested extrudates, SEM was used in 
association with the photographs taken for these samples, before and after the dissolution 
testing, to aid in detection of the corresponding discoloration of these films. As shown in a 
Table 7.7 the transparent appearance of the FM-A and FM-B extruded films changed into 
white dispersion after the dissolution, indicating Gelucire 44/14 hydration (Svensson et al., 
2004). After drying for one week, the samples separated into white and transparent phases. 
The white zone could be related to the crystals of the Gelucire 44/14, because it is a white 
semi-solid waxy material as mentioned in Chapter 2. However, MTDSC and PXRD results 
did not support this suggestion for the FM-A system. Therefore, SEM can provide 
compelling evidence as to whether this white zone is actually crystalline Gelucire 44/14 or 
not. If not, it could be solubilised Gelucire 44/14. SEM images of the tested FM-A (Gelucire 
44/14 Eudragit RS PO ratio of 1:6) and FM-B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) 
extruded films from the dissolution bath are shown in Figures 7.34 and 7.35, respectively. 
These extrudates were characterised previously using SEM in section 7.2.2.2 and represent 
the control or untested films. 
 
 
Gelucire 44/14: 
Eudragit RS PO  
ratio 
Formula 
code 
Control  
(t=0 hr) 
Test  
(t=24 hrs) 
Test 
(0%RH/25°C/1wk)  
1:6 FM-A 
 
  
2:5 FM-B 
 
  
 
Table 7.7: Photographs illustrating the colour changes of the hot melt extruded films of 
the FM-A and FM-B systems pre and post the dissolution experiment 
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 (A-S)                                                               (A-Cs) 
 
    
 
(B-S)                                                                (B-Cs) 
 
    
 
Figure 7.34: SEM images of the surfaces (S) and cross sections (Cs) of FM-A extruded 
films after the dissolution testing (t=24 hrs) represented by A series, followed by drying 
at 0%RH/25°C for one week and shown in B series. Examples on the micro-cracks are 
enclosed by orange rectangles. See text for composition 
 
After dissolution, the surfaces of the FM-A films developed micro-cracks, whereas the cross 
sections deformed with a fluffy appearance as illustrated in Figure 7.34. These changes 
remained after drying with disappearance of the white colour in the cross section. No visible 
crystals were detected on the surfaces or cross sections of these samples. This could infer 
that the white colour observed earlier (Table 7.6) is more likely related to the solubilised 
Gelucire 44/14. The surface imperfections or formation of these cracks on the surfaces of 
these samples could be rationalized with the removal of some Gelucire 44/14 into the 
dissolution bath during the test. Water was proven to be absorbed by these extruded samples 
(water absorption capacity measurements). As a result, the glass transition temperature was 
decreased (MTDSC experiment), offering a greater system mobility i.e. softening. 
Collectively this would impact the diffusion of the amphiphilic Gelucire 44/14 into the 
dissolution medium, which is believed to be washed out, thus a weight loss and increase of 
the glass transition temperature were observed after the test. The increase of the glass 
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transition could also contribute to possible matrix contraction that has been reported to 
initiate similar cracks (Khan and Craig, 2004). 
 
Comparing the SEM images of the FM-B extruded films in Figure 7.35 with the control 
samples clearly demonstrates the effect of the dissolution experiment. The surface was 
associated with a rough appearance and micro-cracks and the cross section was characterised 
with layered white scales. In comparison to the FM-A system, these cracks occurred with 
greater propensity and the cross section of the FM-B system was more congealed. The first 
would be expected for a relatively higher amount of the Gelucire 44/14 leaving the structure, 
while the second can be related to a more plasticized system that would result in a smoother 
more uniform appearance of the swelled films. Following storage for one week under 
0%RH/25°C to allow drying, the surface of these films showed small distribution of 
granules, while the cross section was still free from crystals similar to the control samples. 
This would indicate recrystallization after the removal of the water. In conjunction with the 
MTDSC findings, this observation could be explained with the following scenario: 
 
• The glass transition temperature of the extruded system was less than the 
temperature of the dissolution test (37°C) by approximately 44%, which could be 
reflected on the enhanced Gelucire 44/14 mobility during the dissolution.  
• The Gelucire 44/14 is believed to migrate towards the surface of the films to flow 
into the aqueous dissolution medium, owing to its amphiphilic properties.  
• Immediately after the test, the water in the sample was enough to solubilise or dilute 
nuclei of the Gelucire 44/14 and the system was characterised by a single glass 
transition temperature of 13.9±0.3°C.  
• After the water removal, the Gelucire 44/14 was able to rearrange into fine 
crystallites distributed sparsely on the surface and detected by MTDSC. 
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 (A-S)                                                             (A-CS) 
 
    
 
(B-S)                                                              (B-CS) 
 
    
 
(B-S-1) 
 
 
 
Figure 7.35: SEM images of the surfaces (S) and cross sections (Cs) of FM-B extruded 
films after the dissolution testing (t=24 hrs) represented by A series, followed by drying 
at 0%RH/25°C for one week and shown in B series. (B-S-1) is an insert showing 
magnification of granules (dashed orange square) detected on the surface of FM-B 
extruded films after drying. Examples on the micro-cracks are enclosed by orange 
rectangles. See text for composition 
 
To communicate the changes that can affect FM-A (low level of Gelucire 44/14) and FM-B 
(high level of Gelucire 44/14) extruded systems after the application to the skin, Franz-type 
diffusion cells (in vitro model) were used. The films were hydrated to mimic occlusive 
conditions. These changes were characterised in a similar manner to the dissolution studies 
and the techniques of TGA, MTDSC and SEM were used, in addition to polarized light 
microscopy and ATR-FTIR.  
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In Table 7.8 and 7.9, the water content, absorption capacity and swelling ratio values 
increased with testing time and as the level of Gelucire 44/14 was increased. This effect was 
addressed similarly in dissolution testing, but we can observe here that after four hours the 
values approached near a maximum, for both FM-A and FM-B extruded systems. This 
would indicate that incubation for a longer time under these conditions is less likely to 
enhance their ability to uptake the water from the surrounding environment.  
 
Time (Hours) Water content 
(w/w %)  
Water absorption capacity 
(w/w %) 
Swelling ratio  
(%) 
0 (Control) 0.25   
0.25 1.32 3.60 10.60 
1 1.77 10.20 21.20 
2 2.20 23.30 33.00 
3 2.43 27.00 34.30 
4 4.64 34.70 35.70 
24 4.99 43.10 39.90 
 
Table 7.8: Water uptake properties of the hot melt extruded films of FM-A system as 
analysed at each sampling time in Franz-type diffusion cells 
 
Time (Hours) Water content  
(w/w %) 
Water absorption capacity 
(w/w %) 
Swelling ratio  
(%) 
0 (Control) 0.28   
0.25 1.45 13.40 20.10 
1 2.60 34.90 43.20 
2 4.31 46.80 51.80 
3 5.33 51.80 55.20 
4 5.80 58.70 63.40 
24 6.42 63.10 66.60 
 
Table 7.9: Water uptake properties of the hot melt extruded films of FM-B system as 
analysed at each sampling time in Franz-type diffusion cells 
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The reversing heat flow signals of the MTDSC experiment were used for the detection of 
both glass transition temperatures and melting endotherms to separate out other overlapping 
events such as observed dehydration peaks. For FM-A extruded system (Gelucire 44/14 
Eudragit RS PO ratio of 1:6), the glass transition temperature as seen in Figure 7.36 (A) has 
been decreased as a function of water involvement which acted as a plasticizing agent. 
However, the water played a dual role in the studied FM-B extruded system (Gelucire 44/14 
Eudragit RS PO ratio of 2:5) as illustrated in Figure 7.36 (B). On one hand it lowered the 
glass transition temperature (plasticization effect) and on the other hand it aided in 
solubilisation of Gelucire 44/14 crystals, thus the melting peaks were decreased over time as 
a function of water content. Interestingly, both FM-A and FM-B systems showed a glass 
transition value at the end of the diffusion test similar to the one reported after the 
dissolution experiment, despite the higher water content measured in the latter. This 
similarity would indicate that the extent of the glass transition temperature depression 
induced by water is limited.  
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(A) 
 
 
(B) 
 
 
Figure 7.36: MTDSC reversing heat flow signals of hot melt extruded FM-A (A) and 
FM-B (B) films after testing in the Franz-type diffusion cells at different times and 
compared to their respective controls (t=0 hour). Underlying scan rate of 1°C min-1 
with a modulation amplitude of ±0.265°C and a period of 100 seconds. See text for 
composition 
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The next step in the characterisation is to identify the surface morphology of the samples and 
detect any change in their structures through examination of surfaces and cross sections of 
these extrudates. While these structures and surface artefacts can be observed efficiently 
using the SEM, due to the built in features of high resolution, magnification and greater 
depth of the applied field, the standard light microscope was used in its polarized mode 
(PLM) as a conjunction technique to confirm suspected crystals on the surfaces of the tested 
extrudates. Figure 7.37 shows the SEM photos of the FM-A extruded films tested at 
different times. Imperfections or micro-cracks were formed on the surfaces similar to the 
dissolution testing results. However, the swelling of the cross sections was less 
distinguishable compared to the samples tested in the dissolution bath. This is expected 
because of less aqueous medium available herein to cause swelling of these matrices. 
Polarized light images enhanced the contrast at the edges of the observed fissures (cracks) 
and revealed an orange colored material without birefringence. Therefore, formation of 
crystalline Gelucire 44/14 is precluded and this is also supported by previous MTDSC 
measurements.  
 
In a previous study by Khan and Craig (2003) a similar material was observed for Gelucire 
50/13 and was described as an ‘oil streak’. Gelucire 50/13 and Gelucire 44/14 have shared 
features such as they are both derived partially from hydrogenated palm kernel oil 
(Gattefosse s.a, St Priest, France). Therefore, it is highly expected that this material is an oily 
part of the Gelucire 44/14 transferred to the surface due to the enhanced mobility of the 
components after plasticization by water and solubilisation in the buffer solution. 
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Time 
(Hours) (Surfaces)                                (Cross sections)                  PLM (Surfaces) 
0.25        
1             
2             
3             
 4            
 24          
 
 
Figure 7.37: SEM images of the surfaces and cross sections of FM-A extruded films at 
different testing times using Franz-type diffusion cells. PLM images represent pattern 
of the tested surfaces with polarized light microscopy  
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Previous investigations in section 7.3 have demonstrated that the ATR-FTIR technique can 
be used to differentiate crystalline Gelucire 44/14 in the extruded samples at two 
characteristic absorbance peaks (1347 and 1107 cm-1). Consequently, it has been used to 
further confirm the physical nature of this material observed in the PLM photos. In Table 
7.10, we can see that over time the changes were mainly at the region of the peak denoted as 
(C) around 1107cm-1. This peak was a little more distinct than a shoulder over time, but with 
definite broadening and a new adjacent broad peak was observed and designated as peak 
(II). This would suggest that it is less likely to have crystalline material yet the appearance of 
this new peak around 1096 cm-1 could support the hypothesis that the observed orange 
material under PLM is an oil leakage into the surface, because palm oil (from which 
Gelucire 44/14 is derived) absorbs at this wavelength (Ajiwe et al., 2003) related to C-H 
deformation of alkyl groups. 
 
Sample       Time  Peak (A) at  
1347 cm-1 
Peak (C) at 
1107 cm-1 
Inside FM-A 
extrudate 
 
  
 
Table 7.10: Summary of the assignments of the proposed crystalline peaks of Gelucire 
44/14 from Eudragit RS PO-subtracted extruded films ATR-FTIR spectra of FM-A 
(Gelucire 44/14 Eudragit RS PO ratio of 1:6) system tested at different times using 
Franz-type diffusion cells 
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In Figure 7.38, the richness of this ‘orange’ material was more observed as would be 
envisaged from higher amount of Gelucire 44/14 in the FM-B extruded films. This is also 
associated with more extended micro-cracks as observed from the SEM images. After 15 
minutes of testing, PLM  could still detect  small sparkling aggregates of the crystals on the 
surface of these samples, which soon disappeared from the film removed after one hour of 
testing and onwards. This implies that the solubilisation of Gelucire 44/14 crystals was 
occurring as previously demonstrated using MTDSC experiment. The cross sections showed 
notable swelling, due to increased access of the aqueous medium over time as indicated in 
Table 7.9. 
 
In similar manner to the FM-A system, the extruded films of FM-B systems were monitored 
using ATR-FTIR as presented in Table 7.11. Crystalline Gelucire 44/14 was observed in 
peak (A) around 1347 cm-1, but disappeared after the first hour of testing. This is consistent 
with the PLM findings, where sparkling crystal aggregates were not visible after one hour of 
the test. It was noted; however, that peak (C) around 1107cm-1 seems to start to sharpen 
during the first two hours of the testing, but in fact it was separating from another peak 
marked as (II) and detected at 1096 cm-1. Giving rise to this peak, which is possibly ascribed 
to the palm oil, indicates that the process of solubilisation is taking place in a gradual 
manner. Therefore, part of the crystalline Gelucire 44/14 responsible on peak A dissolved 
completely, followed by other components responsible for peak (C) accompanied with the 
evolution of peak (II). This behaviour could be reasonably expected from Gelucire 44/14 
owing to its many components, which can hydrate and dissolve depending on the 
temperature and amount of water available as addressed by Svensson et al. (2004). 
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Figure 7.38: SEM images of the surfaces and cross sections of FM-B extruded films at 
different testing times using Franz-type diffusion cells. PLM images represent pattern 
of the tested surfaces with polarized light microscopy  
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Sample       Time  Peak (A) at  
1347 cm-1 
Peak (C) at 
1107 cm-1 
Inside FM-B 
extrudate 
 
 
 
Table 7.11: Summary of the assignments of the proposed crystalline peaks of Gelucire 
44/14 from Eudragit RS PO-subtracted extruded films ATR-FTIR spectra of FM-B 
(Gelucire 44/14 Eudragit RS PO ratio of 2:5) system tested at different times using 
Franz-type diffusion cells 
 
In summary, the changes associated with these unloaded extruded films of Gelucire 44/14 in 
Eudragit RS PO examined in a dissolution bath or under occlusive conditions in Franz-type 
diffusion cells are mainly surface imperfections, possible leakage of the Gelucire 44/14 into 
these surfaces and softening of the films accompanied with appreciable swelling of the 
matrices. While the mechanisms of the enhanced drug release from these matrices were 
defined kinetically in Chapter 6, this set of observations is also important to the fundamental 
understanding of the underpinning mechanism(s) of the drug release process from these 
matrices. Two scenarios are possible as indicated in a review by Craig (2002) to describe 
such mechanisms. The principle of the first one could be interrelated with the possible 
Gelucire 44/14 transfer into the surface and enrichment of the dissolving layer. The drug 
particles will be dissolved into this layer first and then introduced to the receptor medium as 
molecular dispersion and thus referred to as ‘carrier-controlled dissolution’.  
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The second scenario is dependent on the drug properties such as the degree of crystallinity, 
size, etc. The release in this case is ‘drug-controlled’. The drug is assumed to transfer as 
intact particles into the receptor medium and in our case this can be facilitated by the cracks 
created on the surface of the extrudates upon hydration. It is also useful to know that if the 
first scenario will dominate, the physical form of the drug will have no effects on the release 
rate (in the most cases) as argued by Lloyd et al. (1999). It is then proposed that a further 
inspection on the ageing influence on the drug solid state structure and subsequent release 
properties might provide valuable information about the mechanism of the drug release in 
these systems as will be introduced in the following section.  
 
7.5 The behaviour of aged Eudragit RS PO/Gelucire 44/14 hot melt extruded 
films with and without ibuprofen 
 
This section explores the changes in the unloaded and ibuprofen-loaded Eudragit RS PO-
Gelucire 44/14 carrier systems on storage. The aged films with the drug will be further 
evaluated for their permeation properties.   
 
7.5.1 Methodology 
 
Hot melt extruded films of FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-B 
(Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems, as described in section 7.2.1, were 
characterised after ageing under three conditions for one month. The first two conditions 
were performed at room temperature (25°C) with varied relative humidity of 0%RH under 
phosphorous pentoxide (P2O5), creating dry conditions and supersaturated solution of 
sodium chloride (NaCl) in distilled water to control humidity to a level of 75%RH, for high 
humidity. The third condition utilized the same salt to create 75%RH at 40°C as 
recommended in the literature (O’Brien, 1948); this last condition was used to assess the 
combined effect of relatively high temperature with high humidity. Airtight jars were used 
as storage chambers, whereby the temperature was controlled in a vacuum oven and the 
humidity level was checked using both hygrometer and humidity strips.  
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Characterisation involved MTDSC, PXRD, SEM, and ATR-FTIR as explained in Chapter 3. 
In addition, TGA was used for water content determination as documented in Chapter 4. 
DVS was used to detect the hydration behaviour of the samples that have been stored for one 
month at dry conditions as a function of temperature variation over the range from 22 to 
48°C in 5°C steps, in which the samples were held for one hour at each temperature. The 
samples were equilibrated before the experiment for one hour at 0%RH/22°C.  
 
The loaded films of ibuprofen were prepared as described in Chapter 6, these hot melt 
extruded FM9 and FM10 films were stored at the same aforementioned conditions for one 
month with subsequent characterisation using the same methods of MTDSC, PXRD, and 
water content determination using TGA. Ibuprofen: Gelucire 44/14: Eudragit RS PO ratios 
of 3:1:6 and 3:2:5 were used in FM9 and FM10 systems, respectively. 
 
HSM studies were performed to visualise thermal events associated with the aged films and 
involved a video capture microscope while exposing the samples to a controlled temperature 
program heating from 25°C to 100°C at 1°C min-1. Photos of the blends were taken to show 
the events and were correlated with the ones obtained via MTDSC measurements which 
used the same underlying rate of heating of 1°C min-1. The permeation studies were also 
carried out for the aged films following the same procedure in Chapter 5 under hydration 
conditions. Each film was hydrated using a 0.3 ml of the used receptor medium (PBS, 
pH=7.2) applied to these samples in the donor chambers of Franz-type diffusion cells. It is 
noteworthy that ratios of Gelucire 44/14:Eudragit RS PO of (1:6) and (2:5) in FM-A and 
FM-B systems, respectively are equivalent to the used ratios in the loaded films of FM9 and 
FM10 systems, respectively, wherein  the drug ‘ibuprofen’ loading is 30%(w/w). All the 
reported values were measured as mean±S.D. (n=3) unless otherwise mentioned in the 
relevant section. 
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7.5.2 Results and discussion 
 
7.5.2.1 Characterisation of the aged carrier systems of Eudragit RS PO/Gelucire 44/14 hot 
melt extruded films 
 
Further to the importance of water in the effectiveness of these carrier systems for drug 
delivery, the storage study at relative high humidity of 75%RH can aid in understanding of 
how water can affect their physical stability. To achieve that, samples were divided into 
three groups dealing with each selected storage condition for one month, where the samples 
were kept under dry conditions (0%RH/25°C) represent the control of the samples tested at 
(75%RH/25°C) and highlighting the impact of water at room temperature. While samples 
stored at 75%RH/25°C can be considered as a control to those tested at 75%RH/40°C and 
would indicate the role of temperature increase. However, the universal control will be the 
fresh samples representing zero ageing time, thus giving an insight into the ageing influence 
at different storage conditions. 
 
As illustrated in Figure 7.39 (A), the reversing heat flow signals of the MTDSC scans for the 
FM-A extruded samples (Gelucire 44/14 Eudragit RS PO ratio of 1:6) indicated a single 
glass transition temperature (37.6± 1.8°C) slightly above the glass transition temperature of 
the fresh samples reported in section 7.2.2.1.2 i.e. 37.1±0.5°C, after ageing under dry 
conditions. This would be expected as the water content was measured to be 0.09± 0.54 
(w/w%) that is also slightly less than amount found in the fresh samples (i.e. 0.25 ±0.46 
w/w%). During the storage at 75%RH/25°C, an indication of phase separation was 
manifested as two glass transition temperatures of 30.8±1.2°C and 41.8±0.7°C were 
detected. The first Tg  might indicate an amorphous system of both Gelucire 44/14 and 
Eudragit RS PO that has a lower glass transition temperature in comparison to the fresh 
samples due to water presence, whereby the measured water content was 0.91± 0.04 
(w/w%). The second Tg (41.8±0.7°C) indicates more likely a polymer-rich phase of Eudragit 
RS PO, as the value approaching its glass transition temperature (53.3±0.5°C); however, it is 
still plasticized due to water inclusion in the structure. At a higher temperature of 40°C with 
75%RH, the aged system under these conditions exhibited also two glass transition 
temperatures. The first Tg was approximately 33% less than the recorded Tg of the fresh 
samples and the second Tg indicated Eudragit separation but with a reduced Tg. This could 
be explained by the role of water as a plasticizer, whereby the measured water content was 
1.20 ±0.19 (w/w%). Samples at all storage conditions showed relaxation endotherms in their 
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non-reversing heat flow signal as exemplified in Figure 7.39 (B). Alternatively, this 
relaxation can contribute to the phase separation of polymer-rich regions as can be seen in 
samples stored at 75%RH humidity level at 25°C or 40°C. 
  
(A) 
 
 
(B) 
 
 
Figure 7.39: MTDSC reversing heat flow signals (A) for aged hot melt extruded FM-A 
films at different storage conditions for one month whereby (B) is showing 
representative MTDSC profile of samples stored at 75%RH/25°C with enlarged insert 
of the relaxation endotherm occurring simultaneously after the glass transition 
temperature and detected in the non-reversing heat flow signal. Underlying scan rate 
of 1°C min-1 with a modulation amplitude of ±0.265°C and a period of 100 seconds 
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For FM-B extruded systems (Gelucire 44/14 Eudragit RS PO ratio of 2:5), the solid 
dispersion two-phase system was maintained over all storage conditions as can be seen in 
Figure 7.40. At dry conditions (0%RH/25°C), the observed changes from the reversing heat 
flow signals indicated a sharper melting endotherm with an increased melt ΔH in comparison 
to the fresh samples examined in section 7.2.2.1.2, suggesting an increase in the crystalline 
fraction of the Gelucire 44/14 over time. In addition, an increase in the glass transition 
temperature was detected in comparison with the fresh samples, mainly due to efficient 
water loss, whereby the water content of these samples equals 0.08±0.12 (w/w%). After 
ageing at 75%RH; however, the melting endotherm was broadened and the melt ΔH 
decreased due to possible solubilisation of the Gelucire 44/14 crystals and the observed glass 
transition temperatures were lowered, all as a function of water involvement at a level of 
0.93±0.29 (w/w%). Samples stored at 40°C and 75%RH showed the effect of water presence 
more clearly (with a water content of 1.29±0.9 w/w%) as characterised with even a lower 
melt ΔH melting endotherm and almost 50% reduction of the glass transition temperature in 
comparison to the fresh samples.  
 
 
 
Figure 7.40: MTDSC reversing heat flow signals for aged hot melt extruded FM-B 
films at different storage conditions for one month. Underlying scan rate of 1°C min-1 
with a modulation amplitude of ±0.265°C and a period of 100 seconds 
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In summary of the MTDSC experiments, the glass transition temperatures of the FM-A and 
FM-B extruded systems were reduced the most as a function of both temperature and water, 
under storage conditions of 75%RH/40°C. These conditions also aid in more solubilisation 
of the crystalline Gelucire 44/14 inside FM-B extruded aged systems. An amorphous phase 
indicates polymer-rich areas in the tested films was detected after storage at 75%RH/25°C 
and 75%RH/40°C for FM-A system. The occurrence of this phase is more relevant to the 
polymer relaxation observed at 75%RH humidity level. Extruded system relaxation to 
relieve the mechanical stress associated with the HME process can result in phase separation 
(Qi et al., 2010) as shown in our systems. On that basis it is now obvious why the FM-A 
system aged at dry conditions is more difficult to exhibit this phase separation, owing to its 
higher Tg than the used storage temperature (25°C).  
 
It is also expected that water and increased temperature can work collaboratively to enhance 
the mobility inside these systems. While temperature above the Tg can increase system 
fluidity and improves the moisture ingress, the moisture (or the water) itself will reduce the 
glass transition temperature making the effect of temperature more influential on these 
systems. This is further supported by the observed water uptake increase as a function of 
stepping up the temperature at a fixed relative humidity of 75%RH, for films aged at 
0%RH/25°C for FM-A (low level of Gelucire 44/14) and FM-B (high level of Gelucire 
44/14) systems in Figure 7.41. In this figure we can also observe increased water uptake as a 
function of increasing the amount of the Gelucire 44/14 in these films as addressed in 
previous discussions. 
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Figure 7.41: Weight change percent profiles at 75%RH humidity level versus 
temperature for the aged FM-A (Gelucire 44/14 Eudragit RS PO ratio of 1:6) and FM-
B (Gelucire 44/14 Eudragit RS PO ratio of 2:5) systems under 0%RH/25°C for one 
month 
 
Throughout previous characterisation of the fresh FM-A and FM-B systems using PXRD, no 
crystalline peaks were detected even though MTDSC results indicated crystalline Gelucire 
44/14 in FM-B films (see section 7.2.2.1.2). As with these samples, no diffraction pattern of 
the crystalline Gelucire 44/14 was obtained for FM-A and FM-B systems after storage at 
different conditions as shown in Figure 7.42. Instead a broad hump in the XRD pattern, 
characteristic of amorphicity, was seen in all the samples. While this finding supports the 
presence of amorphous material as such, detected using MTDSC in FM-A films, it did not 
show the second population of the newly existed amorphous material, suggesting lower 
extent of phase separation. On the other hand, PXRD could not reveal diffraction peaks of 
crystalline Gelucire 44/14 detected by MTDSC measurements in the FM-B system, 
indicating less amount of the crystalline material that can be detected using this technique in 
comparison to the diffraction pattern detected for its equivalent physical mixture.  
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Figure 7.42: Overlay of X-ray powder diffraction profiles of FM-A and FM-B extruded 
system aged for one month at 0%RH/25°C, 75%RH/25°Cand 75%RH/40°C 
 
The impact of the storage conditions on the morphology aspects of these aged samples was 
traced using SEM as seen from Figure 7.43 through to Figure 7.44. The surface of the FM-A 
films after storage at dry conditions revealed few micro-granules as indicated in the blue 
circle in Figure 7.43, whereas the cross section was free from any crystals. For the samples 
stored at the same temperature but higher relative humidity of 75%RH, micro-cracks were 
seen on the surface associated with more developed micro-granules protruding from these 
fissures. The cross section deformed in a similar way to the films tested after hydration in 
section 7.4.2.2, indicating swelling. In this case, we can ascribe the swelling to both polymer 
chains’ relaxation as observed in the MTDSC experiment and water uptake. For the samples 
stored at 75%RH and 40°C, the micro-cracks were tempered owing to enhanced flow of the 
material above its detected glass transition temperature, which seems to play a role in sealing 
these cracks. However, this ‘sealing’ was not efficient, because the matrix showed signs of 
swelling as appeared in the cross section. Micro-granules were also detected on the surface 
of these samples. Therefore, it can be concluded that ageing after one month resulted in 
Gelucire 44/14 crystallization under all the used storage conditions. 
 
Samples of this system (FM-A) stored under 75%RH/25°C developed micro-cracks on their 
surfaces, which are more likely ascribed to the association of the hydrophilic chains on the 
surface with the adsorbed water (see section 7.4.2.2). Gelucire 44/14 also seems to leach into 
these edges and crystallise as micro-granules to lower the surface energy. At higher 
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temperature of 40°C and 75%RH, the same scenario took place owing to the same humidity 
level, but the material fluidity is expected to increase, therefore leached Gelucire 44/14 
seems to fill these cracks because smoother surfaces were observed.  
 
Storage Condition   (Surfaces)                                  (Cross sections) 
(A) 0%RH/25°C        
 
 
(B) 75%RH/25°C       
 
 
                                (B-I)   
 
  
(C) 75%RH/40°C      
 
 
Figure 7.43: SEM images of the surfaces and cross sections of FM-A extruded films at 
different storage conditions for one month. (B-I) is an insert showing magnification of 
granules (dashed orange square) detected on the surface of FM-A extruded films aged 
under 75%RH/25°C. Examples on the observed micro-cracks and granules (crystals) 
are enclosed by orange squares and blue circles, respectively 
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The changes in the morphological features of the aged films of FM-B system as displayed in 
Figure 7.44 are similar to the ones observed for the aged FM-A extruded systems with few 
variations. Firstly, the propensity of crystalline regions after ageing at 0%RH/25°C is higher 
than FM-A system which is expected from this solid dispersion system that had these 
granules originally on its surface. This finding was supported in MTDSC results as sharper 
melting peak with increased melt ∆H were observed. Furthermore, the average diameter of 
these micro-granules increased to about 2.5-7 microns in comparison to their average 
diameter of about 0.4-2.6 microns in fresh samples, indicating crystal growth. The crystal 
development into large crystals in lipids such as Gelucire 44/14 is known as ‘blooming’ and 
it is usually associated with more softened lipids (Khan and Craig, 2004). Therefore, it 
would be expected to have even larger granules in the systems stored at 75%RH/25°C and 
75%RH/40°C as their glass transition temperatures were reduced far beyond the used storage 
temperatures which would enhance Gelucire 44/14 mobility and diffusivity into the surface 
with high propensity to build up into larger crystals. This conforms to the observed largest 
granules on the surfaces of the FM-B aged films where more plasticized systems (lower Tg) 
such as the ones stored at 75%RH/40°C showed the largest granule with approximate 
diameter of 25 microns in comparison to the granules observed after storage at 
75%RH/25°C, with a maximum approximate diameter of only 5.3 microns. 
 
Secondly, the swelling of the cross sections was more pronounced especially at the storage 
conditions of 75%RH/25°C, implying more water involvement as a function of Gelucire 
44/14 high level in FM-B films in comparison to the FM-A films. 
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Storage Condition     (Surfaces)                                     (Cross sections) 
(A) 0%RH/25°C       
 
(B) 75%RH/25°C     
 
                                  (B-I)  
 
(C) 75%RH/40°C      
 
                                    (C-I)   
 
Figure 7.44: SEM images of the surfaces and cross sections of FM-B extruded films at 
different storage conditions for one month. (B-I) and (C-I) are inserts showing 
magnifications of granules (dashed orange square) detected on the surface of FM-B 
extruded films aged under 75%RH/25°C and 75%RH/40°C, respectively. Examples on 
the observed micro-cracks and granules (crystals) are enclosed by orange squares and 
blue circles, respectively 
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As opposed to the MTDSC and PXRD results, SEM indicated the presence of Gelucire 
44/14 crystallites on the surfaces of the aged FM-A films at all storage conditions. SEM 
might carry some limitations in the identification of the crystals, such as misinterpretation of 
the topological features of the samples with the granule formation or otherwise electron 
beam interaction with the tested surface, whereby hump-like structures can form. Therefore 
ATR-FTIR was used to further investigate the presence of Gelucire 44/14 crystals in the 
aged samples of either FM-A or FM-B films. Using characteristic absorption bands of 
crystalline Gelucire 44/14 as detailed in section 7.3.2, Table 7.12 to Table 7.13 were 
constructed and revealed interesting observations. For the aged FM-A systems, the presence 
of crystalline Gelucire 44/14 was consistent with the SEM findings for samples stored at 
0%RH/25°C and 75%RH/25°C. In these samples, the characteristic peaks for crystalline 
Gelucire 44/14 denoted as A (1347 cm-1) and C (1107 cm-1) retained sharper appearance in 
comparison to the fresh samples; however, peak C was boarder after storage at 75%RH/25°C 
compared to the samples stored under dry conditions, indicating solubilisation of this lipid. 
This resembles hydrated films’ behaviour with the differentiation into another peak (denoted 
as II, 1096 cm-1) that was assumed in section 7.4.2.2 to result from the solubilisation of the 
Gelucire 44/14 with subsequent oil leakage into the surface. 
 
For the samples stored at 75%RH/40°C, the solubilisation was increased as a function of 
both water and high temperature and peak A was not detected whereas peak C (1107 cm-1) 
showed only the new peak (II) around 1096 cm-1, which is another indication of 
solubilisation of Gelucire 44/14. At 75%RH/40°C there are few small crystallites as 
indicated by SEM but the process of their solubilisation was dominant as indicated by ATR-
FTIR results, thus could not stand as a distinct crystalline peak in the spectrum. Therefore, 
we can conclude that the aged films of FM-A composition exhibited crystallites at all 
storage conditions with varying extent. 
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Sample Peak (A) at  
1347 cm-1 
Peak (C) at 
1107 cm-1 
Inside FM-A 
extrudate 
  
 
Table 7.12: Summary of the assignments of the proposed crystalline peaks of Gelucire 
44/14 from Eudragit RS PO-subtracted extruded films ATR-FTIR spectra of FM-A 
(Gelucire 44/14 Eudragit RS PO ratio of 1:6) system examined after storage for one 
month at different conditions 
 
For FM-B aged films, the crystals detected using ATR-FTIR were mainly at storage 
conditions of 0%RH/25°C and 75%RH/25°C. As shown in Table 7.13, these samples 
exhibited distinct sharp peaks at the location of previously identified peak A (1347 cm-1) 
similar to the raw crystalline Gelucire 44/14. This sharpness in comparison to the Gelucire 
44/14 crystals in the fresh extruded samples would be assumed to correspond to more 
developed crystallites coincided with the detected ‘blooming’ effect on the surfaces of these 
films using SEM. For the films stored at 75%RH/40°C, the peak A resembles the fresh 
samples with even more diffused character, due to possible solubilisation of the Gelucire 
44/14 crystals facilitated by the presence of water and temperature. This was supported by 
MTDSC findings of very broad melting endotherm and low melt ∆H in comparison to other 
aged extrudates. This is also manifested at the peak C (1107 cm-1), wherein the solubilised 
fraction of the expected oily part from Gelucire 44/14 is indicated in the observed peak 
around 1096 cm-1 (II) shown in Table 7.13.  
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Sample Peak (A) at  
1347 cm-1 
Peak (C) at 
1107 cm-1 
Inside FM-B 
extrudate 
  
 
Table 7.13: Summary of the assignments of the proposed crystalline peaks of Gelucire 
44/14 from Eudragit RS PO-subtracted extruded films ATR-FTIR spectra of FM-B 
(Gelucire 44/14 Eudragit RS PO ratio of 2:5) system examined after storage for one 
month at different conditions. The spectrum of the raw Gelucire 44/14 extracted from 
the equivalent physical mixture spectrum (no thermal treatment) was displayed along 
other spectra at peak (A) region to show similarity  
 
In summary, the aged films of FM-A and FM-B extruded films at the selected storage 
conditions for one month developed crystalline Gelucire 44/14 to varying extent. A moisture 
level of 75%RH and a temperature of 40°C were able to make efficient solubilisation of the 
Gelucire 44/14 crystals without a marked swelling as the one detected at 75%RH/25°C. This 
could be attributed to more tempered cracks facilitated by enhanced material flow at higher 
temperatures on the surface of the extruded film which might impede further diffusion of the 
water into the matrices, thus a lesser extent of swelling would be expected.  
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7.5.2.2 Characterisation of the aged hot melt extruded films of Eudragit RS PO/Gelucire 
44/14 loaded with ibuprofen  
 
Gelucire 44/14:Eudragit RS PO ratios of (1:6) and (2:5) in FM-A and FM-B systems, 
respectively, are equivalent to the ratios used in the loaded films of FM9 and FM10 systems, 
respectively, wherein the drug (ibuprofen) was loaded at 30%(w/w) level, as developed in 
Chapter 6. These medicated samples (FM9 and FM10 systems) were stored for one month 
using the same previous conditions of the carrier systems (without the drug). These samples 
were characterised accordingly using MTDSC, PXRD, HSM and TGA.  
 
In an attempt to relate the behaviour of the aged carrier system (Gelucire 44/14 in Eudragit 
RS PO) to the complex aged medicated system, MTDSC has been used in a similar 
convention to the previous section. Thus the reversing signals were used to observe the 
melting and glass transition events wherein the trend of changes will be addressed with 
expected reliable deconvolution from other mixed events such as dehydration peaks or 
relaxation endotherms, which would appear in total and non-reversing heat flow signals.   
 
As can be seen from Figure 7.45, FM9 extruded films containing a lower level of Gelucire 
44/14 than FM10 films showed two melting peaks after storage at dry conditions of 
0%RH/25°C, indicating recrystllisation. The glass transition temperature was increased in 
comparison to the fresh samples with a Tg (Mid-point) of 8.8±0.6°C, as both ibuprofen and 
Gelucire 44/14 may contribute to the reduction of the resultant glass transition temperature 
of the extruded film and the recrystallization of one or both might affect their efficiency as 
plasticizers. A greater proportion of the crystalline material was detected in the second broad 
peak (higher melt ΔH) with a Tm
 (onset) of 40.6±0.3°C preceded by the smaller melting 
endotherm (lower melt ΔH) with a Tm
 (onset) of 30.6±1.2°C. In comparison to these samples, 
storage at 75%RH/25°C resulted in one broader melting peak with a Tm
 (onset) of 27.6±0.2 
shifted to a lower temperature and accompanied with a depressed glass transition 
temperature of 2.3±1.0°C. Consequently, the water involved in these films played two roles. 
Possible solubilisation of the crystalline material as indicated from the shifting of the 
melting endotherm and as plasticizing agent with a profound impact on the reduction of the 
glass transition temperature though a moisture content of only 0.58±0.05 ( w/w%) was 
measured.  At 75%RH/40°C storage conditions, the resulting composition was characterised 
by the absence of the melting endotherms starting approximately in the range of 27.6-30.6°C 
and appearance of a very broad melting peak with a Tm(onset) of 52.4±1.1°C. Though this 
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peak was shifted to a higher temperature it was associated with the lowest melt ∆H in 
comparison to the samples stored at all other storage conditions.  
 
 
 
Figure 7.45: MTDSC reversing heat flow signals of aged hot melt extruded FM9 films 
(Gelucire 44/14: Eudragit RS PO: ibuprofen ratio of 1:6:3) at different storage 
conditions for one month in comparison to the fresh tested film 
 
As addressed earlier (section 7.5.2.1), temperature and water (75%RH/40°C) can lead to 
greater solubilisation for Gelucire 44/14 crystals in the aged films of the carrier systems 
(FM-A and FM-B). Therefore, it could be inferred that disappearance of these peak herein is 
associated with the crystalline material solubilisation under these conditions while the 
remaining peak represents the slight excess of unsolubilised crystalline material. 
Furthermore, two glass transition temperatures were visible in the reversing heat flow signal. 
While a glass transition temperature (Mid-point) was observed at -8.6±0.4°C which reflects 
the water’s influence as a plasticizing agent with a measured water content of 0.65±0.08 
(w/w%), another glass transition temperature was detected at 39.6±0.3°C (Mid-point Tg) 
similar to the Tg of the FM-A carrier system (without the drug) stored at the same conditions 
(Figure 7.45). This might indicate a possible Eudragit RS PO-rich phase as inferred from the 
FM-A system (carrier system without the drug). Therefore, it could be concluded that 
storage at 40°C will yield a complex response in terms of phase separation, which may be 
described as extensive in comparison to other storage conditions.   
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As per this discussion, it would be expected that Gelucire 44/14 in the aged FM9 films is 
contributing to the observed melting peaks as these endotherms shifted to a lower 
temperature or decrease as a function of exposure to water in comparison to the ones stored 
at dry condition, because Gelucire 44/14 crystals are miscible with water. In addition, the 
studied aged carrier system (FM-A) of these films (unloaded), showed crystalline Gelucire 
44/14 in all storage conditions whereby storing at 75%RH/40°C led to almost disappearance 
of these crystals. However, PXRD profiles of the aged FM9 films (loaded) as illustrated in 
Figure 7.46 demonstrated only ibuprofen crystals at all storage conditions. This could 
indicate a low amount of crystalline Gelucire 44/14 in these aged films. 
 
 
 
Figure 7.46: Overlay of X-ray powder diffraction profiles of FM9 extruded systems 
aged for one month at 0%RH/25°C, 75%RH/25°C and 75%RH/40°C in comparison to 
their corresponding fresh sample, physical mixture and pure crystalline components 
i.e. ibuprofen and Gelucire 44/14 
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Collectively, all aforementioned observations are expected to be a result of the drug 
dissolution over a wide range of the molten carrier (Gelucire 44/14 in Eudragit RS PO) as 
reported by Lloyd et al. (1997). Consistent with these findings, a hot stage microscopy 
(HSM) experiment showed that the melt process occurred over a wide range, wherein the 
Gelucire 44/14 crystals melted first followed by gradual melting of the ibuprofen crystals. 
As we can see in Figure 7.47, ibuprofen crystals exhibit rod-shape whereas Gelucire 44/14 
crystals exhibit a spherulitic structure. A series of images were captured accordingly for the 
aged FM9 samples stored at different conditions and heated at 1°C min-1. These images 
correspond to the softening of the sample, the melt onset and complete disappearance of the 
crystals as illustrated in Figure 7.48. For example, the samples stored at 0%RH/25°C started 
to soften and expand in the approximate range of 32.1-42.1°C and the melt onset observed 
around 50°C, then mixed crystals were detected around 55.5° of both Gelucire 44/14 and 
ibuprofen. The disappearance of the spherulites related to the Gelucire 44/14 was almost 
completed by 61.2°C followed by melting of the remaining observed rod-shape crystals due 
to ibuprofen which finished around 70.3°C.   
 
(A) 
 
(B) 
 
 
Figure 7.47: Polarized light images of the (A) ibuprofen crystals and (B) Gelucire 44/14 
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(I) 
 
(II) 
 
 
Figure 7.48: Hot stage microscope images capturing the melting of the crystals after 
ageing for one month of the FM9 samples (I) under 0%RH/25°C and (II) under 
75%RH/25°C. Samples were heated at 1°C min-1. Arrows indicate the area associated 
with the onset of melting (in black), the Gelucire 44/14 spherulites (in thick yellow) and 
ibuprofen crystals (in red). Orange cross marks the movement of the sample as a result 
of its expansion. Circular bubbles are due to nitrogen gas entrapped during 
manufacturing of these loaded samples 
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(III) 
 
 
Figure 7.48 (Contd.): Hot stage microscope images of the FM9 samples stored at 
75%RH/40°C for month. These samples showed only signs of liquefaction or glass 
disappearance as displayed in (III) set. Samples were heated at 1°C min-1. Arrows 
indicate the area associated with the onset of softening (in black) 
 
MTDSC data (Fig.7.45) showed a reasonable agreement with the observed melting in this 
HSM study (Fig.7.48). In particular the broadest peak (last peak) in the case of the samples 
stored at 0%RH/25°C and the peak observed for samples stored at 75%RH/25°C. The 
temperature at the peak of the melting endotherm (MTDSC profile) fairly corresponds to the 
temperature associated with the visual disappearance of the spherulites. The temperature at 
which this melting endotherm returns to the baseline in the MTDSC thermogram is in a good 
agreement with the complete melt of the ibuprofen crystals, Table 7.14. However, small 
shoulders or peaks (lower melt ΔH) for the samples stored at 0%RH/25°C and at 
75%RH/40°C and observed in Figure 7.45 were difficult to detect using HSM as they were 
subtle (an enthalpy in the approximate range of 0.28-0.66 J/g). Furthermore, samples stored 
at 75%RH/40°C showed signs of softening followed by complete disappearance of a 
wrinkled texture into smoother one around 37.3°C that agreed well with the predicted glass 
transition temperature in the MTDSC reversing heat flow signal characteristic for this 
system (around 39.8°C).  
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Reference  Figure 7.48 
(I)  
Figure 7.45 
Aged at 0%RH/25°C 
Figure 7.48 
(II) 
Figure 7.45 
Aged at 75%RH/25°C 
Image 
symbol 
Temp.(°C)  Temp.(°C) 
 
 
E   53.1(*) 47.9 
Tm(p) 
F 61.2(*) 54.6 
Tm(p) 
62.2(**) 63.6 
Tm(b) 
G 70.3(**) 66.0 
Tm(b) 
  
 
Table 7.14: A summary of the correlation between the temperatures associated with 
disappearance of the spherulites (*) and rod-shape crystals (**) as obtained from hot 
stage microscopy and the melting temperature at the peak (Tm(p)) and at the baseline 
(Tm(b)) of the last peak recorded from MTDSC reversing heat flow signals (aged FM9 
films) 
 
It should also be noted that variation of the data resulting from comparison between HSM 
and DSC is expected and this could be ascribed to the differences in the measuring 
techniques. For example, samples tested using DSC were enclosed in aluminium pans under 
nitrogen gas whereas samples in HSM were exposed to open environment and under 
atmospheric conditions, this would result in a different heat flux experienced by the samples. 
Moreover, DSC technique averages the behaviour of all crystals that melt at similar 
temperature while HSM measurements indicate that for individual crystals (Sutananta et al., 
1994). 
 
In a similar way to the approach used to characterise aged FM9 films, the aged FM10 films 
(higher level of Gelucire 44/14) were tested as seen from Figure 7.49 through to Figure 7.51. 
Previously, the melting endotherm observed for the fresh FM10 film had been assumed to be 
ascribed only to the crystalline ibuprofen based on the PXRD data (Chapter 6). However, the 
carrier system (without the drug) which corresponds to this formula i.e. FM-B films showed 
crystalline Gelucire 44/14 supported by MTDSC and ATR-FTIR measurements in the 
previous sections. Therefore it is more logical to consider that the detected broad peak of the 
fresh films resulted from both crystalline ibuprofen and Gelucire 44/14. The reversing heat 
flow signals of the MTDSC experiment are presented for the fresh sample compared to the 
aged ones in Figure 7.49.  
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As shown in Figure 7.49, ageing of these samples under dry conditions (0%RH/25°C) for 
one month was associated with differentiation of the melting peak of the fresh samples 
(Tm(onset) = 29.3±1.5°C) into a broad one with a melting onset temperature (Tm(onset)) at 
39.3±1.5°C preceded by a sharper melting peak with a Tm(onset) of 29.3±1.5°C. The glass 
transition temperature detected for these aged samples was at 10.2±0.6°C (Tg-Midpoint), 
which is less than the one recorded for the fresh samples (21.8±0.4°C). As addressed before, 
ibuprofen can act as a plasticizer and Gelucire 44/14 also aids in the reduction of the glass 
transition temperature of the mixture. Thereof the amorphous phase detected in this system 
and characterised with this depressed glass transition temperature is expected to be enriched 
with amorphous state of one of these components or both.  
 
 
 
Figure 7.49: MTDSC reversing heat flow signals for aged hot melt extruded FM10 
films (Gelucire 44/14: Eudragit RS PO: ibuprofen ratio of 2:5:3) at different storage 
conditions for one month in comparison with the fresh tested film 
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For the samples stored at the same temperature but at higher level of humidity 
(75%RH/25°C), as shown in Figure 7.49, the glass transition temperature was significantly 
reduced into 0.9±0.1°C due to the presence of water which can act as a powerful plasticizer, 
and the measured water content of these samples was only 0.68±0.44 (w/w%). Furthermore 
the water influence on these samples was manifested in one broad peak (Tm(onset) = 
29.7±0.2°C) associated with low melting enthalpy and shifting to a lower temperature as 
observed from the melting temperature at the apex, which could be attributed to possible 
solubilisation of the Gelucire 44/14. The latter impact was even more obvious in the samples 
stored at higher temperature of 40°C in presence of water at humidity level of 75%RH, 
because, as mentioned earlier, Gelucire 44/14 water uptake enhanced as a function of 
temperature with subsequent possible solubilisation. The shifting of the broad peak was 
observed mainly from the decrease of the temperature of the melting endothrem apex to a 
lower value and appearance of a shoulder-like melting peak with a Tm
 (onset) of 49.7±0.3°C 
(Figure 7.49). The glass transition temperature of the system did not show a significant 
change in comparison to the systems stored at 75%RH/25°C and a Tg value of 0.9±0.4°C 
(Mid-point Tg) was observed with a measured water content of these samples of about 
0.76±0.12 (w/w%). 
 
PXRD measurements as depicted in Figure 7.50 supported the presence of crystalline 
Gelucire 44/14 and ibuprofen crystals in all aged samples as linked with the diffraction 
peaks observed in their diffractograms. This coincided with the broad peaks obtained by 
MTDSC results. Since the fresh samples, though having these broad peaks which are most 
likely to be a function of both crystalline ibuprofen and Gelucire 44/14, did not show the 
diffraction peaks of Gelucire 44/14, this may be related to the low level of this material in its 
crystalline state in the fresh samples compared to the aged ones. However, it can be argued 
that solubilised Gelucire 44/14 after storage at high relative humidity of 75%RH  should 
result in a low level of crystalline Gelucire 44/14 during testing that is hard to be detected 
using PXRD. Despite this, it is believed that these samples undergo rapid recrystallization, 
probably due to water evaporation, which was observed visually especially for the samples 
stored under 75%RH/40°C, as they transformed within almost 15 minutes into opaque films, 
indicating recrystallization. Thus the time needed to handle the samples and to test them 
using PXRD (approximately one hour for each sample) is expected to be enough to render 
recrystallization of the solubilised Gelucire 44/14 in enough amount to be detectable using 
PXRD technique in these aged samples. 
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Figure 7.50: Overlay of X-ray powder diffraction profiles of FM10 extruded systems 
aged for one month at 0%RH/25°C, 75%RH/25°C and 75%RH/40°C in comparison to 
their corresponding fresh sample, physical mixture and pure crystalline components 
i.e. ibuprofen and Gelucire 44/14 
 
Additionally, the appearance and melting of these aged films were examined using HSM as 
illustrated in Figure 7.51. In both samples stored at 0%RH/25°C and 75%RH/25°C, the 
crystalline ibuprofen with rod-shape appearance and spherulites related to Gelucire 44/14 
were observed. For the samples stored at 75%RH/40°C, the ibuprofen crystals were visible 
and their complex mixture with Gelucire 44/14, Eudragit RS PO and water was manifested 
as a wrinkled-like texture that soon liquefies and clear around 29.4°C, implying that the 
phase is amorphous or more likely a mixed phase of amorphous material and solubilised 
Gelucire 44/14 crystals as supported by MTDSC findings in which the Tm(onset) of the first 
melting endotherm was about 28.7±0.5°C. This correlates well with the temperature 
associated with the smoothness of the ‘wrinkled’ texture as observed in HSM (29.4°C) that 
is believed to be facilitated by high mobility of the amorphous phase with very low glass 
transition temperature predicted around 0.9±0.4°C (Mid-point Tg). 
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(I) 
 
(II) 
 
 
Figure 7.51: Hot stage microscope images capturing the melting of the crystals after 
ageing for one month of the FM10 samples (I) under 0%RH/25°C and (II) under 
75%RH/25°C. Samples were heated at 1°C min-1. Arrows indicate the area associated 
with the onset of melting (in black), the Gelucire 44/14 spherulites (in thick yellow) and 
ibuprofen crystals (in red). Orange cross marks the movement of the sample as a result 
of its expansion. Circular bubbles are due to nitrogen gas entrapped during 
manufacturing of these loaded samples 
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(III) 
 
 
Figure 7.51 (Contd.): Hot stage microscope images capturing the melting of the crystals 
after ageing for one month of the FM10 samples stored at 75%RH/40°C which showed 
mainly signs of liquefaction or glass disappearance as displayed in (III) set. Samples 
were heated at 1°C min-1. Arrows indicate the area associated with the onset of melting 
or softening (in black) and ibuprofen crystals (in red)  
 
Though limitations associated with the direct comparison between DSC and HSM data, 
mentioned in the earlier discussion, Table 7.15 demonstrates that they were closely related to 
each other. Mainly the visual disappearance of the spherulites was linked to the melting peak 
temperature (Tm(p)) and the observed melting of the ibuprofen rod-shaped crystals with the 
melting temperature at the baseline (Tm(b)), both of the last melting endothermic peaks in the 
reversing heat flow thermograms (Figure 7.49).  
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Reference  Figure 7.51 
(I)  
Figure 7.49 
Aged at 0%RH/25°C 
Figure 7.51 
(II) 
Figure 7.49 
Aged at 75%RH/25°C 
Image 
symbol 
Temp.(°C)  Temp.(°C) 
 
 
F 55.6(*) 53.5 
Tm(p) 
52.8(*) 44.6 
Tm(p) 
G 68.4(**) 64.6 
Tm(b) 
69.9(**) 60.1 
Tm(b) 
 
Table 7.15: A summary of the correlation between the temperatures associated with 
disappearance of the spherulites (*) and rod-shape crystals (**) as obtained from hot 
stage microscopy and the melting temperature at the peak (Tm(p)) and at the baseline 
(Tm(b)) of the last peak recorded from MTDSC reversing heat flow signals (aged FM10 
films) 
 
In summary, ageing under all conditions enhanced recrystallization of both ibuprofen and 
Gelucire 44/14 in the loaded films of the FM9 and FM10 compositions as indicated by 
MTDSC and HSM findings. A humidity level of 75%RH is sufficient to solubilise Gelucire 
44/14 crystals and this effect was enhanced at a higher temperature of 40°C. This moisture 
level was also sufficient to reduce the glass transition temperatures associated with the tested 
samples. PXRD data were useful for qualitative assessment of the degree of crystallinity of 
Gelucire in the tested samples. For example, fresh samples of FM10 are now considered to 
have both crystalline Gelucire 44/14 and ibuprofen as related to the carrier FM-B system and 
supported by MTDSC broad peaks, though PXRD revealed only ibuprofen crystals. After 
ageing, the X-ray diffractograms of the FM10 samples indicated recrystallization of both 
ibuprofen and Gelucire 44/14, possibly due to increase of the amount of recrystallized 
Gelucire 44/14, which become easier to be detected. The increase of extent of 
recrystallization was observed clearly in the reversing heat flow signals for samples stored 
under dry conditions, where the effect of Gelucire 44/14 solubilisation is precluded. Thus, it 
could be inferred that fresh samples of FM10 contained approximately less than 5% of 
crystalline Gelucire 44/14 and upon ageing this percent level increased and made crystalline 
Gelucire 44/14 detectable, whereby 5% value represents the common detection level of the 
crystalline material by the PXRD technique (Shah et al., 2006). Also it could be concluded 
that ibuprofen is the main constituent to cause phase separation and to recrystallize, in 
addition to ageing impact which will be manifested as an increase in the extent of phase 
separation where Gelucire 44/14 crystals are fully developed and detectable. 
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However, the question remains how that will be reflected on the permeation profiles. This 
knowledge will be useful not only to evaluate the efficiency of these systems as function of 
their stability, but also to determine the mechanism of the drug release in these devices as 
described in section 7.4.2.2. Therefore, the release profiles of the FM9 and FM10 will be 
discussed in the following section wherein the combined effect of ageing and hydration are 
assessed using Franz-type diffusion studies. 
 
7.5.2.3 In vitro permeation studies of ibuprofen from Eudragit RS PO/Gelucire 44/14-based 
extruded films: Effect of ageing 
 
In Chapter 6, the permeation-enhanced profiles of the ibuprofen from FM9 and FM10 films 
were achieved by hydration. Thus the hydration level associated with highest permeation of 
the ibuprofen was used here to assess the permeation behaviour of the aged films in 
comparison with the fresh samples. As demonstrated in Figure 7.52 and Figure 7.53, the 
aged films of each tested formula showed similar permeation behaviour to each other 
regardless of their storage conditions. For example, samples of FM9 system stored under dry 
condition (0%RH/25°C) exhibited a similar release profile compared to the samples stored 
under 75%RH/25°C. Moreover, the aged films of the FM9 formula manifested a slower 
permeation profile in comparison to the fresh samples. This retardation was even more 
dramatic for the aged films of the FM10 compared to their respective fresh films. Figure 
7.54 addresses the observed retardation using the time needed to achieve 80% or higher of 
the percent cumulative permeation in vitro. One day was needed to achieve this cumulative 
percentage of permeation for fresh FM9 formulation and two days for the aged ones. For 
those containing higher level of Gelucire 44/14 i.e. FM10 films, the aged formulations 
needed one day whereas the fresh films only three hours.  
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Figure 7.52: Ibuprofen diffusion (permeation) profiles from hot melt extruded films of 
aged FM9 system (1:6:3 ratio of Gelucire 44/14:Eudragit RS PO:ibuprofen) for one 
month at different conditions and compared to the fresh samples, tested approximately 
at 32°C and permeated across silicone membrane into phosphate buffer solution 
(pH=7.2) at 37±0.1°C. Aliquot 0.3 ml of this solution was applied into each film to 
achieve hydration. Each data point represents the mean±S.D. of no less than three 
measurements 
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Figure 7.53: Ibuprofen diffusion (permeation) profiles from hot melt extruded films of 
aged FM10 system (2:5:3 ratio of Gelucire 44/14:Eudragit RS PO:ibuprofen) for one 
month at different conditions and compared to the fresh samples, tested approximately 
at 32°C and permeated across silicone membrane into phosphate buffer solution 
(pH=7.2) at 37±0.1°C. Aliquot 0.3 ml of this solution was applied into each film to 
achieve hydration. Each data point represents the mean±S.D. of no less than three 
measurements 
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Figure 7.54: The time corresponding to 80% or higher of the cumulative percentage 
permeation of ibuprofen from the hot melt extruded films of aged FM9 (lower content 
of Gelucire 44/14) and FM10 (higher content of Gelucire 44/14) systems for one month 
at different conditions and compared to their respective fresh samples, tested 
approximately at 32°C and permeated across silicone membrane into phosphate buffer 
solution (pH=7.2) at 37±0.1°C. Aliquot 0.3 ml of this solution was applied into each film 
to achieve hydration 
 
These observations suggest common feature(s) which led to the similarity of the permeation 
profiles of these aged films on one hand. On the other hand they implied that a different 
environment caused the permeation delay with respect to the fresh films. As shown in the 
previous section (7.5.2.2), aged films of FM9 and FM10 systems contain both crystalline 
ibuprofen and Gelucire 44/14. Therefore, it would be difficult to ascribe the cause for this 
slow permeation to one of these materials. However, we know now that fresh films of FM10 
contain these materials in crystalline form and still achieve very fast release after being 
hydrated with 0.3 ml level. It is also believed that these films upon ageing will contain 
higher fraction of crystalline Gelucire 44/14 of 5% or higher as assumed from PXRD 
evaluation. This suggests that crystalline Gelucire 44/14 might play a major role for slowing 
down the permeation or ‘controlling’ the release regardless of the physical state of the 
ibuprofen. Furthermore, the dramatic change of the cumulative amount permeated in the 
aged films of FM10 system in relation to the fresh films was also associated with different 
appearance of the samples after the test.  
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In other words, the fresh films hydrated with 0.3 ml or 0.14 ml as shown in Chapter 6 and 
tested for their permeation were seen to be homogenised with the applied solution for 
hydration to form liquid-like emulsion. Whereas the aged films (rectangular shape) swell 
and jellified, adapting the shape of the diffusion area (circular shape) in a like manner to the 
hydrated fresh or aged FM9 films without being transformed into a liquid-like emulsion 
(Figure 7.55). Therefore, the suggested dispersion of the drug is less likely to be as efficient 
as in the liquid state, which might affect the release rate. Consequently, it could be 
speculated that the presence of more fraction of Gelucire 44/14 crystals may adversely affect 
the speed of the release and subsequent permeation, which means that the drug release 
mechanism is highly expected to be carrier-controlled.  
 
           
(A) Before the test   (B) After the test  
 
Figure 7.55: Representative photographs of the aged FM10 films demonstrating shape 
change appearance seen before (A) and after (B) the permeation study using Franz-
type diffusion cells with applied hydration volume of 0.3 ml PBS (pH=7.2) 
 
Additionally, the release mechanism of the studied films can be described using model 
fitting as detailed in Chapter 5. As seen in Table 7.16, the permeation profiles were fitted to 
different kinetic models, where the correlation coefficient, R2, was used to assess the fit of a 
model equation, so the ‘best’ model would be the one with the highest R2 value. Of these 
models, the first order kinetic model seems to prevail in the permeation profiles of all the 
tested hydrated films, whether they are fresh or aged samples.  
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Used Kinetic model  First order 
model 
Zero order 
model 
Higuchi square-root of 
time model 
Tested sample 
(Hydrated with 0.3 ml PBS, 
pH=7.2) 
R2 R2 R2 
(A) FM9 Films    
Fresh films 0.9741 0.8156 0.9108 
Aged films at 0%RH/25°C 0.9653 0.9435 0.9414 
Aged films at 75%RH/25°C 0.9607 0.9309 0.9262 
Aged films at 75%RH/40°C 0.9696 0.9450 0.9533 
(B) FM10 Films    
Fresh films 0.9742 0.2198 0.4133 
Aged films at 0%RH/25°C 0.9795 0.8636 0.9381 
Aged films at 75%RH/25°C 0.9890 0.8563 0.9521 
Aged films at 75%RH/40°C 0.9801 0.8721 0.9416 
 
Table 7.16: Fit correlation coefficients (R2) of different applied kinetic models for the 
permeation profiles of the FM9 and FM10 films tested after ageing at different 
conditions for one month and compared to the fresh films 
 
The power model was used to give further insight into the involved release mechanism(s) 
using the measured release exponent as shown in Table 7.17. For all the aged films of FM9 
system, the release was described as ‘anomalous’, wherein both swelling and diffusion 
mechanisms are expected to control the release while their fresh films are controlled mainly 
by swelling as known by case-II transport. The proximity of the release exponent values; 
however, suggest that ageing did not cause appreciable change of the release mechanism as 
compared to the fresh samples and overall, swelling is believed to contribute to the drug 
release from these matrices (fresh or aged). 
 
 Characterisation of the aged films of the FM10 films, where a higher amount of Gelucire 
44/14 is incorporated, showed a tendency to release ibuprofen by swelling and relaxation i.e. 
super case-II transport mechanisms, similar to the fresh samples except for the samples aged 
under 75%RH /40°C. Alternatively, the release from these samples was predicted in this 
model to be governed by swelling and diffusion i.e. anomalous. This is possibly associated 
with their storage conditions, as a high temperature of 40°C might be sufficient for these 
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systems to cause the relaxation of the polymeric chains and lipid material for one month, and 
after testing with the a set temperature in the donor chamber of the diffusion cells 
(approximately 32°C) the samples would be expected to show minimal relaxation to control 
the release which occurs otherwise significantly for other aged samples that has been stored 
at 25°C.   
 
Kinetic model  Korsmeyer-Peppas 
model (Power law) 
Tested sample 
(Hydrated with 0.3 ml PBS, 
pH=7.2) 
R2 Release exponent 
(n) 
Expected release  
mechanism 
(A) FM9 Films    
Fresh films 0.9253 1.00 Case-II transport 
Aged films at 0%RH/25°C 0.9648 0.95 Anomalous transport 
Aged films at 75%RH/25°C 0.9533 0.94 Anomalous transport 
Aged films at 75%RH/40°C 0.9664 0.86 Anomalous transport 
(B) FM10 Films    
Fresh films 0.9538 2.52 Super case-II transport 
Aged films at 0%RH/25°C 0.9753 1.31 Super case-II transport 
Aged films at 75%RH/25°C 0.9780 1.51 Super case-II transport 
Aged films at 75%RH/40°C 0.9133 0.85 Anomalous transport 
 
Table 7.17: Interpretation of the measured release exponents from the power law 
model and their correlation coefficients (R2) for the permeation profiles of the FM9 
and FM10 films tested after ageing at different conditions for one month and compared 
to the fresh films  
 
If we have a closer look at the in vitro permeation profiles of the aged films of both FM9 and 
FM10 systems, there appear to be an interesting implication in the associated delayed release 
compared to the fresh films. If we link figures from Figure 7.52 through to Figure 7.54, we 
can see that the majority of the drug released (80% or higher) from the fresh and aged films 
is associated with steady state release phase demonstrating ‘zero order’ release. The fitness 
coefficients of zero order model for this part was shown to be satisfactory as illustrated in 
Table 7.18. This phase is followed by plateau or gradual release during the rest time, thereby 
the whole release phase could be characterised preferably by simultaneous mechanisms of 
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release i.e. zero order followed by first order kinetic. As the aged samples exhibited a longer 
period of this nearly zero order release, the subsequent absorption from these samples would 
be expected to be concentration independent, providing, in theory, predictable uniform drug 
release for a longer time than fresh samples.  
 
Kinetic model Zero order model  
 
Tested sample 
(Hydrated with 0.3 ml PBS, pH=7.2) 
R2 Phase interval (Hours) 
(A) FM9 Films   
Fresh films 0.9817 0-24 
Aged films at 0%RH/25°C 0.9971 0-48 
Aged films at 75%RH/25°C 0.9887 0-48 
Aged films at 75%RH/40°C 0.9990 0-48 
(B) FM10 Films   
Fresh films 0.9839 0-3 
Aged films at 0%RH/25°C 0.9682 0-24 
Aged films at 75%RH/25°C 0.9710 0-24 
Aged films at 75%RH/40°C 0.9925 0-24 
 
Table 7.18: Fit correlation coefficients (R2) of the zero order model describing the first 
phase of the permeation profiles of the FM9 and FM10 films tested after ageing at 
different conditions for one month and compared to the fresh films  
 
Overall, ageing of either FM9 or FM10 extruded films for one month at varying conditions, 
between low (dry) to high relative humidity with different temperatures, resulted in similar 
permeation profiles which are notably lower than their corresponding fresh films. The data 
relating to the FM10 films is believed to shed the light on the possible role of recrystallized 
Gelucire 44/14 as a matrix which can act to control the release of the ibuprofen from the 
studied films. It can also be observed that the aged films carry promising behaviour in the 
release in terms of kinetics, through achieving a steady-state release of the drug for a longer 
time than the equivalent fresh samples.  
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7.6 Conclusions 
 
The aim of the work described in this chapter was to continue studying the extruded films 
based on Eudragit RS PO with Gelucire 44/14 but without ibuprofen to specifically address 
their role as promising carrier systems for potential transdermal drug delivery activated by 
hydration. Thus with the objective to further understanding their properties, the 
characterisation of solid state structure was carried out in section 7.2. cDSC and MTDSC 
allowed prediction of miscibility between Eudragit RS PO and Gelucire 44/14 on the basis  
that Eudragit RS PO lowered the melting enthalpy of Gelucire 44/14 during heating of their 
physical mixes at the used concentrations. MTDSC, PXRD and SEM results confirmed solid 
solution formation of the extruded films containing lower level of Gelucire 44/14 i.e. FM-A 
system, whereas at higher level of this lipid i.e. FM-B system, a molecular dispersion of 
Gelucire 44/14 in the Eudragit RS PO as a solid dispersion was formed as detected by 
MTDSC and supported by SEM investigations.  
 
In the light of these results ATR-FTIR was used in section 7.3 to reveal the nature of 
molecular interaction that could exist between these components. Characteristic bands of the 
Gelucire 44/14 in Eudragit RS PO have shown different intensities as indicated from 
changes in the calculated relative percentage areas under their spectra after thermal treatment 
and extrusion. These changes were explained by three possible hypotheses, namely, change 
in transition dipole, change in optical properties and migration of the alkyl groups and no 
evidence of significant interactions was revealed. ATR-FTIR could differentiate between the 
crystalline and amorphous nature of Gelucire 44/14 based on the lack of structural 
uniformity associated with the amorphous material. 
 
A further preliminary visual observation of the physical mixtures of Gelucire 44/14 in 
Eudragit RS PO treated thermally was undertaken using HSM. Affinity between these 
components at the compositions of the FM-A and FM-B formulae were indicated, through 
formation of clear miscible blends simulating to a limited degree the extrusion process. 
Section 7.4 allows us to reveal the sorption behaviour of these ‘unloaded’ films using DVS. 
An increase of water uptake as a function of increasing the level of the Gelucire 44/14 was 
observed. A specific emphasis was placed on the changes associated with the hydration of 
these carrier systems using in vitro model (Franz cells) under occlusive conditions and using 
dissolution test. TGA, MTDSC, PXRD, SEM, PLM and ATR-FTIR were used to track these 
changes. The unloaded extruded films showed surface imperfections, possible leakage of the 
Gelucire 44/14 into their surfaces and softening of the films accompanied with appreciable 
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swelling of the matrices after being hydrated. It could therefore be inferred that this 
enhanced mobility of the materials, indicated by lowering of the glass transition temperature 
of the studied systems (softening), and the soluble parts of the Geluicre 44/14 caught out 
into the surfaces of these films (leakage) and formation of the cracks as consequences of 
hydration, could lead to creating paths for the release of the active ingredient and its 
solubilisation when loaded in these vehicles. The combined techniques strategy used here to 
probe these changes showed that MTDSC and ATR-FTIR can be better techniques to reveal 
the crystalline Gelucire 44/14 in comparison to the PXRD method.  
 
A fundamental issue regarding the development of these carrier systems for extended 
applications for other medications is the physical stability which was detailed in section 7.5. 
Short term storage at different humidity levels and temperatures showed molecular 
arrangement changes of these systems. While FM-A systems showed a limited degree of 
Gelucire 44/14 crystallization and formation of a solid dispersion as supported by SEM and 
ATR-FTIR results, an extended phase separation was observed for the originally solid 
dispersed FM-B systems supported by MTDSC, SEM and ATR-FTIR findings. High 
humidity of 75%RH at room temperature is believed to aid in solubilisation of crystalline 
Gelucire 44/14 and reduction in the observed glass transition temperature with subsequent 
softening. The combination of this humidity level with higher temperature of 40°C further 
aided in the solubilisation of the Gelucire 44/14. This phenomenon is well suited with the 
trend of enhanced water uptake of these films as a function of increased temperature as 
found by DVS investigations.   
 
If one considers the variations which impacted the stability of these formulations, it would 
form a good basis for understanding their behaviour when loaded with the drug and aged 
under the same conditions. Thus aged systems containing ibuprofen were characterised 
using MTDSC, PXRD, TGA and HSM techniques and compared to their aged carrier 
systems (unloaded films). HSM was used to get insight into the nature of the broad melting 
peaks detected from MTDSC profiles of the aged loaded films, and it was demonstrated that 
the drug could be molten over a broad range of temperatures with concomitant melting of 
Gelucire 4/14 crystals. In light of these findings and in relation to the aged carrier systems, it 
was concluded that aged loaded FM9 and FM10 formulations which contain 30%w/w 
ibuprofen and used FM-A and FM-B carrier systems, respectively, had crystalline  materials 
of  ibuprofen and Gelucire 44/14.  
 
Investigation into Eudragit RS PO/Gelucire 44/14 hot melt extruded films as promising 
carrier systems for ibuprofen transdermal delivery 
Chapter 7 
 
366 
 
PXRD indicated the presence of crystals of this lipid in the aged FM10 films (ibuprofen 
Gelucire 44/14 Eudragit RS PO ratio of 3:2:5) but not in the aged FM9 films (ibuprofen 
Gelucire 44/14 Eudragit RS PO ratio of 3:1:6), despite being identified using other 
techniques. The poor sensitivity of the PXRD is precluded, providing that Gelucire 44/14 
crystalline peaks were detected in the corresponding physical mixes of these formulations 
(FM9 and FM10). It was therefore concluded that the quantity of crystallites in the FM9 is 
less than in the FM10 extruded systems after ageing, falling below the detection limit of this 
technique (~5%). These aged extruded films were further assessed for their in vitro 
permeation behaviour using diffusion cells. The hydration level which was associated with 
the maximum permeation profiles from the fresh films (Chapter 6) was used to clearly 
indicate changes in the performance as a result of the ageing of these loaded films. It is 
believed that drug recrystallization did not influence the effective utilisation of the films for 
rapid release formulations under the used hydration level. Instead, it is more likely that 
recrystallized Gelucire 44/14 has a retardation effect on the release and permeation rate of 
the ibuprofen from these matrices after ageing. Alternatively, this influence, as described 
kinetically, was not assumed to be negative. This is because slow permeation profiles of the 
ibuprofen from these aged films were associated with prolonged steady state zero order 
release.  
 
Kinetic models were also used side by side to propose possible mechanism(s) of drug release 
from the tested matrices. It was found that permeation profiles of these aged loaded films 
were best fitted to the first order release kinetics for the whole permeation profiles and more 
accurately as profiles composed of simultaneous zero order release followed by first order 
release pattern. The Power model indicated the role of swelling and relaxation in controlling 
the drug release. Overall, the mechanism of drug release from these devices under the 
influence of hydration is believed to be more related to the carrier rather than the drug. This 
provides promise in using these carrier systems for potential transdermal drug delivery 
where more control can be achieved using these carrier regardless of the physical state of the 
drug. Additionally, the approach used herein to release the drug rivals conventional methods 
for transdermal drug delivery through simple, yet effective, activation using hydration that 
could be created using skin occlusion.  
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Chapter 8: Influence of occlusion-induced hydration on the 
properties of Eudragit RS PO/Gelucire 44/14 hot melt extruded 
systems: in vivo behaviour 
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8.1 Introduction 
 
Hydration of the stratum corneum may result from skin occlusion. The occlusion process 
enhances the accumulation of water diffusing from underlying tissues of the skin or resulted 
from secretions of eccrine sweat glands (Hurkmans et al., 1985; Taylor and Machado-
Moreira, 2013). This occlusion-induced hydration often produces marked increase of skin 
permeation as detailed in Chapter 1. In this work, hydration is also essential to promote drug 
release from Gelucire 44/14-containing extruded systems as described in Chapter 6. The 
previous chapter discussed the physicochemical properties of Eudragit RS PO/Gelucire 
44/14 extruded films and structural changes associated with the hydration of these matrices 
without the drug. Because these studies were conducted using an in vitro model, the 
hydration created after application to the occluded skin has not been elucidated yet. 
Therefore, this chapter aims to continue the study of these films to gain insight into their in 
vivo behaviour. This is essential to understand the structural changes of these matrices, 
which could impart in the drug release mechanism, when applied to the human skin. More 
specifically, the hydration resulting from occlusion may serve the dual purposes of altering 
skin permeability and altering the structure of the Eudragit RS PO/Gelucire 44/14 films, 
potentially acting as a trigger mechanism for release. It is therefore necessary to understand 
the manner in which occlusion, as opposed to in vitro hydration, may influence film 
structure. For this purpose, drug-free films were used, although clearly if these studies were 
to prove promising then a drug absorption study would be highly desirable.   
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8.2 Methodology 
 
The hot melt extruded films were prepared from mixtures of Eudragit RS PO loaded with 
different levels of Gelucire 44/14 as described in Chapter 7 (section 7.2.1). FM-A extruded 
system containing approximately 15% w/w Gelucire 44/14, while FM-B system contains 
approximately 30% w/w Gelucire 44/14. These extruded films were cut manually and the 
dimensions were measured with an electronic digital caliper (MS092Toolzone Vernier 
Caliper, UK). Films of size (24.12 ± 1.31 mm3) were prepared for each system. An average 
film weight of (24.94 ± 1.17 mg) and (25.85 ± 1.45 mg) were used for FM-A and FM-B 
films, respectively. These films were attached to 3M Blenderm ® occlusive, hypoallergenic 
adhesive tape measuring 5 cm by 2 cm to prepare strips. These strips were applied on dry, 
clean inner forearms of four healthy-skin volunteers; two males and two females (age range 
28-35, mean age 32.5±3.1 year old). The study was divided into two parts, the first part for 
assessment of FM-A extruded films and the second part for FM-B extruded films. In each 
part four strips of these films were attached randomly on the left or right forearm of each 
volunteer and arranged for removal after 3, 5, 8 and 24 hours of application to the skin and 
occlusion by the used adhesive tape.  
 
In addition, strips of these films were kept under controlled humidity condition of 75%RH at 
room temperature, representing control samples. Supersaturated solution of sodium chloride 
in distilled water was used to control humidity to a level of 75%RH at room temperature and 
an airtight jar was used as a storage chamber. The humidity level was checked using a 
hygrometer. Water absorption capacity, swelling ratio measurements and characterisation 
performed using MTDSC, PLM, SEM, ATR-FTIR were conducted as detailed in Chapter 7 
section 7.4.2.1 for the films hydrated in vitro using Franz-type diffusion cells. TA-XT2 
Texture Analyzer (Stable Micro system, UK) was used to assess the hardness of the 
investigated films. The measuring principles as well as the parameters employed were 
described in details in Chapter 2 (section 2.2.2.6). The faculty research ethics committee of 
university of East Anglia at Norwich had approved the study (enclosed in the Appendix).  
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8.3 Results and discussion 
 
The first objective in this study was to confirm whether or not the Eudragit RS PO/Gelucire 
44/14 hot melt extruded systems will be hydrated after application to the skin under 
occlusion. Therefore, water absorption capacities were determined for these extruded films 
of FM-A and FM-B systems containing approximately 15% and 30% (w/w) Gelucire 44/14, 
respectively. As shown in Figure 8.1 and Figure 8.2, the films of both systems absorbed 
water after being hydrated under the influence of skin occlusion and the percent of water 
absorption capacity with subsequent swelling ratio increased with increasing occlusion time 
and Gelucire 44/14 concentration. In comparison to the in vitro model (Franz cells) detailed 
in Chapter 7, these values were markedly less, indicating possible overhydration conditions 
used in Franz-type diffusion cells. On the other hand, the young age of the volunteers might 
produce less hydration than elderly after stratum corneum perturbation by occlusion as 
suggested by Roskos and Guy (1989). However, the water absorption percent and swelling 
ratio were higher than control samples incubated at 75%RH and room temperature, which 
might indicate higher relative humidity levels under skin occlusion in this study and/or warm 
wet conditions which enhanced water uptake properties of these films.  
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(A) 
 
 
(B) 
 
 
Figure 8.1: The percent water absorption capacity of the hot melt extruded films of (A) 
FM-A and (B) FM-B systems at different time intervals of hydration. Control samples: 
samples incubated under 75%RH/25°C. Test (a) samples: samples applied to the skin 
under occlusion. Test (b) samples: samples removed from Franz diffusion cells after 
being hydrated using PBS solution (detailed in Chapter 7). Error bars represent ±S.D. 
of not less than three measurements 
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(A) 
 
 
(B) 
 
 
Figure 8.2: The percent swelling ratio of the hot melt extruded films of (A) FM-A and 
(B) FM-B systems at different time intervals of hydration. Control samples: samples 
incubated under 75%RH/25°C. Test (a) samples: samples applied to the skin under 
occlusion. Test (b) samples: samples removed from Franz diffusion cells after being 
hydrated using PBS solution (detailed in Chapter 7). Error bars represent ±S.D. of not 
less than three measurements 
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The reversing heat flow signals of the MTDSC experiment were used for the detection of 
glass transition temperatures (Mid-point Tgs) as reported in Figure 8.3. It is clear from this 
figure that there is a reduction in the glass transition temperatures for both FM-A and FM-B 
systems over hydration time under skin occlusion. This could be explained by the water 
plasticization effect. However, lowering of the glass transition temperature appears to be 
comparable to that observed for samples tested in Franz diffusion cells (in vitro model), 
though the samples hydrated more in the latter. This observation is consistent with the one 
aforementioned in Chapter 7. The hydration induced glass transition temperature depression 
was concluded to be limited. In that discussion the values of the glass transition temperatures 
at the end of hydration using Franz cells and after soaking in the dissolution bath were 
similar. This was observed in spite of higher level of hydration after the dissolution test as 
indicated by water absorption capacity and swellability of the tested samples.   
 
The total heat flow signals of the MTDSC scan were used to probe changes on the melting 
peaks of Gelucire 44/14, originally detected in the fresh samples of FM-B extruded system. 
In Figure 8.4, the melting enthalpy of the hydrated samples under occlusion was decreased 
over time, indicating solubilisation of water soluble Gelucire 44/14 crystals. This reduction 
was observed as a function of hydration level, thus the samples well-hydrated in Franz cells 
showed the lowest melting enthalpy value. Interestingly, control samples showed an increase 
of melting enthalpy. This increase of melting fraction indicates an increase of the Gelucire 
44/14 recrystallization over time under storage conditions of 75%RH/25°C. This emphasizes 
that hydration and high temperature potentiate the solubilisation of Gelucire 44/14 as 
detailed in Chapter 7 and detected for samples applied to the skin under occlusion.  
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(A) 
 
 
(B) 
 
 
Figure 8.3: Glass transition temperatures detected from MTDSC reversing heat flow 
signals scans of (A) FM-A and (B) FM-B system at different time intervals of 
hydration. Underlying scan rate of 1°C min-1 with a modulation amplitude of ±0.265°C 
and a period of 100 seconds. Control samples: encompass fresh sample (t=0hours) and 
samples incubated under 75%RH/25°C, tested at different times. Test (a) samples: 
samples applied to the skin under occlusion. Test (b) samples: samples removed from 
Franz diffusion cells after being hydrated using PBS solution (detailed in Chapter 7). 
Error bars represent ±S.D. of not less than three measurements 
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Figure 8.4: Melting enthalpies detected from MTDSC total heat flow signals scans of 
FM-B system at different time intervals of hydration. Underlying scan rate of 1°C min-1 
with a modulation amplitude of ±0.265°C and a period of 100 seconds. Control 
samples: encompass fresh sample (t=0hours) and samples incubated under 
75%RH/25°C, tested at different times. Test (a) samples: samples applied to the skin 
under occlusion. Test (b) samples: samples removed from Franz diffusion cells after 
being hydrated using PBS solution (detailed in Chapter 7). Error bars represent ±S.D. 
of not less than three measurements 
 
Occluded samples of FM-A and FM-B films were further examined using scanning electron 
microscopy (SEM) and polarized light microscopy (PLM) as depicted from Table 8.1 
through to Table 8.3. Images photographed with PLM in Table 8.1 revealed that samples at 
different levels of Gelucire 44/14 concentrations captured a print of the skin. This indicates 
flexibility of these films after being hydrated as supported by the MTDSC findings, where 
the glass transition temperature reduced as a function of hydration time under occlusion. The 
plasticization of these films and this behaviour (flexibility) is not only important 
aesthetically to adapt skin irregularities upon application, but also can increase the effective 
contact area necessary for efficient drug delivery. In common to the samples hydrated in 
vitro (Chapter 7), the oil-like streaks were also detected on the surface of these samples and 
will be, similarly, further investigated using ATR-FTIR. The density of the sparkling fine-
crystallite regions detected on the surface of the control sample containing higher level 
Gelucire 44/14 (FM-B) increased as a function of hydration time supporting MTDSC results.  
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 FM-A extruded films FM-B extruded films 
Time (Hours) Control Test Control Test 
3 
 
 
 
 
5 
  
  
8 
    
24 
    
 
Table 8.1: Representative polarized light microscope images capturing the surface 
appearance of the FM-A and FM-B extruded films, occluded on the skin at various 
time points in comparison to their corresponding control samples incubated at 
75%RH/25°C. Examples on the observed oil-like streaks are enclosed by orange 
squares, and fine crystallites by blue circles. (      ) Represents a scale bar that 
corresponds to 300 µm 
 
Scanning electron microscopy of samples of FM-A and FM-B extruded films containing 
approximately 15% (w/w) and 30% (w/w) Gelucire 44/14 in Eudragit RS PO, respectively, 
revealed that the hydrated films printed the shape of the skin cells similar to the PLM 
findings, supporting their elasticity. More importantly, these films developed micro-cracks 
on their surfaces and swelled as observed from their corresponding cross sections as shown 
in Table 8.2 and Table 8.3. This is consistent with previous chapter observations in vitro. In 
brief, it was speculated that hydration of these films with subsequent softening, aids Gelucire 
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44/14 mobility and leakage into the surface, wherein solubilised material leaving the films 
might contribute to the formation of the surface imperfections or micro-cracks.  
 
It is noteworthy that the control samples of FM-B films showed swelling signs in their cross 
sections after 8 hours of occlusion, indicating high affinity of water absorption as a function 
of increasing the level of this lipid compared to the control samples of FM-A films. Sparse 
crystallites on the surfaces of these samples were also detected, similar to the PLM findings 
and supported by MTDSC results. 
 
Table 8.2: Representative SEM images showing surfaces and cross-sections of the FM-
A extruded films (circa 15 % w/w Gelucire 44/14), occluded on the skin at various time 
points and compared to the control samples incubated at 75%RH/25°C. Examples on 
the observed micro-cracks are enclosed by orange squares  
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 Surfaces Cross-sections 
Time (Hours) Control Test Control Test 
3 
   
 
5 
  
  
8 
  
  
24 
   
 
Table 8.3: Representative SEM images showing surfaces and cross-sections of the FM-
B extruded films (circa 30% w/w Gelucire 44/14), occluded on the skin at various time 
points and compared to the control samples incubated at 75%RH/25°C. Examples on 
the observed micro-cracks and small crystallites are enclosed by orange squares and 
blue circles, respectively  
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Previous investigation in Chapter 7 has demonstrated the utility of the ATR-FTIR to 
distinguish crystalline Gelucire 44/14 in the extruded samples at two characteristic 
absorbance peaks around 1107 cm-1 and 1347 cm-1. Thus the occluded samples of FM-A 
films and FM-B films were examined accordingly and compared to their corresponding 
control samples stored at high humidity of 75%RH at room temperature. The Gelucire 44/14 
within extruded films with FM-A composition (circa 15% w/w  G44/14) showed no signs of 
crystallinity, as indicated from flattened and broadened peaks at the aforementioned 
locations in the ATR-FTIR spectra (data not shown here). This complies with previous 
MTDSC, PLM and SEM findings. However, around 1107 cm-1 peak there was a small 
change for the samples applied to the skin as shown in Figure 8.5. In this figure, it was 
noticed that while control samples exhibit almost smeared smooth line in this region at 
different times, the occluded samples start to show shoulders around this region which 
differentiate into two parts over hydration time. The first shoulder at 1107 cm-1 is very 
diffused and broadened, precluding possible crystallinity. The second shoulder is more 
differentiated over time, occurred around 1096 cm-1 and denoted as (II) in the ATR-FTIR 
spectra. This region dissipated after 24 hours of occlusion and it was assigned in previous 
chapter to the absorbance band related to palm oil, from which Gelucire is derived. This 
could explain the oil-like streaks observed on the surface of these samples.   
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Figure 8.5: Overlay plot of representative ATR-FTIR spectra of Gelucire 44/14 inside 
FM-A extruded films (Gelucire 44/14 Eudragit RS PO ratio of 1:6) at different 
occlusion times arranged in ascending order (3-24 hours) and compared to the 
Gelucire 44/14 spectrum in the equivalent control extruded film incubated at 
75%RH/25°C. (I) and (II) represent shoulders around 1107 cm-1 and 1096 cm-1, 
respectively. These spectra were obtained through subtraction of Eudragit RS PO 
spectra  
 
Gelucire 44/14 in FM-B extruded films (circa 30% w/w G44/14) showed an increase of the 
crystallinity over time of incubation at 75%RH/25°C as shown in Figure 8.6 and Figure 8.8. 
In these figures, the aforementioned sensitive absorbance bands for Gelucire 44/14 
crystallization become more distinct, indicating an increase in the structural uniformity 
associated with crystalline material. This conforms to previous MTDSC, PLM and SEM 
findings. In contrast, occluded films applied to the skin showed a decrease of the 
crystallinity over time, as illustrated in Figure 8.7. In this figure, the peak around 1107 cm-1 
denoted as (I) almost flattened to the baseline after 24 hours of occlusion, indicating 
solubilisation of the Gelucire 44/14 crystals. This was concomitant with an increase of the 
oil-related peak around 1096 cm-1 and observed on the surface of these films using PLM. 
However, these samples retained some crystalline regions, as indicated by well-defined 
absorbance peaks around 1347 cm-1 presented in Figure 8.8. This could be attributed to 
lower level of hydration achieved after skin occlusion that was not sufficient to solubilise 
these crystals over the time of the experiment i.e. 24 hours. 
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Figure 8.6: Overlay plot of representative ATR-FTIR spectra of Gelucire 44/14 inside 
control extruded samples of FM-B composition (Gelucire 44/14 Eudragit RS PO ratio 
of 2:5) at different times of storage at 75%RH/25°C arranged in ascending order (3-24 
hours). (I) and (II) represent shoulders around 1107 cm-1 and 1096 cm-1, respectively. 
These spectra were obtained through subtraction of Eudragit RS PO spectra  
 
 
 
Figure 8.7: Overlay plot of representative ATR-FTIR spectra of Gelucire 44/14 inside 
FM-B extruded films (Gelucire 44/14 Eudragit RS PO ratio of 2:5) at different 
occlusion times arranged in ascending order (3-24 hours). (I) and (II) represent 
shoulders around 1107 cm-1 and 1096 cm-1, respectively. These spectra were obtained 
through subtraction of Eudragit RS PO spectra  
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Figure 8.8: Representative  plots of ATR-FTIR spectra of Gelucire 44/14 around 1347 
cm-1 peak , inside FM-B extruded films at different occlusion times (left side plot) and 
compared to the Gelucire 44/14 spectra in the equivalent control extruded film 
incubated at 75%RH/25°C (right side plot), overlaid  in ascending order of sampling 
times (3-24 hours). These spectra were obtained through subtraction of Eudragit RS 
PO spectra  
 
The flexibility of these extruded films, with occlusion (test) and without occlusion (control), 
was investigated using hardness measurements. The parameter measured was the peak 
hardness force (PHF) needed to penetrate these films according to the experiment 
methodology detailed in Chapter 2 (section 2.2.2.6). As shown in Figure 8.9, there was a 
decrease in the PHF for the films occluded on the skin over time. Moreover, the PHF of the 
occluded samples was lower than those without occlusion (fresh and stored under 
75%RH/25°C) at different testing times. This correlates well with the MTDSC findings. The 
control samples (without occlusion) showed higher glass transition temperatures than those 
with occlusion, indicating lower flexibility. Thus higher force will be required to compress 
the harder, less flexible films. Therefore, plasticization by water was manifested by a 
decrease in both the glass transition temperature and hardness (PHF) of the samples hydrated 
by occlusion. 
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(A) 
 
 
 (B) 
 
 
Figure 8.9: Effect of hydration time on the measured peak hardness forces of the 
extruded films of (A) FM-A and (B) FM-B compositions applied to the skin under 
occlusion, referred as test samples and compared to their corresponding control 
extruded samples stored at 75%RH/25°C. Error bars represent ±S.D. of no less than 
three measurements 
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A summary of the obtained peak hardness forces for the extruded films of approximately 
15%(w/w) and 30%(w/w) Gelucire 44/14 concentrations in FM-A and FM-B systems, 
respectively, is shown in Figure 8.10. This summary demonstrates that for each set of data, 
fresh, control and occluded samples, the films containing higher level of Gelucire 44/14 
(FM-B composition) are more flexible as indicated by lower measured PHF values. 
 
 
 
Figure 8.10: Effect of the Gelucire 44/14 concentration on the measured peak hardness 
forces of the extruded films of (A) FM-A and (B) FM-B compositions applied to the 
skin under occlusion, referred as test samples and compared to their corresponding 
control extruded samples. Controls encompass fresh sample (t=0hours) and samples 
incubated under 75%RH/25°C, tested at different times. Error bars represent ±S.D. of 
no less than three measurements 
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8.4 Conclusions 
 
The hydration of the extruded films of FM-A and FM-B formulation was possible when 
applied to the skin under occlusion, as indicated by water absorption capacity and swelling 
ratio measurements. The in vivo behaviour of these films showed that both formulations 
underwent similar pattern of changes after hydration. These changes were mainly surface 
imperfections and softening of the films accompanied with swelling of their matrices. These 
changes were more evident over time due to increased hydration of these occluded films. In 
addition, a gradual decrease of crystalline Gelucire 44/14 in FM-B samples was observed as 
a function of occlusion time, indicating solubilisation. Further, these samples with higher 
level of Gelucire 44/14 i.e. FM-B films, exhibited a distinctly higher water absorption 
capacity and swelling with subsequent extended structural changes and more flexibility as 
indicated by lower measured PHF values. All these structural changes are believed to be 
contributing to an enhanced drug delivery from these extruded Eudragit RS PO/Gelucire 
44/14 matrices upon hydration. 
 
Flexibility of the extruded films of FM-A and FM-B systems was indicated by reduction in 
both glass transition temperatures and hardness values. This elasticity resulted from 
plasticization effect of water. These occluded films captured a print of the skin due to this 
flexibility, and therefore, represent a promise for application to the skin regardless of its 
surface irregularities, thereby achieving higher contact area.  
 
Since the observed patterns of structural changes using in vivo model in this study were 
similar to the ones probed using in vitro model using Franz cells, we could use this in vitro 
model as a predictive approach for the behaviour of these samples when loaded with the 
drug in vivo, as performed in Chapter 6 and 7. However, no statement can be made on the 
quantity of the drug released using in vitro model, because in vivo experiment revealed that 
it is associated with overhydration. It is therefore believed that the employed in vitro model 
using Franz cells to mimic skin occlusion could be only supportive for further clinical 
settings, and incorporation of the drug in these matrices for in vivo assessment is necessary 
to confirm their therapeutic efficiency. Nevertheless, it could be concluded at this stage of 
drug delivery development that FM-A and FM-B extruded films under the influence of 
human skin occlusion hold a promise for potential transdermal drug delivery in a relevant 
way to the ongoing interesting approach of improved drug release by hydration.     
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9.1 Conclusions 
 
The design of a delivery system involves not only the selection of the correct material 
composite, but also needs the proper equipment for its production. HME is a solvent-free 
technology and was utilized in this project as the main method of manufacture. This 
technique has moved from plastics industry to being well-recognized, viable technology in 
pharmaceutical industry for preparation of various dosage forms, ranging from oral to 
transdermal. This project attempted to craft a novel strategy for transdermal drug delivery. 
Thus the work herein was focused on the variation of design parameters and developing 
various formulations using HME technology that would ultimately synergize the concept of 
simplicity and enhanced release program in one system for transdermal application. These 
investigations were assisted by multiple analytical techniques which were exploited to 
evaluate the usefulness of the developed hot melt extruded films and their optimization as 
potential transdermal patches. 
 
Chapter 3 set out a general assessment of physicochemical properties of ibuprofen as a 
model drug throughout this work and the carrier excipients used to embed this drug by 
means of hot melt extrusion (HME). Screening tools as TGA, DSC, MTDSC, SEM, ATR-
FTIR and PXRD were used to characterise these properties. The information derived formed 
the basis for interpreting subsequent data from multi-component systems. All these materials 
exhibited a range of thermal stability of not less than 140°C, thus providing an estimate for 
the temperature range in which HME can be used. 
 
Chapter 4 took the principle of physicochemical characterisation further by studying 
composite mixtures of ibuprofen and Eudragit RS PO and their hot melt extruded 
formulations. The key findings obtained can be summarized by:  
 
• TGA results demonstrated minimal weight losses after thermal treatment of their 
physical mixes at the selected extrusion temperature (100°C) for the intended mixing 
time (four minutes), indicating low degradation and thermal stability at these 
conditions. 
• Extrudability was enhanced by the presence of a plasticizer i.e. ibuprofen. 
• Hot melt extrusion technology was utilized successfully for the development of solid 
solutions of ibuprofen at high loading (up to 35% w/w) incorporated in Eudragit RS 
PO. 
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• The theoretical approaches of miscibility estimation using solubility parameters and 
melting point depression provided relatively good prediction of the practical 
solubility found for the studied extruded systems. 
• Ibuprofen and Eudragit RS PO did not exhibit significant interactions but appeared 
to form compatible blends, supported by the one phase system existence of these 
systems i.e. solid solutions.  
• The extent of solid state miscibility or equilibrium saturation solubility was 
approximated for the resulted extruded solid solutions under two relative humidity 
levels for one month. It was noted that the equilibrium solubility composition of the 
extruded mixture without phase separation or drug recrystallization slightly dropped 
under dry conditions (0%RH/25°C) to 30% (w/w) drug loading. Indicating good 
physical stability in dry conditions. However, a significant decrease in miscibility 
was noted on storage at 60% RH/25°C to about 10% (w/w) drug loading, despite the 
water uptake being relatively low. This indicates extra molecular mobility resulting 
from the strong plasticizing effect of water, wherein the drug is also poorly soluble.   
• Supplementary information has been provided with regard to the fragility of the 
extruded ibuprofen-Eudragit RS PO solid solution systems. The results predicted 
strong glassy systems, and thus storage below their glass transition temperatures 
might not affect their stability in terms of drug recrystallization. 
 
Chapter 5 demonstrated in vitro drug release and permeation profiles from hot melt extruded 
Eudragit RS PO films. Basing evaluation off their in vitro performance, a number of main 
points were highlighted as follows:  
 
• The drug release was dependent on the drug load. 
• A key feature of these hot melt extruded films was a significant retardation of drug 
release. This finding is consistent with those of Azmari et al. (2005) and Hasanzadeh 
et al. (2009), who found that thermal treatment of Eudragit RS PO matrices could 
control the drug release.  
• With respect to the in vitro permeation behaviour, the retarding role of the Eudragit 
matrices on the drug permeation was evident in comparison to the diffusion of the 
ibuprofen from its saturated solution across the used silicone membranes. 
• Films maintained stability after ageing at wet conditions (60%RH/25°C) studied in 
previous chapter at 10% (w/w) drug loading extrudate liberated drug more than their 
corresponding aged dry extrudate. Thus water inclusion in these films might 
facilitate drug release. Therefore, adjustments of these formulations to achieve 
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desired release may involve judicious choice of hydrophilic components, enabling 
fluid access into these extruded films. 
• The glassy solid solution films at 30% w/w drug loading were chosen as a prototype 
to introduce further advents to optimise and establish usefulness of these 
formulations. Good physical stability of these films addressed in previous chapter 
after one month of ageing under dry conditions was demonstrated here as 
comparable in vitro release and in vitro permeation profiles between aged samples 
and fresh samples. 
• Both in vitro release/dissolution and in vitro permeation studies aided in better 
understanding of the release of the ibuprofen from the tested films and directed the 
need of a modification.  
 
Chapter 6 attempted to address the issue of what modification can be introduced to improve 
ibuprofen release and permeation from hot melt extruded formulations. The key points were 
found to be: 
 
• Formulation-based parameter, which involved modulation of formulation 
composition (carrier excipient type and the ratio used), resulted in changes of the 
molecular distribution of the drug in the extrudable matrices. 
• Only extruded films made up of Eudragit RS PO, ibuprofen and small amounts of 
xanthan gum (FM5) or Gelucire 44/14 (FM9), among other prepared multiple 
component systems, maintained their miscibility without detected phase separation. 
• In vitro drug release studies identified the hydrophilic components that decreased 
the release retardation effect of the Eudragit RS PO. The most plausible general 
explanation of release enhancement was the improving of water ingress into the 
extruded films or exposure of the ibuprofen into the dissolution medium. 
• Information derived from solid state characterisation, physical appearance and in 
vitro release properties were used to decide the encouraging formulations for further 
exploration of their in vitro permeation properties. Formulations which completely 
dissolved the drug as FM5 (xanthan gum) and FM9 (~10% (w/w) Gelucire 44/14) 
together with formulations showed superior release profile with acceptable physical 
features were selected, and included FM7 (Pluronic® F127) and FM10 (~20% 
(w/w) Gelucire 44/14) films. 
• Problems led to limited in vitro permeation properties from the selected 
formulations were addressed. Recrystallization of the drug and lack of proper 
hydration appeared to define, or at least contribute to these problems. 
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• Attention was drawn towards the role of hydration as an enhancement technique for 
in vitro permeation of ibuprofen from two major types of selected optimized 
extruded formulations. This embraced formulations of FM5 (xanthan gum) and FM9 
(~10% (w/w) Gelucire 44/14) wherein the drug is completely miscible, and FM10 
(~20% (w/w) Gelucire 44/14) wherein higher overall permeation achieved in the dry 
state amongst other formulations. 
• The variations of the vehicle used or the applied hydration level in the same 
composition resulted in a different permeation program, which included immeditae 
and sustained release schemes. In addition, the proposed mechanism of drug release 
using power model was changed for most systems as a result of the hydration. 
• Hydration, especially in films containing Gelucire 44/14 was  notably influential and 
appeared as a key parameter which allowed for improved ibuprofen permeation 
profiles, in terms of the amount permeated and extent. It is therefore preferable to 
use these films under occlusive conditions.  
• An in vitro simulative study of the hydration under skin occlusion supported the 
usefulness of extruded films containing Gelucire 44/14 to enhance ibuprofen 
permeation. 
• Hydration of these extruded films represents a strategy towards simple yet effective 
approach to release the drug and modulate its permeation program in the same 
system; therefore it rivals conventional methods for transdermal drug delivery. 
• Intriguing consistency changes driven by hydration to activate drug release from 
Eudragit RS PO/Gelucire 44/14 carrier systems presents a promising possibility as 
smart transdermal drug delivery systems.  
 
Chapter 7 focused on the characterisation of the key features of Eudragit RS PO/Gelucire 
44/14 extruded films based on their relevance for potential applications as transdermal 
delivery activated by hydration. The ageing effect  was outlined for these extruded systems 
formulated with and without  the drug. Dealing with these issue, the data suggested that: 
 
• Gelucire 44/14 was found to be in solid solution within the extruded formulation 
conatining Gelucire 44/14:Eudragit RS PO in the ratio of 1:6 (FMA), whereas the 
ratio of 2:5 (FMB) demonstrtaed a solid dispersion. 
• ATR-FTIR investigations suggested a possibility of certain rearrangments between 
these components wherein the interiors of these extruded systems are enriched with 
the C-H groups, in which hydrophobic side chains would be expected to be more 
involved in interactions; thereby the remaining functional groups will be “expelled” 
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or become readily available on the surfaces of these extrudates. However, no 
evidence of significant interaction was detected. 
• HSM further supplemented the hypothesis of a certain affinity between Gelucire 
44/14 and Eudragit RS PO, and DVS complement ATR-FTIR results about the 
possibility of specific arrangement between these extruded materials of concentrated 
hydrophilic regions on the surface, in addition to the increase of water uptake as the 
level of the lipid i.e. Gelucire 44/14 increased. 
• Changes associated with the hydration of these extruded carrier systems without the 
drug were probed in vitro and endeavoured to further understanding of their possible  
mechanism of drug delivery. Hydration consequences involved: surface 
imperfections, possible leakage of the Gelucire 44/14 into these surfaces and 
softening of the films accompanied with appreciable swelling of the matrices. These 
changes could impart in creating paths of active ingredients release and its 
solubilisation when loaded in these vehicles. 
• Changes of molecular arrangements of the studied extruded systems were detected 
at different used humidity and temperatures in the conducted basic storage studies. 
While FM-A extruded systems showed limited degree of Gelucire 44/14 
crystallization and formation of solid dispersion as supported by SEM and ATR-
FTIR results, an extended phase separation was observed for the originally solid 
dispersed FM-B systems supported by MTDSC, SEM and ATR-FTIR findings. A 
combination of high humidity 75%RH and high temperature 40°C is believed to aid 
in the solubilisation of Gelucire 44/14 formed crystallites, as a function of increased 
water uptake tendency as indicated by DVS investigations.  
• By using the same storage conditions, it was possible to relate the physical stability 
of corresponding extruded systems conjugated with the drug. On that basis 
alongside MTDSC and HSM studies, it was concluded that Gelucire 44/14 and 
ibuprofen recrystallized in these systems containing 30%(w/w) ibuprofen and 
Gelucire 44/14: Eudragit RS PO ratios of 1:6 or 2:5. 
• In vitro permeation studies conducted for these aged extruded films with the 
ibuprofen under hydration. Considering rapid release from corresponding fresh 
extruded formulations containing crystalline drug in the previous chapter, it was 
inferred that observed retardation of release from these aged films is primarily a 
function of Gelucire 44/14 recrysatllization. Alternatively, this impact, as described 
kinetically was not assumed to be negative because a delayed release of these tested 
aged films was associated with prolonged ‘steady state’ zero order release. Overall, 
the mechanism of drug release from these devices under the influence of hydration 
is believed to be more related to the carrier rather than the drug. This provides a 
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promise of using these carrier systems for drugs intended for skin application 
wherein a more control can be achieved using these carrier regardless of the physical 
state of the drug. 
• Kinetic models were also used side by side to propose the possible mechanism of 
the drug release from the tested matrices. Fitting to first order release kinetic was 
suggested for the whole profile and more accurately as a profile composed of 
simultaneous zero order release followed by first order release pattern. Power model 
indicated the possible role of swelling and relaxation in controlling the drug release. 
 
During development of the Eudragit RS PO/Gelucire 44/14 extruded systems by establishing 
them as drug carriers for transdermal delivery, interests sparked by improved in vitro 
ibuprofen permeation and consistency changes (Chapter 6), in addition to the observed 
structural changes of these carriers without the drug (Chapter 7), all after hydration. These 
impacts of hydration gave an intuitive reason for proceeding with investigations of these 
carrier systems when applied to the skin under occlusion in Chapter 8. Two main points 
were embedded in this chapter. The hydration of the extruded films of Gelucire 44/14: 
Eudragit RS PO in ratios of 1:6 and 2:5 was possible when applied to the human skin under 
occlusion. The structural changes observed in vitro for these films in Chapter 7 after 
occlusion simulation in Franz diffusion cells were consistent with those observed in this in 
vivo study, giving confidence in the use of these carrier systems as platforms for potential 
transdermal drug delivery in a relevant way to the ongoing interesting approach of improved 
drug release by hydration. This also provides a natural guide towards future research as will 
be suggested in the following section.    
 
Overall, this thesis presented that extruded one layer ibuprofen-Eudragit RS PO based 
transdermal patch could be developed using HME technology, which enabled fabrication 
with consistent and high process yield without solvent concerns. Various analytical 
techniques were used to understand how well the extruded system meets the desired 
physicochemical properties and drug release, and therefore accompanied the project 
framework to provide thorough characterisations, from the point of the production through 
to performance channels evaluated by in vitro drug release and permeation studies. Eudragit 
RS PO carrier matrices offered a stable embedding system for the drug but showed retarding 
impact on the ibuprofen release. Because desired drug release is one of the most critical 
aspects determining performance success, these matrices were modified for improving drug 
release by addition of other auxiliary components. Considerable emphasis was directed 
towards achieving reasonable effective release from these extrudable systems. It was found 
that the matrix-type transdermal patches of ibuprofen exhibited better permeation with the 
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Eudragir RS PO/Gelucire 44/14 matrices upon hydration. This satisfies or at least enables to 
proceed with the advancement of the desired aim of the project of introducing a novel 
strategy for transdermal drug delivery. The structural elements of this delivery strategy were 
tied into two things, simple Eudragit RS PO/Gelucire 44/14 extrudate and hydration as a safe 
enhancement technique. To allow active delivery, the films should be hydrated upon the 
application to the skin. As a delivery mechanism, hydration can be achieved by skin 
occlusion. These carrier systems were able to hydrate after application to the human skin in 
vivo under occlusion.  
 
9.2 Future work 
 
An integrated multi-disciplinary approach is usually required for a development process. 
Pharmaceutically, this approach involves communication between proper physicochemical 
properties of the drug and the delivery system used to achieve desired bioavailability. 
Understanding stability requirements, investigating factors that drive patient compliance and 
scale-up feasibility for commercialization purposes are also important to be identified during 
this process to find the applications of the final pharmaceutical product. 
 
In this work, the fundamental feasibility of designing transdermal patches using hot melt 
extrusion was established. The analytical techniques used and approaches offered a 
comprehensive understanding of the investigations and streamlined the development 
process, and thus would be of benefits to characterise other pharmaceutically relevant 
extruded materials. The design of hydration-responsive compositions of lipid-contained 
extruded matrices is to be considered a promising drug delivery approach that can realize 
concentration enhancement when applied to the skin under occlusion. Research on that 
domain approached the basic level of maturity and presented possible future areas of this 
research. In order to progress the development of this study, interventions structured 
horizontally and vertically are proposed. 
 
Saturated drug concentration within the formulation with appropriate stability is important to 
maximize the flux into the skin. Therefore, a delicate balance is preferred to be found 
between saturation concentration of the drug inside the carrier system enough to load 
amounts required for sufficient therapeutic dose for the intended time, and the stability of the 
drug. Thus as a first step in the vertical line modifications, we will reduce the total amount 
of incorporated drug in the studied extruded systems from 30% to about 10% (w/w) as a 
crystallization inhibition approach. If the drug recrystallization is avoided, then in vivo study 
of the ibuprofen loaded extruded matrices shall be conducted and the films shall be applied 
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to the skin under occlusive conditions. The estimation of hydration level of the occluded 
human skin will also be considered using for example trans-epidermal weight loss 
measurements, thus a quantitative relationship can be established between this level and the 
drug bioavailability. A change to horizontal line can be implemented at this stage. 
Interesting permeation enhancement and structural changes induced by hydration can also be 
elucidated for other drugs, expanding the utility of these carrier systems, and further our 
understanding if the ibuprofen was the only answer for these extruded systems activated by 
hydration with accompanying intriguing consistency changes and possibility of emulsion 
formation.  
 
At this point of research, the work said that all the inputs are directed towards a plausible 
conclusion of a carrier-controlled ibuprofen release from Eudragit RS PO/Gelucire 44/14 
matrices. Therefore, particle size or the physical forms of the drug are of minimal 
importance. However, the presence of the drug in a solid solution system is favourable to 
enhance its escaping tendency to the surrounding environment. This is ascribed to the 
tendency of glassy solid solution to reach high initial supersaturation (Albers et al., 2009) 
associated with high thermodynamic activity. Therefore, its stabilization would be important 
to empower the leaving tendency of the drug once applied to the skin with subsequent 
concentration and flux enhancement. The horizontal line of development is continued at this 
stage. Limiting the amount of the drug incorporated in the used matrices can be avoided by 
changing the Eudragit RS PO. The ideal candidate would be a crystallization inhibitor 
polymer, miscible with the Gelucire 44/14, does not affect the drug release negatively and 
preferably plasticized under the influence of applied hydration to ease liberation of the drug 
by the proposed strategy in this work.  
 
Polymeric constituents of other Eudragits have been utilized during the work, which was 
selected to have more hydrophilic character than RS PO grade with a potential for 
crystallization inhibition such as Eudragit RL (Kotiyan and Vavia, 2001) and Eudragit L100 
(Warren et al., 2010). However, these polymers showed drug recrystallization at 30% (w/w) 
ibuprofen loading without even incorporation of the third constituent (Gelucire 44/14).  
Therefore, the next stage will be investigation of other groups of polymers, known of their 
crystallization inhibition properties and application in transdermal dosage forms like highly 
dispersed silicon, macromolecules such as cyclodextrins, polyvinylpyrrolidones, and 
polyvinyl alcohol (Lipp et al., 1997). Polyvinyl alcohol was also tried and found un-
extrudable at the selected extrusion temperature with the ibuprofen. Miscibility estimations, 
extrudability, storage at different temperature and humidity and monitoring of the 
performance in vitro would accompany all these investigations to facilitate further 
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developments of these systems. In these multi-component extruded systems of the drug, 
Gelucire 44/14 and the new polymer, it would be recommended to carry out investigation in 
a step-wise manner as described throughout this work. While the main emphasis would be 
directed on the performance and the ability of the newly-introduced material to form stable 
solid solution with the drug, it would also be beneficial to investigate the stabilization of the 
bulk carrier matrix itself. At this stage of design it might be proper to determine the required 
scheme of the drug release, through elucidation of the drug release mechanism. For example, 
if it is maintained as carrier-controlled release process and prolonged release is desired, it 
may be adequate to have crystalline Gelucire 44/14 to control the drug release. This 
approach, for instance, is derived from the insights gained during the assessment of the aged 
films with ibuprofen, Eudragit RS PO and Gelucire 44/14, which represents another avenue 
for future research. 
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